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This thesis documents a new approach for the identification of a small biologically 
active molecule's site of interaction, through the rapid synthesis of molecular probes. 
A marked library approach has been developed whereby a biocompatible marker is 
attached onto the small molecule's molecular scaffold. This marker plays no role in 
the screening process itself, but facilitates the formation of a range of molecular 
probes from active marked library members. As an example of molecular probe 
formation, site selective biotinylation will be discussed in the introduction. 
3. synthesise 
o__(I) 
2. screen 	molecular probe 
 4. re-screen 
4910 1. library 	 5. identify target 
synthesis 
[Lecrenci: ()= library 0 = marker 	= tag] 
This marked library concept has been applied to the natural product anisomycin A. 
Investigations focused on development of a detailed structure activity relationship for 
anisomycin's activation of the stress activated protein kinase (SAPK) pathway, along 
with the synthesis of a number of marked library analogues. The active marked 
library members were then converted to a range of functional molecular probes 
utilising the copper(I) catalysed Huisgen cycloaddition as the key coupling step. 
These molecular probes are being used in the elucidation of anisomycin's biological 





In a further demonstration of this strategy, a focused library of marked steroids has 
been synthesised based on the functional isation of dehydroepiandrosterone B. 
Directed by the results of preliminary biological screening, a number of marked 
library members have been converted into fluorescent molecular probes. These 
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Chapter 1 	 Introduction 
1 Introduction 
1.1 Biotin 
Biotin 1, also known as vitamin H, is a water-soluble co-factor that is extensively 
utilised by Nature.' It is involved in a number of biologically important processes 
including gluconeogenesis, lipogenesis, amino acid metabolism and energy 
transduction. The structure comprises two fused heterocycles, a tetrahydrothiophene 
and an imidazolidinone. Biotin possesses three contiguous stereocentres and a 
pendant five carbon atom chain that ends in a carboxylate group (Figure 1.1). The 
chain acts as a swinging arm and the carboxyl functionality allows the coupling of 
biotin to proteins. This structural arrangement allows for eight possible stereoisomers 








Figure 1.1: Structure of D-biotin I and the abbreviation that will be used in this review. 
Biotin is synthesised by most plants and bacteria and is one of only a handful of co-
factors required by Nature. It is covalently linked to proteins via its carboxylate 
through the action of a biotin protein ligase (BPL). This coupling reaction is a 
remarkably specific process with most organisms having fewer than five biotinylated 
proteins present. 2 Once coupled, biotin is involved as a carbon dioxide carrier in a 
number of biologically important processes. 
BPL catalyses the formation of a new amide bond between the carboxylate of biotin 
and the c-amino group of a specific lysine residue of the biotin carrier protein (BCP). 
The coupling occurs in a two step ATP dependent process, in which biotin 1 is firstly 
* Co-factors are non-protein components of enzymes that are required to catalyse certain biochemical 
reactions. 
1 
Chapter 1 	 Introduction 
activated as the mixed anhydride by reaction with ATP to form biotinoyl-AMP 2. 
The activated intermediate 2 then reacts rapidly with the c-amine of the lysine 
residue to form the biocytin linkage 3 (Scheme 1.1).27 
0 
8-OH 	 AMP 
H2NBCP 	
NBCP 
ATP 	pPj 	 BPLorBirA 	
H 
1 	 2 	 3 
Scheme 1.1: Coupling of biotin I to the biotin carrier protein, via activation of biotin with ATP. 
Once coupled to the BCP the biotin moiety plays a key role in the carboxylation of 
acetyl-SCoA in the fatty acid biosynthetic pathway. 8, 9 This involves the reaction of 
hydrogencarbonate 4 with ATP to form the short-lived mixed anhydride 5 (Scheme 
1.2). This anhydride 5 subsequently reacts selectively with the N 1 of 3 in a process 
catalysed by a carboxylase enzyme, forming carboxy-biotin 6. The 16 A 'swing' arm 
provided by the biocytin moiety allows the flexibility to move between different 
active sites; thus allowing carboxy-biotin 6 to move from the carboxylase site to the 
transcarboxylase site. 10 A formal Claisen condensation then takes place between the 
enolate of acetyl-SCoA and 6 in a sequence catalysed by the transcarboxylase 
enzyme. This leads to the formation of malonyl co-enzyme A 7 and the regeneration 














E Ql SC0A 	+ 
3 
Scheme 1.2: Illustration of biotin's role within the fatty acid synthesis pathway. Activation of 
hydrogencarbonate 4 forms the mixed anhydride 5, which reacts with biocytin to form 
carboxy-biotin 6. A Claisen condensation then extends the acetyl-SC0A carbon backbone by 
coupling a one carbon carboxyl unit from carboxy-biotin 6 with the enolate of acetyl-SCoA to 
form malonyl SCoA 7. 
Recently biotin has been applied in a range of scientific settings including chemical 
biology, drug delivery and materials chemistry. 11-13  This primarily exploits the 
interaction between biotin and the protein avidin which is one of the strongest non- 
2 
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covalent interactions known at Ka = 2.5 x 1015  M'.' 4 Avidin is a tetrameric protein 
which can bind a single biotin molecule per subunit. The exceptional binding affinity 
and slow dissociation rates of the ligand result from a network of hydrogen bonds 
between the protein and the heterocyclic core of biotin. The pair of ureido nitrogens 
form hydrogen bonds with Thr35 and AsnI 18, the ureido oxygen forms contacts with 
Serló and Tyr33, while the hydrophobic tetrahydrothiophene interacts with Phe79, 
Trp97, and TrpllO. In addition, hydrogen bonding occurs between the biotin 
carboxylic acid and avidin residues A1a39, Thr40, and Ser75.' 5 
The related tetrameric bacterial protein streptavidin shares 33% of the conserved 
amino acids with that of avidin and a strong binding affinity for biotin (Ka = 1.0 x 
1012 M) (Figure 1.2, part a).' 6 Specific interactions include hydrogen bonding 
between the nitrogens of the urea with Ser45 and Asp128 and oxygen contacts with 
Asn23, 5er27, and Tyr43 (Figure 1.2, part b). This network of hydrogen bonding in 
conjunction with hydrophobic interactions with four Trip residues (Trp 79, 92, 108, 
and 120) and the tetrahydrothiophene are responsible for the high binding affinity. 17, 
18 
Figure 1.2: Illustration of (a) the streptavidin tetramer with a molecule of biotin bound per 
monomer; and (b) showing the distinct hydrogen bonding interactions between biotin and 
streptavidin.1920 
Therefore, biotin-(strept)avidin systems have been used in a plethora of 
biotechnological applications such as affinity isolation and purification, 
immunoassay, diagnostics, localisation and biosensors. However, the incorporation 
of a biotin unit still poses a number of challenges. Herein, we review the strategies 
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utilised for the site specific (and not so specific) incorporation of biotin into a range 
of molecules over the last few years. 
1.2 Biotin Linkers 
In order to couple biotin to the molecule of interest, whether it is a protein or a small 
molecule, a linker component is typically inserted to separate biotin from the other 
functionalities of the target molecule. The linker has a number of further roles to play 
including controlling the flexibility, influencing the cell permeability and regulating 
the binding of biomolecules to the molecular probe. 
The two main categories of linker typically used in the formation of biotinylated 
molecular probes are based on carbon and polyethylene glycol (PEG) backbones 
(Figure 1.3; 8 and 9)2I  In addition to the constituents of the linker, the length of the 
backbone plays an important role in regulating the properties of the biotinylated 
species. Biotin itself has a 5-carbon side arm that provides a natural 13.5 A spacer, 
and this can then be extended by coupling to an appropriate linker. Typically the 
linker varies from 4-atoms which extends the arm to ---17.5 A, up to 14-atoms which 
has a length of —30.5 A. 22 Control of the linker's length allows for the regulation of 
target binding, with a longer linker allowing the capture of molecules with greater 
steric hindrance. However, the downside in using a long linker is that it often leads to 
the binding of proteins and small peptides to the linker itself. Therefore, the choice of 
linker length has to be selected on a case by case basis, based on the desired 
application of the biotinylated molecule. 
0 	 0 
HNANH 	 HNANH 
H—) -H 	 H—) (H 	
H 
	
) ., N 	
OSuc 
0 	 0 	 0 
8 9 
Figure 1.3: Structure of two biotin-NHS reagents that vary in the type of linker unit. (a) 8, has 
a carbon linker and (b) 9 has a polyethyleneglycol (PEG) linker. 
4 
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A novel class of linkers has also been developed which contain a cleavable unit 
within the linker. This allows the biotinylated molecule to be attached to a 
strept(avidin) column, but under specific conditions the linker can be cleaved leading 
to elution. This strategy allows the molecule to be purified and identified without the 
need for the harsh elution conditions (8 M guanidine'HCl, pH 1.5; excess biotin or 
boiling in SDS) usually required to release biotin from an strept(avidin) column. 23 
This cleavable linker strategy takes a number of forms. However, the use of the 
disulfide functionality is by far the most popular (Figure 1.4; 10). This S-S bond is 
stable over a range of physiological conditions but can be selectively cleaved by 
reduction. 24  Other cleavable linkers have been developed which utilise photoreactive, 
oxidative, alkali sensitive and fluoride sensitive moieties. 25-28t 
0 
HNANH 
H'.-) (-'H 	 H 
0 	 0 
10 
Figure 1.4: Structure of a biotinylation reagent 10 containing a disulfide linker that can be 
selectively cleaved. This allows release of the bound protein of interest from the 
strept(avidin) binding protein, thus removing the need for harsh eluting conditions that are 
often required. 
1.3 Biotinylation Through a Range of Functionalities 
The biotinylation of biological molecules has been used as a tagging technique for 
over 30 years. 29-31  It has several advantages over techniques such as radiolabeling, as 
it removes the hazard and disposal issues associated with radioisotopes. 32 ' 33 
Therefore, a number of biotinylation reagents have been developed, thus allowing a 
range of synthetic approaches to be used to incorporate biotin into a molecular 
scaffold. This section will focus on the range of reactive functionalities that have 
been successfully employed over the last ten years, as well as the alternatively useful 
biotinylation techniques that have emerged during the last decade. 
For the purpose of this review the linkers are abbreviated to L; however, the specific structures of the 
linkers are shown in the appropriate schemes. 
5 
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1.3.1.1 Coupling with Biotin 
With the development of an array of coupling reagents and additives that can be used 
to form amide/ester bonds,  34,35  one of the most common methods of biotinylation is 
to couple a molecule of interest directly to biotin 1. This direct coupling approach 
has been applied to a range of molecules including polysaccharides and cyclodextrins 
with high yields of the resultant products (Scheme 1.3; 11—+12, 13_14).36 37 
0 
s 	









0H D---- Y-8  
13 	 14 
Scheme 1.3: (a) 1, TBTU, DMF, Et3N (85%);36  (b) 1, DCC, HOBt, DMF (8%). 37 
The same amide coupling strategy with extended linkers (L) has been utilised by 
Rando to form molecular probes for identification of the retinol binding protein, 38 

















L = (CH2)4CH(NHBoc) 
8~kHN , L y0H  
19 	 H 
0 	 0 
S 20 	R 
L=(CH2)5 
Scheme 1.4: (a) 16, EDC, DMAP, DMSO/DCM (78%);38  (b) 19, DIC, HOBt, Et3N, DMF 
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However, transfer of the use of coupling reagents to complex multi-functional 
biological substrates is not directly applicable due to the presence of numerous acid, 
amine and alcohol functionalities. This leads to a lack of selectivity in the coupling 
reaction and biotinylation at a number of sites within the biomolecule. 
1.3.1.2 Biochemical Coupling using BPL and BirA 
The incorporation of biotin into a protein's structure in a site specific manner is 
successfully achieved in Nature in a range of biological systems using BPL. The use 
of BPL as a catalyst for introducing biotin into protein scaffolds has been 
investigated. Characterisation of the amino acid sequence required by naturally 
biotinylated proteins has led to the development of peptide tags that direct 
biotinylation. Biotinylation can be carried out by the cell's endogenous biosynthetic 
machinery or through co-expression of an exogenous biotin ligase, in most cases to 
date this has been the 35 kDa E. coli biotin ligase enzyme (BirA) (Scheme 1.5). 
P rote 	 B1rA, Biotin 	Protein of 
Interest 






Scheme 1.5: Conversion of a tagged protein of interest 21 into the analogous biotinylated 
protein 22. Coupling takes place between biotin and the F--amine of the lysine residue within 
the tag in a process catalysed by BirA. 
The discovery of a highly conserved Ala-Met-Lys-Met recognition sequence within 
the C-terminus of the (de)carboxylases has allowed the development of a number of 
fusion tags. 2,4044  These tags can be used at the C-terminus, N-terminus and within a 
protein's structure allowing in vivo or in vitro site specific biotinylation of 
recombinant proteins. Moreover, enzymatic biotinylation of these tags has been 
shown to have kinetics comparable to that of the natural biotin acceptor sequence. 
The commercially available BioEaseTM  tag is based on a 72 amino acid domain that 
is derived from the a subunit of K pneumoniae oxalacetate decarboxylase, with the 
whole 72 amino acid sequence being required for recognition (Figure 	This 
approach provides a significant reduction in bulk over other widely utilised fusion 
7 
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sequences such as GFP (238 amino acids, 27 kDa). However, a 72 amino acid 
sequence is still a substantial size to append to a biomolecule for the purpose of 





Figure 1.5: The abbreviated 72 amino acid BioEaseTM  tag and the full 15 amino acid 
AviTagTM sequence with the key lysine residue highlighted. 
There are a number of advantages to using a smaller tag; it is much less likely to 
affect the structure and thus properties of the tagged protein, it is less likely to be 
recognised by endogenous biotin ligases; and their small size means there is no need 
for the extra complication of protecting groups associated with some larger tags. 
Consequently, a series of smaller tags have been developed over a number years, 
through numerous screening rounds of combinatorial peptide libraries for sequences 
biotinylated by BirA.469 The resultant peptides have been used to carry out site 
specific biotinylation of fusion proteins in E. coil cells. A 15 amino acid sequence 
derived from the E. coil BCP subunit of acetyl CoA carboxylase has been 
commercialised under the name AviTagTM [also known as acceptor protein (AP)] 
(Figure 1.5).°' 51  Within the 15 amino acid sequence, the two Met residues flanking 
the Lys in the natural sequence have been altered to Gin and Ilu. This, provides a 
robust, highly efficient tag that allows the site specific biotinylation of proteins in 
vivo in both bacterial and mammalian cells. 50-52 
The BirA technology has recently been expanded by Ting et al. to the coupling of 
ketone biotin As ketone functionalities are. not normally present in cell surfaces, 
this probe makes an excellent bioorthogonal substrate which can be site specifically 
conjugated to hydroxylamine or hydrazide functionalised molecules. Therefore, AP -
fused recombinant proteins 23 can be coupled to ketone biotin 24 in the presence of 
BirA in a highly specific manner. The coupled ketone biotin unit 25 can then be 
modified using Schiff base reactions with hydroxylamine or hydrazide probes 26 
under physiological conditions (Scheme However, this methodology is 
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limited by the lack of affinity ketone biotin has for streptavidin and the extended 
timescale associated with a two step coupling strategy, which prevents the 
investigation of rapid biological processes. In addition it is also restricted to 
investigating molecules on cell surfaces due to the number of ketone and aldehyde 
containing small molecules within the cell that would remove the specificity of the 
Schiff base condensation. However, it seems likely that the development of this new 
coupling approach utilising ketone biotin will provide a useful extension to the BirA 




Cell surface 	 24 	0 
protein—. r''' 	BIrA 










25 	 27 
Scheme 1.6: BIrA catalysed coupling of ketone biotin 24 to the AP 23. Followed by a Schiff 
base condensation between ketone 25 and hydrazide 26 (or hydroxylamine) to form  27. 53 
1.3.1.3 Coupling with Activated Esters of Biotin to Form Amides 
The most widely utilised reactive functionality for biotinylation is an activated acid 
in the form of a hydroxyl succinimidyl ester. This functionality reacts readily with 
primary and secondary amines to form amides, and has been used in conjunction 
with a variety of linker types and lengths. 
The coupling of biotin-N-hydroxysuccinimide (biotin-NHS) has been extensively 
used to tag proteins, peptides and antibodies and is used as a standard technique in 
the purification of biomolecules. 29 Biotinylation proceeds readily at pH 6-8 over a 
short period of time. More recently, this has been expanded to the solid phase 
synthesis of biotinylated antibodies, whereby the biotin-NHS derivative 29 has been 
coupled to a primary amino functionality 28 to form 30, prior to release from the 
solid support (Scheme 
Ell 
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S/ 	,LOSuc 	 S 	 /' 





Scheme 1.7: Illustration of amine 28 directed biotinylation of antibodies on solid support . 54 
Modification of the succinimide structure by incorporation of a sulfo group onto the 
ring alters the properties of the biotinylation reagent dramatically; stopping the 
reagent from crossing the cell membrane. 55 This modification allows the specific 
labelling of extra-cellular biomolecules. For example, Scheurer et al. recently 
labelled membrane proteins in metastatic and nonmetastatic teratocarcinoma cells, 
thus facilitating their capture on streptavidin sepharose, before digestion and 
subsequent analysis of the isolated proteins by MS-MS. 56 
In contrast, more synthetic applications have used biotin-NHS derivatives to 
biotinylate small molecule scaffolds in high yields, often as the final step in a 
synthetic sequence. Peterson introduced the biotin moiety in the final step in his 
synthesis of tagged estradiol derivatives (Scheme 1.8; 31—.33), which were then 
used in yeast three-hybrid screens. 57  This NHS coupling strategy has been widely 
applied to a range of biologically interesting molecules including carbohydrates 34, 
steroids 35 and a number of drugs including ezetimibe 36, a cholesterol inhibitor and 
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Scheme 1.8: (a) 32, DIEA, DCM/MeOH, (93%)57 
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Figure 1.6: Structures of modified (a) Fucose a(1-2) galactose 34, (b) 2-cyano-3,12-
dioxooleana-1 ,9(1 I )-dien-28-oic acid 35, (c) 2-azetidinone 36 and (d) paclitaxel 37 which 
have all been coupled with biotin-NH S.58 -61 
1.3.2.1 Coupling with Biotinylated Amines to form Amides 
In an alternative approach, a number of biotinylated amines have been developed to 
allow coupling of small molecules, peptides and the C-terminal of proteins to biotin. 
This procedure, orthogonal to the NHS approach, was utilised by the researchers at 
Merck who were investigating the biological target of L-685,485, a potent y -
secretase inhibitor.  62  A pair of biologically active biotinylated molecular probes were 
synthesised, with the coupling of biotinylated amine 39 with a functionalised acid 38 
shown in Scheme 1.9. Subsequent affinity chromatography utilising both 
biotinylated molecular probes led to the isolation of the same labelled protein, 
presenilin 1 (PSI); allowing the conclusion to be drawn that PSI contains the active 





















0 0 	 0 	
H 0 	o 
38 	 40 
L= [CH215 
Scheme 1.9: (a) 39, EDC, HOBT, Et3N, DMF (63%) . 63 
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1.3.2.2 Coupling with Biotinylated Amines to form Amines 
Weizel et al. utilised a biotinylated amine 42 in the formation of a multifunctional 
target identification reagent 43 which includes a biotin moiety, a photoreactive 
functionality and an attachment point for the ligand under investigation. 64  The amine 
42 was coupled to 41 by reductive amination in the presence of sodium 
cyanoborohydride in good yield (Scheme 1.10). 
	
F3C.jJ 	 F3C 'N 
9 NLNH 




0 	 0 
L= CH2-[CH20CH2] 2-CH 2 
Scheme 1.10: (a) 42, NaCNBH 3 , MeOH, TFA (60%) . 64 
1.3.3.1 Coupling with Biotinylated Hydroxylamines and Hydrazines 
to form Oximes and Hydrazones 
The use of biotinylated hydroxylamine and hydrazine reagents has also been 
exploited as a method to introduce biotin into molecular architectures. This approach 
relies on the high selectivity of the reagent to undergo Schiff base condensations with 
a carbonyl functionality within the parent structure. This condensation reaction has 
recently been used in the development of a new strategy for the detection of 0-
G1cNAc proteins, whereby a modified keto-sugar has been incorporated onto the 
protein's structure using the natural biosynthetic machinery. 65 The glycosylated 
protein 44 can then be tagged selectively using biotinylated hydroxylamine 45, 
which reacts with the ketone marker within the sugar moiety to form 47 (Scheme 
1.11). Addition of the biotin component allowed for the subsequent detection of the 
proteins using streptavidin-conjugated HRP as an antibody. 
12 
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Scheme 1.11: (a) 45, pH 6.7 buffer (100%).65 
Oxime formation using a hydroxylamine derived biotin has also been used to couple 
the ring opened aldehyde form of pyrimido[l,2-a]purin-10(3H)one (M1G) 47 
(Figure 1.7), resulting in the development of a new reagent to measure M1G 
levels.  66  Lacom et al. have used this oxime based approach to generate a series of 
biotinylated steroids based on the coupling of 48 (Figure 1.7). The biotinylated 
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Figure 1.7: Structures of (a) modified M1G 47 and (b) estradiol 48 which have been coupled 
with biotin-hydroxylamine reagents. 66' 67 
In an analogous coupling approach Danishefsky used a biotinylated hydrazine to 
attach a tag to the core of a migrastatin analogue.  68  (+)-Migrastatin 49 is a macrolide 
natural product with antimetastatic properties that was isolated from fermentation 
broths of Streptomyces sp. 6972 Synthesis of the natural product and a series of 
analogues led researchers to conclude that the core structure could be dramatically 
simplified while still retaining biological activity.  68  In an attempt to identify the 
biological target of this macrocycle, a biotin unit 51 was coupled to the simplified 
macrocycle 50 in high yield using a Schiff base condensation (Scheme 1.12). The 
molecular probe 52 was then tested for its ability to inhibit tumour cell migration, 
13 
Chapter 1 	 Introduction 
showing retention of its activity with only a slight decrease in comparison to the 
natural product itself. 
  
0 












L= CH2-[CH20CH2] 4-CH2 
Scheme 1.12: Structure of (+)-migrastatin 49 and coupling conditions (a) 51, EtOH, 55 °C 
(75% 68 
1.3.3.2. Coupling with Biotinylated Hydrazines to form Hydrazides 
and Hydrazines 
Biotinylated hydrazines have also been used with a range of coupling reagents to 
form hydrazides (Scheme 1.13; 53—*55). This coupling reaction has been used in a 
number of studies ranging from carbohydrate and dendrimer chemistry to the 
development of assays . 7375 A biotinylated hydrazine 57 has also been condensed 
onto the reducing end of carbphydrates 56 by reductive amination in the presence of 
sodium cyanoborohydride to form 58 (Scheme 1.13).76 
.0 
AcO OAc AcO OAc H H 
AcO - 
	
-- 	 NHP 	
54 
OAc AcHNO_JH a 
53 	 0 
ACO OAc AcO  _OAc 
AcOs_- 	 NHP 	 0 
OAc AcHNJjL)j 
55 	
0 H H 




NH 	 b 
56 
L= (CH2)5C0 
OH 	 0 
R OHL 
NH H H 
58 
L= (CH2)5 
Scheme 1.13: (a) 54, DCC, HOBT, DMF (68%); (b) 57, NaCNBH 3, DMSO/AcOH, 65 ° C (>95 
%). 75.76 
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1.3.4.1 Coupling with Biotinylated Maleimides via Nucleophilic 
Displacement Reactions 
Attachment of the reactive maleimide functionality on to a biotinylated linker was 
developed as a selective method for coupling thiols. The maleimide reagent allows 
for the selective tagging of cysteine residues within a protein's structure, and has 
been extensively utilised as a method for introducing biotin into biomolecules. 29 
Spence et al. have utilised this coupling reaction in the development of NMR-
biosensors 61 using the magnetic properties of xenon. 77  Functionalisation of the 
xenon cage, cryptophane-A, with a 4 amino acid side chain containing a cysteine unit 
77 59 subsequently allowed the introduction of a biotin moiety 60 (Scheme 1.14). 
This biosensor was used to investigate biosensor/protein interactions to determine the 
relationship between the molecular composition of the xenon biosensor and the 
characteristics of protein-bound resonances. 78 
0 	0 	 0 
8N_ L.. JJ H 








Scheme 1.14: Illustration of biotin maleimide 60 used in the synthesis of biosensor 61 
designed to target Xenon .77 
This maleimide coupling has also been used in the development of a DNA 
hybridisation biosensor, the final step in the synthetic sequence being the coupling 
(in high yield) of maleimide-biotin with an oligodeoxynucleotide. 79 In another 
example, Oba et al. coupled a thiol modified analogue of xestoquinone 62 to 
biotinylated maleimide 63 to form the molecular probe 64. The probe was then used 
to investigate the natural product's role as an inhibitor of Ca 2 ATPase (Scheme 
1 . 15) 80 
15 
Chapter 1 	 Introduction 
8)LLJ 
OMe 	 ° (SH 	63 
i 	I 	









L= (CH2) 5C0 NNCH2CH2 
Scheme 1.15: (a) 63, CH3CN:H 20; (b) CAN, CH 3CN (29 % over 2 steps). 80 
1.3.4.2 Coupling with Biotinylated Maleimides via Diets-Alder 
Reactions 
In an alternative approach the maleimide functionality has also been used as a 
reactive dieneophile which can be coupled to a functionalised diene using a Diels-
Alder cycloaddition reaction. Saito et al. has coupled a number of oligonucleotides 
incorporating a reactive diene unit to a series of functionalised maleimides. 8 ' These 
reactions proceeded via a Diels-Alder cycloaddition followed by a [1,3]-H shift and 















L= CH2-[CH20CH 2] 2-CH2NHCOCH2CH2 
Scheme 1.16: (a) 66, MeOH, 0 °C (>95 %)•81 
Biotin maleimides have also been used as the dieneophile in the selection of Diels-
Alderases from combinatorial RNA libraries. 82, 83 RNA molecules with catalytic 
properties are termed ribozymes, and some have been shown to accelerate the 
carbon-carbon bond forming process in the Diels-Alder reaction by up to 20000-  
fold . 84 Initially this reaction would only proceed when the diene 68 was tethered to 
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the RNA (R = RNA) (Scheme 1.17) .84  However, recent advances have led to the 
coupling of dieneophiles 69 with dienes 68 (R= alkyl) in the presence of an 
untethered 49-mer ribozyme catalyst. 85  Under these conditions the reaction 
undergoes significant rate enhancement and results in the formation of 70 and 71 





C?-  -a RO 	 OR R 
68 	 70 	 71 
L= NHCO(CH 2)5 
Scheme 1.17: Illustration of the RNA-catalysed coupling of biotin-maleimide 69 with 
anthracene 68. (a) 69, 49-mer ribozyme, pH 7.4 buffer. 85 
1.3.5.1 Coupling with Biotinylated lodoacteyls via Nucleophilic 
Displacement Reactions 
In a complementary approach to that using the malaimide functionality, a biotin 
moiety containing a reactive iodoacetyl functionality has also been developed. This 
reagent allows the selective biotinylation of the thiol functionality of cysteine 
residues within a biomolecule, while also allowing the use of a number of other non-
biological nucleophiles. 29 
This iodoacetyl coupling was applied to the biotinylation of a peptide sequence 
derived from the N-terminal region of the P-selectin glycoprotein ligand 1 (PSGL- 1), 
a major ligand of the selectin family involved in leukocyte adhesion to the vascular 
endothelium during inflammation. 86  The key peptide was synthesised using Fmoc 
solid phase synthesis and glycosylated to form 72. Selective biotinylation of the C-
terminal cysteine residue of 72 was then carried out using iodoacetyl biotin 73 to 
form 74 (Scheme 1.18). 87 
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SH 
Ac-Tyr(S03H)-Asp-Phe-Leu-Pro-G1u-Lys-G1u-Cys-CO- 	HO OH 
	
I 	 HO 
HFJ OH 
e H 	 a 	 0 	HO 72 - 
73 'V c 1Jt_ 
o 
Ac-Tyr( SO3H)AspPhe-Leu-Pro-G1u-Lys-G1u-Cys-CO-Q 	HO OH 
I 	 HO 
HN 
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L= CH2-[CH20CH2]2-CH2 	 0 	HO 
74 
Scheme 1.18: Biotinylation of glycosylated peptide 72 via nucleophilic displacement reaction 
with iodoacetyl biotin 73 (a) 73, pH 7.3 buffer/CH3CN (1:1)87 
The iodoacetyl reactive functionality 76 has also been used in the construction of 
new biosensors. The probe molecule [N-(biotinoyl)-N'-(acetyl 4,4'-
pyridylpyridinium iodide) ethylenediamine (BPP+) 77 consists of a biotin molecular 
recognition fragment coupled to a pyridinium unit and was synthesised in one step 
from 75 (Scheme 1.19).88  When 77 is added to a solution of poly[lithium 2-methoxy-
5 -(3' -propyloxysulfonate)- 1 ,4-phenylenevinylene] (Li+-MPSPPV), a weak 
electrostatic complex forms between the pyridinium and sulfonate groups, which 
brings the quencher molecule into close proximity with the optically active 
backbone. This leads to a very efficient fluorescence quenching of Li+-MPS-PPV by 
BPP+. The addition of avidin, which binds the biotin substructure, has been shown to 
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H 	H 	I 
77 
L= CH2CH2 
Scheme 1.19: (a) 76, DMSO (49%)88 
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1.3.6.1 Coupling with Biotinylated Cysteine via Native Chemical 
Ligation 
The native chemical ligation developed by Kent et al. has been widely used in the 
synthesis of proteins as the key step in the coupling of peptide fragments of varying 
sizes. 89 This reaction allows the formation of new peptide bonds by coupling a 
peptide containing a C-terminal thioester 78 with a second peptide containing an N-
terminal cysteine 79, in the presence of an exogenous thiol catalyst. In a 
thermodynamically-controlled reversible first step, a transthioesterification occurs to 
form 80. This product 80 then rearranges irreversibly under the reaction conditions to 




jR 	 HS 
78 2 
S® 	
H2N 	 deA 	NN( peptide B] 
0 H)__~_ 
- —peptide B] L
_
pepti de B )—NH 	 0 
H2N'ff' 	 80 	 81 
0 
79 
Scheme 1.20: Mechanism of the native chemical ligation. 90 
The native chemical ligation has now been expanded to allow the coupling of a 
biotinylated-cysteine moiety 84 to proteins, in an intein-directed coupling strategy. 91, 
92 Inteins are biochemical markers that can be cleaved tracelessly from the protein 
under investigation by attack of a nucleophile, thus facilitating the formation of a 
new amide bond (Scheme 1.21; 82—+85). The intein unit is displaced, allowing 
biotinylation to take place site specifically without a residual tag on the biomolecule. 
0 




ins— 	 84 	i n NXL(8 
0 
82 	 83 	 85 
L= (CH 2) 3NHCO 
Scheme 1.21: Overview of intein mediated native chemical ligation. (a) lntein-mediated 
rearrangement; (b) native chemical ligation with cysteine-biotin 84.91 , 92 
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This methodology has been applied both in vivo and in vitro, with the protein of 
interest being site specifically biotinylated, without the requirement for a tag that is 
retained within the final molecule.  93,94  However, the precursor inteins are bulky, the 
coupling site is limited to a cysteine residue, and the rates of the ligation reaction is 
still in the order of hours, making this approach unsuitable for the monitoring of 
rapid biological processes. 
1.3.7.1 Coupling with Biotinylated Alkynes 
Azides and alkynes have gained widespread acceptance as biocompatible 
functionalities over the past few years. 91, 96 This has led to the development of a 
number of bioconjugate reactions that can be utilised to couple these functionalities 
in a range of settings including: the Staudinger-Bertozzi ligation; strain promoted 
cycloaddition; and the copper(I) catalysed Huisgen cycloaddition. 9698 
Following the 2003 publication from the Cravatt and Sorensen research group, 99 a 
number of propargyl biotin reagents have been prepared. Having previously 
synthesised FR182877, 110102  a complex natural product which has a number of 
interesting biological roles, these groups set out to identify the molecule's biological 
site of action. The key coupling step in the formation of$he molecular probes 88 was 
the copper(I) catalysed Huisgen cycloaddition. This bioorthogonal reaction was used 
to couple a number of propargyl functionalised tags including biotin and rhodamine 
87 to an azido analogue of FR1 82877 86 (Scheme 1.22). 99  
N3 	
—tag 	
0 & f;  N ' '~ N 
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Scheme 1.22: (a) 87, CuSO4 (10 mol%), NaAsc (20 mol%), tBuOH:H20  (50 %)•99 
One of the main exponents of propargyl biotin has been Tirrell who has utilised this 
reagent in a number of examples of protein and cell surface engineering. 103 Co- 
translational replacement of methionine residues in the outer membrane protein 
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(Omp) C in E. coil cells with azidohomoalanine 89 (Figure 1.8), allows coupling to 
a biotin-alkyne reagent 90 under 'click' reaction conditions before analysis by 
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89 	 90 
Figure 1.8: Structure of (a) azidohomoalanine 89 and (b) biotin propargylamide 90•104 
This tagging methodology has recently been used to investigate protein synthesis 
upon environmental stimulation. 105 By incorporating an azide modified amino acid 
during in vivo protein synthesis, the newly formed proteins can be tagged with an 
analogous propargyl biotin reagent. The tagged proteins can be subsequently purified 
and identified by tandem MS. 105 
However, the copper(I) catalysed Huisgen cycloaddition has limited applications in 
biological systems due to the fact that copper(I) is toxic to both bacterial and 
mammalian cells. 104  Therefore Bertozzi et al. set about applying a catalyst free [3+2] 
cycloaddition to biological systems. 106  This was based on work carried out by Wittig 
and Krebs in 1961 who found that the reaction of phenyl azide and cyclooctyne 
"proceeded like an explosion to give a single product", the triazole) °7 Bertozzi 
subsequently showed that the biotin derivatised cyclooctyne 91 reacts rapidly with a 
number of azides 92 to form an equal amount of the two possible regioisomers 93 
and 94 (Scheme 1.23). 106  In addition, they illustrated the formation of the triazole in 
living cells without the toxicity witnessed under copper(I) catalysed conditions. As a 
result the development of the strain promoted cyclisation has provided a useful 
extension of the [3+2] cycloaddition methodology and has been subsequently utilised 
in a number of biological applications.' 08,109 
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L= CH2CH2-[CH20CH2]3-CH2CH 2NHCO-pArCH2 
Scheme 1.23: (a) 92, pH 7.4 buffer. 106 
In an alternative use of the alkyne functionality Arterburn et al. have recently 
synthesised an alkyne derivative of biotin 95 which has been utilised in Pd-catalysed 
Sonogoshira cross coupling reactions (Figure 1.9). 110 This approach provides a 
contrasting method for biotinylation that does not rely on the formation of amide, 
ester or thiol functionalities and forms a linkage which cannot be cleaved by 
endogenous biotinidase enzymes." 112  Although the Sonogashira coupling provides 
useful new approaches for biotinylation, it has the limitation that it is not readily 
applicable in vivo due to the requirement for copper(I) and palladium(II). 
H NA  NH 
H-)jTH 
95 
Figure 1.9: Structure of biotin derived alkyne 95. 110  
1.3.7.2 Coupling with Biotinylated Azides 
In an inverse approach to that described in section 1.3.7.1, the coupling of biotin 
azide with propargyl marked molecules has also been carried out in a number of 
instances. The first example of a biotin azide was published by Bertozzi and was 
utilised as a key step in the development of an azido-ELISA assay using the 
Staudinger ligation as the key bioconjugation reaction. 113,114 
More recently biotin azides have been utilised by Lin et al. in a protein engineering 
experiment where the maltose binding protein (MBP) was modified with small 
organic components containing a propargyl moiety 96.115  This labelling was 
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followed by coupling of the protein 96 to the orthogonally reactive azide partner 97 
to form 98 (Scheme 1.24). This coupling procedure has been extended to the 
development of microarrays by modification of glass slides with propargyl or azide 
functional ities. 1 1 5  Lin et al. have subsequently illustrated the power of the copper(I) 
catalysed Huisgen cycloaddition for the immobilisation of proteins site specifically 
onto glass surfaces in the form of microarrays. 
HS 	
- 	 0 
$ 
: 'IS N S N L NA8 
96 	 98 
L= (CH2)3 
Scheme 1.24: (a) 97, CuSO4, TCEP, tri(triazolyl)amine. 115 
In an alternative setting, Lahann et al. have used a biotin azide as a key reagent in the 
synthesis of a biofunctional surface which has potential applications in diagnostics, 
biosensors, and biomedical device coatings. 116  Firstly, a polymer coating containing 
an alkyne functionality was synthesised using chemical vapour deposition 
polymerisation 99 (Scheme 1.25).1 16 The polymer was subsequently coated with a 
thin film of biotin azide and sodium ascorbate, and dried. This was followed by a 
patterned stamp which was inked with a solution of copper(II) sulfate and kept in 
contact with the substrate for 12-18 h. The biotinylated surface 100 was then probed 
with rhodamine-labelled streptavidin and the product 101 analysed. The result 
showed that the alkyne groups on the polymer surface are reactive and can be 
effectively used as anchoring sites for surface modifications. 
NN_ 0 	 NN10tmfl 	Streptavidin 
b 
99 	 100 	 101 
Scheme 1.25: Immobilisation of biotinylated azide on a reactive alkyne polymer. (a) 
Subsequent coupling occurs when the CuSO 4 catalyst is microcontact printed on to a 
preadsorped layer of biotin azide. (b) Incubation with streptavidin. 116 
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1.4 Conclusions 
The attachment of biotin to a range of molecular scaffolds is an important synthetic 
technique which allows the identification, visualisation and localisation of a range of 
proteins and small molecules. Over the last 30 years a wide range of approaches for 
the incorporation of biotin into biologically interesting molecules has been 
developed, facilitating biotinylation with varying degrees of success. However, these 
reactions have often resulted in low site specificity and poor yields. In addition, these 
reactions have been restricted to the coupling of a narrow range of functional groups 
including acids, amines and thiols. 
In recent years a number of new strategies, both chemical and biochemical, have 
made site-specific biotinylation more widely achievable. This has been accomplished 
by applying new bioconjugate reactions to biotinylation, such as the Staudinger-
Bertozzi ligation, the native chemical ligation and the copper(I) catalysed Huisgen 
cycloaddition. As a result, through careful selection of coupling reactions, reagents 
and conditions, site-selective biotinylation can now be successfully achieved across a 
range of substrates in high yields (see Table 1.1). 
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Biotin functionality Reactive partner Coupling reaction 
R-0O2H 
R 1-NH2 Peptide formation 
R 1-NH2 BirA catalysed coupling 
R 1-OH Esterification 
R-0O2X R 1-NH2 Peptide formation 
R-NH2 
R 1-0O2 H Peptide formation 
R 1-CHO Reductive amination 
R-NHNH 2 R 1 CHO/R 1 R2C=O Schiff Base condensation 
R-NHNH 2 
R 1 CHO/R 1 R2C=O Schiff Base condensation 
R 1 CHO/R 1 R2CO Reductive amination 
R 1-c02H Hydrazide formation 
O 
R-N' 	-11 
R 1-SH Nucleophilic displacement 
Diels-Alder Reaction 
R-'--] R 1-SH/R 1 -NH2/R 1 R2 N H Nucleophilic displacement 
R(_SH 0 
Native Chemical Ligation 
R 1-N3 






Copper(l) catalysed Husigen 
 cycloaddition 
MeOOC - 
(Ph) 3PR 1 
Staudinger-Bertozzi 
Ligation 
Table 1: Table of biotinylation coupling reactions. 
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2 A Marked Library Approach to Anisomycin 
2.1 Anisomycin 
Anisomycin 102 was first isolated from the fermentation broths of Streptomyces 
griseolus and Streptomyces roseochromogenes by Sobin and Tanner in 1954,117 
while more recently it has been isolated from Streptomyces sp. SA3079 and No 
638118, 119 Its structure was elucidated in 1965,120  with its relative stereochemistry 
being established three years later by NMR studies and X-ray crystallography. 121-123 
The absolute stereochemistry was finally confirmed as 2R,3S,4S by chemical 




Anisomycin was found to exhibit selective and potent activity against pathogenic 
protozoa and certain strains of fungi. Its antibiotic activity was first tested by Lynch 
et al. in 1954, they discovered that anisomycin inhibited E. histolytica, T vagina/is, 
T foetus and Candida albicans.'25  This led to clinical trials for the treatment of 
amoebic dysentery and vaginitis. However, anisomycin was found to be inactive 
towards bacteria at medicinally useful concentrations, with S. aureus, S. faecalis and 
gram positive organisms all requiring greater than 100 p.g per ml for inhibition. 
More recently it has been reported that anisomycin has been isolated as an 
antitumour substance showing in vitro cytotoxicity against human tumour lines, such 
as HBL 100, RAS A and MCF 7 in the nM region. 118, 126 Recent studies have implied 
that anisomycin may be used in a synergistic fashion with a cyclin-dependent protein 
kinase inhibitor to kill carcinoma cells. 127  Since its introduction over 15 years ago as 
a tool for activation of the stress kinase pathway at 'sub-inhibitory' levels, 
anisomycin has been widely used as a tool in molecular biology.' 28-133  However, the 
cellular target of anisomycin and therefore the precise signalling pathway have yet to 
be elucidated. 
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2.2 Signal Transduction 
A cell is highly responsive to a wide variety of stimulants. Therefore, understanding 
how a cell responds to these stimuli and processing of the resultant responses is 
covered by the field of signal transduction. Signal transduction cascades act as 
'molecular circuits' and can detect, amplify and integrate a diverse range of external 
stimuli thus allowing a wide range of signalling controls within a biological 
system. 114, 135 This can subsequently generate a series of downstream responses 









Figure 2.1: An environmental signal such as a hormone or other small molecule is first 
received by interaction with a cellular component (e.g. a cell surface receptor). The 
information that the signal has arrived is converted to another chemical form, or transduced. 
The signal is then passed downstream before evoking a response. Feedback pathways 
control the entire signalling process. 
Signal transduction covers a wide range of biochemical processes from the transfer 
of information from a cell's exterior to interior, to the role played by primary and 
second messengers in this process. Herein, we will focus on the role played by 
protein phosphorylation in regulating the signal transduction process. 
27 
Chapter 2 	 Results & Discussion 
2.3 Protein Phosphorylation 
The modification of a protein by phosphorylation and dephosphorylation of 
Ser/Thr/Tyr residues by protein kinases and protein phosphatases respectively, can 
lead to the alteration of cellular function in a vast number of ways; by increasing and 
decreasing its biological activity, by facilitating or inhibiting its movement between 
subcellular compartments, or by disrupting protein-protein interactions, to name but 
a few. Thus, making this regulatory process the most important adopted in eukaryotic 
cells. 136, 137 
The discovery of the first observed protein kinase activity in 1954 by Kenedy, was 
subsequently followed by Fischer and Krebs, as well as Wosilait and Sutherland. 138-  
141 These researchers showed that interconversion of phosphorylase b to 
phosphorylase a occurred via a phosphorylationldephosphorylation mechanism. 
Fischer and Krebs also illustrated that the b form could be converted into the a form 
in the presence of Mg- adenosine triphosphate (ATP) and an enzyme they called 
phosphorylase kinase, now called a protein kinase (Figure 2.2). 131, 140 This was 
found to occur via transfer of the y-phosphoryl group of ATP to a specific serine 
residue in phosphorylase b. 142 However, phosphorylase a can be converted back into 
its b form upon catalysis with a protein releasing enzyme, now termed protein 
phosphatase.' 43 
000 	N1IIIIIII 
- -o o -11;;jO 	
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Protein Kinase 	 Protein Phosphatase 
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Figure 2.2: Reversible protein phosphorylation: ATP interacts with a protein kinase and a 
hydroxyl on a protein's backbone, resulting in the phosphorylation of the protein and ADP. In 
the reverse process a protein phosphatase dephosphorylates the protein in the presence of 
ADP, forming ATP and the native protein. 
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For this discovery Fischer and Krebs were awarded the Nobel Prize for Medicine in 
1992 'for their discoveries concerning reversible protein phosphorylation as a 
biological regulatory mechanism'. It is now widely accepted that reversible protein 
phosphorylation of proteins is a major regulatory process in biological systems. More 
recently this has expanded into the field of drug discovery, where protein kinase and 
protein phosphatase inhibitors now account for multi billion dollars expenditure in 
R&D and are now available in the clinic for the treatment of numerous cancers. 144 
With the publishing of the human genome in 2002, Manning et al. undertook the 
challenge of cataloguing the protein kinase complement of the human genome. They 
discovered 518 putative protein kinase genes of which 71 had never been reported 
before, while extending or correcting the protein sequence of a further 56 kinases 
(Appendix 1).' This work classified protein kinases primarily by sequence of the 
catalytic domains, while also utilising known biological function and the structure 
outside the catalytic site. Therefore, the field of protein phosphorylation continues to 
develop and be an area of major scientific interest almost half a century after its 
initial discovery. 
2.3.1 Mitogen Activated Protein Kinase (MAPK) Cascade 
The first protein kinase cascade was identified back in 1968.146  However, it was a 
further 20 years before another example of this type of cascade structure would be 
identified. An insulin stimulated protein kinase that phosphorylates microtubule-
associated protein 2 (MAP2) was identified in 1987 and termed MAP kinase) 47 
However, its name was later changed to mitogen activated protein kinase (N.B. still 
MAP kinase) as a way of emphasising its activation by many mitogens and growth 
factors. From these beginnings, the study of the mitogen-activated protein kinase 
(MAPK) pathway has grown rapidly. 
It is now recognised that the MAPK superfamily is made up of four main and distinct 
signalling pathways: the extra cellular signal-regulated protein kinases (ERK5), the c-
Jun N-terminal kinases or stress activated protein kinases (JNK/SAPK1), the p38 
family of kinases (or SAPK2) and the big MAPKs (BMKs) (Figure 2.3). 148,149 
29 
Chapter 2 	 Results & Discussion 
- 	 ,IrZPII1' 	 M*l4Ks 
4WD 	 Of 
IMEIIK2 	 MEKXIV 
- 	 TAXI 










MAPK. 	 MARKs 
C2004 Prosinlounp-mm 








Chapter 2 	 Results & Discussion 
The core unit of the MAPK pathways is a three-membered protein kinase cascade 
whose components are evolutionary and highly conserved in structure and 
organisation. 111, 152 In this cascade the MAPKs are phosphorylated and activated by a 
MAPK kinase (MAPKKIMKK). The MAPKKs are 'dual-specific' kinases that 
catalyse the phosphorylation of MAPKs at Thr and Tyr sites, specifically targeting a 
Thr-X-Tyr motif on MAPK (where X is glutamate, proline and glycine for the ERK, 
JNK and p38 modules, respectively). 113-116 Phosphorylation of the MAPKs, results in 
a conformational change and a >1000-fold increase in specific activity, so that in 
effect, MAPKs are inactive unless phosphorylated by their respective upstream 
kinase.' 57 ' 59  The MAPKKs are themselves phosphorylated and activated by a 
Ser/Thr kinase that acts as a MKK kinase (MAPKKKi'MKKK). Upstream of the 
MAPKKKs additional protein kinases may participate in the signal transduction 
process along with small GTPases, or cell surface receptors. 158,160 However, efficient 
signal transduction by the MAPK cascades requires the components of the cascade to 
be colocalised within the cell. 
The MAPKs themselves represent a family of kinases that can phosphorylate other 
cytoplasmic proteins and translocate from the cytoplasm to the nucleus to regulate 
the activity of transcription factors. Hence, the controlled regulation of MAP kinase 
cascades can result in cell proliferation, differentiation and cell repair/apoptosis. 
2.3.2 JNKISAPK1 Cascade 
The JNK protein kinases are encoded by three different genes; INK 1 and iNK 2 are 
expressed ubiquitously, whereas .JNK 3 has a more limited pattern of expression and 
is mainly brain-specific. 156  These genes are alternatively spliced to create ten JNK 
isoforms.' 6 ' Transcripts derived from all three genes encode proteins which are 
without a COOH-terminal extension to create both 46 and 55 kDa isofornis. 
However, the functional significance of these spliced variants is unclear. 
As the name implies the SAPK1 pathway is activated in response to stresses such as 
heat shock, UV, alkylating agents, inflammatory cytokins and inhibitors of protein 
synthesis, resulting in cell cycle arrest or apoptosis.' 62 The JNKs are activated by two 
MKKs, •MKK4 [also know as SAPKIERK kinase (SEK)] and MKK7 (Figure 
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2.4). 131, 163, 164 The MKK7 protein kinase has been described with six distinct 
isoforms each containing a different NH2 and COOH termini and has been shown to 
be primarily activated by cytokines (interleukin (IL) and tumour necrosis factor 
(TNF)).'49' 165  In contrast, three MKK4 isoforms have been identified and have been 
shown to be activated by environmental stress. Direct comparison of MKK4 and 7 
have shown that although both kinases activate JNK through dual phosphorylation on 
Thr and Tyr, there are many differences in substrate specificity. 
Upstream of the MKKs the network is even more complex. The kinases reported to 
be operating at this level include MEKK 1-4, the mixed linkage kinases (MLK 1-3), 
the ASK group (apoptosis signal-regulating kinase 1 and 2) and TAK 1 
(transforming growth factor-f3-activated kinase).'49' 156  In turn, the MKKKs can be 
activated by a series of GTP-binding proteins and by germinal centre kinase (GCK). 
MAPKKK I MEKK 1-4, ASK 1-2, MLK 1-3, TAK 1 
IL 	I 
	
MAPKK] 	 MKK4, MKK7 
IL J. 
MAPK 1 	SAPKI/JNK 
Figure 2.4: The three tier cascade of the SAPKI/JNK pathway, overview of some of the 
proteins involved at MAPK, MAP2K and MAP3K levels. 
Downstream JNKs are activated and translocate across the nuclear membrane. 166 
iNK was originally identified as being responsible for the phosphorylation of c-Jun, 
leading to increased activity of the activator protein-i (AP-1) transcription factor. 155, 
167 The other major substrates for INK are activating transcription factor-2 (ATF-2), 
Elk-1, deleted in pancreatic cancer-4 (DPC4) and nuclear factor of activated T cells 
(NAFT4).'58' 168 This selective focus on transcription factors contrasts with the 
actions of the ERK and p38 pathways, which phosphorylates targets both inside and 
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outside the nucleus.' 69 Therefore the regulation of transcription factors by INK helps 
to regulate gene expression in response to a variety of cellular stimuli including 
stress events, cytokines and growth factors. Consequently, activation of the iNK 
cascade generally results in apoptosis, although it has been shown to promote cell 
survival under certain conditions (e.g. in cardiac myocytes after oxidative stress). 
2.3.3 p38/SAPK2 Cascade 
There are currently four members in the p38 family, p38a, 3, 'y and 6. The p38a and 
3 genes are ubiquitously expressed. 154  However, the p38y and 6 are differentially 
expressed with the y isoform predominant in skeletal muscle, 170  while the 6 isoform 
is enriched in the lung, kidney, pancreas, testis and in the small intestine. 171 
Like the JNKJSAPK1 pathway they are activated by most environmental stresses, 
including heat, osmotic and oxidative stresses, ionising radiation as well as 
inflammatory cytokines and tumour necrosis factor (TNF) receptor signalling, 
resulting in cell cycle arrest or apoptosis. 154" 72 Certain proinflammatory cytokines, 
such as IL- 1 and TNF-a, also activate the p38 pathway, suggesting a potential role in 
the regulation of the cellular inflammation response. 173, '' 
MAPKKK I 	MEKK 1-3, ASK 1, MLK 3, TAK I 
I 
	
MAPKK I 	MKK3, MKK6 
MAPK 1 	SAPK2/p38 
Figure 2.5: The three tier cascade of the SAPK2/p38 pathway, overview of some of the 
proteins involved at MAPK, MAP2K and MAP3K levels. 
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The upstream kinases acting on p38 include MKK3, 4 and 6.175178  Specifically, 
MKK6 which is 80% homologous to the isoform MKK3 can target all four isoforms 
of p38. In contrast, MKK3 preferentially activates p38a, y and 8, while MKK4 
activates p38a and & (Figure 2.5). 172, 179 This suggests that substrate selectivity may 
be a key factor in why each MKK has a distinct function. In turn, greater diversity 
occurs upstream at the MKKK level, which may be one of the reasons that the p38 
pathway can be activated by a wide range of stimuli. At the MKKK level a range of 
kinases are involved including MTK1-3, MLK3, ASK1 and TAK1. 180182 However, 
activation of many of theses kinases also leads to activation of both the p38 and JNK 
pathways. Above the MKKK level Rac, CDC42 and the Rho small family of 
GTPases have been found to be potential regulators of the p38 pathway. 157 
Consequently, the precise nature of this signal transduction pathway is still under 
investigation. 
Downstream, regulation of p38 MAPKs can lead to the phosphorylation of a large 
group of regulatory protein kinases, as well as controlling a range of transcription 
factors. The most studied of the downstream protein kinases is MAPK-activated 
protein kinase 2 (MAPKAP-K2 or MK2), whose role has been recently reviewed.' 72 ' 
179 Moreover, the p38 MAPK can also influence a series of transcription factors 
which includes AFT1/2, cyclic AMP response element binding proteins (CREBs), 
Elk-i and myocyte enhancer factor (MEF) 2A and 2C. Therefore, regulation of the 
p38 pathway has a profound effect on inflammation, cell growth, cell differentiation, 
the cell cycle and cell death. 
2.3.4 SAM Regulation 
Below the MAPK level the iNK and p38 pathways are two independent units. 
However, above this level numerous cross-talk mechanisms exist between the two 
pathways (Figure 2.6).'' 162  MKK 7 and MKK3 specifically activate the JNK and 
p38 pathways respectively, while MKK 4 has the capacity to activate both the iNK 
and p38 pathways by phosphorylation of both the threonine and tyrosine 
phosphorylation sites. The complexity of the pathway is further increased on going to 
the M3K level where TAK 1, ASK 1 and MLK3 have all been shown to activate both 
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the MAPK 3/6 and 4/7 cascades. 149, 156, 160, 162 Thus illustrating the intricate network 
of processes involved in signal transduction. 
The regulation of these pathways only becomes more complicated upon introducing 
the fact that a series of protein phosphates act within the SAPK cascade to 
dephosphorylate and thus regulate these processes (Figure 2.6).  183 - 185  Protein 
phosphatases are classified into three groups; Ser/Thr phosphatases, Ser/Thr/Tyr 
phosphatases and Tyr phosphatases, depending on their phosphoamino acid 
specificity. As phosphorylation of both Thr/Tyr residues is required in a dual specific 
manner for SAPK pathway activation, dephosphorylation of either or both amino 
acid residues is sufficient to inactivate the pathway. This allows negative regulation 
of the pathway to occur at numerous points throughout the cascade. 
Therefore, understanding the overall regulation of the SAPK signal transduction 
pathways is a complex and challenging biochemical problem that is being studied by 
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Figure 2.6: The JNK/SAPK1 and p38/SAPK2 pathways, illustrating upstream and 
downstream targets as well as cross-talk between the pathways and the site of interactions 
of a number of protein phosphatases. 
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For the last 15 years anisomycin has been known to strongly activate both stress 
kinase pathways at a level widely considered to be higher that M3K. Recently Bloem 
et al. have shown that the selective MLK-7 kinase inhibitor DHP-2 inhibits 
downstream activation of the SAPK pathway when stimulated by UV or anisomycin, 
but not upon activation by IL-i or TNF-a.' 86 These results suggest that stimulation of 
the SAPK pathways by anisomycin proceeds through MLK-7. However, above the 
M3K level there still remains a large amount of uncertainty with regards to both 
activation and negative regulation of the SAPK pathway. Thus, its precise site of 
action and therefore precise regulatory mechanism has still to be fully understood. 
2.4 Protein Biosynthesis 
Protein biosynthesis is the complex multi-step process by which cells build proteins. 
For the purpose of this thesis the basic processes involved in protein biosynthesis 
will be touched on as a means of explaining anisomycin's mode of action as an 
antibacterial antibiotic. 
2.4.1 Transcription 
Protein biosynthesis starts in the nucleus where the process of transcription catalysed 
by the enzyme RNA polymerase, converts DNA into RNA.'87' 188  This process can be 
broken down into three key areas; initiation, elongation and termination.' 34 
Transcription begins with RNA polymerase searching for a promoter site or simply 
promoters within the DNA. This promoter acts as a binding site and initiator for 
RNA polymerase. As the RNA polymerase binds to the DNA strands they begin to 
unwind, producing a pair of single strands of DNA (Figure 2.7).187. 188 The RNA 
polymerase then controls the elongation of one of the two unravelled strands of DNA 
by complementary base pairing (A-U, C-G).' 89 As the RNA polymerase moves along 
the DNA backbone, the base pairs of the two individual strands recombine behind it 
and the DNA recoils. This process continues along a single DNA strand until the 
RNA polymerase reaches a terminator sequence, where transcription ends. 190 
In eukaryotes the newly transcribed RNA forms the short lived pre-messenger RNA 
(pre-mRNA).' 9 ' This can be further modified by the addition of a 5' cap which 
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protects it from degradation and a 3' tail which increases its stability and enhances its 
translational efficiency.'92' 193  Within the structure of the pre-mRNA two different 
components termed exons and introns exist. The exons code for a specific region of 
the target protein, while introns do not and are required to be removed before 
translation can occur. The removal of introns occurs via a process called splicing to 
produce messenger RNA (mRNA).'94' 195 
RNA polymerase transcription bubble 
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Figure 2.7: Transcription bubble illustrating the elongation of an RNA transcript. Double 
strand DNA is unwound at the forward end of RNA polymerase and rewound at the rear end. 
The RNA-DNA hybrid rotates during elongation. 
2.4.2 Translation 
Transfer RNA (tRNA) is a cloverleaf shaped biomolecule that contains an amino 
acid attachment site and a template recognition site (Figure 2.8). 196  Esterification of 
an amino acid's carboxyl group with the 2'- or 3'-hydroxyl on the ribose unit at the 
3' end of the tRNA chain forms aminoacyl-tRNA. This process is catalysed by 
aminoacyl-tRNA synthetase and is driven by the cleavage of ATP, forming an 
'activated' ester that is used as the building block in protein synthesis. 197 
On reaching the ribosome, the mRNA previously transcribed from DNA begins the 
next stage in protein synthesis. The mRNA contains a nucleotide sequence called a 
ribosomal binding site which binds to the 40S ribosomal subunit. The subunit scans 
the mRNA code starting from the 5' end and, on finding an initiation AUG 
(methionine) codon, forms an initiation complex comprising aminoacyl-tRNA and a 
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group of proteins called initiation factors. 198-201  The 60S ribosomal subunit then 
attaches to the complex forming an 80S ribosome with a mass of 4200 kDa. 202 ' 
3* 
0 loop TWC loop 
Anticodon 
Figure 2.8: Transfer RNA (tRNA) illustrating the cloverleaf secondary structure, the 
anticodon loop and the 3' acceptor stem which is used to couple to amino acids. 
The 80S ribosome is made up of three key sites, an acceptor site (A site), a peptide 
site (P site) and an exit site (E site). 134  In the first cycle the initiator tRNA linked to 
methionine sits in the P site, with the A site occupied by an aminoacyl-tRNA. 
Formation of the peptide bond can now take place, with the amine of the aminoacyl-
tRNA attacking the activated ester of the initiator tRNA (Figure 2.9, step 2).203 204 
The newly formed amide is now attached to the tRNA in the A site, with the 
uncharged tRNA now in the P site. 
In order for elongation of the peptide to occur the mRNA must be translocated so 
that the codon for the next amino acid can be placed in the A site ready for peptide 
The discussion within this section has covered protein biosynthesis in eukaryotic cells. In bacterial 
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bond formation. This occurs using the enzyme elongation factor G', which leads to 
the movement of peptidyl-tRNA to the P site, as well as removal of tRNA from the P 
site via the E site. 201,204  On completion of this step the peptidyl-tRNA is found in the 
P site with the new aminoacyl-tRNA in the A site and the process is ready to begin 
again. 205  This sequence of processes continues along the mRNA backbone codon by 
codon, extending the amino acid chain of the new peptide until a stop codon on the 
mRNA backbone is reached. At this point a series of proteins called release factors 
are utilised to terminate the protein synthesis . 206 Although the precise mechanism is 
still to be fully elucidated it is clear that the release factors act as a Trojan horse, 
carrying a water molecule into the peptidyl transferase centre. Once at the reactive 
centre the water molecule is released and hydrolyses the ester linkage of the peptidyl 
tRNA, leading to the release of the polypeptide which subsequently leaves the 
ribosome. Finally, the 80S ribosome is dissociated by a ribosome release factor 
which breaks the ribosome into its individual components (tRNA, mRNA, 40S 
ribosome and 60S ribosome) ready to be recycled. 206 
1111- 
KEY: 0 E site 	• P Site 	A Site 	or 	Aminoacyl-tRNA 	• 	tRNA 	11111W mRNA 
Figure 2.9: Mechanism of protein synthesis. The cycle begins with tRNA in the P site. An 
aminoacyl-tRNA then binds in the A site. With both sites occupied the peptide bond is 
formed. The tRNA and aminoacyt-tRNA are translocated through the action of elongation 
factor C, moving the tRNA to the E site and subsequently removing it. A new aminoacyl-
tRNA can then occupy the A site and the sequence can begin again. 
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2.4.3 Protein Synthesis Inhibition 
When anisomycin was first discovered it was found to be an antibacterial antibiotic 
against a range of fungi. 125  During the subsequent decade, research found that 
anisomycin is a potent, structurally specific and reversible inhibitor of protein and 
DNA biosynthesis. 207  On administering anisomycin at concentrations that cause 95% 
inhibition of protein synthesis, RNA synthesis was unaffected. However, DNA 
synthesis was reduced. 208  This response was believed to be a direct result of the 
inhibition of protein synthesis. 
A series of papers published by Vazquez found that anisomycin inhibits the peptide 
bond formation step in a range of systems by blocking the peptidyl transferase centre 
in the 60S ribosomal subunit (Figure 2.9, step 2).20213  In addition anisomycin also 
leads to increased levels of native 60S subunits. 214  This effect is explained by the fact 
that the binding of native 60S subunits to the Met-tRNA-mRNA-40S initiation 
complex is inhibited. 
More recently, crystallographic studies on the peptidyl transferase centre of the 60S 
ribosomal subunit have further elucidated anisomycin's role . 215 The peptidyl 
transferase centre in the 60S subunit contains two large hydrophobic crevices which 
play an important role in interactions with antibiotics. The A-site crevice is found in 
the peptidyl transferase active site and is the part of the A-site that interacts with 
amino acid side chains of A-site substrates (Figure 2.10). While the second crevice 
is located at the entrance to the exit tunnel, both crevices are strongly hydrophobic 
and can effectively bind small molecules. 
	
."A2486(2451) 	Active Site Crevice 
a) 	 A2406 
Jr( 
47 	.... 
1ÜUUUJUUJIJV 	 U2539L.. U2635 Adnmqw- 
Figure 2.10: Two different angles showing anisomycin's binding site in the 60S ribosomal 
subunit. Interactions show ribosomal nucleotides that are protected or deprotected from 
chemical modification are shown in green or whose mutations confer resistance are shown 
in orange.215 
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Anisomycin was found to insert its aryl moiety into the A-site crevice and stack on to 
C2487, while its pyrrolidine ring binds into an oblong pocket next to the active 
site . 215  The NH forms a hydrogen bond to the N3 of C2487 and the hydroxyl group 
forms a hydrogen bond with U2535. With the p-methoxy phenyl group of 
anisomycin completely filling the hydrophobic crevice that is usually filled by the 
amino hide chain of the A-site bound aminoacyl-tRNA, anisomycin can inhibit 
protein synthesis. The binding of anisomycin also induces a small conformational 
change in the peptidyl transferase centre of the ribosome, leading to a loss in non-
canonical base pairing and the formation of a buckled base pair. 
2.5 Summary of Anisomycin's Biological Role 
Since its discovery in 1954 anisomycin has been identified as having a range of 
biological 17, 125 Initially anisomycin was found to be an antifungal 
antibiotic for the treatment of amoebic dysentery and vagmitis."7' 125 However, it 
was found to be inactive towards bacteria at medicinally useful concentrations. 
Anisomycin has found widespread use in studies of protein synthesis both in vivo and 
in vitro, as it is a known peptidyl transferase inhibitor, binding to the large ribosomal 
subunit in eukaryotes. 209213 '215 
More recently it has been used in a number of studies investigating 'fear 
memories'. 216218  These studies showed that anisomycin injections into the amygdale 
or hippocampus of rats after conditioning causes long term effects in contextual 
freezing. However, the same injections after contextual retrieval have short term 
reversible effects. 217 
In 1993 anisomycin was reported to show antitumour cytotoxicity in vitro against 
human tumour lines in the nM region. 111, 126 Further studies have implied that 
anisomycin may be used in a synergistic fashion with a cyclin-dependent protein 
kinase inhibitor to kill carcinoma cells. 127  Anisomycin has also been found to induce 
rapid apoptosis in human lymphoid cells in contrast to the delayed apoptosis induced 
by many other protein synthesis inhibitors that do not activate the SAPK pathways, 
suggesting an important role of the kinases in anisomycin induced apoptosis in 
tumour cells. 2 19222 
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This small pyrrolidine antibiotic has also been utilised as a chemical stimulant for the 
activation of the SAPK pathways, with a well characterised response downstream of 
the MAPK level. ' 2833 In mammalian cells the ribotoxic stress response involves 
activation of the JNK and p38 pathways, with subsequent transcriptional induction of 
immediate early genes such as c-jun and c-fos. Above this level, the activation of the 
SAPK pathways and concomitantly anisomycin's mode of activation have yet to be 
determined. However, inhibition of protein synthesis does not stimulate the SAPK 
pathways, with efficient kinase activation being achieved at concentrations of 
anisomycin that inhibit protein synthesis by less than 50%. Therefore, the mode of 
action whereby anisomycin activates the SAPK pathways and induces it's antitumour 
activity are both unknown. Consequently, identification of anisomycin's biological 
target for the activation of the SAPK pathways would provide new information on 
the regulation of these pathways, while generating a new target for therapeutic 
agents. 
2.6 Synthesis of Anisomycin 
Anisomycin 102 and it's deacetyl precursor 106 have been synthesised over 25 times 
by a number of research groups over the past 35 years.' 24, 126, 223-244 Previous work 
carried out within the Hulme group led to the synthesis of anisomycin in 13 steps 
with high diastereocontrol and an overall yield of 35% (Scheme 2.1; 102*105).245 
A further series of anisomycin analogues were then synthesised using the 
methodology developed during the initial work, giving a small library of twenty 
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Scheme 2.1: Retrosynthesis approach to anisomycin carried out within the Hulme group. 245 
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Although the precise target of anisomycin is unknown, the downstream effects on the 
SAPK pathways have been well documented. 128 ' 33 The treatment of mammalian, 
yeast and insect cells with anisomycin is known to strongly activate both the 
JNKISAPK1 and the p38/SAPK2 pathway, resulting in phosphorylation of their 
substrates, such as INK and MAPKAP-K2 respectively. In order to assess the levels 
of activation of each compound, the small library of anisomycin analogues was 
tested for activation of the SAPK pathway. As commercial antibodies against both 
the phosphorylated and non-phosphorylated states of JNK and MAPKAP-K2 were 
available, it was simple to assess the activation of these pathways by the different 
analogues. 
The structure activity relationship (SAR) produced gave an insight into the 
functionality required for activation of the JNKIp38 pathways. These studies showed 
that the presence of an ester functionality at the C3 position on the pyrrolidine ring is 
essential for activity, with both the acetate (anisomycin) and propionate ester shown 
to be active compounds. The studies also showed that large groups (benzyl) were not 
tolerated on N1 and C 4-OH. However, the most interesting discovery was the activity 
possessed by the C4-Me 107 and C4-H 108 analogues. Both of these compounds were 
found to be active, with the C 4-H analogue being found to show similar levels of 
activation to that of anisomycin. 246 
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2.7 A Chemical Genetics Approach to Anisomycin 
The work carried out on anisomycin can therefore be categorised in a forward 
chemical genetics sense; 247249 whereby a small library of analogues have been 
produced and an initial SAR determined for the SAPK phenotype: 246  However, the 
biological target of anisomycin has yet to be determined. 
Despite rapid advances in the generation and testing of small molecule libraries in 
recent years, current strategies for the identification of the biological targets of 
library members in forward chemical genetics screens still require the synthesis of an 
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appropriate molecular probe. The structure of this molecular probe is typically based 
on an active library member which has been modified by introduction of a tag, such 
as a biotin moiety, or a photoactivatable-, radio-, or fluorescent label (Figure 2.11). 
Biologically 
Tag 	 Linker 	 active 
molecule 
Figure 2.11: Model of a molecular probe comprising tag, linker and biologically active 
molecule, in this case anisomycin, or an anisomycin analogue. 
The synthesis of a series of anisomycin molecular probes was therefore envisaged. 
Testing of the molecular probes would then take place to assess if activation of the 
SAPK phenotypic response had been retained, before utilising the molecular probes 
to identify and isolate the biological target of anisomycin. 
However, the synthesis of molecular probes can often be a cumbersome process; the 
National Institute of Health's drug development timeline (Figure 2.12) published in 
2002 has allocated a year to go from the initial hit to the successful synthesis of a 
molecular probe. 
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Figure 2.12: National Institute of Health's (NIH's) drug development timeline; illustrating the 
process involved in drug development from taking an initial target to a marketable drug and 
the timescales involved. 
More often that not, the synthetic route to the active library member may have to be 
redesigned to allow tagging of the small molecule at various sites around its 
molecular scaffold (Figure 2.13, part 4). Moreover, a number of the molecular 
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probes synthesised in this manner will have lost their activity due to structural 
perturbations upon addition of the tag (Figure 2.13, part 5). These factors combined 
can make the synthesis of molecular probes a time consuming and challenging 
process. 
1. library 	 2. screen 	i synthesis  
II 	II 	I S 
4. synthesise 
molecular probe t3. deconvolute 
& identify 'hit' 
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-------- 0- 
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Figure 2.13: Strategies for small molecule library design. Traditional approach involving 
library synthesis, biological screening, synthesis of molecular probes, re-screening and 
target identification. 
Therefore, a more direct approach has been designed which is based on the concept 
of a marked library, where each individual library member carries a small 
biocompatible marker which plays no role in the screening process itself, but may be 
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Figure 2.14: Strategies for small molecule library design. Marked library strategy involving 
library synthesis incorporating a biocompatible marker, biological screening followed by 
target identification. 
Although this is a new approach to small molecule library design, this concept has 
precedent in chemical biology, where for example modified amino acids, sugars etc. 
with chemical markers such as azides, alkynes and phosphines etc., have been 
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incorporated into a range of biomolecules.95' 96  These markers may then be coupled 
to orthogonally reactive tags such as biotin, fluorophores, etc. utilizing biologically 
compatible reactions such as the Staudinger-Bertozzi ligation, and the copper(I) 
catalysed Huisgen 1,3-dipolar cycloaddition, thus allowing the visualization, 
purification and identification of the biomolecule of interest. In a closely related 
example to our proposed marked small molecule library strategy, Chang et al. have 
designed a triazine library with a built-in linker containing an amino functionality to 
facilitate target identification. 250  More recently, Cravatt has generated a natural 
product analogue library based on a protein-reactive moiety with a pendant alkynyl 
functionality; allowing subsequent target identification after functionalisation with a 
fluorescent, and/or biotinylated azide. 99 
2.8 A Marked Library Approach to Anisomycin 
We therefore set out to synthesise a focused library of marked compounds based 
upon the molecular architecture of anisomycin to prove the concept of a marked 
library strategy and to further investigate the SAR for this small molecule's 
activation of the SAPK pathways. The previous SAR data indicated that two key 
sites existed within anisomycin's scaffold that may allow incorporation of the 
marker; they were the pyrrolidine nitrogen and the phenolic oxygen (Figure 2.15). 
'OH/H 
Figure 2.15: Potential points of attachment for tags' that have been proposed and/or ruled 
out based on structure activity relationship data for anisomycin's activation of the SAPK 
pathways. 
It was proposed that adaptation of the previous synthetic route to the C4-H analogue 
108 carried out within the Hulme would allow incorporation of a silyl protecting 
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group in place of the methyl on the phenolic oxygen. This would allow for selective 
unveiling of the pyrrolidine nitrogen or the phenolic oxygen and addition of the 
















Scheme 2.2: Retrosynthetic analysis of the C 4-H analogue of anisomycin. 
2.8.1 A Marked Library Approach to the C4-H Analogue 
Commercially available D-tyrosine 113 was converted to its methyl ester 
hydrochloride salt 114 quantitatively by refluxing the amino acid in methanol and 
acetyl chloride (Scheme 2.3). The amine 114 was then selectively protected using di-
tert-butyl dicarbonate in the presence of sodium bicarbonate to give 115 in a 
quantitative yield. Treatment of 115 with tert-butyldimethylsilyl triflate in the 
presence of 2,6-lutidine gave the TBS-protected phenol 116. The Boc protecting 
group was then removed by stirring 116 in TFA overnight, to give the free amine 117 
in 100% yield. The amine 117 was then converted to the NN-dibenzylamine 118 by 
reaction with benzyl bromide and potassium carbonate. 
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Scheme 2.3: (a) AcCI, MeOH, reflux (100%); (b) Boc20, NaHCO3, DCM (100%); (C) 
TBSOTf, 2,6-lutidine, DCM (60%); (d) TFA, DCM (100%); (e) BnBr, K2CO3,  CH3CN (71%). 
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At this point it was believed that lithium hydroxide hydrolysis would successfully 
yield the functionalised acid required for a Claisen condensation. However, heating a 
solution of 118 in THF:water with lithium hydroxide gave a mixture of products 
(Scheme 2.4; 119 and 120). Attempts to purify this mixture proved to be problematic 
and led to a loss of material. Analysis of the crude 1 H NMR showed two compounds, 
the first was the desired acid 119, while the second was the acid with loss of the TBS 
protecting group 120. The integrals of the 1 H NMR spectrum showed that 119 was 
approximately 60%, with the other 40% being the deprotected compound 120. 
Attempts to improve the yield of the desired product 119 by altering reaction 
temperature and time were found to have no effect on the yield. Investigation of the 
recent literature showed that LiOH had been found to selectively deprotect aryl silyl 
ethers when stirred in DMF, 25 ' therefore it is highly conceivable that LiOH would 
carry out the same reaction in aqueous THE As a result, it was decided to investigate 
other routes to the Claisen precursor 119. 
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Scheme 2.4: LiOH, reflux, THF: H 20 (95%,119:120, and 60:40). 
2.8.2 An Alternative Route to the C4-H Analogue 
A new route was therefore developed ensuring that the phenol protection was the 
final step in the synthesis of the acid 119, thus removing the possibility of base-
induced deprotection of the phenol (Scheme 2.5). Once again, starting from D-
tyrosine 113, the methyl ester hydrochloride salt 114 was formed quantitatively. The 
hydrochloride salt 114 was then converted to the dibenzylamine by refluxing 114, 
benzyl bromide and diisopropylethylamine in THF, to give 121 in 85% yield. The 
ester 121 was then hydrolysed to the acid 120 by heating with lithium hydroxide to 
give product as a single spot by tic. Previous studies within the Hulme group have 
found that when lithium hydroxide was employed as a base for similar hydrolysis 
reactions it gave the highest yields with the lowest levels of racemisation. 252 The 
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TBS functionality was then added using two equivalents of TBSOTf to form the di-
protected species 122. This was followed by stirring 122 in acetic acid:THF:water for 
8 h to remove the TBS group selectively from the carboxylic acid to give the desired 
product 119 in 91% yield. Thus giving the tyrosine derived acid 119 required for the 
Claisen condensation in four high yielding steps. 
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Scheme 2.5: (a) AcCI, MeOH, reflux (100%); (b) BnBr, DIEA, reflux (85%); (c) LiOH, reflux, 
THF:H 20 (87%); (d) I) TBSOTf, 2,6-Iutdine, DCM; ii) AcOH:THF:H 20 [3:1:1] (91%). 
The decision to convert the methyl ester to the imidazolide prior to Claisen 
condensation was based on work carried out by Hoffman.  253  He showed that 13-keto 
esters formed via the reaction of a-amino esters with lithium enolates were subject to 
a loss in enantioselectivity. This was confirmed by work previously carried out 
within the Hulme group on the Claisen condensation of a serine-derived methyl 
ester.  252  However, conversion of the methyl ester to the imidazolide was found to 
reduce racemisation substantially. 
The Claisen condensation was• initiated by the formation of the imidazolide 123 
which was produced in situ by reaction of the acid 119 with carbonyldiimidazole 
(CDI) in THF (Scheme 2.6). Meanwhile, the lithium enolate of ethyl acetate was 
formed by addition of lithium hexamethyldisilazide (LHMDS) in THF to freshly 
distilled ethyl acetate at -78 °C. The enolate was then cannulated into a solution of 
the imidazolide at -78 °C. A variety of reaction conditions were investigated, varying 
the time, temperature, and the species being cannulated. The best yields were found 
to occur when the reaction was stirred at -78 °C for 40 min after cannulating, 
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warming to 0 °C over 30 min and stirring at 0 °C for a further 1.5 h. This gave the 13-
keto ester 124 in 68% yield and allowed the reaction to be carried out on a 5 g scale. 
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Scheme 2.6: (a) I) CDI, THF; ii) LHMDS, EtOAc - CH 2C(OLi)OEt (68%). 
Precedent within the group has also shown that sodium cyanoborohydride is the most 
effective reagent for the stereoselective reduction of 13-keto esters giving >95:5 
diastereoselectivity. 252 Therefore, the f3-keto ester 124 was treated with sodium 
cyanoborohydride to give the alcohol 126 in 80% yield, with no reduction of the 
ester moiety (Scheme 2.7). 
0 0 	 OHO 	 OHO 
OEt  a 	( (}OEt + 	 OEt 
TBSO'L 	
Bn2 	 TBSOk 	NBn2 	TBS0L 	Bn2 
124 	 125 	 126 
minor enantiomer 	 major enantiomer 
Scheme 2.7: (a) NaCNBH3 , MeOH, AcOH, Et0 2 (80%). 
The diastereoselectivity of the sodium cyanoborohydride reduction can be 
rationalised using a Felkin-Ahn model for the nucleophilic attack of a sp 2 hybridised 
centre. Placing the large electronegative dibenzyl protected amine perpendicular to 
the carbonyl forms the most reactive conformer with best orbital overlap. Therefore, 
attack by the nucleophile at the Burgi-Dunitz angle of 109° forms the desired 
product 126 with high stereoselectivly (Scheme 2.8). 
Ar—\ 	 Ar—\0H 
NBn 	 H 	NBn2 
-
RH2(0)OEt 	
H H2 C(0 )OEt 
Nu 
Scheme 2.8: Felkin-Ahn model for the stereoselective reduction of -keto esters. 
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At this point a racemic synthesis of the -hydroxy ester from (±)-tyrosine was carried 
out so that its enantiopurity could be determined. Analysis was carried out by chiral 
HPLC which gave two peaks of equivalent area for the racemic compound, and a 
major and minor peak for the enantiomerically enriched material. The enantiomeric 
excess of 126 was calculated to be 66% ee, thus showing that the chiral centre of the 
amino acid had epimerised prior to the Claisen condensation. It was suspected that in 
this case the use of Hunig's base in the dibenzylation step could have lead to the loss 
in enantiopurity as it is widely used in aldol type reactions for deprotonation alpha to 
a carbonyl group. 
2.8.3 A Modified Route to the C 4-H Analogue 
At this point it was decided to investigate the dibenzylation of the hydrochloride salt 
114 in detail. Therefore a new dibenzylation strategy was developed utilising a 
milder base, so that the new reaction conditions could be applied to the previous 
route to give the desired acid 119, without a loss in enantiopurity. 
Previous work within the group has shown that the dibenzylation of tyrosine, 
although appearing trivial, is a tricky reaction to carry out in practice, leading to a 
mixture of mono-, di- and tri-benzylated species in varying yields. 254  The standard 
method of forming NN-dibenzylamino acids (including serine and threonine 
derivatives) was to react five equivalents of potassium carbonate with four 
equivalents of benzyl bromide in acetonitrile. However, on reacting 114 under these 
conditions not unsurprisingly the tri-benzylated species 127 was formed in high 
yields (Table 2.1, entry 1). Therefore, the number of equivalents of base and benzyl 
bromide was reduced to 3.0 and 2.1 respectively; leading to a moderate yield of the 
desired product 121 (Table 2.1, entry 2). Various other solvent systems were then 
tried as the solubility of the starting material in acetonitrile was questioned. 
However, no improvement was made. On returning to acetonitrile the yields of the 
reaction were increased on adding the reagents sequentially; base first, followed 30 
min later by benzyl bromide. The fully optimised conditions were found to give 
yields of consistently greater than 75% (Table 2.1, entry 5). 
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121 	 127 
Entry Eqv K2CO3 Eqv BnBr Solvent Yield 121 Yield 127 
1 5 4 CH3CN 62 30 
2 3 2.1 CH3CN 61 - 
3 3 2.1 DMF 45 - 
4 3 2.1 H20 20 - 
5 1 	3 2.3 CH3CN 76 - 
Table 2.1: Table of results for dibenzylation of 114. (a) Br,Br, K2CO3,  CH3CN. 
The new benzylation methodology was then applied to the previous synthetic route, 
giving the acid 119 in four steps from D-tyrosine 113; the carbon chain was then 
extended via Claisen condensation as previously described (Scheme 2.9; 119—*124). 
o 	1 	 0 0 
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Scheme 2.9: (a) i) CDI, THE; ii) LHMDS, EtOAc --+ CH 2C(OL1)OEt (79%). 
The 0-keto ester 124 was then reduced using sodium cyanoborohydride to give the 13-
hydroxy ester 126 (Scheme 2.10). On this occasion analysis by chiral HPLC gave a 
major peak that was calculated to have an >97% ee (Apendix 2). This allowed the 
conclusion to be drawn that the previously observed epimerisation of the derived 
amino acid was due to the use of diisopropylamine. 








Scheme 2.10: (a) NaCNBH 3, MeOH, AcOH, Et 20 (86%). 
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The 3-hydroxy ester 126 was then reduced using lithium aluminium hydride to give 
the corresponding diol 128 (Scheme 2.11). The work-up for this reaction was carried 
out by quenching with IM NaOH, dilution with DCM and addition of saturated 
sodium potassium tartrate which was stirred vigorously overnight in order to remove 
the aluminium residues and give an optimised yield of 97%. 







Scheme 2.11: (a) LiAIH 4, THE (97%). 
Pyrrolidinium formation was effected by activation of the primary alcohol 128 with 
triisopropylbenzenesulfonyl chloride (TIBSCI) and DMAP. This reaction proceeds 
via formation of the TIBS-sulfonate, by selective reaction of TIBSC1 with the 
primary alcohol. The lone pair on the amine then acts as an intramolecular 
nucleophile attacking the C1 position forming the pyrrolidine ring and ejecting the 
TIBSO as a leaving group in a 5 exo tet cyclisation (Scheme 2.12). However, these 
reaction conditions led to a mixture of two salts with different counter ions balancing 
the tetravalent nitrogen. The compounds were therefore subjected to ion-exchange 
chromatography on a column that had been pre-treated with 1% hydrochloric acid. 
This gave the chloride salt 129 in 96 % yield. 
OH 
OH 








Scheme 2.12: (a) I) TIBSCI, DMAP, DCM; ii) Dowex (C1) ion-exchange resin (96%). 
Analysis of the 'H NMR of 129 proved to be interesting as it contained many 
unusual signals associated with a dibenzylated amine (Figure 2.16a). Under normal 
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conditions a dibenzylated amine has a large multiplet around 7.30 ppm that integrates 
for ten protons, and two doublets (3-4 ppm) that correlate to two protons each, with a 
geminal coupling constant of approximately 14.0 Hz. However, the 'H NMR 
spectrum of 129 contained two doublets (5.59 and 4.10 ppm. 13.0 Hz) that integrated 
for one proton each and a multiplet at 4.95 ppm that accounted for the other two 
benzylic protons. Moreover, the 10 proton aromatic multiplet ranged from 7.6-7.2 
ppm. The unusual nature of this spectrum can only be explained by the tetravalent 
nitrogen attached to the two benzyl groups. 
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Figure 2.16: 1 H NMR (250 MHz) of 129 and 130. 
Careful hydrogenation of the dibenzyl compound 129 under 1 atm of hydrogen in the 
presence of 5% Pd/C and potassium carbonate for only 25 min gave the 
monobenzylated compound 130 as a colourless foam in 89% yield (Scheme 2.13). 
Analysis of the 'H NMR of 130 showed that the signals associated with the benzylic 
CH2's group had returned to the more familiar pair of doublets (13.0 Hz), each 
integrating in this case for a single proton (Figure 2.16b). 
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Scheme 2.13: (a) H2, 5% Pd/C, K2CO3,  MeOH, 25 mm (89%). 
Addition of the acetate was then carried out by reaction of the secondary alcohol 130 
with acetic anhydride, triethylamine, and a catalytic amount of DMAP, to give 1091n 









Scheme 2.14: (a) Ac20, Et3N, DMAP, DCM (96%). 
At this point a protecting group switch was carried out by removing the benzyl group 
and replacing it with a tert-butoxy carbamate. This was proposed to remove any 
complications with the final deprotection step once the C4-H analogue had been 
marked. Thus, allowing the final synthetic step of the marked library members to be 
a straightforward deprotection of the amine under mild acid conditions, to give the 
desired product. 
An initial attempt to remove the benzyl protecting group and form the HC1 salt in 
situ, was carried out via hydrogenation of 109 with Pearlman's catalyst in the 
presence of ethereal hydrochloric acid (Scheme 2.15). This led to the removal of 
both the benzyl and the silyl protecting groups to give 131. At this point it was 
believed that the ethereal hydrochloric acid was facilitating the removal of the TBS 
protecting group. However, when the reaction was carried out in the absence of the 
acid, the TBS group was still found to be labile. Altering the solvent from methanol 
to ethanol was found to be the most suitable solution to this issue, leading to the 
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selective removal of the benzyl protecting group over the TBS protecting group to 
give the desired product 132 in high yield (Scheme 2.15).. 
H _ _ H 
N • HCI 
HO 	I)J 
- 	 a 
TBSO.-E13I_) 	
b 
AcO 	 TBSO  jo"aD 
131 	 109 	 . 	 132 
Scheme 2.15: (a) H2, Pd(OH) 2, IM HCI in Et20, MeOH (100%); (b) H 2 , Pd(OH)2 , EtOH 
(98%). 
The amine 132 was then reprotected by reacting it with di-tert-butyl dicarbonate in 
the presence of triethylamine to give compound 133 (Scheme 2.16). Thus, allowing 
the protecting group switch to take place in near quantitative yield and providing the 
key advanced stage intermediate required for the synthesis of the C4-H marked 
library. 




AcO 	 TBSO'JC~  
132 	 133 
Scheme 2.16: (a) Boc20, Et3N, DCM (97%). 
At this point it was decided to make the copper catalysed Huisgen 1,3-dipolar 
cycloaddition of an azide and a terminal alkyne the key reaction to couple together 
the tag and the marked library member (discussed in Chapter 3). It was believed that 
the incorporation of the small, non-polar, bioorthogonal propargyl moiety would 
cause the least perturbation to the molecular scaffold, while providing the required 
handle that would allow incorporation of a fluorescent or biotin tag at a later date. 
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2.8.4 C4-H 0-Marked Analogues 
Careful manipulation of the protecting groups was then carried out in order to obtain 
the desired marked compound. Removal of the TBS protecting group from 133 was 
carried out using triethylamine buffered hydrofluoric acid to give phenol 134 in 96% 
yield (Scheme 2.17). 
	




TBSO 	AcO 	 AcO 
133 134 
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Scheme 2.17: (a) HF.3Et3N, THF (96%); (b) HCECCH 2 Br, K2CO3,  DMF (99%); (C) TEA, 
DCM (97%). 
The phenol 134 was converted to the propargyl ether 135 by reaction with potassium 
carbonate and propargyl bromide in high yield (Scheme 2.17), before deprotection 
with TFA to give the O-propargyl compound 136 in three high yielding steps. 
Incorporation of the propargyl moiety into the molecular scaffold of the anisomycin 
analogue was confirmed by NMR which showed two distinctive peaks in the proton 
spectra. A fine doublet at 4.63 ppm with a small coupling constant of 2.4 Hz was 
shown for the CH2. The signal associated with the CH of the propargyl functionality 
was a triplet at 2.50 ppm with 2.4 Hz coupling constant (Appendix 3). Thus, 
confirming that marking of the anisomycin analogue's structure had been carried out 
successfully. 
2.8.5 C4-H N-Marked Analogues 
We then turned our attention to the synthesis of the N-marked analogue from 133, 
which proved to be rather more complicated. Initial attempts focused on sequential 
removal of the Boc protecting group, propargylation of the amine and removal of the 
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silyl protecting group, all which could be carried out in near quantitative yields. 
However, attempts to methylate the phenol with methyliodide and potassium 
carbonate led to quaternisation of the pyrrolidine nitrogen. Manipulation of the 
methylation conditions by reducing the volume of methyl iodide to a single 
equivalent also led to a complicated mixture of products. It was believed that the 
greater nucleophilicity of the pyrrolidine nitrogen still led to the quaternisation of 
this centre, thus making this route unfavourable. 
It was therefore decided to retain the carbamate as a method of masking the amine 
until the phenolic oxygen had been methylated. Consequently, the N-propargyl 
compound was synthesised from the phenol 134 by reaction with methyl iodide and 
potassium carbonate to form 137 (Scheme 2.18). The amine 138 was then revealed 
quantitatively by removal of the Boc functionality from 137 with TFA. Addition of 
the propargyl group under standard conditions (propargyl bromide, potassium 
carbonate, DMF) went to completion and could be monitored by tic and mass 
spectrometry. However, isolation of this material proved problematic and led to a 
very low yield. Altering the base from potassium carbonate to solid supported 
piperidine and therefore removing the aqueous work-up, led to isolation of the 
marked propargyl analogue 139. This was followed by purification on silica gel 
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Scheme 2.18: (a) Mel, K2CO3,  DMF (74%); (b) TEA, DCM (100%); (c) HCCCH 26r, 





Chapter 2 	 Results & Discussion 
2.9 Anisomycin Marked Analogues 
Anisomycin 102 was converted to 140 by reaction of one equivalent of propargyl 
bromide with anisomycin in the presence of potassium carbonate (Scheme 2.19). 
This proved to be a gratifying result as we were initially concerned about the 
selectivity of propargyl addition, as this could have occurred at the pyrrolidine 
nitrogen and/or the C 40H. A series of NMR experiments were therefore carried out 
as a means of confirming the connectivity of the propargyl marker to anisomycin's 
pyrrolidine ring (Appendix 3). Using 2D-NMR to interrogate the structure of 140, 
the direct proton carbon con-elation was confirmed by COSY and HSQC (Figure 
2.17). The experiments confirmed that the propargyl moiety had been incorporated at 
only one site within the molecules scaffold, as well as illustrating the very large 
splitting (0.72 ppm) between the two diastereotopic protons at the C 5 carbon centre. 
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Figure 2.17: Fully assigned HSQC spectrum of 140 at 600 MHz. 
59 
Chapter 2 	 Results & Discussion 
It was believed that analysis of the HMBC spectrum of compound 140 would 
confirm the connectivity of the propargyl unit (Figure 2.18), as this experiment 
shows correlations of up to four bonds. A distinct correlation between the C 51-12 and 
the CH2 from the propargyl unit was observed, while there was no apparent 
correlation from the propargyl unit to the C 41-1. This result was confirmed by a 1D-
NOE experiment which on irradiation of the propargyl CH 2 brings about 
enhancement of the C 5H2, C 2!!, and C BHA H B signals, confirming the N-
propargylation of anisomycin 140. 
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Figure 2.18: Fully assigned HMBC spectrum of 140 at 600 MHz. 
Having successfully synthesised the propargyl compound 140 it was decided to 
further probe the SAR of anisomycin by synthesising the mono-N-benzyl analogue. 
Previous results within the group have shown that the di-NO-benzyl compound 
shows no phenotypic response for SAPK activation. Therefore, testing the N-benzyl 
compound would clarify the allowed positions of substituents around the pyrrolidine 
ring. Anisomycin 102 was reacted under analogous alkylation conditions, with 
benzyl bromide and potassium carbonate: purification by column chromatography 
gave the desired product 141 in high yield (Scheme 2.20). As carried out previously, 
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the regiochemistry of the benzyl group was confirmed by a series of NMR 
experiments which showed the reaction proceeded exclusively at the pyrrolidine 
nitrogen. 
Bn 






OH 	 MeO bH 
102 	 141 
Scheme 2.20: (a) BnBr, K2CO3,  DMF (89%). 
2.10 Introduction to Western Blotting 
With the synthesis of a new series of anisomycin analogues complete, the levels of 
activation of the SAPK pathway were tested to see if the modifications carried out to 
the structures had led to retention of SAPK phenotype activity. 
Human embryonic kidney (HEK) 293 cells were incubated with 9 .tl of a 38 mmol 
stock solution of anisomycin, DMSO or anisomycin analogue for 30 minutes at 37.5 
°C. The cells were then lysed with triton cell lysis buffer and the concentration of 
protein determined by Bradford assay. 
255 The lysates (20 mg) were then separated by 
sodium doceyl sulfate polyacylamide gel electrophoresis (SDS PAGE), before 
transfer to nitrocellulose membranes (Figure 2.19, left hand column). 
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Figure 2.19: Overview of Western Blotting: Separation of cell lysates by SDS-PAGE, 
transfer of proteins to nitrocellulose membranes (left hand column), blocking of membrane 
followed by incubation with primary antibody, then incubation with secondary antibody and 
detection using ECL reagent (right hand column) . 2 
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The nitrocellulose membranes were then blocked in a milk solution for 1 hour, to 
prevent non-specific binding (Figure 2.19, top of right hand column). The primary 
antibody solution specific for phosphorylated JNK (piNK) was then incubated with 
the membranes for 15 hours, before washing the membranes to remove excess 
primary antibody. The secondary antibody containing a horseradish peroxidase 
(HRP) moiety was then added (1 hour) and was followed by washing to remove the 
excess antibody. Immunoreactive proteins were then visualised using enhanced 
chemi luminescence (ECL) detection reagent (Figure 2.20). ECL is a commercially 
available protein detection reagent that is based on a cocktail of chemicals but 
contains a peracid and luminol as the key components .257  The HRP-conjugated 
antibody and peracid react to form active complexes, which in turn leads to the 
oxidation of luminol, and the emission of light. The emission of light is then 
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Figure 2.20: Principles of ECL Western blotting. 257 
The membrane can then be stripped of all antibodies and reblotted using an antibody 
that is equally specific for the phosphorylated and the unphosphorylated form of 
INK. This can then be detected using ECL, as described previously. This experiment 
acts as an internal control by illustrating that even blots that have shown no 
phosphorylation in the initial experiment contain the unphosphorylated protein. Thus, 
confirming that JNK was present but unphosphorylated. 
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2.11 Biological Testing of the Marked Library 
The new anisomycin analogues and marked library members were then tested for 
activation of the JNK/SAPK1 pathway, as described previously. 246, 258 The 
compounds were analysed in a series of experiments with each blot containing a 
negative DMSO standard (lane 1) and an anisomycin positive standard (lane 2). The 
library members could therefore be directly compared to the control lanes on the 
blots, thus allowing the level of SAPK phenotypic response to be analysed. 
Moreover, each figure contains an upper blot showing phosphorylated JNK and a 
lower blot which shows both phosphorylated and unphosphorylated JNK. 
Screening of the library of C4-H anisomycin analogues showed that as expected 
bulky protecting groups, such as Boc or TBS attached to the core structure gave 
compounds that had lost their phenotypic SAPK response (Figure 2.21. lanes 3-6). 
However, incorporation of the propargyl marker onto the phenol functionality and 
removal of the bulk protecting groups in 136 lead to a molecule that activates the 
SAPK pathway (Figure 2.21, lane 7). 
+ 132 133 134 135 136 
pJNK1/2 
JNK1/2 
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Figure 2.21: Im munoblot assay for the phosphorylation of JNK1/2 upon stimulation by 
DMSO (negative standard, lane 1), anisomycin 102 (positive standard, lane 2) and C 4-H 
anisornycin analogues 132 to 136 (lanes 3-7). 
In contrast, marking the pyrrolidine nitrogen on the C 4-H analogue turned out to be 
less fruitful. The marked compound 139 and the protected compound 137 gave no 
response for SAPK activation (Figure 2.22, lanes 9/10 and 5/6 respectively), while 
the unprotected compound 138 showed similar levels of activation to that of the 
previous results within the group (Figure 2.22. lanes 7/8). 
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Figure 2.22: Immunoblot assay for the phosphorylation of JNK1/2 upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 3/4) and C4- 
H anisomycin analogues 137 to 139 (lanes 5-10). 
Attention then turned to testing the anisomycin based analogues that had been 
synthesised. Gratifyingly it was found that the N-propargyl anisomycin 140 gave a 
positive result in the SAPK assay (Figure 2.23, lanes 5/6). In turn, N-benzyl 
anisomycin 141 showed levels of SAPK activation comparable with that of 
anisomycin itself (Figure 2.23, lanes 5/6). These key results allowed us to conclude 
that a number of groups could be attached to the pyrrolidine nitrogen of anisomycin 
while retaining the phenotypic response. Moreover, the activation of the SAPK 
pathway by N-benzyl anisomycin, (in contrast to the lack of SAPK response with 
that of the dibenzyl anisomycin) illustrates that the C4 position can only tolerate 
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Figure 2.23: Immunoblot assay for the phosphorylation of JNK1/2 upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 3/4) and 
anisomycin analogues 140 (lanes 5/6). 
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Figure 2.24: Immunoblot assay for the phosphorylation of JNK1/2 upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 3/4) and 
anisomycin analogues 141 (lanes 5/6). 
With these promising results in hand the Western Blotting of the two active marked 
compounds (136 and 140) was repeated in order to compare their activity directly 
with that of deacetylanisomycin 106, a known activator of the SAPK pathway 
(Figure 2.24). This experiment illustrated that although the marked library members 
show a weak phenotypic response for phosphorylation of JNK, it can be considered 
analogous to that of deacetylanisomycin. 
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Figure 2.25: Immunoblot assay for the phosphorylation of JNK1/2 upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 3/4), 
deacetylanisomycin 106 (lanes 5/6), 0-propargyl C 4-H anisomycin analogue 136 (lanes 7/8) 
and N-propargyl anisomycin analogue 140 (lanes 9/10). 
Overall the results of this library study for activation of the SAPK phenotype are in 
good agreement with the SAR which have previously been determined within the 
Hulme group. 246  The synthesis of N-benzyl 141 and N-propargyl anisomycin 140 has 
confirmed our previous hypothesis that the pyrrolidine nitrogen could be alkylated 
while retaining biological activity. This provided an excellent contrast to the 
65 
Chapter 2 	 Results & Discussion 
dibenzyl compound, which had been previously found to be biologically inactive. It 
can therefore be concluded that bulky groups are not tolerated on the C4-OH but are 
allowed on the pyrrolidine nitrogen. However, at the phenolic functionality, addition 
of the propargyl functionality also led to retention of the phenotypic response. Thus, 
confirming our initial analysis of anisomycin's SAR, where it was proposed that 
functional i sation of both the pyrrolidine ring and the phenolic oxygen would lead to 
retention of biological activity. Therefore, the idea that a small bioorthogonal 
marker, such as a propargyl group, can be incorporated into a biologically active 
molecule, whilst retaining activity has been validated. 
2.12 Summary 
The synthesis of a small library of marked molecules based around the molecular 
scaffold of the SAPK activator anisomycin, incorporating a bioorthogonal marker 
into the structure has taken place. Testing of this library has led to a number of 
biologically active marked library members and the validation of our marked library 
strategy; as well as developing a greater understanding of anisomycin's SAR. 
We therefore envisage the derivatisation of functionalities (alcohols, amines, thiols, 
etc) within a small molecule's scaffold with the attachment of a biocompatible 
marker. This strategy could then easily be expanded to other functional groups such 
as carbonyls, amides and esters allowing the incorporation of the marker moiety 
more generally. Moreover, we imagine the choice of marker being made on a case by 
case basis with a series of markers and the analogous bioorthogonal reactions readily 
available. 
On completion of the biological screening, active compounds that contain markers 
could then be coupled to their orthogonal reactive partner to rapidly form molecular 
probes (see Chapter 3), without the long and often complicated synthesis 
traditionally associated with their formation. The active probes could then be utilised 
in the investigation of the biological role of the molecule of interest. We therefore 
believe that this marked library approach will provide a useful truncation of the 
small-molecule to molecular probe synthetic process through the incorporation of a 
biocompatible marker. 
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3 Anisomycin Based Molecular Probes 
3.1 Traditional Molecular Probes 
Understanding complex cellular processes requires the detailed analysis of biological 
processes at the molecular level. This involves the analysis of a wide range of 
bioniolecules from polymers and ions to proteins and metabolites, by tracking the 
biomolecules of interest within their natural environment. Classically this is done by 
attaching a tag, such as green fluorescent protein (GFP) (Figure 3.0 or biotin, to the 
species of interest thus allowing visualisation and quantification . 259261 However, the 
application of GFP and GFP-like proteins to this task may also cause a series of 
problems, not least the fact that at 27 kDa, GFP can cause major structural 
perturbations to the system under investigation. Therefore, over the last decade the 
attention has turned to an organic chemistry based approach to deliver a series of 
reactions that can be utilised to couple a wide range of tags (biotin, fluorophores, etc) 
to the biomolecule of interest. 95,96,262 
Figure 3.1: Structure of green fluorescent protein (GFP) 
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3.2 'Click' Chemistry 
The terminology 'click chemistry' was first coined by Sharpless et al. in 2001 when 
they used the term to describe their approach to develop a series of powerful, highly 
selective and reliable reactions which would allow for the rapid modular synthesis of 
new compounds and libraries. 98 
Using nature's precedent, they set out to synthesise new compounds by joining 
together two units using a heteroatom linkage (C-X-C). They defined a series of 
stringent criteria to describe 'click' reactions stating that reactions must be: modular, 
stereospecific, wide in scope, very high yielding and allow simple product 
isolation.97' 98  Moreover, the reaction should have simple reaction conditions, using 
benign solvents, while generating inoffensive byproducts that can be removed 
without chromatography. Therefore, 'click' reactions can be thought of in terms of 
being 'spring loaded', with a characteristic high driving force of usually greater than 
20 kcal mol*97' 98  With this work Sharpless raised the bar for the modern organic 
chemist by providing a redesigned toolbox of synthetic reactions that are atom 
efficient, carried out under green conditions and are very reliable. 
3.2.1 Library of 'Click' Reactions 
The first generation of 'click' reactions, were based in areas of carbonyl and olefin 
chemistry.97' 98  This was due to the widespread availability of these functionalities 
from commercially available building blocks, thus allowing a large range of 
reactions to be examined to see if they met the stringent 'click' criteria. This led to 
the researchers in the Sharpless laboratory developing a series of extremely reliable 
processes (Scheme 3.1) that were the first to be defined as 'click' reactions and 
include: 
. Addition to carbon-carbon multiple bonds, especially oxidative cases such as 
epoxidation, dihydroxylation, aziridination and certain Michael additions 
(Scheme 3.1; 142-143). 
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• Nucleophilic substitution chemistry, especially the opening of strained 
heterocyclic rings such as epoxides, aziridines, cyclic sulfates, aziridinium 
ions and episulfonium ions (Scheme 3.1; 143-444). 
• Cycloaddition reactions of unsaturated species, especially from the 1,3-
dipolar cycloaddition family, but also Diels-Alder and hetero-Diels-Alder 
reactions (Scheme 3.1; 142—+145). 
Carbonyl chemistry of the non-aldol type; i.e. formation of oximes, 
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Scheme 3.1: Overview of'click' chemistry reactions. 9798 
Since its inception in 2001 the concept of 'click' chemistry has been utilised across a 
broad spectrum of chemistry from polymer and materials chemistry to 
supramolecular and carbohydrate chemistry. 161-267  Thus illustrating the wide range of 
synthetic areas 'click' chemistry can be applied to. 
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3.2.2 'Click' Reactions in Water 
During the development. of 'click' chemistry researchers found that water was the 
solvent or co-solvent of choice, with reactions proceeding much better that in organic 
solvents. 97 ' 98 This is believed to be due to a range of factors including: 
• The fact that reactions of organic molecules in aqueous media can have a 
higher apparent rate constant than the analogous reaction in organic media. 
This observation has been investigated by a number of groups and many 
explanations have been offered .218-270  However, the key factor may be that the 
free energies of organic molecules are often greater when poorly solvated in 
water, resulting in an imparted increase in reactivity. 271 
• Two subsets of olefin and acetylene 'click' reactions are oxidation by 
electrophiles and cycloaddition reactions respectively. These reactions 
involve either polarisable nuclophile/electrophiles or concerted processes; 
hence water is not an interfering factor in the reaction. 272 
• Nucleophilic additions to strained heterocyclic rings are favoured by solvents 
who respond well to a series of hydrogen-bonding situations during the 
reaction pathway, such as water. 
• Water is also an excellent heat-sink, with a high heat capacity for absorbing 
the large amount of heat given out during 'click' reactions. Therefore making 
it an ideal solvent for performing these reactions on larger scales. 
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3.3 Bioconjugate Reactions 
With the development of a series of 'click' reactions that could be carried out in 
aqueous solvents, a number of interdisciplinary scientists working at the interface of 
chemistry, proteomics and the life sciences have begun to take advantage of this new 
methodology. 95, 96, 262 Investigations have focused on the use of pairs of 
biocompatible functionalities, which were inert towards the biological system but 
could be coupled together using bioconjugate reactions in situ (Table 3.1). This 
research has led to the validation of a series of biocompatible markers (Table 3.1, 
column 1 and 2) which include azides, alkynes, phosphines, oximes, hydrazines, 
ketones, aldehydes and the tetracystine motif. 95 ' 96' 262 
This approach has been successfully applied to a wide variety of biomolecules 
including proteins, glycans and lipids (Table 3.1, column 4), whereby, a marker has 
been incorporated into the biomolecule of interest. The markers can then be coupled 
to their orthogonal partner using a specific bioconjugate reaction, typically at pH 7 
with little or no toxic effects, to form their respective ligation product (Table 3.1, 
column 3). 
There are a significant number of publications dealing with this topic. However, the 
main bioconjugate reactions that have been utilised are the Staudinger ligation and 
the Huisgen cycloaddition. Therefore, an overview to these reactions will be covered 
in the following sections. 
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Chemical Reactive Partner Ligation Target 
Reporter (R' = Tag) Product 
14 ss s 











































Azide N. R 	'N Protein 
R 1 Lipid 
Strain promoted cycloaddition 




R-N3 R Protein 
Alkyne R 1 
Table 3.1: Table of biocompatible markers, their orthogonal partners, the bioconjugate 
reactions the ligation products and the bimolecular system they have been utilised in. 
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3.3.1 Staudinger Ligation 
The Staudinger reduction was first developed in 1919 by Hermann Staudinger and is 
the reaction of an azide 148 and a phosphine 149 to form an amine and trialkyl or 
aryl phosphine oxide (Scheme 3.2).273 274 The reaction proceeds via formation of 
phosphazine intermediate 150, which immediately loses nitrogen to form an 
iminophosphorane 151.275, 276 In the presence of water the iminophosphorane 151 is 
spontaneously hydrolysed to a primary amine 153 and the accompanying phosphine 
oxide 152. 
P- R3 
R1-N3 	149 	R1-N=NN=PR3 
148 150 
R 1 -NH2 + OPR3 44 -HO 	R1-NPR3 
153 	152 	 151 
Scheme 3.2: Mechanism of the Staudinger reaction. 274276 
Likewise, the intermediate in the Staudinger ligation is an iminophosphorane 151 
which contains a nucleophilic nitrogen. Work by Vilarrasa showed that this nitrogen 
can attack an intra- or inter-molecular acyl donor forming an amide, after hydrolysis 
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Ph 	Ph 
156 
Scheme 3.3: Mechanism of the Staudinger-Bertozzi ligation. 
278-280 
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In 2000, Bertozzi first reported the modification of the Staudinger ligation (now the 
Staudinger-Bertozzi ligation) of an organoazide 148 to a specifically functionalised 
phosphine 154 (Scheme 3 •3) •278 279 The reaction proceeds with nucleophilic attack at 
the organoazide, to form an aza-ylide 155. The adjacent methylester traps the aza-
ylide 156, which is subsequently hydrolysed to give the new amide 157.280 
Subsequently the Staudinger-Bertozzi ligation has been applied to a range of 
biological substrates including, the investigation of synthetic azido-sugars, for 
attaching substrates to surfaces and for biological labelling. 28285 Recently, it has 
now been applied to an enzyme-linked immunosorbent assay (ELISA) to give an 
azido-ELISA which has been utilised in the screening of different glycosyl 
transferases (Scheme 3.4).' 13, 114 Moreover, researchers have begun to move beyond 
the test tube to investigate the role of biomolecules in living cells, with the Bertozzi 
research group at the forefront having successfully applied this ligation in living 
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Scheme 3.4: Enzyme-linked immunosorbent assay (ELISA), incorporating the Staudinger-
Bertozzi ligation as a new method for screening glycosyl transferase.113 114. 
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3.3.2 Huisgen Cycloaddition 
The 1,3-dipolar cycloaddition of an azide and an alkyne was developed by Rolf 
Huisgen in the 1960's. 111-2'9 This reaction occurs between an alkyne dipolarophile 
161 and a 1,3-dipole 148 which has a conjugated system of three p orbitals, 
containing 4 electrons over three atoms. This reaction typically results in a mixture 
of regioisomers 145:162 with selectivity varying from >95:5 to a 50:50 mixture 
(Scheme 3.5). 
R1 -N3 
N 	 R1 ,N 
R— 	
148 	N .R1 + 	N 'N 
R' ' 	 R '  
161 	 145 162 
Scheme 3.5: Classical Huisgen 1,3-dipolar cycloaddition forming 1,2-'and I ,4-regioisomers 
as products (162 and 145 respectively). 287-289 
Studies into the mechanism of the 1,3-dipolar cycloaddition were a contentious issue 
within the synthetic community for over 20 years. Huisgen proposed a transition 
state model 165 in which the 4 it-electrons of the dipole 163 interact with the it-bond 
of the dipolarophile 164 (Figure 3.6a).289' 290  This concerted mechanism was based 
on an extensive series of experiments investigating kinetic measurements and 
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164 167 166 
Scheme 3.6: Proposed mechanisms for 1,3-dipolar cycloaddition reaction: (a) Concerted 
mechanism proposed by Huisgen. (b) Stepwise mechanism proposed by Firestone. 293 
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Meanwhile, Firestone passionately believed that these reactions proceeded via a 
singlet diradical intermediate 167 (Figure 3.6b).294297 However, his argument turned 
out to have a fatal flaw. If the reaction was to proceed via the singlet mechanism the 
stereochemistry of the product would be scrambled. Unfortunately for Firestone this 
stereochemical scrambling was not seen under experimental conditions. 298  Therefore, 
the concerted mechanism was accepted as the valid pathway, a result that was later 
confirmed by a series of DFT calculations. 293 
The Huisgen 1,3-dipolar cycloaddition reaction is thermodynamically favourable by 
30-35 kcal moF'. However, classically this reaction requires elevated temperatures or 
pressures to proceed, making these conditions incompatible with living systems. 
This problem was overcome by the resultant work of the Sharpless and Meldal 
research groups who concurrently investigated the catalysis of this reaction. 299, 300 
They successfully developed a copper(I)-catalysed variant of the Huisgen 1,3-dipolar 
cycloaddition that increased the rate of the reaction by 10 6-fold, formed the 1,4-
regioisomer selectively, while only using 10 mol% of the copper catalyst (Scheme 
3.7). This new variation on the classical 1,3-dipolar cycloaddition rapidly became 
know as the 'click reaction' as it was believed to be the premier reaction within the 
'click' chemistry toolbox. 97,98,301 
R1- N3 
	
- 	148 	N" N -R1 R-= 
CU(I) 
R'1 
161 	 145 
Scheme 3.7: Copperçl)-catalysed Huisgen 1,3-dipolar cycloaddition forming the 1 ,4-triazole 
145 regioselectively.9 98, 301 
Investigations into the optimum conditions for the copper(I)-catalysed Huisgen 
cycloaddition found enormous scope for this reaction. The use of copper(II) salts 
(0.25-10 mol%) which are subsequently reduced to copper(I) in situ by ascorbic acid 
or sodium ascorbate were found to be the catalytic system of choice. The reaction 
takes place in 6-36 h in a variety of solvents including ethanol, aqueous tert-butyl 
alcohol and in water alone. In contrast, the direct addition of copper(I) salts required 
the addition of a single equivalent of a nitrogen base (triethylamine or 2,6-lutidine), 
acetonitrile as a co-solvent and often led to a range of side products. 97 
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Since the first detailed reports were published in 2002 a number of subsequent 
reaction conditions have been reported. Tirrell et al. have utilised copper(I) bromide 
as the copper source. 302  However, a key factor in using this methodology is the 
requirement of the copper bromide to be of high purity (>99.999%) and stored under 
anhydrous conditions. While work within the Hulme research group has shown that 
using a copper(II) source and reducing it with a mild biological reductant such as 
glutathione can lead to enhanced reaction rates. 303 
Detailed investigations by Sharpless et al. into the mechanism of the copper(I)-
catalysed Huisgen cycloaddition are still being carried out. However a mechanism 
has been proposed on the basis of a detailed series of DFT calculations. 304, 305 The 
reaction begins with the coordination of the alkyne 161 to the Cu(I) species 168, 
displacing a solvent ligand (Scheme 3.8). The alkyne is then converted to the 
acetylide 169, a process identical to that of the Sonogashira coupling. At this point 
DFT calculations gave a useful insight into the cycloaddition process, ruling out the 
two concerted mechanisms via transition states (Figure 3.2; 173 and 174). 
Transition state 173 was found to have a higher activation barrier than the 
uncatalysed reaction, while the activation barrier to transition state 174 was found to 
be only 2.3 kcal mol' lower than the reaction without copper. It is therefore clear 
that neither of the concerted mechanisms could explain the experimental rate 
enhancement given to this reaction by the addition of copper. 
148 	 169 
Scheme 3.8: Proposed reaction mechanism for the copper(l)-catalysed Huisgen 
cycloaddition based on experimental evidence and DFT calculation S.304,305 
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a) 	
>(".* 011 
Figure 3.2: Two possible transition states for a concerted mechanism for the copper(I)-
catalysed Huisgen cycloaddition. a) 173; b) 174. °° 
Having ruled out the concerted processes, they next proposed replacing one of the 
ligands on the copper by binding the azide moiety 148 to the copper via the nitrogen 
closest to the carbon 170. From this point a stepwise process can occur with the 
terminal nitrogen of the azide attacking the C2 carbon of the acetylide, forming an 
unusual 6-membered copper metallocycle 171. This step was found to have an 
activation barrier of 14.9 kcal moi 1 which is significantly lower than the uncatalysed 
reaction and could explain the 7-8 fold rate enhancement seen for the copper 
catalysed process. The 6-membered metallocycle 171 then contracts to forms the 
triazolyl-copper derivative 172. With water as a ligand the energy barrier for this 
process is only 3.2 kcal mol* Proteolysis of 172 releases the product 145 and 
regenerates the copper catalyst 168, thereby completing the catalytic cycle (Figure 
3.8). These theoretical calculations concur with the experimental findings and give 
an insight to the rate enhancement copper(I) has on this process, as well as 
explaining the regiocontrol. However, further experimental work has still to be 
carried out to confirm these calculations. 
As a consequence of the high reliability, mild reaction conditions, high rates and 
biocompatibility the copper (I)-catalysed Huisgen cycloaddition has become the 
bioconjugate reaction of choice. In 2003, the group of Schultz showed that unnatural 
amino acids 175 and 176 could be incorporated into Saccharomyces Cerevisiae 
(Figure 3•3)306  The azide or propargyl markers could then be coupled to an 
orthogonally marked fluorophore using the copper catalysed cycloaddition. 
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Figure 3.3: A series of marked amino acids that have been incorporated into a protein's 
structure and used in cell surface engineering studies.  104 ' 302 '306 ' 307 
In a similar manner Tirrell et al. showed that they could replace methionine residues 
into the outer membrane protein (Omp) C in E. coil cells with azidohomoalanine 89 
(Figure 3•3)  104,302 The cells containing the azide moiety could then be coupled to a 
biotin-alkyne reagent under 'click' reaction conditions, before analysis by Western 
blotting. In a further example of cell surface engineering, the same researchers have 
labelled a series of proteins by incorporating the modified amino acids 
homopropargylglycine 177 and ethynylphenylalanine 178 into E. coil cells (Figure 
3•3) 307 These modified amino acids have been coupled with an azido-fluorophore to 
give a fluorescently tagged protein. 
In alternative strategy Cravatt et al. have used the copper(I)-catalysed Huisgen 
cycloaddition to carry out activity based protein profiling (ABPP) to interrogate the 
proteome. ABPP is a new postgenomic method in which affinity labels are used to 
profile proteins on the basis of their function within biological systems. However, 
classically the probes are bulky and may inhibit cellular uptake. Therefore, a 'tag free 
strategy' has been developed, whereby addition of the appropriate biocompatible 
marker to the probe 180 allows the probe to be used to investigate the proteome, 
before being coupled to the required tag (Scheme 3.9; 179 +182).30831 However, 
one current limitation within this field is that researchers are carrying out profiling 
where the design of the functional probe relies upon a known protein activity, i.e. this 
methodology has yet to be expanded to target identification strategies. 
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Scheme 3.9: A 'tag free strategy' for affinity based protein profiling (ABPP). Proteins 179 are 
first labelled with a azido-sulfonate ester 180 to give 181, then tagged by reaction with an 
alkyne-tag 87 under copper(l) 'click' chemistry conditions to give 182. 08-311 
As a result of the wide range of applications within biological chemistry it was 
believed that the propargyl-azide partnership would give the ideal pair of 
biocompatible tags to utilise in our marked library strategy. It was expected to be 
relatively easy to introduce both propargyl and azide functionalities into the small 
molecule and tag components respectively. Moreover, we have previously shown 
retention of the SAPK phenotype by anisomycin analogues upon attachment of a 
propargyl marker (Chapter 2). We therefore set about synthesising a series of 
molecular probes based on the two active marked library members (136 and 140) 
utilising the copper(I)-catalysed Huisgen cycloaddition as the key coupling reaction. 
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3.4 Fluorescent Molecular Probes 
Fluorescent labels have been commonly utilised as a tool for investigating the 
mechanism of cellular uptake and intracellular distribution of small molecules, 
peptides and proteins. 112, 313 This is carried out by attachment of a fluorophore, 
classically rhodamine 183, coumarin 184 or dansyl 185, to the molecule of interest 
(Figure 3.4). 314-316  Therefore, it was decided to develop the fluorescent molecular 
probe strategy based around the dansyl fluorophore. This was due to a number of 
factors including the ease in which dansyl's structure could be modified with an 
azide marker, the small size of the fluorophore and the use of the dansyl moiety in a 
number of successful studies investigating the cellular location of small molecules 
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Figure 3.4: Structures of fluorophores rhodamine 183, coumarin 184 and dansyl 185. 
3.4.1 Synthesis of Fluorescent Molecular Probes 
In order to incorporate the azide functionality required to couple the fluorophore to 
the active marked library member, a short linker section containing an azide had to 
be appended to the structure of the fluorophore. It was decided to use the shortest 
possible carbon backbone as the linker, to reduce the unspecific binding of 
biomolecules within the cell to a minimum and to aid cellular uptake. 
The azide linker 187 was successfully synthesised from 2-chioro ethylamine 186 by 
heating in water in the presence of sodium azide (Scheme 3. 10).3  19 The reaction was 
quenched with excess potassium hydroxide to give the free amine as a volatile 
colourless oil isolated in quantitative yield. Analysis of the 'H and ' 3C NMR spectra 
showed little alteration from the starting material. However, analysis of the JR 
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spectrum showed a distinctive stretch at 2100 cm' characteristic of the azide 
functionality. Storage of 187 proved to be problematic, even when stored in the 
freezer at -20 °C, with complete loss of the product occurring after 72 hours. 
Therefore, the linker was carried through to the next reaction immediately in order to 




186 	 187 
Scheme 3.10: (a) NaN 3, H 20, 80 °C (100%). 
Coupling of the free amine 187 with the commercially available dansyl chloride 188 
occurred readily on stirring the two components in DCM for 2 hours (Scheme 3.11). 
The product 189 was isolated as a golden oil in 98% yield after chromatography. The 
compound was fully characterised by NMR and retained the distinctive azide peak in 
the IR spectrum at 2100 cm- . 
a 
C1 	 N 
188 	 189 
Scheme 3.11: (a) 187, DCM (98%). 
With the desired azido-fluorophore in place, the coupling conditions of the azide and 
alkynes were investigated. Focusing on the catalytic loading of copper sulfate and the 
timescale for the reaction; studies found that the reaction proceeded with a range of 
copper loadings (2-20 mol%) with a two-fold excess of sodium ascorbate reductant 
(4-40 mol%). However, at lower catalyst loadings the reaction times were found to 
increase. Therefore, 10 mol% copper(II) sulfate with 20 mol% sodium ascorbate was 
chosen as our optimum reaction conditions for the 'click' reaction. Investigations 
also looked at the most favourable solvent for carrying out this reaction. However 
studies only confirmed previous findings, that the reaction proceeds well in a wide 
82 
Chapter 3 	 Results & Discussion 
range of solvents including water:tert-butanol (1:1), a range of pH buffers and 
water. 262' 266, 300 
Facile coupling of the azide 189 and alkyne 136 was carried out in the presence of 
copper(II) sulfate (10 mol%) and sodium ascorbate (20 mol%) with a distinctive shift 
to a lower Rf being observed by tic (Scheme 3.12). Purification by column 
chromatography gave the target material 190 in 77% as a single regioisomer. 
H 
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Scheme 3.12: (a) 136, CuSO4. 5H20 (10 mol%), NaAsc (20 mol%), tBuOH:H20 (1:1) (77%). 
An alternative approach was also investigated whereby the click coupling reaction 
was carried out between 135 and the azido-fluorophore 189. The Boc protecting 
group was then removed using TFA to give the desired molecular probe 190 
(Scheme 3.13). However, no significant synthetic advantage was found in utilising 
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Scheme 3.13: (a) 135, CuSO4 . 5H20 (10 mol%), NaAsc (20 mol%), tBuOH:H20 (1:1) 
(76%); (b) TEA, DCM (96%). 
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The molecular probe 190 was rigorously characterised using a series of 1D and 2D 
NMR experiments. The 1 H spectrum showed the removal of the distinctive fine 
triplet associated with the CH of the propargyl unit, while in the aromatic region the 
addition of a singlet at 8.06 ppm was thought to account for the CH of the 1,2,3-
triazole. Further interrogation of the structure of 190 by COSY clearly showed the 
correlation between the new C14H and the C 16112. On comparison of the HSQC 
spectra of the azido-starting material 189 with that of the molecular probe 190 three 
new peaks were clearly visible within the aromatic region of the spectrum (Figure 
3.5). Coupling of the anisomycin moiety to the fluorophore would increase the 
number of peaks in the aromatic region of the HSQC spectra by three, with two 
peaks associated with the aromatic ring of the marked analogue and a further peak 
coming from the C 14H upon formation of the triazole regioselectively. This 
spectroscopic evidence confirmed that the click coupling reaction had been carried 







We 	 c1g 
I 	8 
27 
0 105: 	6 	 22 
4l N 
	







Figure 3.5: Expansion of the aromatic region of the HSQC spectrum of molecular probe 190 
(360 MHz, DMSO). 
With the synthesis of the first fluorescent molecular probe in place, we turned our 
attention to the coupling of the N-propargyl anisomycin 140. Utilising the same 
coupling conditions as used previously, the marked library member 140 was coupled 
to the fluorescent azide 189 (Scheme 3.14). The molecular probe 191 was obtained 
in 71% yield after purification by column chromatography. 









Scheme 3.14: (a) 140, CuSO4. 51-1 20 (10 mol%), NaAsc (20 mol%), tBUOH:H20  (1:1) (71%). 
Analysis of the 'H spectrum of 191 in methanol showed a well defined aromatic 
region with all the relevant protons being accounted for. However the C 1 6-C22 region 
of the spectrum showed a series of broad peaks with little definition. The same 
problem was encountered on assigning the broadband ' 3C NMR and the 2D spectra. 
It was believed that altering the solvent from methanol to DMSO may help to 
remove this problem. However, analysis of the spectra in DMSO proved to have the 
same broad peaks. A series of variable temperature NMR experiments in DMSO 
were then carried out, recording spectra from 20 °C to 60 °C, but once again this did 
little to remove the broadening. The broadening of the C 16-C22 region was believed to 
be associated with two key factors (Figure 3.6): the number of nitrogens in the 
triazole-pyrrolidine core of the molecule; and the hindered rotation that exists around 
the CH2's linking the pendant triazole and phenyl groups to the pyrrolidine ring. 
N 
OH 
MeO AcO OH 
191 
Figure 3.6: Structure of molecular probe 191. Illustrating the nitrogen dense area within the 
molecule (red) and the CH 2 groups that can undergo hindered rotation (blue) which lead to 
broadening on the NMR spectra. 
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The issue was finally resolved upon using deuterated acetonitrile as the solvent for 
spectroscopic characterisation. Analysis in acetonitrile led to a reduction in 
broadening that had previously been observed. Examination of the 1 H NMR showed 
much greater definition, while the carbon skeleton could be fully assigned using 
HSQC (Figure 3.7) and HMBC experiments (Appendix 3). As with the previous 
molecular probe the distinctive CH of the 1 ,2,3-triazole was found to be at 7.57 ppm 
('H) and 126.4 ppm ( 13C). Other distinctive peaks included the large doublet 
corresponding to the pair of diastereotopic protons of the C181-12  and the pair of 
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Figure 3.7: HSQC spectrum of 191 acquired at 360 MHz in acetonitrile. 
Having synthesised fluorescent molecular probe 191 and confirmed it's structure by 
NMR spectroscopy investigations went on to focus on its fluorescent properties, to 
see if coupling of the marked library members had affected its fluorescence. Crude 
investigations carried out in a UV light box typically used for analysis of tic's 
showed that both the azide 189 and the molecular probe 191 had similar fluorescence 
on visual comparison (Figure 3.8a) The fluorescence properties of the probe were 
then compared with that of the parent dansyl azide 189 by carrying out fluorescence 
measurements (Figure 3.8b). These experiments found that the excitation and 
emission spectra for dansyl azide 189 and N-linked probe 191 were found to be 
equivalent (? ex = 345 fliT', 2em = 550 fliT'). 
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iIIIIiI 1.1::! 
Figure 3.8: (a) Investigation of fluorescence using a UV lightbox: solvent control (left), 
molecular probe 191 (middle) and dansyl azide 189 (right). (b) Luminescence measurements 
of 189 and 191 illustrating the excitation and emission spectra. 
Thus in one simple step the convertion of active marked library members to 
functional molecular probes has been successfully carried out, without the need to 
resort to tedious resynthesis often associated with the synthesis of molecular probes. 
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3.4.2 Biological Testing of the Fluorescent Molecular Probes 
Attention then turned to testing the fluorescent molecular probes to see if their 
phenotype activity for activation of the SAPK pathway had been retained on 
coupling of the fluorophore moiety. hnmunoblot assays were carried out as described 
in Chapter 2, probing for the phosphorylation of the protein JNK. The resultant 
immunoblot assay (Figure 3.9) demonstrate that extension of the propargyl ether 
marker in the C 4-H analogue as the fluorescent probe led to the loss of the SAPK 
response, when compared to that of the positive anisomycin control. 
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Figure 3.9: Immunoblot assay for the phosphorylation of JNK1/2 and upon stimulation by 
DMSO (negative control, lanes 1/2), anisomycin 102 (positive control, lanes 3/4) and 
molecular probe 190 (lane 5/6). 
Gratifyingly, formation of the fluorescent molecular probe using the propargyl amine 
marker of the anisomycin derivative, led to a strong phenotypic response in the 
SAPK pathway assay, with activation levels comparable to that of the natural product 
itself (Figure 3.10). 
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Figure 3.10: Immunoblot assay for the phosphorylation of JNK1/2 upon stimulation by 
DMSO (negative control, lanes 1/2), anisomycin 102 (positive control, lanes 3/4) and 
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3.4.3 Application of the Fluorescent Molecular Probe 
Using the active molecular probe, investigations then focused on the cellular uptake 
and sub-cellular localisation of the fluorophore. Investigations began by screening a 
range of molecular probe concentrations (mM-nM) as a means of finding an optimal 
concentration range at which to carry out the more detailed fluorescent experiments. 
Cellular uptake in HEK293 cells was then investigated at increasing concentrations 
(22 - 162 riM) of probe. The cells were stimulated for 30 min with the probe, washed 
with PBS buffer and then the cellular uptake of the fluorophore was analysed by 
fluorescence-flow cytometry. A distinctive shift in the histograms was observed on 
comparing the control cells (red) and cells that had been stimulated with molecular 
probe (green) (Figure 3.11a). Moreover, a direct correlation was observed between 
the level of dansyl fluorescence observed in the cell populations and the initial 
dosing concentrations (Figure 3.1 1 b). 
Figure 3.11: Flow cytometry analysis of cellular uptake of molecular probe 191 in HEK293 
cells. Cells were incubated with 22-162 pM concentrations of Winked probe 191 for 30 mm 
and were analyzed using a MoFlo FACS instrument with a UV laser. (a) Histograms of 
unlabeled cells as a control (red) and cell incubated with 191 at 162 PM (green). (b) 
Histograms illustrating increasing fluorescence intensity with increasing concentrations of 
191 (0, 22, 42, 66, 86, 108, 131, 162 pM). 
Using the results of the flow cytometry, an optimum concentration (109 [IM) for cell 
stimulation was selected which allowed visualization of the probe uptake, initially at 
20-fold magnification (Figure 3.12). The results of this experiment showed strong 
fluorescence of the cells. However, this experiment could not confirm if the 
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fluorophore had either undergone cellular uptake or had become attached to the cell's 
surface. 
Figure 3.12: Cellular localization and uptake of molecular probe 191. Cells were incubated 
for 30 min with 109 liM of 191, washed with PBS and fixed. Analysis of cells was carried out 
using a Leica DM IRE2 confocal microscope with a UV laser. (a) Brightheld image of cells at 
20-fold magnification. (b) Fluorescent image of cells at 20-fold magnification. 
Subsequent experiments using microscopy at 63-fold magnification (Figure 3.13) 
showed a much clearer picture. Comparison of the brightfield image and the 
fluorescent images showed that the fluorophore was consistently found in the same 
cellular location, the cytosol (Figure 3.13, d-f). Moreover, upon carrying out 
confocal microscopy and taking a series of slices through the cluster of cells, the 
images obtained show clearly the uptake of the probe into the cytosol of the HEK293 
cells. 
As a control experiment, the cells were incubated with the unreactive dansyl azide 
189 under the same experimental conditions as used previously. Thus, allowing the 
specificity of the fluorophore's subcellular location without the anisomycin moiety to 
be investigated. Analysis of the fluorescent images of the cells at 63-fold 
magnification showed a distribution of fluorophore throughout the cells, with 
analysis of the overlay plot confirming these findings (Figure 3.13, a-c). 
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Figure 3.13: Cellular localization and uptake of parent dansyl azide 189 (a-c) and molecular 
probe 191 (d-f). Cells were incubated for 30 min with 109 iM of 189 or 191, washed with 
PBS and fixed. Analysis of cells was carried out using a Leica DM IRE2 confocal 
microscope. (a and d) Brightfield image of cells at 63-fold magnification. (b and e) 
Fluorescent image of cells at 63-fold magnification. (c and f) Overlay of brightfield and 
fluorescent images. 
These experiments allowed us to conclude that the binding of the fluorescent 
molecular probe 191 in the cytosol is directly correlated to the attachment of the 
anisomycin moiety to the fluorophore. Therefore, it is highly probable that the 
subcellular target of anisomycin is a cytosolic based protein. Thus, narrowing the 
field of search by ruling out the family of membrane bound proteins that had been 
previously postulated as possible targets. 
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3.5 Biotinylated Molecular Probes 
The addition of a biotin tag is one of the methods of choice for identification of a 
small molecule's binding site. 38' 63,68  The biotin tag binds to avidin with a Kd of 10 
M, allowing the molecular probe to be attached to an avidin column through biotin. 14 
While, at the opposite end of the probe the protein target is covalently attached to the 
small molecule of interest. This allows the non-specific cell lysates to be removed by 
washing and the target protein to be eluted and identified. 
Investigations then focused on the synthesis of a series of biotinylated molecular 
probes based on the active marked library members synthesised in Chapter 2. 
Coupling of the marked library members through the copper(I)-catalysed Huisgen 
cycloaddition to a series of biotinylated azides would readily give us access to a 
focused library of molecular probes. Subsequent immunoblot assays of the probes 
would allow the selection of an active molecular probe to be utilised in the target 
identification process. 
3.5.1 Synthesis of 'Clicked' Biotinylated Molecular Probes 
Initial investigations focused on the formation of a biotinylated azide, utilising the 
short chain-C2-azide 187 synthesised previously and coupling it to biotin-NHS 192. 
The activated ester 192 was commercially obtainable or easily synthesised in one 
high yielding step from biotin 1. Coupling of these two components (I87and 192) 
proceeded readily in methanol with triethylamine as a base to give the biotinylated 
azide 193 in 96% (Scheme 3.15). Purification by column chromatography gave a 
colourless solid which was fully characterised by NMR and showed a distinctive 
azide stretch at 2103 cm' upon analysis by JR spectroscopy. 
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Scheme 3.15: (a) 187, Et3 N, MeOH (96%). 
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The synthesis of a series of control probes with structure similarity to that of the 
anisomycin-based probes but inactive for SAPK pathway activation was envisaged. 
These control probes could then be used during affinity chromatography to simplify 
the results by removing non-specific protein binding that may occur on the linker and 
biotin moieties. The control compound 195 was readily synthesised from the 
analogous phenol 194 using propargyl bromide in the presence of potassium 
carbonate (Scheme 3.16). Coupling of the propargyl phenol 195 to the biotinylated 
azide 193 under 'click' reaction conditions gave the desired molecular probe 196 in 
86% yield (Scheme 3.17). 
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Scheme 3.16: HCECCH 2 Br, K2CO3,  DMF (77%). 
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Scheme 3.17: (a) 195, CuSO4. 5H20 (10 rnol%), NaAsc (20 mol%), tBUOH:H20  (1:1) (86%). 
Having synthesised the control molecular probe 196 studies then went on to 
investigate the coupling of the active marked library members to the biotinylated 
azide 193. The reaction of N-propargyl anisomycin 140 with 193 proceeded readily 
to give molecular probe 197 (Scheme 3.18). 
0 













Scheme 3.18: (a) 140, CuSO4 . 5H20 (10 mol%), NaAsc (20 mol%), tBUOH.H20  (1:1) (71%). 
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A detailed investigation of the structure of 197 was then carried out using a series of 
NMR techniques (Appendix 3). On comparison of the NMR spectra of the two 
starting materials 140 and 193 with that of the product 197, the transfer of signals 
from each of the components can be clearly observed (Figure 3.14). Coupling of the 
two fragments does however lead to one new peak in the proton spectrum, from the 
C 1 8H proton of the triazole, which can be clearly seen as a broad singlet at 7.96 ppm. 
A full assignment of the HSQC spectrum of 197 (Figure 3.15) was possible upon 
comparison with the HSQC spectra of the synthetic precursors and the results of the 
other 2D NMR experiments undertaken. 
MeO 	AcO OH 
140 
HN 	H 
H- (-H 	H 
193 
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80 	 70 	 60 	 40 	 40 	 30 	 2.0 
00M An  
Figure 3.14: NMR stack plot of 140 (top), 193 (middle) and 197 (bottom) at 360 MHz. 
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Figure 3.15: Fully assigned HSQC spectrum of 197 at 360 MHz in DMSO. 
Our attention then turned to the coupling of the O-propargyl marked analogue 136. 
Initial synthetic attempts led to the coupling of the two components when monitoring 
the reaction by tic. However, purification of the free amine proved to be challenging 
(Scheme 3.19). Upon column chromatography the amine was found to streak on the 
column, resulting in the isolation of impure product. Attempts to purify the mixture 
by HPLC and reverse phase column chromatography also proved unsuccessful. 
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Scheme 3.19: (a) 136, CuSO4. 5H20 (10 mol%), NaAsc (20 mol%), tBuOH:H20 (1:1). 
However, on coupling the Boc protected marked analogue 135 to the biotinylated 
azide 193 the product could be isolated cleanly and in high yields (Scheme 3.20). 
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Scheme 3.20: (a) 135, CuSO4 . 5H 20 (10 mol%), NaAsc (20 mol%), tBuOH:H20  (1:1) (70%); 
(b) TEA, DCM (98%). 
With the three molecular probes in hand, it was decided to expand this methodology 
to explore what role the length of the carbon linker between the biotin tag and the 
anisomycin analogue had on activation of the SAPK pathways. Starting from 6-
amino hexan-l-ol 199 the azide could be readily converted into the desired amino 
azide linker 201 in two steps. Firstly the alcohol 199 is reacted with thionyl chloride 
to form the chloride analogue 200; then the chloride is displaced with sodium azide 
to give the desired azide 201 in 90% over two steps (Scheme 3.21). The azide 201 
can then be coupled to biotin-NHS 192 using a procedure analogous to that used for 
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Scheme 3.22: (a) 201, Et3N, MeOH (89%). 
Applying the same 'click' reaction conditions utilised in the previous coupling, the 
longer azido-C 6-biotin 202 was coupled to the control compound 195, the N- 
propargyl anisomycin 140 and the O-propargyl analogue 135, forming 203, 204 and 
M. 
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205 respectively, all in high yields. All the molecular probes were characterised by 
extensive 2D NMR experiments and were found to have very similar spectra to the 
analogous shorter linker probes. The key differences were found in the alkyl region 
of the spectra where the C 16-C 1 9 Cl-h's of the linker were found to be overlapping 
with the C9-C11 CH 2 's of the biotin chain. 
The synthesis of all the biotinylated molecular probes formed using 'click' chemistry 
has been summarised (Table 3.2). Across the board the coupling of the propargyl 
marked molecules to the biotinylated azide has occurred in high yields and with high 
regioselectivity. Thus illustrating the strength of the copper(I)-catalysed Huisgen 
cycloaddition as a powerful reaction for coupling of two orthogonally marked units. 
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86% (196) 75%(203) 
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Table 3.2: Summary of click coupling reactions used to form a series of biotinylated 
molecular probes. 
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3.5.2 Synthesis of 'Classical' Biotinylated Molecular Probes 
As a contrasting approach to the synthesis of molecular probes, the decision was 
taken to investigate a more 'classical' approach to the biotinylation of small 
molecules. Classically, biotin would be attached through the formation of amide or 
ester bonds. However, in our case this was believed to be an unfeasible strategy as 
this would generate a number of issues at our proposed coupling sites. At the 
phenolic functionality, formation of an ester would give a phenolic ester; which are 
notoriously unstable. In contrast, formation of an amide at the pyrrolidine nitrogen 
would give a strong bond, however there are no reports in the literature or within the 
Hulme group that amides [or carbamates] are tolerated for activation of the SAPK 
phenotype. We therefore decided to apply a different strategy by utilising 
nucleophilic displacement chemistry as the 'classical' coupling reaction. For this 
strategy the commercially available iodoacetyl-C 2-biotin 76 (Molecular Probes) was 
utilised as a direct comparison to our azido-C 2-biotin 193. Coupling of the phenol 
control compound 194 to the iodoacetyl biotin 76 occurred readily in the presence of 
potassium carbonate base upon heating at 80 °C in DMF (Scheme 3.23). This gave 
the desired product 206 in 86% yield after purification by column chromatography. 
With this initial good result in hand; we set about synthesising the analogous 
molecular probes based on anisomycin's scaffold. 
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Scheme 3.23: (a) 194, K2CO3,  DMF, 80 OC (86%).320 
Initial attempts focused on applying the successful coupling conditions used for the 
control compound to the coupling of anisomycin 102 (Scheme 3.24). However, the 
high yields obtained on coupling the control compounds were found to be impossible 
to reproduce when coupling the more complicated substrate. Heating the two 
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coupling components 76 and 102 with potassium carbonate in DMF for 5 days led to 
the isolation of 34% of the target material 207. 
0 
HN NH 






Scheme 3.24: (a) 102, K2CO3,  DMF, 80 ° C (34%); or 102, K2CO3,  Bu 4 NI, acetone; or 102, 
K2CO3, KI, DMF, iwave. 
Due to the long timescale of this reaction it was believed that a feasible option was to 
carry out the reaction in a microwave. The fragments to be coupled 76 and 102 were 
irradiated in DMF in the presence of potassium carbonate for 5-20 mm. However, 
upon analysis of the crude NMR spectra the loss of the acetate moiety from 
anisomycin was clearly shown, even after 5 mm. Therefore, the base was altered 
from potassium carbonate, as this was believed to be facilitating the removal of the 
acetate under microwave conditions, and replaced with triethylamine. However, 
these alterations did not improve the reaction, with starting materials being recovered 
in all cases. 
We therefore turned our attention back to the original conditions and carried out the 
coupling of the phenolic analogue 134, to obtain the molecular probe in 31% yield 
(Scheme 3.25). Removal of the carbamate protecting group occurred in high yield to 
give the desired molecular probe 208. 
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Scheme 3.25: (a) 134, K2CO3,  DMF, 80 °C (31%); (b) TEA, DCM (95%). 
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Having synthesised the classically linked short chain molecular probes our attention 
therefore moved on to the development of a longer carbon linker; thus allowing a 
direct comparison to the coupling of the azido-C 6-biotin 202. lodo- and chioro-acetyl 
biotin linkers 210 and 211 were synthesised within the group in three synthetic steps 
from biotin-NHS 192 and mono-Boc hexane-1,6-diamine 209 (Scheme 3.26). 
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Scheme 3.26: Three ste synthesis of iodo/chloroacetyl-C6-biotin 2101211 from biotin-N-
succinimidyl ester 192.32 
Using the reaction conditions previously optimised iodoacetyl biotin 210 was 
coupled to the control compound 194 to give 212 in 72%. However, on altering the 
nucleophile to anisomycin 102 the reaction only gave 35% of 213 after purification 
by column chromatograph; while in the case of the phenolic analogue 134 no trace of 
coupled product was isolated. Investigations into the coupling reaction of the 
chioroacetyl biotin 211 found that it gave analogous results to that of the iodoacetyl 
reagent 210 in all cases. 
The 'classical' coupling results for the nucleophilic displacement reactions are 
summarised (Table 3.3). The data shows that, as with the 'click' couplings, the 
length of linker does not play a key factor in the reproducibility of the coupling 
reaction. However, the nature of the nucleophile (either steric or electronic) plays a 
key role in couplings of this manner. It can be concluded that coupling of simple 
substrates using this nucleophilic methodology can be achieved in high yield, but on 
more complex substrates the applicability of this methodology rapidly diminishes. 
100 
Chapter 3 	 Results & Discussion 
0 	 0 
HNANH 	 HNANH 
H H H 	 H0/HNR1R2 
	 H H 
K2CO3, DMF 	s 
0 	0 	 0 	0 
o 	 Classical Coupling 
H NA NH 
H-4----H 	 H 	H 














31%(208) 	 N/A 
134  
Table 3.3: Summary of classical' coupling reactions used to form a series of biotinylated 
molecular probes. 
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3.5.3 Comparison of 'Click' v 'Classical' Coupling Strategies 
On comparison of the two coupling strategies a number of distinct advantages were 
found using the 'click' approach. These included the ease with which the biotinylated 
azides were synthesised, the high yields and regioselectivities observed across a 
range of coupling partners and the ease with which the products could be purified. In 
contrast, the 'classical' approach suffered difficulties from the outset, as the synthesis 
of the iodoacetyl-C 6-biotin proved problematic. Upon the successful synthesis of the 
iodoacetyl-C 6-biotin, the coupling reaction to structurally simple coupling partners 
proceeded in high yield. However, on attempting to couple to more complex 
molecules this reaction failed to give even moderate yields and purification proved 
challenging. 
The 'classical' approach to the biotinylated molecular probes encountered a range of 
synthetic issues, in contrast to the straightforward methodology applied to the 'click' 
substrates, where the coupling partners were easily derivatised with the required 
azide-alkyne functionality and the coupling proceeded readily. These results further 
illustrate the power of the copper(l)-catalysed Huisgen cycloaddition, as a key 
coupling reaction across a broad range of molecular architectures. 
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3.5.4 Biological Testing of the Biotinylated Molecular Probes 
On completing the synthesis of the biotinylated molecular probes, we set out to 
investigate the response of the SAPK pathways upon stimulation with these 
molecules. Immunoblot assays were carried out as previously described and tested 
for the phosphorylation of the protein JNK.246' 258  The molecular probes were 
classified and tested according to linker length and the coupling reaction used in their 
formation. The blots show negative (lanes 1/2) and positive standards (lanes 3/4), 
followed by the control molecular probe (lanes 5/6), the N-linked molecular probe 
(lanes 7/8) and the 0-linked molecular probe (lanes 9/10). 
Immunoblot assays for the series of probes formed by the 'click' reaction of the 
azido-C 2-biotin 193 showed that the control probe 196, as intended, did not activate 
the SAPK pathway (Figure 3.16, lanes 5/6). The N-linked molecular probe 197 
showed levels of activation analogous to that of anisomycin itself (Figure 3.16, lanes 
7/8), while the 0-linked molecule 198 was not found to give any phenotypic SAPK 
response (Figure 3.16, lanes 9/10), 
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Figure 3.16: Immunoblot assay for the phosphorylation of JNK1/2 and upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 3/4), control 
molecular probe 196 (lanes 5/6), Winked molecular probe 197 (lanes 7/8) and 0-linked 
molecular probe 198 (lanes 9/10). Molecular probes were formed by the click' reaction of the 
short chain biotinylated azide 193. 
Biological testing of the next series of molecular probes, formed by the click' 
reaction of the long chain-C 6-azide 202 showed an identical pattern for SAPK 
activation (Figure 3.17). Again, the control probe 203 and the 0-linked probe 205 
were found to be inactive (Figure 3.17, lanes 5/6 and 9/10 respectively), while the N- 
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linked molecular probe 204 formed by a 'click' reaction of the long chain C 6-
biotinylated azide 202 shows a strong phenotypic response (Figure 3.17, lanes 7/8). 
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Figure 3.17: Immunoblot assay for the phosphorylation of JNK1/2 and upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 314), control 
molecular probe 203 (lanes 5/6), Winked molecular probe 204 (lanes 7/8) and 0-linked 
molecular probe 205 (lanes 9/10). Molecular probes were formed by the 'click' reaction of the 
long chain biotinylated azide 202. 
On altering from the 'click' coupled molecular probes to the classically formed 
probes with the short chain, an identical pattern was found upon testing (Figure 
3.18). Positive phenotype responses were obtained from the anisomycin standard and 
the N-linked molecular probe 207 (Figure 3.18, lanes 7/8). As with the previous 
cases the control and 0-linked probes (206 and 208) were found to be inactive in 
testing for phosphorylation of JNK (Figure 3.18, lanes 5/6 and 9/10 respectively). 
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Figure 3.18: Immunoblot assay for the phosphorylation of JNK1/2 and upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 3/4), control 
molecular probe 206 (lanes 5/6), Winked molecular probe 207 (lanes 7/8) and 0-linked 
molecular probe 208 (lanes 9/10). Molecular probes were formed by the nucleophilic 
displacement reaction of the short chain biotinylated iodoacetyl 76. 
104 
Chapter 3 	 Results & Discussion 
The final series of long chain classical probes were then tested for the phenotypic 
SAPK response and were found, reassuringly, to show the same trends as the 
previous series (Figure 3.19). Once again the N-linked molecular probe 213 was 
found to activate the pathway in a comparable level to that of the anisomycin 
positive standard (Figure 3.19, lanes 7/8), while the other molecular probes tested 
were found to give no response (Figure 3.19, lanes 5/6 and 9/10 respectively). 
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Figure 3.19: Immunoblot assay for the phosphorylation of JNK1/2 and upon stimulation by 
DMSO (negative standard, lanes 1/2), anisomycin 102 (positive standard, lanes 3/4), control 
molecular probe 212 (lanes 5/6), Winked molecular probe 213 (lanes 7/8) and DMSO (lanes 
9/10). Molecular probes were formed by the nucleophilic displacement reaction of the long 
chain biotinylated lodoacetyl 210. 
With these results in hand, it can be concluded that we have synthesised four 
biotinylated molecular probes that active the SAPK pathway. Each active molecular 
probe was structurally different with varying linker lengths (C2 and CO  and was 
formed using a different coupling strategy ('click' chemistry and 'classical' 
nucleophilic displacement chemistry). However, two key factors emerged in the 
synthesis of active molecular probes. Firstly, the structure of the anisomycin moiety 
must be based solely on the anisomycin core, not the C 4-H analogue. Moreover, the 
coupling reaction should be carried out at the pyrrolidine nitrogen of anisomycin's 
molecular scaffold in order to form functionally active molecular probes. 
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3.5.5 Affinity Chromatography 
Having successfully synthesised a number of biotinylated molecular probes, work 
began on the identification of anisomycin's binding site. Utilising a series of 
biochemical techniques, a number of preliminary experiments were carried out to 
find the most applicable method of target identification. 
Starting with affinity chromatography using streptavidin-sepharose as the affinity 
media, the HEK293 cell lysates were precleared to remove all endogenously 
biotinylated proteins. The molecular probes 196 and 197 were then added to the cell 
lysates and rotated for 1 h. The excess lysates were removed and the streptavidin-
sepharose denatured in SDS. The denatured proteins were separated by SDS-PAGE 
and stained with Ponceau S. However, analysis of this gel showed a large 
background response making the detection of individual protein bands impossible. 
Our attention then turned to using magnetic Dynabeads ® with streptavidin instead of 
streptavidin-sepharose. It was believed that this alteration would reduce the levels of 
background response and improve the sensitivity of the experiment. Carrying out the 
pull-down experiment using the previous conditions but with Dynabeads ® led to 
significant improvements (Figure 3.20). Firstly, the large background that had 
obscured any protein bands during the initial experiment had been removed, while a 
series of bands distinct from the control lanes (Figure 3.20, lanes 1/2) were found in 
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Figure 3.20: SDS-PAGE of cell lysates removed from Dynabeads ® and stained with 
Ponceau S. Lane 1/2: internal standards using the control molecular probe 196. Lane 3/4: 
pulldown experiments using active molecular probe 197. 
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However, our concern was raised when the bands in lanes 3/4 were found not to 
match, even though this experiment had been carried out in duplicate. Despite this 
anomaly the protein bands of interest were cut from the gel, digested in tripsin and 
analysed by MS-MS. The protein bands were identified as widely expressed protein 
that had been pulled down in a non-specific manner. However, we believe that the 
use of the Dynabeads®  will lead to an improved experimental procedure for future 
work. 
We therefore turned our attention to using Western blotting and Far Western blotting 
to identify the biological target of anisomycin. Western blotting was carried out in an 
identical manner to previous experiments, with HEK293 cell lysates being treated 
with molecular probes 196, 197 and 207 for 30 min before lysis. The protein were 
separated by SDS-PAGE and transferred to nitrocellulose membrane. An avidin-
HRP secondary antibody was then incubated with the membranes and 
immunoreactive protein visualised using ECL, in an attempt to identify the biological 
target of the molecular probe. However, no distinctive protein bands were identified 
on comparing the control lanes to the probes 196, 197 and 207 (Appendix 4a). On 
altering the protein separation conditions from denaturing to non-denaturing, the 
immunoblot assay resulted in the visualisation of a single protein band across the 
control and active probe lanes (Appendix 4b). 
The Far Western blotting experiment took the untreated cell lysates and separated 
them using SDS-PAGE, before transferring the proteins to nitrocellulose membrane. 
The membranes were then treated with the molecular probes 196 and 197, utilising 
them as a primary antibody. Subsequently incubation with avidin-HRP as a 
secondary antibody, allowed the immunoreactive proteins to be visualised using 
ECL. The experiment utilising denaturing conditions led to the visualisation of a 
large number of proteins, however no bands were found to differ from that of the 
control lanes (Appendix 4c). On utilising native gels to separate the proteins a single 
protein band was visualised but once again it was found in both the control and 
active probe lanes (Appendix 4d). 
At this point in time the library of biotinylated molecular probes was handed over to 
our collaborators at the MRC Protein Phosphorylation Unit in Dundee to continue 
the affinity chromatography experiments. 
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3.6 Solid Supported Anisomycin 
Having successfully synthesised a series of biotin and fluorophore derived molecular 
probes based on coupling anisomycin through its pyrrolidine nitrogen; we next 
focused on applying our coupling strategy to the synthesis of solid supported 
anisomycin. The solid support utilised was Affi-gel-10 214 (Bio-Rad), an agarose 
based affinity media that contains a neutral 10-atom spacer arm and a reactive N-
hydroxysuccinimide ester (Figure 3.21).321  It is designed to couple to a primary 
amino group in both aqueous and non-aqueous systems, and appeared ideal for our 
purpose. 
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Figure 3.21: Structure of Affi-gel-1O 214. 
Coupling of Affi-gel-10 214 to the short chain azide 187 was carried out readily in 
methanol in the presence of 5 equivalents of azide to give 215 (Scheme 3.27). After 
extensive washing with methanol and isopropyl alcohol, the introduction of the azide 
functionality was confirmed by JR spectroscopy which showed an azide stretch at 
2109 cm'. 
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Scheme 3.27: (a) 187, MeOH (100%). 
The functionalised azide 215 was then coupled to N-propargyl anisomycin 140 using 
the copper(I)-catalysed Huisgen cycloaddition reaction in a water:'butanol (1:1) 
mixture (Scheme 3.28). The presence of N-propargyl anisomycin 140 was monitored 
by tic during the reaction and the reaction stopped upon complete incorporation of 
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the propargyl moiety. The solid support anisomycin 216 was washed with 'butanol 
and the organics concentrated to recover trace amounts of unreacted 140, thus 
confirming the coupling of the anisomycin to the solid support. 
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Scheme 3.28: (a) 140, CuSO 4. 5H20 (10 mol%), NaAsc (20 mol%), tBuOH:H20  (1:1) (98%). 
The solid supported anisomycin probe and a sample of the solid supported azide have 
also been passed onto our collaborators (MRC PPU, Dundee). The solid supported 
and biotinylated molecular probes are currently being utilised in an attempt to 
identify anisomycin's subcellular binding partner. 
3.7 Summary 
The synthesis and characterisation of a number of fluorescent molecular probes 
based on the active marked library members has been successfully carried out. 
Immunoblot assay for the activation of the SAPK pathway showed the synthesis of 
an active fluorescent molecular probe 191. Subsequent FACS and microscopy 
investigations into the subcellular location of anisomycin were carried out utilising 
191. These investigations have allowed us to conclude that there is selective uptake 
of the molecular probe in the cytosol of HEK293 cells. 
A series of biotinylated molecular probes (196-198 and 203-205) have also been 
synthesised using the same marked library members. A comparative study of 
coupling reactions was carried out between the copper(I) catalysed 'click' reaction 
and a 'classical' nucleophilic displacement. The experimental results 
overwhelmingly favoured the 'click' reaction, which gave the desired molecular 
probes in high yields over a range of substrates. In contrast, the 'classical' reaction 
proved to be slow and unreliable for the coupling of complex substrates. 
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A distinctive trend emerged during the synthesis of the molecular probes. All the 
compounds linked through the pyrrolidine nitrogen of anisomycin showed the 
phenotypic SAPK response. This trend was continued over a wide range of 
molecular probes whether 'classically' or 'click' coupled, with C2 or C6 linkers, with 
dansyl or biotin. This series of results provides us with new detailed SAR 
information for anisomycin's activation of the SAPK pathways. Based on this new 
SAR data the synthesis of a solid supported analogue of anisomycin was readily 
achieved from commercially available Affigel. The biotinylated and solid supported 
molecular probes are now being used to identify anisomycin's biological site of 
action. Consequently, identification of the target protein will lead to a greater 
understanding of the mechanism of activation of the SAPK pathways and may also 
generate new therapeutic targets. 
Small molecule chemical genetics screens can generate large numbers of active 
compounds. However current strategies for the development of these "hits" into 
active molecular probes for further biological investigation are often cumbersome. In 
the case of anisomycin, it has been demonstrated that the incorporation of a 
biocompatible propargyl marker into the molecular scaffold can lead to the rapid 
generation of active molecular probes based on both the dansyl fluorophore and 
biotin. 
Due to the wide range of biocompatible reactions which have been developed over 
the last few years, there are a number of options for the choice of bioorthogonal 
markers. This allows the tailoring of this strategy to the small molecule library under 
investigation. Therefore, future library design using this marked library approach 
should provide a useful truncation of the small-molecule to molecular probe 
synthetic process. 
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4 Steroid Marked Libraries and Molecular Probes 
4.1 Steroids 
The term steroid covers a large series of biomolecules based on a carbon skeleton 
arranged in four fused rings. These molecules have a wide range of biological function 
with common categories including: anabolic steroids which are often used as 
performance enhancing drugs; corticosteroids which regulate many aspects of 
metabolism, renal excretion and immune function; sex steroids which include the 
oestrogens and androgens and phytosterols which are found in a range of plants. 134 
4. 1.1 Steroid Nomenclature 
The common names of steroids are widely recognised such as cholesterol, 
testosterone, etc. However, systematic nomenclature is becoming more prevalent 
making familiarity with both nomenclatures increasingly important. The steroid rings 
are designated as A, B, C and D rings, with the numbering of the carbon skeleton 





1 19 C D 16 AXt a 14 15 3 HO 	4 	6 
217 
Figure 4.1: General steroid architecture, illustrating the nomenclature used to describe the 
four fused rings and the numbering of the carbon backbone. 322,323 
The classification of steroids is based on the number of carbon atoms within the 
molecule's structure. Steroids with 21 carbon atoms are classified as pregnanes, 
whereas those with 19 and 18 carbon atoms are classified as androstanes and estranes 
respectively. Prefixes are often used whereby nat- defines the naturally occurring 
enantiomer, ent- the opposite enantiomer and rac- the racemic steroid. On top of this 
the signs a/13 indicate the relative stereochemistry with relation to the plane of the 
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molecule; where a substituent below the plane is termed a and one above the plane 13. 
Therefore, 217 is found under a number of names including dehydroepiandrosterone 
(DHEA), prasterone and 3f3-hydroxy-5-androsten-17-one to name but a few. 
4.1.2 Steroid Biosynthesis 
Despite the number of steroids that have been identified in plants, animals and humans 
the vast majority of steroids are derived from the acetyl CoA biosynthetic pathway.' 34, 
324 The first sequence of reactions in this biosynthetic process involves the synthesis of 
squalene 225, the key C30 building block in the formation of steroids. Starting from 
the small building blocks acetyl and acetoacetyl SCoA (219 and 218), condensation 
and subsequent hydrolysis forms mevalonate 220, before decarboxylative elimination 
to form isopentenyl pyrophosphate (IPP) 221 (Scheme 4. 1).121-321  Six units of IPP 221 
are then condensed resulting in the formation of the C30 squalene unit 225. This occurs 
in a convergent manner combining three C5 (isopentenyl) units 
(221+222—*223+221----*224) to give a C15 (farnesyl) unit 224 which can then dimerise 















Scheme 4.1: Biosynthesis of squalene 225 the key intermediate in the formation of steroid 
architecture. 
134, 324-528 
The next series of biotransformations leads to the formation of the steroid core, a 
sequence which begins with the activation of squalene 225 via epoxidation of the 
terminal double bond to give 226 (Scheme 4.2). 329-331  A facile cyclisation catalysed by 
oxidosqualene cyclase then takes place in a remarkable concerted biotransformation 










Chapter 4 	 Results & Discussion 
then rearranges to form lanosterol 228, which can be converted into cholesterol 229 
through a number of biosynthetic steps. 329-331 
H 	 19 
HO 	
Steps c# HO 
229 	 H 228 
Scheme 4.2: Biosynthesis of cholesterol 229 from squalene 225; through formation of a 
terminal expoxide, concerted cyclisation and rearrangement to form the steroid core, before a 
number of functional group modifications to give cholesterol 
.121-131 
Cholesterol 229 is mainly synthesised in the liver, with the intestine also forming 
significant amounts. 134 In addition it can be obtained from dietary sources; with an 
adult on a low cholesterol diet typically synthesising about 800 mg of cholesterol per 
day. 134  Cholesterol has an important biochemical role in the formation and 
maintenance of cell membranes, the manufacturing of bile and the metabolism of 
vitamins A, D, E and K, as well as being the key intermediate in the biosynthesis of a 
wide range of steroids. 332 
The conversion of cholesterol 229 to pregnenolone 230 is accomplished by the 
cleavage of the cholesterol side chain unit, a process which is catalysed by a 
cytochrome P450 enzyme termed P450scc, where scc stands for side chain cleavage 
(Scheme 4•3)333 This enzyme catalyses three distinct sequential reactions on a 
single active site, firstly the hydroxylation of C22, followed by the hydroxylation of 
C20 and .then the cleavage of the C20-C22 bond to give 230 and isocaproaldehyde. Each 
of these individual steps requires a pair of electrons from NADPH, which are passed 
via a flavoprotein to an iron/sulfur protein and on to the P450. 335 
Pregnenolone 230 is then' converted to DHEA 217 in a two step process that is 
catalysed by a single cytochrome enzyme, P450c17. 333 ' 334 The first step in this process 
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is the 17a-hydroxylation of the steroidal core to give 231. This is followed by the 
cleavage of the C 17-C20 bond in a lyase reaction, which is stimulated by the presence 
of cytochrome b5, forming DHEA 217. The role of cytochrome b5 in this process has 
not been confirmed but experimental data suggest that it acts as an allosteric activator 
of the lyase reaction, rather than an alternative electron donor. 336  In addition the 
phosphorylation state of P450c17 is a key factor in regulating the lyase reaction, with 
phosphorylation of the serine/threonine residues of the cytochrome leading to an 
increase in lyase activity. 337  It has been proposed that increased phosphorylation 











Scheme 4.3: Biosynthetic conversion of cholesterol 229 to DHEA 217 via two P450 catalysed 
oxidative cleavage reaction S.333,334  
DHEA 217 is the most abundantly produced steroid hormone which plays a number of 
biological roles, but it can also be converted to a range of downstream steroid 
metabolites. 338' These include 4-androstene-3, 1 7-diol 232 and 4-androstene-3, 17-
dione 234 (Scheme 4.4), which in turn can be converted into the biologically 
important steroids testosterone, estrone and estradiol. DHEA 217 can also be sulfated 
at the C3-hydroxyl by the enzyme DHEA-sulfotransferase which is expressed in the 
339 human liver and adrenals forming dehydroepiandrosterone sulfate (DHEAS) 233. 
340 On the whole DHEAS represents the hydrophilic storage form of the steroid 
circulating in the blood stream, however only lipophilic DHEA can be converted into 
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androgéns and estrogens intracellularly. Therefore, hydrolysis of the sulfate 
functionality by a sulfatase enzyme is required before the conversion to the 
downstream metabolites can occur. Thus differential tissue expression of DHEA, 
DHEAS, sulfotransfêrase and sulfatase can regulate the formation of the sex 
steroids. 339,340 
bS HO 	 b 
217 
170-HSD/ STSI SULT2A1 \-HSDH 
Hedge 
03SO 
232 	 233 	 234 
Scheme 4.4: Conversion of DHEA 217 in to downstream metabolites via reduction, sulfation 
or oxidation to give 232, 233 and 234 respect ively. 338 ' 339 
4.1.3 Biological Action of DHEA and DHEAS 
DHEA and DHEAS are the most abundant steroids in the human circulation and exert 
a strong age-associated pattern. Serum DHEA and DHEAS levels start to increase 
from the ages of 6-10 years and peak between 25-3 5 years of age, a process termed the 
adrenarche. This is followed by a steady decline of —1 .5% per year with age, with 
levels finally residing at 10-20% of peak concentrations by the age of 7Ø•341343  This 
age associated decrease in DHEA secretion has been termed the adrenopause and has 
raised the question of whether some of the increased frailty associated with aging is a 
consequence of decreased levels of DHEA and DHEAS. Although aging is a complex 
process that cannot be explained by one theory, a decrease in steroids can play a 
significant role in the onset of the symptoms of aging. 
DHEA and DHEAS exert their biological function by two modes of action; indirectly 
by conversion to androgens, estrogens or other steroid metabolites (previously 
mentioned); or directly by interactions with receptors. 139, 340 Baulieu et al. were the 
first to publish the direct action of DHEA as a neurosteroid by showing the synthesis 
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of DHEA in the central nervous system (CNS), while also demonstrating that DI-TEAS 
is found at steady concentration in the brain tissue of rats. 344' These steroids can 
therefore be described as classical neurosteroids as both the synthesis and biochemical 
action take place within the CNS. DHEA has been shown to modulate signalling 
through a number of membrane-bound receptors including the stimulation of N-
methyl-D-aspartate (NMDA) receptors and as an allosteric antagonist of the 'y-
aminobutyric acid (GABA) receptor. 146-14'  Therefore, DHEA selectively interacts with 
neurotransmitter receptors which are not classically considered to be steroid receptors. 
Studies have also tried to link DHEA and DHEAS to depression, as depressed patients 
have been shown to have significantly higher levels of plasma DHEAS than control 
patients. 349  Treatment with DHEA has been shown to significantly reduce depression 
on several scales as well as improving energy levels and motivation. 350  However, once 
again there is no evidence to confirm if DHEA or one of its downstream metabolites is 
causing this effect. 
In 'vitro studies have shown that DHEA can modulate immune cell function. Immune 
responses decline with age, termed immunesenescence. Typically with 
immunesenescence the serum levels of interleukin 6 (IL-6) increases while the 
concentration of interleukin 2 (IL-2) decreases. 111, 112  On administration of DHEA the 
synthesis of IL-2 by T lymphocytes is stimulated, while the production of IL-6 is 
inhibited, thus reversing some of the effects of the immunesenescence process. 353-355 
However, it is possible that immunological effects of DHEA are only mediated 
indirectly, as a consequence of downstream steroid metabolites. 
To date no receptor specific for DHEA has been characterised. However, a number of 
researchers have recently focused on the theory that steroids may have a distinct 
binding site within the cell, with studies into DHEA's site of action focussing 
extensively on membrane bound targets. 356  Research by Dillon et al. into the 
membrane initiated action of DHEA led to the conclusion that the steroid interacts 
with high affinity binding to G-protein coupled receptors (GPCR). Further studies 
showed the binding of DHEA to GPCR was functionally linked to an increase in the 
synthesis of NO, whilst operating through a distinct pathway, separate from other 
steroid receptors. 357-359 More recently, work from Quon et al. showed that DHEA can 
be used to regulate vasodilatation and vasoconstriction through regulation of the eNOS 
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and ERK-1 pathways respectively (Figure 4.2) .360  These results suggest that DHEA 
has a high level target within the MAPK cascade, such as a GPCR, that allows 
regulation of a number of signal transduction pathways. 





Figure 4.2: The MAPK pathway, illustrating upstream and downstream targets as well as 
cross-talk between a number of pathways regulated by PDK1, a 'master' kinase. 
In contrast, investigations into the site' of interaction of DHEAS have yet to be 
investigated in the same detail, in part due to the widely held belief that the sulfated 
form of DHEA is biologically inert and functions only as a vehicle for transport of 
DHEA.36 ' Many cells express proteins known as Organic Anion Transporter proteins 
(OATP), which act as cell surface transporters for sulfated steroids such as DHEAS, 
allowing them entry to cells. 362-364  However, a recent publication from our 
collaborators (Prof. J. Lord and Prof. W. Arlt, University of Birmingham) has shown 
that DHEAS can directly activate neutrophils to generate superoxide. 36' Their 
preliminary data has shown that this effect can be blocked by bisindoylmaleimide, a 
protein kinase C (PKC) inhibitor, suggesting that PKC may be the target of DHEAS. 
Subsequent in vitro enzymatic assays have confirmed that DHEAS is able to activate 
PKC. PKC is known to be able to regulate the generation of superoxide in neutrophils, 
via phosphorylation of key elements of the multimeric enzyme NADPH oxidase. 
However, other kinases present in neutrophils can also phosphorylate NADPH oxidase 
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and lie downstream of PKC, namely PKB and MAPK. It has therefore been postulated 
that DHEAS can enter neutrophils via an OATP and then activate NADPH oxidase via 
activation of a protein kinase, which is likely to be PKC, but could also include other 
targets, e.g. MAPK and PKB (Figure 4.2). 
Given the hypothesis that there is a distinct biological target for DHEAS, mediated via 
the PKC/MAPK pathway, the decrease in DHEA(S) with age may play a role in the 
age-related senescence of cells that are able to respond to this steroid, including 
immune cells. Other biological responses associated with DHEA(S), such as the 
control of NMDA receptors, have also been tied to the MAPK pathways with 
phosphorylation of the receptor thought to play a large part in its mechanism. 366 
The role of DHEA and DHEAS as the key steroids in the formation of hormones has 
been well defined. However, the role of these steroids as regulators of immunity and 
signal transduction pathways has yet to be fully defined .311, 357 Therefore, the 
identification of the intracellular target(s) of DHEA and DHEAS would lead to a 
greater understanding of an important signal transduction pathway responsible for the 
regulation of a wide range of biological functions. 
4.2 Strategies for Marking a Range of Functionalities 
In order for the marked library strategy to be widely applicable during the synthesis of 
chemical libraries, incorporation of a biocompatible marker into the parent structure 
has to be achievable at a variety of functionalities. Using the propargyl marker that 
proved successful in the case of anisomycin, the literature was searched for a range of 
alternative reagents that could be used to incorporate the propargyl moiety. 
Previously research had focused on using propargyl bromide and coupling it to a range 
of phenols and amines (Table 4.1, row 1 and 5). However, literature precedent also 
showed that propargyl bromide can be used to couple to a range of alcohols and thiols 
(Table 4.1, row 1 and 8).367369  In addition, propargyl alcohol or amine can be coupled 
to acids, forming the analogous propargyl esters or amides (Table 4.1, row 11 and 
l2).104 While in an inverse approach the propargyl equivalent 3-butyneoic acid 
can be used to mark alcohols or amines within the parent structure (Table 4.1, row 3 
and 6).376378 
118 
Chapter 4 	 Results & Discussion 
Functionality Propargyl Marker Coupling conditions 











Br Base, DMF 
R-NHR 1 or R-NH 2 
OH 












OH DCC, DMAP, DCM 
R-COOH 
TBTU, HOBt, NMO, DMF 
Table 4.1: Illustrating the range of reagents, marking reactions and conditions for the 
incorporation of a propargyl marker into a small molecule's scaffold. 
Over the past few years propargyl chioroformate (PocCl) has been used infrequently 
as a method for protecting alcohols and amines within the fields of peptide and 
carbohydrate chemistry.379' 380  However, its deprotection conditions utilise 
tetrathiomolybdate making it an unusual piece of methodology. 38 ' Nonetheless, the 
ease with which the Poc protecting group can be coupled with a range of nucleophiles 
including alcohols, amines and thiols makes it an ideal alternative method to introduce 
a propargyl marker (Table 4.1, row 4, 7 and 9). 
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With a broad range of coupling to amines, alcohols, thiols and acids available, our 
focus altered to the marking of carbonyl functionalities. The ideal reaction for the 
marking Of this functionality was believed to be the Schiff base condensation, which 
in itself is often classed as a 'click' reaction. 97  Coupling of propargyl hydroxylamines 
has been shown to proceed readily with a range of aldehydes and ketones in high yield 
(Table 4. 1, row 10), thus making an ideal reagent for the introduction of the propargyl 
marker at the carbonyl moiety. 382,383 
A focused search of the literature has unearthed a range of reagents and reaction 
conditions which can be used to introduce a propargyl marker into a small molecule's 
scaffold. Thus illustrating that the concept of a marked small molecule library can be 
expanded beyond our initial study, to a wide range of biologically interesting 
molecules. 
4.3 Marked Steroids 
The role of steroids in the control of biological processes has been well documented. 
However, the precise signalling interaction of a number of these molecules has still to 
be fully. validated. We therefore set out to apply our marked library strategy to a 
number of steroids by incorporating a propargyl moiety into the steroidal scaffold. Our 
initial attention focused on DHEA 217 with incorporation of a propargyl marker 




Figure 4.3: Functionalities within DHEA's scaffold which could be used to attach a 
biocompatible marker: 
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4.3.1 NMR Assignment 
Prior to the incorporation of the propargyl marker, it was decided to investigate the 
structure of DHEA 217. In order to fully characterise DHEA, a combination of 2D 
NMR experiments were used as it was believed that having the fully assigned starting 
material would facilitate the determination of any products formed. 
Analysis of the 'H NMR spectrum obtained showed a distinctive doublet (5.39 ppm) 
for the CH and a triplet of triplets (3.54 ppm) for the C 3HOH (Figure 4.4). While the 
other 26 protons associated with DHEA were clustered together between 2.60 ppm 
and 0.90 ppm (Table 4.2. column 2). In contrast, analysis of the ' 3C broadband and 
DEPT spectra obtained allowed the relative assignment (i.e. Q ,  CH3 , CH2, CH) to be 







 1H' 	: C8H 	 C3H 	 1 J f F I 1 1 I 
0 
--,-- 
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Figure 4.4: 1 H NMR of DHEA 217 (CDCI3 , 600 MHz) 
Correlation of the 1 H spectrum with that of the COSY/HSQC/HMBC spectra obtained 
allowed the assignment of the majority of the structure (Table 4.2, column 4). 
However, determination of three peaks (C2H2, C8H and C 1 2H2) proved problematic as 
they occurred as four distinct regions in the 'H dimension but were found to lie top of 
each other at 31.4 ppm in the ' 3C dimension (Figure 4.5). 
C7 1-1 2 	
C2 H 2 , C8 H, 
• 	 C12H 	
13C 
220 
Figure 4.5: Slice of HSQC spectrum of DHEA 217 (CDCI3, 600 MHz). 
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( 1 H, 13c)  
Fully assigned 
1 H spectrum 
C I HA  CH 2 1.89-1.84, 37.0 1.89-1.84 (m) 
C 1 HB  CH 2 1.11,37.0 1.11 (dt) 
C 2HA  CH 2  1.89-1.84, 31.4 1.89-1.84 (m) 
C2H B  CH 2  1.57-1.46, 31.4 1.57-1.46 (m) 
C3 1-1 3.54 (tt) 71.5 (CH) 3.54, 71.5 3.54 (if) 
C4HA 2.33 (ddd) CH 2 2.33, 42.1 2.33 (ddd) 
C4H B 2.29-2.23 (m) CH 2 2.29-2.23, 42.1 2.29-2.23 (m) 
C5  140.9(Q) 140.9 - 
C6 1-1 5.39 (d) 120.8 (CH) 5.39, 120.8 5.39 (d) 
C7HA  Cl-I a 2.14-2.11, 30.7 2.14-2.11 (m) 
C7 1-1 8  Cl-I 2 1.71-1.63, 30.7 1.71-1.63 (m) 
C8 1-1  CH 1.89-1.84, 31.4 1.89-1.84 (m) 
C9H  CH 1.02, 50.1 1.02 (ddd) 
C10  Q 36.5 - 
C 1I HA  CH 2 1.71-1.63, 20.2 1.71-1.63 (m) 
C 11 HB  CH2 1.57-1.46, 20.2 1.57-1.46 (m) 
C l2H A  CH2  1.71-1.63, 31.4 1.71-1.63 (m) 
C 12 H B  CH2  1.32-1.26, 31.4 1.32-1.26 (m) 
C13  Q 47.4 - 
C 14H  CH 1.32-1.26, 51.6 1.32-1.26 (m) 
C15HA  CH 2 1.96, 21.8 1.96 (ddd) - 
C 15H 5  CH2  1.57-1.46,21.8 1.57-1.46 (m) 
C 16HA 2.47 (dd) CH 2 2.47, 35.7 2.47 (dd) 
C16H8 2.09 (dd) CH 2 2.09, 35.7 2.09 (dd) 
C 17  221.2(Q) 221.2 - 
C 18H 3  0.90(s) 13.4 (Cl-I3) 0.90, 13.4 0.90(s) 
C 19 1-1 3  1.05(s) 19.3 (CH) 1.05, 19.3 1.05(s) 
Table 4.2: Table of NMR data for DHEA 217, illustrating the NMR experiments used to carry 
out the full assignment of this molecule. 
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Attention turned to a series of 1D nOe experiments which it was believed could be 
used to facilitate the assignment of the C2H2, C8H and C12H2 peaks. Irradiation was 
carried out at the C 3H, the C 18H3. and the C 1 9H3 peaks respectively; as they were 
located in close proximity to the protons of interest, while also representing well 
defined signals at which to irradiate (Figure 4.6). However, the highly congested 
nature of the 'H spectrum in the aliphatic region made it impossible to clarify the 




I 	OH3 IjI 	El,830 




nOe C H 
Figure 4.6: Structure of DHEA 217: (a) showing the signals irradiated during nOe experiments 
(b) expected nOe signals. 
The defining experiment was an HSQC-TOCSY which allowed the structure of 
DHEA to be fully characterised by NMR (Appendix 5). This experiment is a 
traditional 2D HSQC that allows for this spin to be passed via a TOCSY transfer prior 
to data acquisition. This relays the original proton-carbon correlation peak onto 
neighbouring protons within the same spin-system, thus producing a ' 3C-dispersed 
TOCSY spectrum (Figure 4.7). 
ITIA 'TIc 	 (b) 	TOCSY 	HSQC (a) Tocsvfll 	J x-peaks peak 
J 	




Figure 4.7: (a) Illustration of the spin transfer in an HSQC-TOCSY experiment, and (b) the 
resultant spectrum with TOCSY cross-peaks in the carbon dimension. 
Therefore, correlating all the previously assigned NMR data, the full characterisation 
of DHEA was completed using the cross peaks from the HSQC-TOCSY spectrum 
(Table 4.2, column 5). Thus, allowing the problematic signals associated with C2H2, 
CH and C 12H2 to be assigned and the 'H and 13C spectra of DHEA to be fully 
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determined (Figure 4.8). Gratifyingly the 1 H data correlates with the proton sequence 
of DHEA produced by Keeler; who has recently used DHEA to develop new pulse 
sequences methodology that can simplifying complex proton spectra. 394  
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Figure 4.8: Slice of assigned HSQC spectrum of DHEA 217 (CDCI3, 600 MHz). 
4.3.2 Marking DHEA 
Having fully characterised DHEA 217 attention now focused on the incorporation of a 
propargyl marker onto the steroidal scaffold. Initial investigations utilised the 
conditions successfully applied to the propargylation of anisomycin (K2CO3, 
propargyl bromide) in order to convert DHEA's hydroxyl moiety into the analogous 
propargyl ether 235. Unfortunately, under these conditions no coupling reaction was 
observed upon monitoring by tic and MS, and after work-up the steroidal starting 
material was recovered (Table 4.3). 
Previous work by Pauson et al. showed the conversion of DHEA's downstream 
metabolite cholesterol to analogous propargyl cholesterol. 385  This was carried out by 
refluxing the steroid in the presence of sodium hydride for 24 h, before addition of 
propargyl bromide to give the desired functionalised steroid. However, this method 
proved to be unsuccessful for the propargylation of DHEA (Table 4.3, entry 16). 
We therefore began a screen of solvents and bases in order to devise a set of 
conditions that would allow the formation of the propargyl ether (Table 4.3). 
Investigations covered a wide range of organic and inorganic bases over a range of 
polar and non-polar solvents. However, each time the reaction was carried out only 
unreacted DHEA was obtained. 
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H0-'C9 
217 	 235 
Base Solvent Additive/Conditions 217 235 
K2CO3 (2 eq) DMF Quant. 
K2CO3 (2 eq) CH3CN Quant. 
pyridine DMF imidazole Quant. 
pyridine CH3CN Quant. 
pyridine DCM Quant. 
pyridine DMF Quant. 
pyridine DMF DMAP Quant. 
pyridine DCM DMAP Quant. 
Cs2CO3 (3 eq) DMF Quant. 
Cs2CO3 (3 eq) DCM Quant. 
2,6-lutidine (2 eq) DCM Quant. 
Et3N (2 eq) DCM Quant. 
imidazole (10 eq) DMF Quant. 
NaH (2 eq) DCM Quant. 
NaH (2 eq) THF Quant. 
NaH (2 eq) DMF heating at 100 °C Quant. 
NaH (4 eq) p-xylene reflux Quant. 
KOtBu (2.5 eq) toluene reflux Unknown 
KOtBU (2.5 eq) CH3CN reflux Unknown 
Table 4.3: Table of basic conditions for the attempted propargylation of DHEA. 
On altering the base to potassium butoxide a new spot was observed by tic (Table 4.3, 
entry 18/19). However, this reaction never proceeded to completion and identification 
of the new spot as the desired product was never possible. 
The final attempt to synthesis the propargyl ether was carried out under acidic 
conditions utilising a method previously developed by Overman to propargylate 
secondary alcohols. 116, 387 This methodology involved the formation of the propargyl 
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acetimidate 237 by reacting propargyl alcohol 236 with trichioroacetonitrile. 
Classically, formation of the acetimidate reagent has been carried out using sodium 
hydride, but more recently it has been found to proceed more cleanly with DBU as the 
base. 388  On adding the trichioroacetonitrile to a solution of DBU and propargyl alcohol 
the solution turned pale orange. After stirring for 2 h the solution was filtered through 
a plug of silica and concentrated. Analysis of the 1 H NMR spectrum showed a broad 
1H singlet at 8.15 ppm from the NH of the newly formed acetimidate 237. While, a 
2H doublet (4.94 ppm) and a 1H triplet (2.56 ppm) with fine splitting associated with 
the propargyl functionality were also present in the spectrum, thus confirming the 
formation of the acetimidate. The acetimidate 237 was rapidly carried through to the 
next step by addition of DHEA 217 and a catalytic amount of triflic acid in an attempt 
to form the propargyl ether 235. However, no reaction between DHEA and the 




236 	 237 
	
235 
Scheme 4.5: (a) CI3CCEN, DBU, DCM (100%); (b) DHEA, TfOH (cat), DCM. 
Having exhausted our efforts trying to synthesise the propargyl ether, our attention 
turned to forming the analogous ester and carbonate as means of introducing the 
propargyl moiety. Coupling of DHEA 217 to 3-butynoic acid 238 proceeded using 
EDI and DMAP but the yields were found to be only moderate. However, on altering 
the coupling agent to DIC the product 239 was isolated in a much more respectable 
75% (Scheme 4.6). Analysis of the proton spectrum of 239 clearly showed that the 
triplet of triplets at 3.54 ppm from the C 3HOH had been replaced by a multiplet at 
4.73-4.64 ppm. A singlet (1.98 ppm) was found to correspond to the CH2 of the 
propargyl moiety, with the corresponding propargyl CH (2.41-2.36 ppm) as part of a 
3H multiplet. However, the most surprising finding on interpreting this molecule's 
spectra was that the CH2 of the propargyl moiety was found to come at 4.0 ppm in the 
carbon dimension. This was a highly unexpected result but was confirmed by a 
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number of 21) NMR experiments including HSQC and HSQCTOCSY.tt  Moreover, 
this correlated with both the 13C spectrum of 3-butynoic acid which has the CH2 at 5.1 







a 	 0 H  
217 	 239 
Scheme 4.6: (a) 238, DIC, DMAP, DCM (75%). 
Coupling of propargyl chioroformate 240 to DHEA 217 was found not to proceed 
when earned out with imidazole in DCM. However, on altering the base from 
imidazole to pyridine, the reaction was found to give a single spot by tic (Scheme 
4.7). Characterisation of this material showed formation of the product 241 in high 
yield, with the distinctive propargyl peaks being observed at 2.53 ppm (1H, t) and 4.72 






a 	 H 
217 	 241 
Scheme 4.7: (a) 240, pyridine, DCM (86%). 
Upon slow evaporation of the NMR solvent colourless crystals were formed. The 
resulting X-ray crystal structure gave an excellent insight into the three dimensional 
arrangement of the steroid core (Figure 4.9 and Appendix 6). This structure illustrates 
the chair conformation of the A and C rings, the envelope-like D ring and the flattened 
B ring due to the presence of the alkene moiety. However, more interesting was the 
conformation of the propargyl functionality. Analysis of the crystal structure showed 
that the propargyl unit adopted a near-linear conformation with a bond angle of 173.8° 
All steroids were characterised by a combination of ID and 2D NMR experiments including 'H, 13 C, 
DEPT, HSQC, HSQC-TOCSY and HMBC. 
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between the C2 1 H2-C23H atoms. While the angle around the C 21 H2 of the propargyl 
was found to be 112.3 1 , more distorted relative to a typical sp 3 carbon. 
- 	
173.8°\ 
Figure 4.9: X-ray crystal structure of 241. 
Turning our attention to the other potential marking site within DHEA's scaffold, 
investigations then focused on the synthesis of an appropriate propargyl 
hydroxylamine. The commercially available N-propargyloxy phthalamide 242 was 
deprotected by stirring with hydrazine monohydrate, to give a colourless precipitate 
which was removed by filtration. Ethereal hydrochloric acid was then added to the 
filtrate and a further solid isolated upon filtration. Analysis of the precipitate by NMR 
showed both the desired product 243 and trace amounts of the 2,3-dihydro-
phthalazine- 1 ,4-dione by-product. However, repeating this synthetic process with 
methyl hydrazine was found to give the desired product 243 in higher yield and as a 
single compound without contamination (Scheme 4.8). 
0 
Q--- 	 HN° a HCI 
242 	 243 
Scheme 4.8: (a) H 2NNHMe, DCM; HCI in Et20 (80%). 
Coupling of the hydroxylamine 243 to DHEA's C 17-carbonyl 217 was found to occur 
readily on stirring the two components in methanol. This gave the desired product 244 
in 97% yield after purification by column chromatography. Characterisation of 244 by 
NMR clearly showed incorporation of the propargyl marker with a 2H doublet at 4.60 
ppm and a 1H triplet at 2.42 ppm. Moreover, analysis of the 2D spectra showed a 
distinctive shift of the C 16H2 from 35.7 ppm to 26.1 ppm in the carbon dimension. 
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Scheme 4.9: (a) 243, MeOH (97%). 
Expanding on the success of the Schiff base coupling, the development of a short 
chain hydroxylamine 247 was envisaged. Coupling the protected acid 245 to propargyl 
amine was carried out readily in the presence of ED! and DMAP to give 246 in high 
yield (Scheme 4.10). The Boc protecting group was then removed under acidic 
conditions using TFA to give the desired hydroxylamine 247. However, isolation of 
this material as its TFA salt proved to be problematic. Therefore, ion exchange to the 
chloride was carried out using Dowex resin pre-treated with HCl. The newly 
synthesised hydroxylamine 247 could then be coupled in a Schiff base condensation 
with DHEA to give 248 in 94% (Scheme 4.11). Once again analysis of the NMR 
spectra obtained showed formation of the oxime with the distinctive shift of the C 16H2 























217 	 248 
Scheme 4.11: (a) 247, MeOH (94%). 
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4.3.3 Marking DFIEAS 
Having successfully incorporated our biocompatible marker into the structure of 
DHEA we switched our focus to its downstream metabolite DHEAS. As this molecule 
is the sulfated form of DHEA, it was proposed that a Schiff base condensation could 
be exploited to couple propargyl hydroxylamines previously utilised to the ketone of 
DHEAS. 
On coupling commercially available DHEAS 233 to hydroxylamine 243 in methanol, 
no reaction was observed after 16 h. Initially this was thought to be due to the polarity 
of the sulfated steroid making it hard to monitor the reaction by tic (Scheme 4.12). 
However, upon work-up no condensation of the hydroxiamine could be observed by 
MS or NMR. In addition an identical problem was also found to occur when 
attempting to couple hydroxylamine 247 to DHEAS (Scheme 4.12). Upon examining 
the literature for synthetic modification of DHEAS only a few examples were found 
but none involved the formation of oximes or hydrazines. Therefore, it was decided to 







Scheme 4.12: (a) 243 or 247, MeOH. 
Taking the previously synthesised oxime 244, investigations focused on the sulfation 
of the C3-hydroxyl. Using sulfur trioxide trimethylamine complex as the key reagent, 
the sulfation of the marked steroid proceeded readily in pyridine (Scheme 4.13). 
Analysis of the product 250 by NMR showed a distinct shift from 3.54 ppm to 4.14 
ppm of the C3H signal associated with the sulfation of the hydroxyl. This could be 
directly contrasted to the analogous spectra of DHEA and DHEAS which show a 
distinctive shift upon incorporation of the sulfate functionality (Figure 4.10). 
However, the use of pyridine as the reaction solvent led to the formation of the 
pyridine salt of the sulfated steroid 250. Treatment of the pyridine salt 250 with 
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ammonium acetate followed by purification by reverse phase chromatography (5% 




PyH 03S0 	 NH403SO 
244 	 250 	 251 
Scheme 4.13: (i) S03 .NMe3 , pyridine; (ii) 5%NH 4OAc solution (85%). 
	
(a) 	 H 
NaO3SO 
233 




3.0 	 20 	 I'D 
217 	 1C3HOH 
5.0 	 4.0 	 3.0 	 2,0 	 1.0 
porn flu 
Figure 4.10: 1 H NMR spectra of (a) DHEAS 233 and (b) DHEA 217: illustrating the 
characteristic shift of the C3H upon addition/removal of the sulfate. 
Repeating this procedure with the short chain oxime 248 gave the desired sulfated 
steroid 253 in 96% yield after cation exchange and purification by reverse phase 
chromatography (Scheme 4.14). Sulfation of the C 3 -hydroxyl was confirmed by the 
movement of the C3H proton from 3.50 ppm to 4.14 ppm, while no loss of the oxime 
functionality was observed. 
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III 	 1  
HN 	 HN 	 HN 
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jw 
HOb
H ap~  H H NH4O3SO 
248 	 252 	 253 
Scheme 4.14: (i) S03.NMe3, pyridine; (ii) 5%NH 4OAc solution (96%). 
Therefore, a focused series of marked steroids have been synthesised based on the 
structure of DHEA and DHEAS. Incorporation of a propargyl marker onto the 
steroidal core has been carried out by functionalising the C3-hydroxyl as an ester or 
carbonate, or the C 17-carbonyl as an oxime. 
The application of our marked library strategy to this range of biologically interesting 
steroids illustrates the scope of functionalities that can be modified with a 
biocompatible marker, such as a propargyl unit. We therefore expect this marked 
library concept to be applied to further series of biologically interesting molecules, 
marking a range of chemical functionalities, through the incorporation of a 
biocompatible marker. 
4.4 Molecular Probe Formation 
An initial round of biological testing revealed that 248 showed excellent levels of 
activity in a chemotaxis assay, resulting in an increase in cell movement in contrast to 
DHEA and DHEAS. Therefore, the synthesis of a fluorescent molecular probe based 
on the scaffold of 248 was envisaged. This probe could then be utilised in subsequent 
investigations to track the steroid in vitro. 
The biologically interesting marked steroid 248 was converted to the analogous 
fluorescent molecular probe 254 in a single step by coupling to dansyl azide 189 
(Scheme 4.15). Utilising the copper(I) catalysed Huisgen cycloaddition reaction as the 
Biological testing was - carried out in Professor Janet Lord's research group at the University of 
Birmingham. 
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coupling step, the standard conditions of 10 mol% copper(II) sulfate and 20 mol% 
sodium ascorbate were utilised. This reaction proceeded in a spot to spot manner with 
a distinctive drop in Rf being observed upon coupling of the two components. The 














Scheme 4.15: (a) 189, CuSO4. 5H20 ( 10  mol%), NaAsc(20 mol%), tBuOH:H20 ( 1 : 1 ) (95%). 
The product 254 was characterised by carrying out a series of 1D and 2D NMR 
experiments to probe its structure (Appendix 5). Comparison of the 'H spectra of the 
two components (248 and 189) with that of the product 254 showed a distinctive 
transfer of signals, with the fluorophore component giving rise to the aromatic signals, 
while the steroid moiety gives rise to the aliphatic signals (Figure 4.11). A number of 
distinctive alterations could be observed upon formation of the triazole, with the two 
peaks associated with the propargyl unit being replaced by a singlet at 7.45 ppm 
(C27H) and a doublet at 4.43 ppm (C25H2). In addition, the CH2 next to the azide has 
been moved downfield from 3.30 ppm to 4.33 ppm upon formation of the triazole. 
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Figure 4.11: NMR stack plot of 248 (top), 189 (middle) and 254 (bottom). 
The synthesis of a second molecular probe was then investigated, based on the 
scaffold of the propargyl carbonate marked steroid 241. Studies focused on whether 
the copper(I) catalysed Huisgen cycloaddition could be used in conjunction with the 
Poc moiety. Initial fears had been raised over the stability of the Poc group in the 
presence of copper; as a di-molybdenum complex facilitates the removal of the Poe 
functionality when it is used as a protecting group.  38 ' However, investigation into the 
coupling of the propargyl carbonate marked steroid 241 to dansyl azide 189 found that 
under standard conditions the coupling reaction proceeds in high yield to give the 
desired product 255 (Scheme 4.16). 
N 
0 
o A'O"C9 a 	 N' c°A  
241 255 
Scheme 4.16: (a) 189, CuSO 4 . 5H 20 (10 mol%), NaAsc (20 mol%), tBuOH:H20  (1:1) (81%). 
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Formation of the molecular probe 255 was confirmed by detailed NMR 
characterisation (Appendix 5). Experiments clearly showed the removal of the 
propargyl peaks at 4.72 ppm and 2.53 ppm and the introduction of the triazole CH at 
7.54 ppm. Upon examining the ' 3C spectrum, the C2 1 quaternary peak of the carbonate 
was clearly present at 154.4 ppm, along with the new triazole peaks at 142.3 ppm and 
125.2 ppm. Investigations then turned to the full structural assignment of 255, which 
was accomplished using HSQC (Figure 4.12) and HSQC-TOCSY experiments. 
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Figure 4.12: Fully assigned HSQC spectrum of 255 at 360 MHz. 
It can be concluded that the initial fears regarding the stability of the Poc functionality 
have been shown to be unfounded. Therefore, the Poc moiety provides a further useful 
method for introducing a propargyl marker onto the molecular scaffold of biologically 
interesting molecules. 
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4.5 Summary 
In conclusion, a series of marked steroids based on the scaffold of DHEA and DHEAS 
has been synthesised. Introduction of the marker component has taken place through 
the coupling of a number of novel propargyl moieties (acid, hydroxylamine and 
chloroformate) to either the C30H or the C 17-carbonyl of the steroidal core. Initial 
biological screening showed that library member 248 showed interesting biological 
activity in the chemotaxis assay. As a result, it was readily converted into fluorescent 
molecular probe 254 which will be utilised in future studies. 
Therefore, we have expanded our concept of a marked library to a new range of 
biologically interesting steroidal molecules. This has allowed us to illustrate that a 
range of different functional groups can be readily manipulated allowing the 
attachment of a bioorthogonal propargyl marker. Subsequently, the copper(I) catalysed 
Huisgen cycloaddition can be utilised as the key coupling step, facilitating the rapid 
formation of molecular probes. Therefore, the application of a marked library 
approach has been shown to dramatically condense the small molecule to molecular 
probe synthetic process across a range of biologically interesting small molecules. 
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5 Experimental 
5.1 General Synthetic Experimental 
'H nuclear magnetic resonance (NMR) spectra were recorded at ambient temperature 
(unless otherwise stated) on Varian Gemini 200 (200 MHz), Bruker AC250 (250 
MHz), Bruker DPX360 (360 MHz) and Bruker AVA600 (600 MHz) Fourier 
transform instruments. The data is presented as follows: chemical shift (in ppm on 
the 8 scale relative to 8TMS = 0), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, br = broad), coupling constant and interpretation. ' 3C NMR 
spectra were recorded at ambient temperatures (unless otherwise stated) on Bruker 
AC250 (62.9 MHz), DPX360 (90.7 MHz) and Bruker AVA600 (151.1 MHz) Fourier 
transform instruments and were referenced to the solvent carbon peak. The data is 
presented as follows: chemical shift (in ppm on the 8 scale), relative intensity and 
assignment; and were confirmed by DEPT9O and DEPT135 and/or HSQC and 
HMBC experiments. 
Infra-red spectra were recorded on a Perkin Elmer Paragon 100 FT-JR machine using 
0.1 mm sodium chloride solution cells, 5 mm sodium chloride plates or potassium 
bromide discs. The wavelengths of maximum absorbance (Um ) are quoted in cm -1 . 
Melting points were determined on a Gallenkamp Electrothermal Melting Point 
apparatus and are uncorrected. 
Optical rotations were measured on an AA-1000 polarimeter with a path length of 
1.0 dm at the sodium D line (589 nm) and are reported as follows: [aI D , 
concentration (c in g/100 cm 3), and solvent. All optical rotations were measured at a 
temperature of 23 °C. 
Fast atom bombardment (FAB) mass spectra were obtained using a Kratos MS50TC 
mass spectrometer at The University of Edinburgh. Electrospray ionisation (ESI) 
mass spectra were recorded on a Finnigan LCQ or Micromass Platform instruments 
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at The University of Edinburgh. The parent ion or relevant fragment is quoted, 
followed by significant fragments and their percentages. 
Chiral high performance liquid chromatography (HPLC) was carried out on a Waters 
786 instrument equipped with a Chiracel OD-H column (internal diameter 4.6 mm) 
and a UV detector. A standard flow rate of 0.5 ml mind was used. All solvents used 
for HPLC analysis were vacuum filtered and degassed prior to use. 
Luminescence measurements were carried out in Hellma 109.000E-QS 10 mm 
precision cell using a fluorimeter with phosphorimeter Jobin-Yvon-Floriba 
Fluoromax-P. 
Tlc was performed on Merck 60F245 (0.25 mm) silica plates and visualised by 
ultraviolet (UV) light, ammonium molybdate,€  potassium permanganate**  or 
anisaldehyde stain.tt  Flash column chromatography was carried out on Merck 
Kieselgel (Merck 9385) under positive pressure by means of a hand pump. Eluent 
compositions are quoted as percentages. 
Reagents were purified by standard techniques. Acetyl chloride, ethyl acetate, acetic 
anhydride, triethylamine and 2,6-lutidine were distilled from calcium hydride and 
stored over calcium hydride under nitrogen atmosphere. Tetrahydrofuran (THF) was 
distilled from sodium metal/benzophenone ketyl and stored under a nitrogen 
atmosphere. Dichioromethane (DCM) was freshly distilled from calcium hydride and 
stored under a nitrogen atmosphere. Anisomycin, Dehydroepiandrosterone and 
Dehydroepiandrosterone sulfate were all purchased from Sigma (Poole, UK). All 
other reagents were used as supplied from Sigma (Poole, UK), Acros 
€ Ammonium molybdate stain was prepared by addition of concentrated sulfuric acid (50 ml) to water 
(950 ml), followed by ammonium molybdate (50 g) and ceric sulfate (3 g). The solution was stirred 
for 2 h and formed a pale yellow solution. 
Potassium permanganate stain was prepared by addition of potassium permanganate (10 g), 
potassium carbonate (50 g) and sodium hydroxide (40 pellets) to a stirred solution of water (1000 ml). 
The solution was stirred until all solid had dissolved, forming a purple solution. 
tt Anisaldehyde stain was prepared by slow addition of concentrated sulfuric acid (35 ml) to a stirred 
solution of ethanol (930 ml), followed by addition of glacial acetic acid (10 ml) and anisaldehyde (2.5 
ml) dropwise. 
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(Loughborough, UK), Novabiochem (Nottingham, UK), Lancaster (Heysham, UK), 
Molecular Probes (Paisley, UK) and Biorad (Hercules, USA). 
All chemical experiments were performed in an inert atmosphere of nitrogen under 
anhydrous conditions, using oven dried apparatus cooled in a desiccator or flame 
dried under nitrogen prior to use. Standard techniques for handling air sensitive 
materials were employed. 391 ' 392 
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5.2 Experimental Procedures 





To a stirred solution of methanol (100 ml) at 0 °C, was added the acetyl chloride 
(5.90 ml, 82.8 mmol). The solution was stirred for 15 min at 0 °C, and then D-
tyrosine 113 (5.32 g, 27.3 mmol) was added portionwise to the solution. The 
resulting solution was heated at reflux for 3 h, before concentration in vacuo to give 
the hydrochloride salt. The salt was recrystallised using methanol to give 114 as a 
colourless solid (6.32 g, 27.3 mmol, 100%); mp 192-193 'C; Vmax (neat)/cm' 4256, 
3338, 1744, 1613, 1592, 1515; 'H NMR 8 (200 MHz, CD30D) 7.07 (2H, d, J 8.5, 
An]), 6.78 (2H, d, J 8.5, An]), 4.88 (2H, br s, NH2), 4.24 (1H, t J 6.6, C21]), 3.8 
(3H, s, OMe), 3.20-3.06 (2H, m, C3H2); ' 3C NMR 8 (62.9 MHz, CD 30D) 168.6 (1C, 
Q), 156.4 (1C, Q), 129.6 (2C, CH), 123.7 (1C, Q), 115.0 (2C, CH), 51.6 (1C, CH3), 
53.5 (1C, CH), 34.7 (1C, CH2); LRMS (ESI+) [M+H] 196 (100). 
All spectroscopic data was in good agreement with that of the literature. 254 
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Methyl 	(2R)-2-tert-butoxycarbonylamino-3-(4 1 -hydroxyphenyl)-propionate 393 
115 
0 
O K1 OMe'  NHBoc 
To a solution of ester hydrochloride salt 114 (6.23 g, 27.3 mmol) in ethanol (60 ml) 
was added sodium hydrogen carbonate (6.88 g, 81.9 mmol) and di-tert-butyl 
dicarbonate (5.95 g, 27.3 mmol). The resulting solution was stirred for 16 h at RT, 
then filtered and concentrated in vacuo to give 115 as a foam (8.07 g, 27.3 mmol, 
100%); R1 [5% MeOHIDCM] = 0.52; 'H NMR 8 (200 MHz, CDC1 3) 6.89 (2H, d, J 
8.2, ArIf), 6.74 (2H, d, J 8.2, An]), 4.98 (1H, br s, NI]), 4.55 (1H, br q, J 8.4, CA, 
3.71 (3H, s, OMe), 3.07-3.00 (2H, m, C3H2), 1.43 (9H, s, 'BuO); ' 3C NMR 6 (62.9 
MHz, CDC13) 172.5 (1C, Q), 154.4 (2C, Q), 130.3 (2C, CH), 127.8 (1C, Q), 115.3 
(2C, CH), 79.9 (1C, Q), 54.4 (1C, CH), 52.1 (1C, CH3), 37.4 (1C, CH2), 28.2 (3C, 
CH3). 
All spectroscopic data was in good agreement with that of the literature. 393 
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To a solution of the phenol 115 (3.19 g,,10.8 mmol) in DCM (30 ml) at 0 °C was 
added 2,6-lutidine (2.28 ml, 19.6 mmol), after 5 min TBSOTf (2.31 ml, 11.9 mmol) 
was added, and the solution stirred for 3 h. The reaction was quenched with saturated 
aq. sodium hydrogen carbonate (100 ml) and extracted with DCM (3 x 40 ml). The 
combined organics were washed with brine (40 ml), dried (MgSO4) and concentrated 
in vacuo. The residue was chromatographed on silica gel [2% EtOAc/hexane] to give 
116 as a clear oil (2.64 g, 6.45 mmol, 60%); Rf [2% EtOAc/hexane] = 0.4; [aJ -32.0 
(c 0.75, CHC13); umax (neat)/cm 3438, 1743, 1711, 1609, 1510; 1H NMR 8 (200 
MHz, CDC13) 7.07 (2H, d, J 8.4, Ark!), 7.00 (2H, d, J 8.4, Ark!), 4.97 (1H, d, J 8. 1, 
NI]), 4.58-4.50 (1H, m, C21]), 3.70 (3H, s, OMe), 3.08-2.99 (2H, m, C3H2), 1.43 (9H, 
s, 'BuO), 0.98 (9H, s, 'BuSi), 0.19 (6H, s, Me2Si); ' 3C NMR 8 (62.9 MHz, CDC13) 
172.3 (1C, Q), 155.0 (1C, Q), 154.6 (1C, Q), 130.1 (2C, CH), 128.5 (1C, Q), 119.9 
(2C, CH), 79.8 (1C, Q), 54.4 (1C, CH), 52.0 (1C, CH 3), 37.5 (1C, CH2), 28.2 (3C, 
CH3), 25.5 (3C, CH3), 18.1 (1C, Q), -4.6 (2C, CH3); m/z (FAB, NOBA) 409 ([M], 
65); HRMS (FAB, NOBA) (Found: [M+H], 409.2280. C2 1 H3 5NO5Si requires m/z, 
409.2285). 
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To a solution of Boc-protected ester 116 (460 mg, 1.13 mmol) in DCM (20 ml) was 
added TFA (0.98 ml) and the solution stirred for 15 h at RT. The reaction was 
quenched with saturated aq. sodium carbonate (10 ml) until the solution was judged 
to be alkaline by litmus paper. The organic phase was separated, and the aqueous 
phase extracted with DCM (3 x 20 ml). The combined organics were dried (MgSO4) 
and concentrated in vacuo to give 117 as an oil (371 mg, 1.20 mmol, 100%); Rf [2% 
MeOHIDCM] = 0.20; [a] 9 +98.8 (c 0. 84, CHC13); umax (neat)/cm 3211, 1740, 1609, 
1510; 1 H NMR 6 (250 MHz, CDCI3) 7.05 (2H, d, J 8.4, ArH), 6.78 (2H, d, 8.4, 
ArR), 3.73-3.70 (1H, m, C2H), 3.71 (3H, s, OMe), 3.03 (1H, dd, J 13.6, 5.3, 
C3HSHT), 2.84 (1H, dd, J 13.6, 7.6, C3HSHT),  1.83-1.81 (2H, m, NH2), 0.98 (9H, s, 
tBuSi), 0.19 (6H, s, Me2Si); 13C NMR 6 (62.9 MHz, CDC13) 175.2 (1C, Q), 154.4 
(1C, Q), 130.1 (2C, CH), 129.5 (1C, Q), 120.0 (2C, CH), 55.8 (1C, CH), 51.8 (1C, 
CH3), 40.1 (1C, CH2), 25.5 (3C, CH3), 18.1 (1C, Q), -4.6 (2C, CH 3); m/z (FAB, 
NOBA) 310 ([M+H], 30%),250 (38), 221 (100); HRMS (FAB, NOBA) (Found: 
[M+H], 310.1841. C 1 6H28NO3Si requires m/z, 310.1839). 
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To a solution of amino ester 117 (300 mg, 970 tmol) in acetonitrile (15 ml) was 
added potassium carbonate (669 mg, 4.85 mmol) and benzyl bromide (460 p1, 3.88 
mmol). The mixture was stirred for 96 h at RT. Water (40 ml) was added to the 
solution and the aqueous phase extracted with EtOAc (3 x 30 ml). The organic 
extract was dried (MgSO4) and concentrated in vacuo. The residue was 
chromatographed on silica gel [10% EtOAc/hexane] to give 118 as a yellow oil (338 
mg, 690 .tmol, 71%); Rf [25% EtOAc/hexane] = 0.80; Vmax (neat)/cm' 1741, 1608, 
1509; 'H NMR 8 (250 MHz, CDCI3) 7.35-7.26 (10H, m, ArH), 6.92 (2H, d, J 8.3, 
ArH), 6.79 (2H, d, J 8.3, ArH), 4.01 (2H, d, J 14.0, NCHHyPh x 2), 3.78 (3H, s, 
OMe), 3.70 (1H, t, J8.3, C2H), 3.59 (2H, d, J 14.0, NCHHPh x 2), 3.20 (1H, dd, J 
14.0, 8.3, C3HSHT), 3.10 (111, dd, J 14.0, 8.3, C3HSHT),  1.07 (9H, s, tBuSi), 0.28 (6H, 
S, Me2Si); 13C NMR 6 (62.9 MHz, CDC13) 172.7 (1C, Q), 154.0 (1C, Q), 139.2 (2C, 
Q), 130.6 (1C, Q), 130.2 (2C, CH), 128.6 (4C, CH), 128.0 (4C, CH), 126.8 (2C, CH), 
119.6 (2C, CH), 62.2 (1C, CH), 54.2 (2C, CH 2), 50.9 (1C, CH 3), 34.8 (1C, CH2), 
25.6 (3C, CH3), 18.2 (1C, Q), -4.5 (2C, CH3); m/z (FAB, NOBA) 490 ([M+H], 
74%), 430 (80), 266 (81), 91 (100); HRMS (FAB, NOBA) (Found: [M+H], 
490.2785. C30H40NO3 Si requires m/z, 490.2778). 
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To a solution of the hydrochloride salt 114 (12.8 g, 55.2 mmol) in acetonitrile (400 
ml) was added potassium carbonate (22.9 g, 166 mmol) followed by benzyl bromide 
(15.1 ml, 127 mmol), and the solution stirred for 48 h at RT. The reaction was 
quenched by addition of water (100 ml). The organics were separated and the 
aqueous extracted with ethyl acetate (3 x 100 ml). The combined organics were 
washed with brine (100 ml), dried (Na2SO4), and concentrated in vacuo to give a 
yellow oil. The oil was chromatographed on silica gel [10% EtOAc/hexane] to give 
the product 121 as a clear oil (16.1 g, 42.3 mmol, 76 %); Rf [30% EtOAc/hexane] = 
0.50; [aID +75.2 (c 1.25, CHC13); Umax (neat)/cm' 3411, 1708, 1614, 1514; 'H NMR 
6 (250 MHz, CDC13) 7.17-7.08 (1 OH, m, ArII), 6.75 (2H, d, J 8.5, Ark!), 6.61 (2H, d, 
J 8.5, Ark!), 5.95 (1H, br s, 01]), 3.84 (2H, d, J 14.0, NCHHyPh x 2), 3.60 (3H, s, 
OMe), 3.53 (1H, t, J 7:8, C211), 3.43 (2H, d, J 14.0, NCHxHyPh x 2), 2.95 (1H, dd, J 
14.0, 7.8, C3HSHT), 2.81 (1H, dd, J 14.0, 7.8, C3HSHT); ' 3C NMR 6 (62.9 MHz, 
CDC13) 173.2 (1C, Q), 154.1 (1C, Q), 139.0 (2C, Q), 130.3 (2C, CH), 129.7 (IC, Q), 
128.5 (4C, CH), 128.0 (4C, CH), 126.8(2C, CH), 114.9 (2C, CH), 62.5 (1C, CH), 
54.3 (2C, CH 2),  51.1 (1C, CH3), 34.7 (1C, CH2); m/z (FAB, NOBA) 398 ([M+Na] +, 
25%), 376 ([M+H], 85%), 316 (73), 268 (98), 91(100); HRMS (FAB, NOBA) 
(Found: [M+H], 376.1912. C24H26NO3 requires m/z, 376.1913). 
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To a solution of ester 121 (16.1 g, 42.3 mmol) in THF:H 20 (200 ml, 4:1) was added 
lithium hydroxide (9.03 g, 215 mmol) and the solution heated at 82 °C for 48 h. The 
reaction was quenched by addition of IN HCI until the solution was judged to be pH 
2 by litmus paper. The aqueous phase was extracted with DCM (3 x 100 ml). The 
combined organics were washed with water (100 ml), brine (1 00 ml), dried (Na2SO4) 
and concentrated in vacuo to give 120 as a yellow foam (14:9 g, 41.4 mmol, 96%); 
Rf [30% EtOAc/hexane] = 0.13; [aID +52.1 (c 3.55, EtOH); Umax (neat)/cm' 3407, 
1731, 1614, 1515; 'H NMR 6 (250 MHz, CD 30D) 7.56-7.44 (1011, m, An]), 7.13 
(211, d, J 8.5, An]), 6.95 (2H, d, J 8.5, ArH), 4.16 (2H, d, J 13.8, NCHxHyPh x 2), 
3.94 (2H, d, J 13.8, NCHxHyPh x 2), 3.86 (1H, dd, J 8.4, 6.8, C2H), 3.33 (1H, dd, J 
14.2, 6.8, C3H5H1), 3.17 (1H, dd, J 14.2, 8.4, C3HSHT); 13C NMR 6 (62.9 MHz, 
CDC13) 173.2 (1C, Q), 155.0 (1C, Q), 137.7 (2C, Q), 129.5 (2C, CH), 128.4 (1C, Q), 
128.1 (4C, CH), 127.4 (4C, CH), 126.4 (2C, CH), 114.1 (2C, CH), 62.5 (1C, CH), 
53.6 (2C, CH2), 33.4 (1C, CH2); m/z (FAB, NOBA) 384 ([M+Na], 63%), 362 
([M+H], 100%), 316 (49), 254 (73), 91 (72); HRMS (FAB, NOBA) (Found: 
[M+H], 362.1756. C23H24NO3 requires m/z, 362.1756). 
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To a solution of phenol 120 (14.9 g, 41.4 mmol) in CH202 (200 ml) at 0 °C was 
added 2,6-lutidine (19.6m1, 168 mmol) and the solution stirred for 30 mm. TBSOTf 
(19.8 ml, 86.3 mmol) was added to the solution and stirred for a further 3.5 h. The 
reaction was poured onto iced 1M phosphoric acid (50 ml) and the aqueous extracted 
with CH202 (3 x 100 ml). The combined organics were washed with water (100 ml), 
brine (100 ml), dried (Na2SO4) and concentrated in vacuo to give the di-TBS 
protected compound 122. 
The crude material was dissolved in acetic acid:THF:H 20 (200 ml, 3:1:1) and stirred 
for 6 h. The reaction was quenched by addition of sodium hydrogen carbonate (-.35 
g), diluted with water (200 ml) and extracted with EtOAc (5 x 100 ml). The 
combined organics were washed with brine (100 ml), dried (Na 2SO4) and 
concentrated in vacuo to give 119 as a foam (15.2 g, 32.1 mmol, 78%); Rf [30% 
EtOAc/hexane] = 0.28; Lulu +23.4 (c 3.40, CHC13); umax (neat)/cm' 3407, 1731, 
1614,1514; 'H NMR ö (250 MHz, CDC13) 9.50 (1H, br s, CO21]), 7.22-7.07 (1 OH, 
m, An]), 6.88 (2H, d, J 8.5, An]), 6.67 (2H, d, J 8.5, An]), 3.70 (2H, d, J 13.6, 
NCHxHyPh x 2), 3.68 (2H, d, J 13.6, NCHxHyPh X 2), 3.61 (1H, dd, J9.1, 5.8, C21]), 
3.15 (1H, dd, J 14.4, 5.8, C3HSHT),  2.90 (1H, dd, J 14.4, 9.1, C3HSHT), 0.89 (9H, s, 
BuSi), 0.12 (6H, s, Me2Si); 13C NMR 5 (62.9 MHz, CDC1 3) 175.7 (1C, Q), 154.2 
(1C, Q), 137.7 (2C, Q), 130.6 (1C, Q), 130.2 (2C, CH), 128.8 (4C, CH), 128.3 (4C, 
Q), 127.4 (2C, CH), 119.9 (2C, CH), 62.5 (1C, CH), 54.2 (2C, CH2), 33.2 (1C, CH2), 
25.6 (3C, CH3), 18.1 (1C, Q), -4.5 (2C, CH3); m/z (FAB, NOBA) 498 ([M+Naf, 
85%), 476 ([M+H], 89%), 430 (84), 91 (100); HRMS (FAB, NOBA) (Found: 
[M+H], 476.2618. C29H3 8NO3Si requires m/z, 476.2621). 
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To a solution of acid 119 (7.27 g, 15.3 mmol) in THF (50 ml) was added carbonyl 
diimidazole (7.44 g, 45.9 minol) and the solution stirred for 2 h, before cooling to -78 
°C. Meanwhile, a stirred solution of ethyl acetate (5.21 ml, 53.6 mmol) was cooled to 
-78 °C, LiHMDS (54.0 ml, 1.0 M in THF) was added and the solution stirred for 20 
mm. The enolate was then transferred via cannula to the imidazolide 123 and the 
solution stirred at -78 °C for 40 mm. The reaction was warmed to 0 °C over 30 mm, 
and stirred for a further 1 h at 0 °C. The reaction was quenched by addition of 1% 
HC1 (15 ml) and diluted with DCM (50 ml). The organic layer was separated and the 
aqueous phase extracted with DCM (3 x 50 ml). The combined organics were 
washed sequentially with water (50 ml) and brine (50 ml), then dried (Na2SO 4), and 
concentrated in vacuo. The residue was chromatographed on silica gel [8% 
EtOAc/hexane] to give 124 as a clear oil (6.66 g, 12.2 mmol, 79 %); R f [30% 
EtOAc/hexane] = 0.83; [ai D +12.7 (c 1.10, CHC13); umax (neat)/cm' 1745, 1717 
1608, 1509; 'H NMR 8 (250 MHz, CDC13) 7.34-7.03 (10H, m, ArH), 7.01 (2H, d, J 
8.6, An]), 6.74 (2H, d, J 8.6, ArH), 4.03 (2H, q, J 7. 1, OCH2CH3), 185 (2H, d, J 
14.0, NCHxHyPh x 2), 3.68 (1H, d, J 15.6, C2HEHF), 3.60 (1H, dd, J9.l, 3.9, CH), 
3.56 (2H, d, J 14.0 NCHxHyPh X 2), 3.37 (1H, d, J 15.6, C2HEHF),  3.14 (1 H, dd, J 
14.0, 9.1, C 5HSHT), 2.81 (1H, dd, J 14.0, 3.9, C5HsH),  1.12 (3H, t, J 7.1, 
OCH2CH3), 1.01 (9H, 5, 'BuSi), 0.20 (6H, s, Me2Si); ' 3C NMR 8 (62.9 MHz, CDC13) 
202.5 (1C, Q), 167.1 (1C, Q), 153.8 (1C, Q), 138.7 (2C, Q), 131.5 (1C, Q), 131.0 
(2C, CH), 128.9 (4C, CH), 128.5 (4C, CH), 127.2 (2C, CH), 119.8 - (2C,  CH), 68.2 
(1C, CH), 60.9 (1 C, CH2), 54.4 (2C, CH2), 46.7 (1C, CH2), 27.7 (1C, CR2), 25.6 (3C, 
CR3), 18.0 (1C, Q), 14.0 (1C, CH3), -4.6 (2C, CH3); m/z (FAB, THIOG) 546 
([M+H], 37%), 430 (85), 221 (71), 91 (100); HRMS (FAB, NOBA) (Found: 
[M+H], 546.3042. C33H44NO4Si requires m/z, 546.3038). 
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To a solution of 0-keto ester 124 (6.66 g, 12.2 mmol), in ether (100 ml), was added 
methanol (20 ml) and the solution adjusted to pH 4 by addition of a few drops of 
acetic acid. Sodium cyanoborohydride (11.5 g, 183 mmol) was added to the solution 
at 0 °C, the solution was allowed to warm to RT and stirred for 19 h. The solution 
was quenched by addition of saturated aq. ammonium chloride (40 ml). The organic 
phase was separated and the aqueous extracted with DCM (3 x 40 ml). The combined 
organics were washed with brine (40 ml), dried (Na2SO 4) and concentrated in vacuo. 
The residue was chromatographed on silica gel [8% EtOAc/hexane] to give 126 as a 
clear oil (5.77 g, 10.5 mmol, 86%); R [10% EtOAc/hexane] = 0.28; [UID  -30.2 (c 
3.05, CHC13); Umax (neat)/cm' 3453, 1732, 1607, 1509; 'H NMR 6 (250 MHz, 
CDC13) 7.41-7.30 (1 OH, mArl]), 7.11 (2H, d, J8.5, ArH), 6.85 (2H, d, J8.5, ArH), 
4.25 (1H, br s, OH), 4.18 (2H, d, J 13.7, NCHHPh x 2), 4.09 (2H, q, J 7.2, 
OCH2CH3), 4.05-4.02 (1H, m, C311), 3.48 (2H, d, J 13.7, NCHHyPh x 2), 3.14 (1H, 
m, CJ]), 2.85-2.75 (2H, m, C5H2), 2.40 (1H, dd, J 15.7, 9.3, C2HEHF), 2.18 (1H, dd, 
.115.7,2.7, C2HEHF),  1.26 (3H, t, .17.2, OCH2CH3), 1.06 (9H, s, 'BuSi), 0.28 (6H, s, 
Me2Si); 13C NMR 6 (62.9 MHz, CDC13) 172.5 (1C, Q), 153.9 (1C, Q), 139.0 (2C, 
Q), 132.4 (1C, Q), 129.9 (2C, CH), 128.9 (4C, CH), 128.3 (4C, CH), 127.1 (2C, CH), 
120.1 (2C, CH), 67.8 (1C, CH), 63.0 (1C, CH), 60.4 (1C, CH2), 54.2 (2C, CH2), 39.7 
(1C, Cl-I2), 30.1 (1C, CH2), 25.6 (3C, CH 3), 18.1 (1C, Q), 14.0 (1C, CH3), -4.6 (2C, 
CH3); m/z (FAB, NOBA) 570 ([M+Na], 826/o), 548 ([M+H], 98%), 430 (100), 91 
(96); HRMS (FAB, NOBA) (Found: [M+H] 4 , 548.3191. C33H46NO4Si requires m/z, 
548.3196); Chiral HPLC (R enantiomer) R, = 5.30 mm, (S enantiomer) R 1 = 6.26 
mm [2% ethanol/hexane], 97% ee. 
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TBSOj 1'  
A solution of ester 126 (5.77 g, 10.5 mmol) in THF (100 ml) was cooled to -78 °C 
and lithium aluminium hydride (53.0 ml, 52.5 mmol, 1.0 M in THF) added. The 
solution was stirred at -78 °C for 6 h, then allowed to warm to RT over 1 h. The 
reaction was quenched by addition of 1 M sodium hydroxide (30 ml), diluted with 
DCM (30 ml) and saturated aq. sodium potassium tartrate (30 ml) and stirred for 16 
h. The organic phase was separated and the aqueous phase extracted with DCM (3 x 
80 ml). The combined organics were dried (Na2SO4) and concentrated in vacuo. The 
residue was chromatographed on silica gel [30% EtOAc/hexane] to give 128 as a 
clear oil (5.17 g, 10.2 mmol, 97%); Rf [30% EtOAc/hexane] = 0.39; laiD  -28.3 (c 
2.40, CHC13); Umax (neat)/cm -1 3376, 1607, 1509; 'H NMR 6 (250 MHz, CDC1 3) 
7.41-7.24 (1 OH, m, An]), 7.12 (2H, d, J 8.4, An]), 6.88 (2H, d, J 8.4, AnII), 4.88 
(1H,br s, OR), 3.95 (2H, d, J 13.2, NCHxHyPh x 2), 3.84 (1H, td, J2.7, 9.0, C31]), 
3.73-3.69 (2H, m, C 1 H20H), 3.45 (2H, d, J 13.2, NCHxHyPh x 2), 3.10 (1H, dd, J 
14.2, 6.5, C5HSHT), 2.99-2.94 (2H, m, C4H, OH), 2.65 (1H, dd, J 14.2, 6.5, C 5HSHT), 
1.66-1.64 (1H, m, C2HEHF), 1.36-1.31 (1H, m, C2HEHF), 1.06 (9H, s, tBuSi), 0.27 
(6H, s, Me2Si); ' 3C NMR 6 (62.9 MHz, CDC13) 154.0 (1C, Q), 138.5 (2C, Q), 132.5 
(1C, Q), 129.9 (2C, CH), 128.9 (4C, CH), 128.4 (4C, CH), 127.2 (2C, CH), 120.2 
(2C, CH), 70.4 (1C, CH), 63.8 (1C, CH), 61.1 (1C, CH 2), 53.6 (2C, CH2), 35.6 (1C, 
CH2), 31.3 (1C, CH2), 25.6 (3C, CH3), 18.1 (1C, Q), -4.6 (2C, CH3); m/z (FAB, 
THIOG) 506 ([M+H], 9%), 430 (12), 284 (35), 221 (55), 91(100); HRMS (FAB, 
THIOG) (Found: [M+H], 506.3091. C31H4NO3Si requires m/z, 506.3091). 
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(2R,3R)-2-(4'-tert-Butyldimethylsilyloxybenzyl)-1,l -dibenzyl-3-hydroxy-
pyrrolidinium chloride 129 
WD  cle 
TBSO I 34 
To a solution of alcohol 128 (5.17 g, 10.2 mmol) in DCM (100 ml) at 0 °C was 
added DMAP (2.05 g, 16.8 mmol) and trisopropylbenzene sulfonyl chloride (3.40 g, 
11.2 mmol). The solution was stirred for 19, h before being diluted with DCM (50 
ml) and water (50 ml). The organic phase was separated and washed with 1% HC1 (2 
x 20 ml) then dried (Na2SO4) and concentrated in vacuo. The residue was 
chromatographed on silica gel [5% MeOHIDCM] to give a colourless foam. The salt 
was subjected to ion exchange chromatography [Dowex Cl; prepared by treating 
Dowex resin with methanol, then 1% HC1, followed by flushing with methanol until 
the eluent returned to pH 7] eluting with methanol to give the chloride salt 129 as an 
amorphous solid (5.14 g, 9.82 mmol, 96%); Rf [5% MeOH/DCM] = 0.12; EL1 D -42.1 
(c 1.50, CFIC13); Vmax (neat)/cm-1 3397, 1607, 1508; 1H NMR 8 (250 MHz, CDC1 3) 
7.78-7.29 (10H, m, An]), 7.26 (2H, d, J 8.5, ArH), 6.65 (2H, d, J 8.5, An]), 6.56 
(1H, br s, OH), 5.73 (1H, d, J 13.4, NCHxHyPh x 1), 5.08 (2H, m, NCHxHyPh x 2), 
4.32 (1H, br s, CA,  4.23 (1H, d, J 13.4, NCHHPh x 1), 3.91 (1H, br d, J 11. 1, 
CHsH1Ar), 3.84-3.81 (1H, m, C5HMHN), 3.53 (1H, br d, J 11. 1, CHsHrAr), 3.33 (1H, 
br t, J 11. 1, C2H), 3.04 (1H, td, 11. 1, 8.7, C5HMHN), 2.58 (1H, td, J 14.1, 7.9, 
C4HEHF), 1.94-1.87 (1H, m, C4HEHF), 0.98 (9H, s, 'BuSi), 0.17 (6H, s, Me2Si); 13C 
NMR 8 (62.9 MHz, CDC13) 154.4 (1C, Q), 133.4 (2C, CH), 133.0 (2C, CH), 130.5 
(3C, CH), 130.2 (1C, CH), 129.2 (2C, CH), 129.0 (2.C, CH), 128.3 (1C, Q), 127.9 
(1C, Q), 127.3 (1C, Q), 120.1 (2C, CH), 76.1 (1C, CH), 67.6 (1C, CH), 62.2 (1C, 
61.6 (1C, CH2), 55.6 (1C, CH2), 31.2 (1C, CH2), 27.4 (1C, CH 2), 25.5 (3C, 
17.9 (1C, Q), -4.6 (2C, Q); m/z (FAB, NOBA) 488 ([M], 100%), 396 (21), 
307 (14), 91(75); HRMS (FAB, NOBA) (Found: [M], 488.2978. C3 1 H42NO2Si 
requires m/z, 488.2985). 
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To a solution of the chloride salt 129 (4.32 g, 8.25 mmol) in methanol (40 ml) was 
added 5% PdJC (300 mg) and potassium carbonate (3.42 g, 24.8 mmol). The mixture 
was exposed to a hydrogen atmosphere and stirred vigorously for 20 mm. The 
suspension was filtered through a pad of celite and concentrated under reduced 
pressure. The residue was dissolved in DCM (15 ml) and washed with water (15 ml). 
The organic phase was separated and the aqueous phase extracted with DCM (3 x 15 
ml). The combined organic phases were dried (Na2SO 4) and concentrated in vacuo to 
give 130 as an oil (2.90 g, 7.30 mmol, 89%); Rf [5%MeOH/DCM] = 0.12; laiD - 
64.3 (c 2.10, CHC13); Umax (neat)/cm' 3397, 1607, 1508; 'H NMR 8 (250 MHz, 
CDC13) 7.35-7.26 (5H, m, ArH), 7.19 (2H, d, J 8.5, ArH), 6.78 (2H, d, J 8.5, ArIf), 
4.17 (1H, d, J 13.0, NCHxHyPh), 3.96-3.92 (1H, m, C3H), 3.26 (IH, d, J 13.0, 
NCHxHyPh), 3.05 (1H, td, J9.2, 3.9, C21]), 2.90-2.93 (2H, m, CH2Ar), 2.50 (1H, td, 
J7.1, 3.9, C5HMHN), 2.15 (1H, td, J9.6, 7. 1, C5HMHN), 2.01-1.97 (1H, m, C4HEHF), 
1.71-1.68 (1H, m, C4HEHF), 0.98 (9H, s, 'BuSi), 0.19 (6H, s, Me2Si); ' 3C NMR ö 
(62.9 MHz, CDC13) 153.8 (1C, Q), 138.3 (1C, Q), 131.8 (1C, Q), 130.1 (2C, CH), 
128.8 (2C, CH), 128.2 (2C, CH), 127.0 (1C, CH), 119.9 (2C, CH), 71.9 (1C, CH), 
70.8 (IC, CH), 57.6 (1C, CH2), 51.4 (1C, CH2), 32.8 (1C, CH2), 32.1 (1C, CH2), 25.6 
(3C, CH3), 18.1 (1C, Q), -4.5 (2C, CH3); m/z (FAB, NOBA) 398 ([M+H], 100%), 
221 (61), 176(90),  91(99); HRMS (FAB, NOBA) (Found: [M+H], 398.2511. 
C24H36NO2Si requires m/z, 398.2515). 
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TBSO'- 	½-; AcO 
To a solution of the alcohol 130 (2.90 g, 7.30 mmol) in DCM (100 ml) was added a 
catalytic amount of DMAP, freshly distilled acetic anhydride (1.38 ml, 14.6 mmol) 
and triethylamine (2.02 ml, 14.6 mmol). The solution was stirred for 18 h at RT and 
then quenched by addition of saturated aq. sodium bicarbonate solution (40 ml). The 
organic phase was separated and the aqueous phase extracted with DCM (3 x 40 ml). 
The combined organics were dried (Na2SO 4) and concentrated in vacuo. The residue 
was chromatographed on silica gel [30% EtOAc/hexane] to give 109 as an oil (3.11 
g, 7.08 mmol, 96%); Rf [30% EtOAc/hexane] = 0.62; [UI D -93.1 (c 2.90, CI-1C1 3 ); 
bmax (neat)/cm' 1738, 1608, 1509; 'H NMR 6 (250 MHz, CDC13) 7.35-7.18 (5H, m, 
ArII), 7.04 (2H, d, J 8.4, An]), 6.75 (2H, d, J 8.4, ArH), 5.02-4.98 (1H, m, C31-f), 
4.05 (1H, d, J 13.1, NCHxHyPh), 3.33 (1H, d, J 13.1, NCHxHyPh), 3.00-2.75 (4H, 
M, CH2Ar, C5HMHN, C211), 2.23-2.13 (2H, m, C4HEHF, C5HMHN), 2.07 (3H, s, OAc), 
1.72-1.70 (1H, m, C4HEHF), 0.97 (9H, s, tBuSi), 0.18 (6H, s, Me2Si); ' 3C NMR 6 
(62.9 MHz, CDC13) 170.4 (1C, Q), 153.8 (1C, Q), 138.1 (1C, Q), 131.6 (1C, Q), 
129.6 (2C, CH), 129.0 (2C, CH), 128.1 (2C, CH), 126.9 (1C, CH), 119.9 (2C, CH), 
74.6 (1C, CH), 68.0 (1C, CH), 58.2 (1C, CH2), 51.5 (1C, CH2), 33.4 (1C, CH2), 30.5 
(1C, CH2), 25.6 (3C, CH3), 21.1 (1C, CH3), 18.1 (1C, Q), -4.6 (2C, CH3); m/z (FAB, 
NOBA) 540 ([M+H], 100%), 380 (51), 218 (96), 91(90); HRMS (FAB, NOBA) 
(Found: [M+H] 4 , 440.2630. C26H38NO3 Si requires m/z, 440.2621). 
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(2R,3R)-3-Acetoxy-2-(4'-hyroxy-benzyl)-pyrrolidine hydrochloride 131 
25 HO_c O c_ ? 
To a solution of monobenzylamine 109 (54.0 mg, 120 tmo1) in EtOH (5 ml) was 
added IM ethereal hydrochloric acid (0.24 ml) and Pearlman's catalyst (20% 
Pd(OH)2/C; 54.0 mg). The solution was exposed to a hydrogen atmosphere (1 atm) 
and stirred vigorously for 2.5 h. The solution was filtered through a pad of Celite 
(prewashed with MeOH, DCM) and concentrated in vacuo to give 131 as a 
colourless solid (33.0 mg, 120 .tmol, 100%); Rf [10% MeOHIDCM] = 0.15; [a] 
+5.00 (c 1.60, EtOH); Umax (neat)/cm . ' 3376, 2950, 1739, 1614, 1517; 'H NMR 
(360 MHz, CD30D) 7.16 (2H, d, J 8.5, ArH), 6.81 (2H, d, J 8.5, ArE), 5.45 (1H, br 
S, C3R), 3.93 (1H, br s, CA,  3.60-3.39 (2H, m, C5H2), 3.07 (1H, dd, J 14.1, 6.1, 
CHSHTAr), 2.95 (1H, .dd, J 14.1, 8.6, CH5HTAr), 2.42-2.31 (H, m, C4HEHF),  2.20 
(3H, s, OAc), 2.20-2.13 (1H, m, C4HEHF); '3C NMR 8 (62.9 MHz, CD30D) 171.6 
(IC, Q), 158.2 (1C, Q), 131.3 (2C, CH), 127.9 (1C, Q), 117.2 (2C, CH), 74.7 (1C, 
CH), 66.5 (1C, CH), 44.7 (1C, CH2), 33.0 (1C, CH 2), 32.2 (1C, CH2), 21.2 (1C, 
CH3); m/z (FAB, NOBA) 235 ([M], 62%), 176 (86), 128 (74), 107 (51); HRMS 
(FAB, NOBA) (Found: [M+H], 236.1284. C13H 1 8NO3 Si requires m/z, 236.1287). 
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(2R,3R)-3-Acetoxy-2-(4'-tert-butyldimethylsilyloxybenzyl)-pyrrolidine 132 
TBSO Q 31'y 4 
A solution of monobenzylamine 109 (1.01 g, 2.29 mmol) and Peariman's catalyst 
(20% Pd(OH)2/C; 300 mg) in EtOH (15 ml) was exposed to a hydrogen atmosphere 
(1 atm) and stirred vigorously for 2.5 h. The solution was filtered through a pad of 
Celite (prewashed with EtOH, DCM) and concentrated in vacuo to give 132 as an oil 
(785 mg, 2.25 mmol, 98%); R1 [5% MeOHIDCM] = 0.16; [U]D -42.3 (c 1.30, 
CHC13); Vmax (neat)/cm 2930, 1742, 1608, 1510; 'H NMR 6 (250 MHz, CDC13) 
7.05 (2H, d, J 8.4, An]), 6.75 (2H, d, J 8.4, ArH), 5.12 (1H, hr s, C311), 3.86 (1H, br 
S, CA, 3.33-3.23 (2H, m, C5H2), 3.07-2.89 (2H, m, CH2Ar), 2.23-2.17 (H, m, 
C4HEHF), 2.17 (3H, s, OAc), 2.13-1.92 (1H, m, C4HEHF), 0.93 (9H, s, 'BuSi), 0.17 
(6H, s, Me2Si); 13C NMR 6 (62.9 MHz, CDC1 3) 170.5 (1C, Q), 154.4 (1C, Q), 130.8 
(1C, Q), 129.8 (2C, CH), 120.3 (2C, CH), 74.4 (1C, CH), 64.4 (1C, CH), 43.8 (1C, 
CH2), 33.9 (1C, CH2), 32.6 (1C, CH2), 25.8 (3C, CH 3), 21.3 (1C, CH3), 18.3 (1C, Q), 
-4.3 (2C, CH3); m/z (FAB, NOBA) 350 ([M+H]F,  100%), 290 (34), 221 (60); HRMS 
(FAB, NOBA) (Found: [M+H], 350.2154. C 19H32NO3 Si requires m/z, 350.2152). 
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To a solution of amine 132 (726 mg, 2.08 mmol) in DCM (15 ml) was added 
triethylamine (456 p1, 3.27 mmol) and the solution cooled to 0 °C. Di-tert-butyl 
dicarbonate (713 mg, 3.27 mmol) was added and the solution stirred for 5 mm, 
before warming to RT and stirring for 15 h. The reaction was quenched with 
saturated aq. sodium bicarbonate (30 ml) and diluted with DCM (50 ml). The organic 
phase was separated and washed with 1% HCl (20 ml) then dried (Na2SO 4) and 
concentrated in vacuo. The residue was chromatographed on silica gel [2% 
MeOH/DCM] to give 133 as an oil (903 mg, 2.01 mmol, 97%); Rf [5% 
MeOH/DCM] = 0.68; [a]0 +3.50 (c 2.00, CHC13); bmax (neat)/cm' 1743, 1697, 1608, 
1509; 'H NMR 6(360 MHz, CDC13 , 323 K) 7.06 (2H, d, J8.4, ArII), 6.73 (2H, d, J 
8.4, An]), 5.13 (1H, br q, J 6.7 CA,  4.29-4.24 (1H, m, C2H), 3.45-3.40 (1H, m, 
C5HMHN), 3.34-3.27 (1H, m, C 5HMHN), 2.94 (1H, br d, CHSHTAr), 2.86-2.80 (ih, dd, 
J 13.8, 8.3, CHsHrAr), 2.08-2.04 (1H, m, C4HEHF), 2.01 (3H, s, OAc), 1.83-1.76 
(1H, m, C4HEHF), 1.47 (9H, s, 'BuO) 0.99 (9H, s, 'BuSi), 0.19 (6H, s, Me2Si); 13C 
NMR 6 (90.7 MHz, CDC13, 323 K) 170.8 (1C, Q), 155.1 (1C, Q), 154.6 (1C, Q), 
131.8 (1C, Q), 130.9 (2C, CH), 120.5 (2C, CH), 80.4 (1C, Q), 73.9 (1C, CH), 59.6 
(1C, CH), 42.0 (1C, CH2), 34.1 (1C, CH2), 33.1 (1C, CH2), 29.1 (3C, CH 3), 26.3 (3C, 
CH3), 21.6 (1C, CH3), 18.9 (1C, Q), -4.4 (2C, CH3); m/z (FAB, NOBA) 450 
([M+H], 9%),221 (83),91 (22); HRMS (FAB, NOBA) (Found: [M+H], 450.2671. 
C24H40NO5Si requires m/z, 450.2676). 
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HO I CO 34 
To a solution of the silyl ether 133 (572 mg, 1.27 mmol) in THE (15 ml) at 0 °C was 
added triethylamine trihydrofluoride (1.02 ml, 6.35 mmol), the solution was stirred 
for 5 min at 0 °C, before warming to RT and stirring for 2 h. The reaction was 
quenched with saturated aq. sodium bicarbonate (30 ml) and diluted with EtOAc (50 
ml). The organic phase was separated and washed with brine (20 ml) then dried 
(Na2SO4) and concentrated in vacuo. The residue was chromatographed on silica gel 
[5% MeOH/DCM] to give 134 as an oil (415 mg, 1.23 mmol, 96%); Rf [5% 
MeOI-IJDCM] = 0.25; laiD +9.30 (c 0.80, CHC13); Umax (neat)/cm- '3350,1741, 1666, 
1615, 1515; 'H NMR 6 (360 MHz, CDC13, 323 K) 7.02 (2H, d, J 8.2, ArH), 6.73 
(2H, d, J8.2, An]), 5.13 (1H, br q, J6.8, C31]), 4.26 (1H, br q, J6.8, C21]), 3.48-3.41 
(1H, m, C5HMHN), 3.36-3.29 (1H, m, C5HMHN),  2.91 (1H, br s, CHSHTAr), 2.80 (1H, 
dd, J 13.7, 8. 1, CH5HrAr), 2.09-2.04 (1H, m, C4HEI-IF),  2.02 (3H, s, OAc), 1.85-1.62 
(1H, m, C4HEHF), 1.45 (9H, s, 'BuO); ' 3C NMR 6 (90.7 MHz, CDCI 3 , 323 K) 170.8 
(1C, Q), 155.4 (1C, Q), 155.3 (1C, Q), 130.9 (2C, CH), 130.4 (1C, Q), 115.8 (2C, 
CH), 80.6 (1C, Q), 73.9 (1C, CH), 59.8 (1C, CH), 43.6 (1C, CH2), 34.6 (1C, CH 2), 
29.4 (1C, CH2), 29.0 (3C, CH 3), 21.2 (1C, CH3); m/z (FAB, THIOG) 336 ([M+H], 
50%), 176 (70); HRMS (FAB, THIOG) (Found: [M+H], 336.1810. C 1 8H26N05 
requires m/z, 336.1811). 
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0 3 4 AcO 
To a solution of the phenol 134 (27.0 mg, 80.0 tmol) in DMF (2 ml) was added 
potassium carbonate (17.0 mg, 120 tmol) and propargyl bromide (15.0 p1, 120 
jtmol), the solution was stirred at RT for 12 h, before quenching with water (5ml) 
and diluting with ether (10 ml). The organic phase was separated and washed with 
brine (10 ml) then dried (Na2SO 4) and concentrated in vacuo. The residue was 
chromatographed on silica gel [2% MeOH/DCM] to give 135 as an oil (30.0 mg, 
80.0 .tmol, 100%); Rf [5% MeOHIDCM] = 0.70; laI n +9.00 (c 1.50, CHC13); Umax 
(neat)/cm' 3286, 1739, 1692, 1610, 1510; 'H NMR ö (360 MHz, CDC13, 318 K) 
7.20 (2H, d, J 8.6, ArR), 6.89 (2H, d, J8.6, ArII), 5.13 (1H, br q, J6.5, CA, 4.66 
(1H, d, J 2.4, HCCCH2) 4.3 (1H, ddd, J 8.2, 6.5, 4.7, C2H), 3.48-3.41 (1H, m, 
C5HMHN), 3.36-3.31 (1H, m, C5HMHN), 2.96 (1H, br s, CHSHTAr), 2.86-2.80 (1H, dd, 
J 13.8, 8.2, CHsHrAr), 2.49 (1H, t, J 2.4, HC_CCH2), 2.08-2.04 (1H, m, C4HEHF), 
1.99 (3H, s, OAc), 1.84-1.78 (1H, m, C4HEHF), 1.45 (9H, s, tBuO); '3C NMR 8 (90.7 
MHz, CDC13, 318 K) 170.2 (1C, Q), 156.4 (1C, Q), 154.6 (1C, Q), 131.9 (1 C, Q), 
130.6 (2C, CH), 115.1 (2C, CH), 79.9 (1C, Q), 79.0 (1C, Q), 75.4 (1C, CH), 73.4 
(IC, CH), 59.4 (1C, CH), 56.2 (1C, CH2), 42.0 (1C, CH2), 34.4 (1C, CH 2), 33.1 (1C, 
CH2), 28.6 (3C, CH3), 21.0 (1C, CH3); m/Z (FAB, THIOG) 374 ([M+H] +, 8°Yo), 318 
(100), 274 (39), 214 (61), 91 (93); HRMS (FAB, THIOG) (Found: [M+H], 
374.1966. C2 1 H28N05 requires ,n/z, 374.1968). 
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(2R,3R)- 3-Acetoxy-2-(4 '-prop-2-ynyloxybenzyl)-pyrrolidine 136 
H 
AcO 
To a solution of carbamate 135 (30.0 mg, 80.0 jimol) in DCM (2 ml) was added TFA 
(0.20 ml, 0.80 mmol) and the solution stirred for 15 h at RT. The solution was 
quenched with saturated aq. sodium bicarbonate (5 ml). The organic phase was 
separated and the aqueous phase extracted with DCM (3 x 10 ml).The combined 
organic phases were dried (Na 2SO4) and concentrated in vacuo to give 136 as an oil 
(18.0 mg, 70.0 tmo1, 87%); Rf [5% MeOH/DCM] = 0.11; [cLJn -24.2 (c 0.95, 
CHC13); Umax (neat)/cm' 3282, 2925, 1730, 1610, 1510; 'H NMR 6 (360 MHz, 
CDC13, 323 K) 7.09 (2H, d, J 8.7, An]), 6.90 (2H, d, J 8.7, ArE), 5.29-5.27 (1H, m, 
C31]), 4.63 (2H, d, J 2.4, HCCCH2), 3.85-3.80 (1H, m, C21]), 3.45-3.32 (2H, m, 
C5H2), 3.05-2.99 (2H, m, CH2Ar), 2.50 (1H, t, J2.4, HCCCH2), 2.29-2.17 (2H, m, 
C4H2), 2.18 (3H, s, OAc); ' 3C NMR 6 (90.7 MHz, CDC1 3 , 323 K) 169.9 (1C, Q), 
157.3 (1C, Q), 130.0 (2C, CH), 128.2 (1C, Q), 115.9 (2C, CH), 78.7 (1C, Q), 75.8 
(1C, CH), 72.6 (1C, CH), 64.5 (1C, CH), 56.2 (1C, CH2), 43.2 (1C, CH 2), 31.8 (1C, 
CH2), 33.3 (1C, CH2), 20.7 (1C, CH3); m/z (FAB, THIOG) 274 ([M+H], 87%), 214 
(57); HRMS (FAB, THIOG) (Found: [M+H], 274.1441. C16H19NO3 requires m/z, 
274.1443). 
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To a solution of phenol 134 (300 mg, 0.90 mmol) in DMF (5 ml) was added K2CO3 
(618 mg, 4.48 mmol) and methyl iodide (279 p1, 4.48 mmol), the solution was stirred 
for 15 h at RT. The solution was quenched with water (5 ml) and DCM (10 ml) 
added. The organic phase was separated and the aqueous phase extracted with DCM 
(3 x 10 ml). The combined organic phases were dried (Na 2 SO4) and concentrated in 
vacuo to give 137 as an oil (230 mg, 0.66 mmol, 74%); Rf[5% MeOFIIDCM] = 0.76; 
[aJn +10.5 (c 1.00, CHC13); Umax (neat)/cm' 1741, 1692, 1612, 1512; 'H NMR 6 
(360 MHz, CDC1 3 , 323 K) 7.12 (2H, d, J 8.6, An]), 6.81 (2H, d, J 8.6, ArH), 5.13 
(1H, br q, J6.6 C31]), 4.26 (lB. ddd, J8.1, 6.6, 4.5, C21]), 3.79 (3H, s, OMe), 3.47-
3.42 (1H, m, C5HMHN),  3.36-3.29 (1H, m, C5HMHN), 2.95 (1H, br s, CHSHTAr), 2.84 
(1H, dd,.J 13.8, 8.1, CHSHTAr), 2.08-2.01 (1H, m, C4HEHF), 2.00 (3H, s, OAc), 1.83-
1.77 (1H, m, C4HEHF), 1.46 (9H, s, 'BuO); '3C NMR 6 (90.7 MHz, CDC13, 323 K) 
170.2 (1C, Q), 158.5 (1C, Q), 154.7 (1C, Q), 131.0 (1C, Q), 130.6 (2C, CH), 114.1 
(2C, CH), 79.9 (1C, Q), 73.6 (1C, CH), 59.6 (1C, CH), 55.5 (1C, CH3), 43.6 (1C, 
CH2), 34.1 (1C, CH2), 29.4 (1C, CH2), 28.6 (3C, CH3), 2 1. 0 (1C, CH3); m/z (FAB, 
THIOG) 351 ([M+H], 18%), 350 ([M], 38%), 294 (66), 190 (59), 122 (56), 91 
(58); HRMS (FAB, THIOG) (Found: [M+H], 350.1965. C 1 9H28N05 requires n7/z, 
335.1968). 
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(2R,3R)-3-Acetoxy -2-(4'-methoxybenzyl)-pyrrolidine 254 138 
MeOxc o 3 NOTFA 
To a solution of carbamate 137 (230 mg, 0.66 mmol) in DCM (15 ml) was added 
trifluoroacetic acid (1.00 ml, 6.60 mmol), the solution was stirred for 7 h at RT. The 
reaction was concentrated in vacuo to give 138 as a foam (239 mg, 0.66 mmol, 
100%); Rf[5% MeOHIDCM] = 0.09; [aID +18.7 (c 1.10, CH30H); Vmax (neat)/cm' 
3004, 1750, 1614, 1516; 'H NMR 6 (360 MHz, CD 3 0D) 7.19 (2H, d, J 8.7, ArH), 
6.89 (2H, d, J8.7, ArII), 5.30 (1H, t, J3.6, C31-f), 3.92-3.87 (1H, m, CA,  3.76 (3H, 
s, OMe), 3.51-3.33 (2H, m, C5H2), 3.07 (1H, dd, J 14.3, 6.7, CHSHTAr), 2.95 (1H,. 
dd, J, 14.3, 8.6, CHSHTAr), 2.40-2.29 (1H, m, C4HEHF), 2.16 (3H, s, OAc), 2.20-2.13 
(1H, m, C4HEHF); 13C NMR 6 (90.7 MHz, CD30D) 170.2 (1C, Q), 160.5 (1C, Q), 
130.9 (2C, CH), 128.9 (1C, Q), 115.5 (2C, CH), 74.3 (1C, CH), 65.9 (1C, CH), 55.6 
(1C, CH3), 44.2 (1C, CH2), 32.6 (1C, CH2), 31.8 (1C, CH 2), 20.7 (1C, CH 3); m/z 
(FAB, THIOG) 499 ([2M+H]', 22.1%), 250 ([M+H], 98%), 190 (70), 121 (74), 91 
(43); HRMS (FAB, NOBA) (Found: [M+H], 250.1442. C 14H20NO3 requires m/z, 
250.1443). 
All spectroscopic data was in good agreement with that of the literature. 254 
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(2R,3R)-3-Acetoxy -2-(4 '-methoxybenzyl)-1-prop-2-ynyl-pyrrolidine 139 
( 
MeO ) C0 34 
To a solution of the amine 138 (54.4 mg, 150 .tmol) in DCM (4 ml) at 0 °C was 
added piperidinomethyl resin (173 mg, 450 tmol) and propargyl bromide (65.0 t1, 
300 tmo1), the solution was stirred for 6 h at RT. The reaction was filtered through a 
cotton wool plug, washing with DCM (15 ml). The organics were concentrated in 
vacuo to give an oil. The residue was chromatographed on silica gel [3% 
MeOH/DCM] to give 139 as an oil (40.5 mg, 140 j.imol, 93%); R1 [5% MeOH/DCM] 
= 0.44; [U]D -1.05 (c 0.95, CHC13); Vmax (neat)/cm' 3282, 2961, 1733, 1612, 1512; 
'H NMR 8 (360 MHz, CDC13) 7.07 (2H, d, .1 8.6, ArH), 6.81 (2H, d, J 8.6, An]), 
4.92 (1H, ddd, J6.7, 4.6, 2.0, C31]), 3.78 (3H, s, OMe), 3.61 (2H, dd, J2.3, 1. 1, 
HCCCH2), 3.10 (1H, ddd, J 12.8, 9.1, 3.7, C5HMHN), 2.96-2.88 (1H, m, C2H), 2.86-
2.81 (1H, m, CHSHTAr), 2.74-2.64 (2H, m, CH5HTAr, C5HMHN),  2.26 (1H, t, J2.3, 
HCCCH2), 2.25-2.15 (1H, m, C4HEHF), 2.12 (3H, s, OAc), 1.81-1.72 .(1H, m, 
C4HEHF); ' 3C NMR 6 (90.7 MHz, CDCI3) 170.7 (1C, Q), 158.2 (1C, Q), 130.6 (1C, 
Q), 129.9 (2C, CH), 114.0 (2C, CH), 77.4 (1C, Q), 74.7 (1C, CH), 74.0 (1C, CH), 
65.7 (1C, CH), 55.4 (1C, CH3), 50.2 (1C, CH 2), 40.2 (IC, CH2), 32.5 (1C, CH2), 30.7 
(1C, CH2), 21.4 (1C, CH3); m/z (FAB, NOBA) 288 ([M+H], 59%), 228 (48), 121 
(66), 106 (54), 91 (51); HRMS (FAB, NOBA) (Found: [M+H], 288.1604. 
Ci 7H22NO3 requires m/z, 288.1600). 
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O 34 OH 
To a solution of anisomycin 102 (20.0 mg, 80.0 tmol) in DMF (2 ml) was added 
potassium carbonate (11.0 mg, 0.08 mmol) and propargyl bromide (12.0 .il, 0. 80.0 
tmol), the solution was stirred at RT for 9 h. The solution was then concentrated in 
vacuo, and the residue was purified by flash chromatography [5% MeOWDCM] to 
give 140 as an oil (22.0 mg, 70.0 p.mol, 95%); R1 [5% MeOI-I/DCM] = 0.22; laiD - 
116 (c 0.90, CHC13); Umax (neat)/cm - '3305,3019, 1726, 1613, 1513; 'H NMR 6 (360 
MHz, CDC13) 7.10 (2H, d, J8.6, An]), 6.81 (2H, d, J8.6, An]), 4.47 (1H, dd, J5.6, 
1.5, CA, 4.13 (1H, td, J 6.8, 1.5, CA,  3.79 (3H, s, OMe), 3.58 (2H, t, J 2.3, 
HCCCH2), 3.36 (1H, dd, J 9.9, 7.1 C5HMHN), 3.22 (1H, qn, J 5.2, C21]), 2.86 (1H, 
dd,J 13.3, 4.7, CH5HTAr), 2.71 (1H, dd,J 13.3, 10.3, CH5HrAr), 2.62 (1H, dd,J9.9, 
6.7. C5HMHN), 2.32 (1H, t, J2.3, HCCCH2), 2.14 (3H, s, OAc); 13C NMR 8 (90.7 
MHz, CDC13) 172.0 (1C, Q), 158.2 (1C, Q), 130.2 (1C, Q), 130.0 (2C, CH), 114.0 
(2C, CH), 82.5 (1C, CH), 76.7 (1C, Q), 75.7 (1C, CH), 74.5 (1C, CH), 63.6 (1C, 
CH), 58.0 (1C, C112), 55.4 (1C, CH3), 40.0 (1C, Cl-I 2), 32.1 (1C, CH2), 21.3 (1C, 
CH3); m/z (FAB, THIOG) 304 ([M+H], 67%), 244 (42), 121 (100), 91(88); HR1'IS 
(FAB, THIOG) (Found: [M+H], 304.1540. C 17H22N04 requires m/z, 304.1549). 
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(2R,SR,4S)-3-Acetoxy-1 -benzyl-4-hydroxy-2-(4 ' -methoxybenzyl)-pyrrolidine 
141 
(p 
MeO' O 34 OH 
To a solution of anisomycin 102 (20.0 mg, 80.0 tmo1) in DMF (1 ml) was added 
potassium carbonate (11.0 mg, 80.0 imo1) and benzyl bromide (10.0 .tl, 80.0 tmol), 
the solution was stirred at RT for 4 h. The solution was then concentrated in vacuo, 
and the residual colourless solid was purified by flash chromatography [4% MeOHI 
DCM] to give 141 as an oil (25.0 mg, 70.0 jimol, 89%); Rf [5% MeOH/DCM] = 
0.33; laiD  -98.0 (c 1.00, CHC13); umax (neat)/cm' 3399, 3053, 1730, 1612, 1512; 1H 
NMR 6 (360 MHz, CD30D) 7.42-7.35 (5H, m, ArH), 7.14 (2H, d, J8.4, An]), 6.87 
(2H, d, J 8.4, ArH), 4.81 (1 H, br d, J 3.0, C311), 4.15 (1H, d, J 12.6, NCHxHyPh), 
4.11-4.09 (1H, m, C411), 3.79 (3H, s, OMe), 3.67 (1H, d, J 12.6, NCHxHyPh), (1H, 
M, CA, 3.36-3.34 (1H, m, C5HMHN),  2.91 (1H, dd, J 13.5,5.3, CHSHTAr), 2.83 
(1H, dd, J 13.5, 9.8, CHSHTAr), 2.58-2.56 (lH, m, C 5HMHN), 2.14 (3H, s, OAc); 13C 
NMR S (90.7 MHz, CD30D) 171.8 (1C, Q), 160.9 (1C, Q), 131.2 (1C, Q), 130.9 
(2C, CH), 130.8 (1C, Q), 130.7 (2C, CH), 129.6 (2C, CH), 129.0 (1C, CH), 115.0 
(2C, CH), 80.8 (1C, CH), 74.5 (1C, CH), 68.7 (1C, CH), 60.8 (1C, Cl-I2), 60.5 (1C, 
CH2), 55.6 (1C, CH3), 33.7 (1C, CH2), 20.9 (1C, CH3); m/z (FAB, THIOG) 356 
([M+H], 90%), 296 (63), 91 (95); HRMS (FAB, NOBA) (Found: [M+H], 
356.1861. C2 1 H26N04 requires m/z, 356.1862). 
164 
Chapter 5 	 Experimental 
2-Azido-1-ethylamine319 187 
N3 
To a solution of 2-chloro-1-ethylamine 186 (500 mg, 4.31 mmol) in water (5 ml) was 
added sodium azide (840 mg, 12.9 mmol) and the reaction mixture heated at 80 °C 
for 15 h. The solution was basified with KOH (solid) and extracted with ether. The 
organics were dried and concentrated to give 187 as a volatile colourless oil (371 mg, 
4.31 mmol, l00%); Umax (neat)/cm' 3375, 2104; 'H NMR ö (360 MHz, CDC13) 3.30 
(2H, t, J 5.7, CH), 2.79-2.74 (2H, m, CH2), 1.43 (2H, s, NH2); ' 3C NMR 8 (90.7 
MHz, CDC13) 54.2 (1C, CH2), 40.9 (1C, CH2); m/z (ESI+) 194 ( [2M+H]). 
All spectroscopic data was in good agreement with that of the literature. 319 
Safety in the Handling of Sodium Azide and other Azides: 394 Sodium azide is 
toxic (LD50 oral (rats) = 27 mgkg 1) and can be absorbed through the skin. It 
decomposes explosively upon heating to above 275 °C; hence its use in airbags in the 
automotive industry. 
Sodium azide reacts vigorously with CS2, bromine, nitric acid, dimethyl sulfate, and 
a series of heavy metals, including copper and lead. In reaction with water or 
Brønsted acids the highly toxic and explosive hydrogen azide is released. It has been 
reported that sodium azide and polymer-bound azide reagents form explosive di- and 
triazidomethane with CH 2C12 and CHC13, respectively. 
Heavy-metal azides that are highly explosive under pressure or shock are formed 
when solutions of NaN 3 or HN3 vapours come into contact with heavy metals or their 
salts. Heavy-metal azides can accumulate under certain circumstances, for example, 
in metal pipelines and on the metal components of diverse equipment (rotary 
evaporators, freeze drying equipment, cooling traps, water baths, waste pipes), and 
thus lead to violent explosions. Some organic and other covalent azides are classified 
as toxic and highly explosive, and appropriate safety measures must be taken at all 
times. 
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To a solution of 2-azido-1-ethylamine 187 (371 mg, 4.31 mmol) in DCM (7 ml) was 
added dansyl chloride 188 (225 mg, 840 imol) and the reaction mixture was stirred 
for 2 h at RT. The solution was concentrated in vacuo, and the residue was purified 
by flash chromatography [25% EtOAc/hexane] to give 189 as a pale yellow oil (260 
mg, 820 tmol, 98%); Rf [30% EtOAc/hexane] = 0.27; Xmax (H20)/nm 345; Umax 
(neat)/cm' 3301, 2942, 2103, 1318; 'H NMR 6 (3 60 MHz, CDC13) 8.57 (1H, br d, J 
8.5, C611), 8.29 (1H, br d, J 8.6, C41]), 8.26.(1H, dd, J 7.3, 1.3, C811), 7.59 (1H, dd, J 
8.6, 7.6, C311), 7.53 (111, dd, J8.5, 7.3 C711), 7.20 (1H, br d, J7.6, CA,  5.28 (1H, t, 
J 5.9, NioJI), 3.30 (2H, t, J 5.7, CiH), 3.06 (211, q, J 6.1, C, 1 H2), 2.90 (6H, s, 
NMe2); ' 3C NMR 6 (90.7 MHz, CDC13) 152.1 (1C, Ar, Q), 134.6 (1C, Ar, Q), 130.9 
(1C, C6H, CH), 130.0 (1C, Ar, Q), 129.7 (1C, C8H, CH), 129.6 (1C, Ar, Q), 128.8 
(1C, C3H, CH), 123.3 (1C, C7H, CH), 118.7 (1C, C4H, CH), 115.5 (1C, C2H, CH), 
51.0 (1C, C12H2, CH2), 45.5 (2C, NMe2, CH3), 42.5 (1C, C1,H2, CH2); m/z (FAB, 
NOBA) 319 ([M], 90%), 170 (100); HRMS (FAB, THIOG) (Found: [M+H], 
320.1184. C 1 4H,8N502S requires m/z, 320.1181). 
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To propargyl ether 135 (45.0 mg, 120 jtmol) in 'BuOH:H20 (3 ml, 1:1) was added 
dansyl azide 189 (40.0 mg, 130 p.mol), followed by copper(II) sulfate (3.0 mg, 10 
moi%) and sodium ascorbate solution (22.0 p.!, 1 M solution, 20 moi%). After 4 
hours stirring at RT the reaction was complete by tic. The solution was concentrated 
in vacuo, and the residue was purified by flash chromatography [60% to 100% 
EtOAc/hexane] to give 190a as a foam (68.0 mg, 92.0 jimo!, 76%); Rf 
[40%EtOAc/hexane] = 0.11;'H NMR 6 (360 MHz, CDC1 3 , 323 K) 8.58 (1H, br d, J 
8.5, An]), 8.24 (2H, d, J 7.6, An]), 7.27 (2H, t, J 7.5, ArI]) 7.46 (1H, br s, C 14J1), 
7.19(1H5 d, J7.5. ArH), 7.11 (2H, d, J 8.5, An]), 6.87 (2H, d, J 8.5, An]), 5.68 (1H, 
t, J3.8, N 101]), 5.14-5.08 (3H, m, C 16H2, C241]), 4.38 (2H, t, J5.6, C 1 2H2), 4.29-4.23 
(1H, m, C23H), 3.49-3.42 (3H, m, C26HMHN,  C11H2), 3.36-3.29 (1H, m, C26HMHN), 
3.00-2.91 (1H, m, C22HSHT),  2.90 (6H, s, NMe 2), 2.80 (1H, dd, J 13.7, 8.5, C22HsH), 
2.10-2.01 (1H, m, C25HEHF), 1.95 (3H, s, OAc), 1.87-1.75 (1H, m, C25HEHF), 1.45 
(9H, s, tBuO); ' 3C NMR 6 (90.7 MHz, CDC1 3 , 323 K) 172.1 (1C, CO'Bu, Q), 170.3 
(1C, OAc, Q), 156.9 (1C, Ar, Q), 152.1 (1C, Ar, Q), 144.4 (1C, C1 5 , Q), 134.9 (1C, 
Ar, Q), 131.6 (1C,Ar, Q), 130.9 (1C,ArH, CH), 130.6 (2C,ArH, CH), 130.2 (IC,Ar, 
Q), 129.8 (1C, Ar, Q), 129.7 (1C, ArH, CH), 128.8 (1C, ArH, CH), 124.2 (1C, C1 4H, 
CH), 123.4 (1C, ArH, CH), 119.1 (1C, ArH, CH), 115.7 (1C, ArH, CH), 115.2 (2C, 
ArH, CH), 79.9 (IC, 'Bu, Q), 73.5 (1C, C24R, CH), 62.2 (10 5 C16H2, CR2), 59.5 (1C, 
C23H, CH), 50.3 (1C, C 12H2 , CR2), 45.6 (2C, NMe2, CH3), 43.1 (1C, C26H2, CR2), 
42.9 (1C, C11 H2, CH2), 34.4 (IC, C22H2, CH 2), 28.7 (3C, 'BuO,CR 3), 28.7 (1C, 
C25H2, CH2), 20.9 (1C, OAc, CH3); nv'z (FAB, NOBA) 693 ([M+R], 35%), 91(56); 
HRMS (FAB, NOBA) (Found: [M-I-H], 693.3071. C35H4 5N607S requires m/z, 
693.3071). 
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Method 1: To propargyl ether 136 (32.6 mg, 120 pmol) in 'BuOH:H20 (3 ml, 1:1) 
was added dansyl azide 189 (40.0 mg, 130 imo1), followed by copper(II) sulfate (3.0 
mg, 10 mol%) and sodium ascorbate solution (22.0 p1, 1 M solution, 20 mol%). 
After 4 hours stirring at RT the reaction was complete by tic. The solution was 
concentrated in vacuo, and the residue was purified by flash chromatography [5% to 
10% MeOH/ DCM] to give 190 as a foam (54.5 mg, 90.0 .tmol, 77%). 
Method 2: To a solution of carbamate 190a (68.0 mg, 92.0 p.mol) in DCM (5 ml) 
was added trifluoroacetic acid (500 tl), the solution was stirred for 4 h at RT. The 
reaction was concentrated in vacuo to give 190 as an oil (63.0 mg, 89.0 tmol, 96%); 
Rf [5%MeOHIDCM] = 0.24; ?max (H20)/nm 345; H NMR 6 (360 MHz, DMSO) 
8.47 (1H, br d, J 8.5, CH), 8.27 (1H, t, J 5.8, N911), 8.22 (1H, br d, J 8.7, C41]), 8.26 
(1H, d, J 7.9, CA,  8.06 (1H, s, C 14H), 7.65-7.56 (2H, m, C3H, C7H), 7.27 (1H, d, J 
7.4, CH), 7.20 (2H, d, J 8.6, ArH), 7.00 (2H, d, J 8.6, ArH), 5.16 (1H, t, J 3.8, 
C24H), 5.03 (2H, s, C 1 6H2), 4.41 (2H, t,J5.9, C1 2H2), 3.89-3.81 (1H, m, C2311), 3.34-
3.24 (2H, m, C26H2), 3.26 (2H, br q, J 5.8, C 1 1 H2), 2.98-2.88 (2H, m, C22H2), 2.84 
(6H, s, NMe2), 2.30-2.19 (1H, m, C25HEHF), 2.12 (3H, s, OAc), 2.05-1.98 (1H, m, 
C25HEHF); 13C NMR 6 (90.7 MHz, DMSO) 169.7 (1C, OAc, Q), 157.2 (1C, Ar, Q), 
151.2 (1C,Ar, Q), 142.5 (1C, C15, Q), 135.5 (1C,Ar, Q), 130.1 (2C,ArH, CH), 129.7 
(1C, ArH, CH), 129.1 (1C, Ar, Q), 129.0 (1C, Ar, Q), 128.8 (1C, Ar, Q), 128.5 (1C, 
ArH, CH), 128.1 (1C, ArH, CH), 125.0 (1C, C 14H, CH), 123.8 (1C, ArH, CH), 119.3 
(1C, ArH, CH), 115.4 (1C, ArH, CH), 114.9(2C, ArH, CH), 72.9 (1C, C24H, CH), 
63.5 (1C, C23H, CH), 61.1 (1C, C16H2, CH2), 49.4 (1C, C1 1H2, CH2), 45.2 (2C, NW, 
CH3), 42.8 and 42.5 (2C, C 12H2 + C26H2, CH2), 31.1 (1C, C22H2, CH2), 30.6 (1C, 
C25H2, CH2), 20.9 (1C, OAc, CH3); m/z (FAB, NOBA) 593 ([M+H], 43%), 91(52); 
HRMS (FAB, NOBA) (Found: [M+H] t , 593.2548. C30H37N605S requires m/z, 
593.2546). 
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To propargyl amine 140 (27.0 mg, 90.0 tmo1) in tBuOH:H20 (2 ml, 1:1) was added 
dansyl azide 189 (26.0 mg, 80.0 tmol), followed by copper(II) sulfate (2.0 mg, 10 
mol%) and sodium ascorbate solution (20.0 .tl, 1 M solution, 20 mol%). After 5 
hours the reaction was complete by tic. The solution was concentrated in vacuo, and 
the residue was purified by flash chromatography [5% to 10% MeOH!DCM] to give 
191 as a foam (40.0 mg, 60.0 p.mol, 71%); Rf [10%MeOH/DCM] = 0.34; Xmax 
(H20)/nn 345; 1H NMR 5 (3 60 Hz, CD3CN) 8.54 (1H, d, J8.5, ArH), 8.19 (1H, d, J 
8.7, ArH), 8.16 (1H, dd, J7.3, 1.3 ArH), 7.59-7.54 (3H, m, 2ArH, C1 4R), 7.25 (1H, 
d, J 7.6, ArH), 7.21 (2H, d, J 8.5, An]), 6.87 (2H, d, J 8.5, ArH), 4.66 (1H, br s, 
C20H) 5 4.35 (2H, q, J 5.0, C11H2), 4.03 (1H, br s, C19H), 3.97 (1H, br d, J 13.6, 
C16HxHy), 3.86-3.84 (1H, m, C16HxHy),  3.76 (3H, s, OMe), 3.56-3.54 (1H, m, C2111), 
3.47-3.43 (1H, m, C18HMHN)3  3.30 (2H, br t, J6.1, C 1 2H2), 3.05 (1H, dd, J 13.4, 5.7, 
C22HSHT), 2.86 (6H, s, NMe2), 2.85 (1H, m, C18HMHN),  2.84 (1H, dd, J 7.2, 5.7, 
C22HsHr), 2.07 (3H, s, OAc); 13C NMR 8 (90.7 MHz, CD3CN) 170.9 (1C, OAc, Q), 
159.4 (1C, Ar, Q), 152.6 (1C, Ar, Q), 141.6 (1C, C14, Q), 136.1 (1C, Ar, Q), 131.2 
(2C, ArH, CH), 130.6 (1C, Ar, Q), 130.3 (1C, Ar, Q), 130.2 (1C, Ar, Q), 130.1(10 5 
Ar, Q), 130.0 (1C, ArH, CH), 129.2 (1C, ArH, CH), 126.4 (1C, ArH, CH), 124.4 
(1C, ArH, CH), 119.9 (1C, ArH, CH), 116.2 (1C, ArH, CH), 114.9 (2C, ArH, CH), 
79.7 (1C, C20H, CH), 73.9 (1C, C191-I, CH), 67.7 (1C, C21H, CH), 59.6 (1C, C18H25  
CH2) 3 55.8 (1C, OMe, CH3), 50.9 (1C, C11H2, CH2), 49.0 (1C, C16H2 , CH2), 45.7 (2C 5 
NMe2, CH3), 43.6 (1C, C 2H2, CH2), 32.2 (1C, C22H2, CH2), 21.1 (1C, OAc, CH3 ); 
m/z (FAB, NOBA) 623 ([M+H], 60%) 3 501 (46%) 5 91 (68%); HRMS (FAB, 
NOBA) (Found: [M+H], 623.2655. C 31 1-139N606S requires m/z, 623.2652). 
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To a solution of biotin-NHS 192 (60.0 mg, 170 tmol) in methanol (2 ml) was added 
triethylamine (73.0 p.1, 530 p.mol) and 1-azido-ethylamine 187 (90.0 mg, 1.06 mmol), 
and the solution stirred at RT for 6 h. The solution was concentrated in vacuo, and 
the residue was purified by flash chromatography [8% to 12 % MeOH/DCM] to give 
193 as a colourless solid (48.0 mg, 160 p.mol, 94 %); Rf [8% MeOHIDCM] = 0.19; 
Umax (neat)/cm' 3286, 2103, 1694, 1651; 'H NMR 8 (360 MHz, DMSO) 8.06 (1 H, t, 
J 5.8, N 14H), 6.44 (1H, br s, N611), 6.38 (1H, br s, N41]), 4.31-4.28 (1H, m, C311), 
4.16-4.12 (1H, m, C 71]), 3.32 (2H, t, J 5.8, C16H2), 3.23 (2H, t, J 5.8, C 15H2), 3.09-
3,07 (1H, m, C8!]), 2.87 (1H, dd, J 12.5, 5.1, C2HAHB),  2.56 (1H, d, J 12.5, C2HAHB), 
2.07 (2H, t, J7.4, C12H2), 1.52-1.28 (6H, m, C9H2, C 1 0H2, C 1 1 H2); '3C NMR 8 (90.7 
MHz, DMSO) 172.7 (1C, C13, Q), 1610 (1C, C5, Q), 61.2 (1C, C7, CH), 59.4 (1C, 
C3, CH), 55.7 (1C, C8, CH), 50.2 (1C, C16, CH2), 40.1 (1C, C2, CH2), 38.4 (1C, C15, 
CH2), 35.4 (1C, C12, CH2), 28.4 (1C, C105  CH2), 28.3 (1C, C9, CH2), 25.4 (1C, C11, 
CH2); m/z (FAB, THIOG) 313 ([M+H], 48%), 45 (100); HRMS (FAB, THIOG) 
(Found: [M+H], 313.1445. C 1 2H2 1 N602S requires m/z, 313.1447). 
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To a solution of phenol 194 (80.0 mg, 440 pmol) in DMF (4 ml) was added 
potassium carbonate (125 mg, 0.88 mmol) and propargyl bromide (200 jtl, 1.60 
mmol), the solution was stirred at RT for 30 h. The reaction was quenched by 
addition of water (10 ml) and diluted with ether (20 ml). The organic phase was 
separated and the aqueous phase extracted with ether (3 x 20 ml). The combined 
organics were washed with brine (10 ml), dried (Na2SO4) and concentrated in vacuo. 
The product 195 was obtained as an oil (75.0 mg, 340 jtmol, 77%); Rf [20% EtOAc/ 
hexane] = 0.43; umax (neat)/cm' 3286, 1735, 1610, 1510; 'H NMR ö (360 MHz, 
CDC13) 7.16 (2H, d, J 8.7, Ark!), 6.92 (2H, d, J 8.7, ArH), 4.67 (2H, d, J 2.4, 
HCCCH2), 4.24 (2H, t, J 7.1, CH2), 2.89 (2H, t, J 7.1, CH2), 2.53 (1 H, t, J 2.4, 
HCCCH2), 2.04 (3H, s, OAc); ' 3C NMR 6 (90.7 MHz, CDC13) 170.9 (1C, Q), 15 6. 0 
(iC, Q), 130.6 (1C, Q), 129.7 (2C, CH), 114.7 (2C, CH), 78.4 (1C, Q), 75.3 (1C, 
CH), 64.9 (1C, CH2), 55.6 (1C, CH2), 34.0 (1C, CH2), 20.8 (1C, CH3); m/z (FAB, 
THIOG) 219 ([M+H], 20%), 159 (79), 120 (23), 91(92); HRMS (FAB, THIOG) 
(Found: [M+H], 219.1023. C 13H1503 requires m/z, 219.1021). 
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To biotinylated azide 193 (30.0 mg, 90.0 imol) in H20: tBuOH (2 ml, 1:1) was added 
195 (24.0 mg, 100 tmol), followed by copper(II) sulfate (2.00 mg, 10 mol%) and 
sodium ascorbate solution (20.0 p1, 1 M solution, 20 mol%). The solution was stirred 
for 15 h at RT. The solution was concentrated in vacuo, and the residue was purified 
by flash chromatography [8% to 15% MeOHIDCM] to give 196 as a colourless solid 
(41.0 mg, 77.4 tmol, 86%); R f [20% MeOH/DCM] = 0.30; 'H NMR 8 (600 MHz, 
DMSO) 8.18 (1H, s, C 1 8R), 8.00 (1H, t, J5.9, N1411), 7.17 (2H, d, J8.6, ArH), 6.96 
(2H, d, J 8.6, An]), 6.44 (1H, br s, N61]), 6.38 (1H, br s, N41]), 5.09 (2H, s, C20H2), 
4.42 (2H, t, J 5.9, C 1 6H), 4.28-4.27 (1H, m, C31]), 4.16 (2H, t, J 7.0, C27H2), 4.14-
4.09 (1H, m, C 71]), 3.48 (2H, br q, J5.9, C151-12), 3.10-3.05 (1H, m, CA,  2.81 (2H, t, 
J7.0, C26H2), 2.79 (1H, dd, J 12.2, 5.2, C2HAHB), 2.54 (1H, d, J 12.2, C2HAHB), 2.03 
(2H, t, J7.4, C 1 2H2), 1.98 (3H, s, OAc), 1.56-0.86 (6H, m, C9H2, C 10H2, C 11 H2); 13C 
NMR 8 (151.1 MHz, DMSO) 173.5 (1C, C13, Q), 171.2 (1C, C29, Q), 163.6 (1C, C5, 
Q), 157.6 (1C, Ar, Q), 143.4 (1C, C19, Q), 131.0 (1C, Ar, Q), 130.6 (2C, ArH, CH), 
125.6 (1H, C18, CH), 115.5 (2C,ArH, CH), 65.6 (1C, C27, CH2), 62.1 (1C, C20, CH2), 
61.9 (1C, C7, CH), 60.2 (1C, C3, CH), 56.3 (1C, C8, CH), 49.8 (1C, C16, CH2), 40.8 
(1C, C2, CH2), 38.7 (1C, C15, CH2), 36.0 (1C, C12, Cl-I2), 34.4 (1C, C26, CH2), 29.3 
(1C, C10, CH2), 28.0 (1C, C9, CH2), 26.0 (1C, C11, CH2) 3 21.6 (1C, C30, CH3); nilz 
(FAB, THIOG) 531 ([M+H]F,  27%), 270 (22) 227 (16) 3 45 (100); HRMS (FAB, 
THIOG) (Found: [M+H], 531.2390. C25H35N605S requires m/z, 531.2387). 
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To biotinylated azide 193 (27.0 mg, 90.0 .tmol) in H20:'BuOH (2 ml, 1:1) was added 
N-propargyl anisomycin 140 (17.0 mg, 50 tmol), followed by copper(II) sulfate (2.0 
mg, 10 mol%) and sodium ascorbate solution (20.0 tl, 1 M solution, 20 mol%). The 
solution was stirred for 15 h at RT. The solution was concentrated in vacuo, and the 
residue was purified by flash chromatography [8% to 15% MeOHJDCM] to give 197 
as a colourless solid (22.0 mg, 35.5 tmol, 71%); Rf [20% MeOI-IIDCM] = 0.35; 'H 
NMR 6(360 MHz, DMSO) 7.98 (1H, t, J5.4, N 14H), 7.96 (1H, s, C 1 811), 7.11 (2H, 
d, J 8.6, An]), 6.82 (2H, d, J 8.6, An]), 6.43 (1H, br s, N6!]), 6.38 (1H, br s, N41]), 
5.10 (1H, d, J 3.9, 01]), 4.48 (1H, dd, J 4.5, 1.8, C241]), 4.39 (2H, t, J 6. 0, C 1 6H2), 
4.32-4.28 (11-I, m, C3!]), 4.15-4.10 (1H, m, C7!]), 3.92 (1H, d, J 14.1, C20HxHy), 
3.81-3.78 (1H, m, C231]), 3.71 (3H, s, OMe), 3.63 (1H, d, J 14.1, C20HxHy), 3.48 
(2H, br q, J 5.8, C 15H2), 3.18 (1H, dd, J 10.3, 6.2, C22HMHN), 3.09 (1H, ddd, J 8.2, 
6.1, 4.5, C8!]), 3.01-2.93 (2H, m, C25H, C26HSHT), 2.81 (1H, dd, J 12.4, 5.0, 
C2HAHB), 2.60-2.53 (2H, m, C2HAHB, C26H5Hr), 2.24 (1H, dd, J 10.3, 4.5, 
C22HMHN), 2.04 (3H, s, OAc), 2.02 (2H, t, J 7.4, C12H), 1.48-0.80 (6H, m, C9H2, 
C 1 0H2, Cii!])); ' 3C NMR 6 (90.7 MHz, DMSO) 173.5 (1C, C13, Q), 169.7 (IC, OAc, 
Q), 162.7 (1C, C5, Q), 157.5 (1C, Ar, Q), 143.0 (1C, C19, Q), 131.0 (1C, Ar, Q), 
129.8 (2C, ArH, CH), 123.8 (1C, C18, CH), 113.7 (2C, ArH, CH), 79.5 (1C, C24 , 
CH), 72.9 (1C, C23, CH), 64.8 (1C, C25, CH), 61.0 (1C, C7, CH), 59.2 (1C, C3, CH), 
55.4 (IC, 62, CH2), 49.9 (2C, CH, CH3, Cr8, c32), 48.7 (1C, C16, CH2), 47.0 (1C, C20, 
CH2), 39.8 (1C, C2, CH2), 38.7 (1C, C15, CH2), 35.0 (1C, C12, CH2), 32.2 (1C, C26, 
CH2), 28.1 (1C, Cio, CH2), 28.0 (1C, C9, CH2), 25.1 (1C, C11, CH2), 20.8 (1C, OAc, 
CH3); m/z (FAB, THIOG) 615 ([M+H], 19%); HRMS (FAB, THIOG) (Found: 
[M+H], 616.2916. C29H42N706S requires m/z, 616.2917). 
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To biotinylated azide 193 (50.0 mg, 160 jimol) in H20:'BuOH (3 ml, 1:1) was added 
O-propargyl analogue 135 (60.0 mg, 170 imol), followed by copper(II) sulfate (3.5 
mg, 10 mol%) and sodium ascorbate solution (37.0 Vd, 1 M solution, 20 mol%). The 
solution was stirred for 15 h at RT. The solution was concentrated in vacuo, and the 
residue was purified by flash chromatography [5% to 15% MeOH/DCM] to give 
198a as a colourless oil (76.0 mg, 111 tmol, 70%); Rf [10% MeOHJDCM] = 0.19; 
'H NMR 6 (360 MHz, CDC13, 323 K) 7.71 (1H, s, C 1 8H), 7.11 (2H, d, J 8.4, ArH), 
6.89 (2H, d, J8.4, An]), 5.14 (2H, s, C20H2), 5.10 (1H, br q, J7.0, C281]), 4.54-4.57 
(3H, m, C3H, C 16H2), 4.36-4.31 (1H, m, C7H), 4.26-4.21 (1H, m, C271]), 3.70-3.76 
(2H, q, J 5.8, C1 5H2), 3.48-3.41 (1H, m, C30HMHN),  3.35-3.28 (1H, m, C30HMHN), 
3.16-3.11 (1H, m, C81A  3.03-2.96 (1H, m, C26HSHT),  2.89 (1H, dd, J 13.0, .4.9, 
C2HAHB), 2.80 (1H, dd, J 13.8, 8.6, C26H5Hr),  2.70 (1H, d, J 13.0, C2HAHB), 2.18 
(2H, t, J6.5, C 1 2H2), 2.09-2.01 (1H, m, C29HEHF),  1.97 (3H, s, OAc), 1.85-1.76 (1H, 
M, C29HEHF), 1.72-1.38 (6H, m, C9H2, C,0H2, C 11H2), 1.45 (9H, s, 'BuO); '3C NMR 
(90.7 MHz, CDC13, 323 K) 174.3 (1C, CO'Bu, Q), 172.7 (1C, C13, Q), 170.3 (1C, 
OAc, Q), 156.9 (1C, C5, Q), 155.5 (1C,Ar, Q), 144.3 (1C, C19, Q), 131.7 (1C,Ar, Q), 
130.7 (2C, ArH, CH), 124.1 (1C, C18, CH), 115.1 (2C, ArH, CH), 80.0 (1C, 'Bu, Q), 
73.5 (1C, C28, CH), 62.3 (1C, C7, CH), 62.2 (1C, C20, CH2), 60.7 (1C, C3, CH), 59.6 
(IC, C27, CH), 55.7 (1C, C8, CH), 49.8 (1C, C16, CH2), 43.7 (1C, C30, CH2), 40.6 
(1C, C2, CH2), 39.5 (1C, C15, CH2),35.8 (1C, C12, CH2), 34.3 (1C, C26, CH2), 29.8 
(1C, C29, CH2), 28.7 (3C, 'Bu, CH3), 27.9 (1C, C10, CH2), 27.8 (1C, C91  CH2), 25.1 
(1C, C11, CH2), 20.0 (1C, OAc, CH3); m/z (FAB, THIOG) 686 ([M+H], 16%), 586 
(60); HRMS (FAB, THIOG) (Found: [M+H] 4 , 668.3336. C33H48N707S requires m/z, 
686.3336). 
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To a solution of carbamate 198a (25.0 mg, 36.0 p.mol) in DCM (2 ml) was added 
trifluoroacetic acid (27.0 jtl, 360 .imol), the solution was stirred for 4 h at RT. The 
reaction was concentrated in vacuo to give 198 (23.0 mg, 32.9 tmol, 91%) as a 
colourless foam; Rf [20% MeOH/DCM] = 0.16; 1H NMR 8 (360 MHz, DMSO) 8.19 
(1H, s, C181f), 8.01 (1H, t, J 5.6, N1411), 7.20 (2H, d, J 8.6, An]), 7.02 (2H, d, J 8.6, 
An]), 6.76 (1H, br s, N61]), 6.44 (1H, br s, N 41]), 5.16 (1H, t, J3.7, C281]), 5.10 (2H, 
S, C20H2), 4.42 (2H, t, J 6.0, C 1 6H2), 4.31-4.28 (1H, m, C311), 4.13-4.10 (1H, m, 
C7H), 3.87-3.84 (1H, m, C2711), 3.49 (2H, q, J5.8, C15H2), 3.33-3.23 (2H, m, C30H2), 
3.11-3.06 (1H, m, C81]), 2.98-2.85 (2H, m, C26H2), 2.80 (1H, dd, J 12.4, 5.0, 
C2HAHB), 2.57 (1H, d, J 12.4, C2HAHB), 2.30-2.20 (1H, m, C29HEHF),  2.12 (3H, s, 
OAc), 2.03 (2H, t, J 7.4, CiH), 2.01-1.97 (1H, m, C29HEHF), 1.64-1.21 (6H, m, 
C9H2, C 10H2, C 11 H2); ' 3C NMR 8 (90.7 MHz, DMSO) 172.1 (1C, C13, Q), 169.3 (1C, 
OAc, Q), 162.1 (1C, C5, Q), 157.1 (1C, Ar, Q), 142.1 (1C, C19, Q), 129.7 (2C, ArH, 
CH), 128.3 (1C, Ar, Q), 124.5 (1C, C18, CH), 114.5 (2C, ArH, CH), 72.5 (1C, C28, 
CH), 63.0 (1C, C27, CH), 60.7 (1C, C20, CR2), 60.7 (1C, C75  CH), 58.9 (1C, C3, CH), 
55.1 (1C, C8, CH), 48.7 (1C, C16, CH2), 42.5 (1C, C30, CH2), 39.6 (1C, C2, CR2), 
38.5 (105  C15, CH2), 34.9 (1C, C12, CH2), 30.7 (1C, C26, CH2), 30.1 (1C, C29, CH2), 
27.9 (1C, C10, CH2), 27.7 (1C, C9, CH2), 24.8 (1C, C11, CH2), 20.5 (1C, OAc, CH3); 
m/z (FAB, THIOG) 586 ([M+H], 29%); HRMS (FAB, THIOG) (Found: [M+H] +, 
586.2812. C28H40N705S requires m/z, 586.2812). 
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6-Azido-1-hexylamine 320 201 
H2N 	
N3 
A solution of 6-amino-hexan-1-ol 199 (1.17 g, 10.0 mmol) and soc12 (3.28 ml, 45.0 
mmol) in toluene (10 ml) was heated at reflux for 1 h. The solvent was removed in 
vacuo and the intermediate 6-ch!oro-1-hexylamine 200 was obtained as a 
hygroscopic solid; m/z (ESI+, MeOH) 136 ([M+H]', 100), 138 ([M+H], 33). To a 
solution of sodium azide (1.95 g, 30.0 mmol) in water (10 ml) was added 6-ch!oro-l-
hexylamine 200 and the reaction was stirred at 90 °c for 2 h. The solution was 
basified (pH 12-14) with KOH (solid), extracted with DCM, dried (MgSO 4) and 
concentrated in vacuo. The product 201 was obtained as a colourless solid (1.28g, 
9.01 mmo!, 90% over two steps); 'H NMR ö (360 MHz, DM50) 3.40-3.20 (4H, m, 
CH2NH2, cH2N3), 1.75-1.45 (4H, m, 2CH2), 1.41-1.22 (4H, m, 2cH2); 13C NMR ö 
(90.6 MHz, DMSQ) 51.0 (1C, cH2), 39.4 (1C, CH 2), 29.6 (1C, cl-I2), 29.5 (1C, 
cH2), 27.2 (1C, cH2), 26.8 (1C, CH2); mit (ESI+, MeOH) 143.0 ([M+H], 100%); 
HRMS (FAB, NOBA) (Found: [M+H], 143.1297. C6HI5N4 requires m/z, 143.1297). 
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To a solution of 6-azido-1-hexylamine 201 (316 mg, 1.46 mmol) and triethylamine 
(202 pJ, 1.46 mmol) in methanol (20 ml) was slowly added a solution of biotin-NHS 
192 (500 mg, 1.46 mmol) in methanol (10 ml). The reaction was stirred for 15 h at 
RT. The solution was concentrated in vacuo, and the residue was purified by flash 
chromatography [5% MeOH/DCM] to give 202 as a pale yellow solid (479 mg, 1.30 
mmol, 89%); Rf [10% MeOH/DCM] = 0.11; Vmax (neat)/cm 3301, 2099, 1704, 
1638; 'H NMR 8 (3 60 MHz, DMSO) 7.76 (1H, t, J5.5, N1411), 6.44 (1H, br s, NA, 
6.38 (1H, br s, NA, 4.32-4.29 (1H, m, C31]), 4.15-4.11 (1H, m, C71]), 3.31 (2H, t, J 
6.9, C20H2), 3.12-3.06 (1H, m, C81]), 3.01 (2H, dt, J 12.5, 6.7, C 15H2), 2.82 (1H, dd, J 
12.5, 5.1, C2HAHB), 2.58 (1H, d, J 12.5, C2HAHB), 2.04 (2H, t, J7.4, C12H2), 1.54-
1,25 (14H, m, C9H2, C 10112, C 11 H2, C 16H2, C 17H2, C 1 8H2, C 19H2); 13C NMR 6 (90.7 
MHz, DMSO) 172.1 (1C, C13, Q), 163.0 (1C, C5, Q), 61.3 (1C, C7, CH), 59.4 (1C, 
C3, CH), 55.7 (1C, C8, CH), 50.8 (1C, C20, CH2), 39.9 (1C, C2, CH2), 38.5 (1C, C15, 
CH2), 35.5 (1C, C12, CH2), 29.3, 28.5, 28.3, 26.2, 26.1, 25.6, 25.5 (7C, C9, C10, C11, 
C16, C17, C18, C19, CH2); m/z (FAB, THIOG) 369 ([M+H] +, 58%),258 (46); HRMS 
(FAB, THIOG) (Found: [M+H], 369.2074. C 16H29N602S requires m/z, 369.2073). 
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1-(N-Biotinyl-6-aminohex-1-yl)-4- [4 1 -(2"-acetoxyeth-1 ' '-yl)phenyloxymethylj - 
1H-[1,2,3] triazole 203 
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To biotinylated azide 202 (50.0 mg, 140 .tmol) in H20:'BuOH (5 ml, 1:1) was added 
O-propargyl analogue 195 (30.0 mg, 140 tmol), followed by copper(II) sulfate (4.0 
mg, 15 mol%) and sodium ascorbate solution (28.0 .tl, 1 M solution, 20 mol%). The 
solution was stirred for 24 h at RT. The solution was concentrated in vacuo, and the 
residue was purified by flash chromatography [2% to 5% MeOH/DCM] to give 203 
as a colourless solid (62.0 mg, 105 tmol, 75%); Rf [10% MeOH/DCM] = 0.08; 'H 
NMR 8 (360 MHz, DMSO) 8.30 (1H, s, C2211), 7.72 (1H, br s, N14H), 7.16 (2H, d, J 
8.5, ArII), 6.95 (2H, d, J 8.5, ArR), 6.40 (1H, br s, N6H), 6.35 (1H, br s, N41f), 5.09 
(2H, s, C24H2), 4.34 (2H, t, J7.1, C20H2), 4.32-4.30 (1H, m, C311), 4.15 (2H, t, J6.9, 
C31 H2), 4.14-4.10 (1H, m, C 7H), 3.12-3.06 (1H, m, C8H), 3.01 (2H, dt, J 12.5, 6.7, 
C 15H2), 2.81 (2H, t, J6.9, C30H2), 2.80 (1H 5 dd, J 12.2, 5.1, C2HAHB), 2.58 (1H, d, J 
12.2, C2HAHB), 2.04 (2H, t, J 7.3, C i H), 1.97 (3H, s, OAc), 1.80 (2H, qn, J 6.9, 
C 19H2), 1.66-1.16 (12H, m, C9H2, C 1 0H2, C 11 H2, C 1 6H2, C1 7H2, C 1 5H2); '3C NMR 
(90.7 MHz, DMSO) 171.7 (1C, C13, Q), 170.1 (1C, OAc, Q), 162.6 (1C, C5, Q), 
156.6 (1C, Ar, Q), 142.5 (1C, C23, Q), 130.2 (1C, Ar, Q), 129.6 (2C, ArH, CH), 
124.2 (1C, C22, CH), 114.5 (2C,ArH, CH), 64.4 (1C, C31, CR2), 61.0 (1C, C24, CR2), 
60.8 (1C, C7, CH), 59.0 (1C, C3, CH), 55.3 (1C, C8, CH), 49.0 (1C, C20, CH2), 39.6 
(1C, C2, CH2), 38.1 (1C, C15, CH2), 35.0 (1C, C12, CH2), 33.2 (1C, C30, CH2), 29.4 
(1C, C19, CH2), 28.8, 28.0, 25.8, 25.7, 25.2, 25.1 (6C 5 C9, C10, C11, C16, C17, C, 
CH2) 5 20.5 (1C, OAc, CR3); m/z (FAB, THIOG) 587 ([M+H], 18%) 5 91(78); 
HRMS (FAB, THIOG) (Found: [M+H], 587.3020. C 29H43N605 S requires m/z, 
587.3016). 
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C 6-Click N-linked anisomycin biotin molecular probe 204 
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To biotinylated azide 202 (47.0 mg, 130 imol) in H20: tBuOH (3 ml, 1:1) was added 
N-propargyl anisomycin 140 (42.0 mg, 140 jtmol), followed by copper(II) sulfate 
(3.0 mg, 10 mol%) and sodium ascorbate solution (28.0 p1, 1 M solution, 20 mol%). 
The solution was stirred for 15 h at RT. The solution was concentrated in i'acuo, and 
the residue was purified by flash chromatography [8% to 15% MeOH/DCM] to give 
204 as a colourless solid (64.0 mg, 95.0 .tmol, 73%); Rf [20% MeOI-IIDCM] = 0.35; 
'H NMR 8 (360 MHz, 323 K, DMSO) 8.13 (1H, br s, C221]), 7.58 (1H, t, J 5.6, 
N 14H), 7.09 (2H, d, J 8.6, An]), 6.83 (2H, d, J 8.6, An]), 6.26 (1H, br s, NA, 6.23 
(1H, br s, N41]), 5.06 (1H, br s, OH), 4.58 (1H, dd, J4.9, 2. 1, C28H), 4.33 (2H, t, J 
7.0, C0H2), 4.32-4.28 (1H, m, CA,  4.15-4.12 (1H, m, C 7H), 3.98 (1H, br d, J 13.9, 
C24HxHy), 3.90-3.86 (1H, m, C 27H), 3.75 (1H, br d, J 13.9, C24HxHy), 3.72 (3H, s, 
OMe), 3.25-3.10 (2H, m, C26HMHN,  C291]), 3.08 (1H, ddd, J8.1, 6.6, 4.8, C81]), 2.98 
(2H, br q, J6.6, C15H), 2.91 (1H, dd, J 13.3, 4.6, C30HSHT), 2.83 (1H, dd, J 12.4, 5. 1, 
C2H4HB), 2.60 (1H, d, J 13.3, C30H5Hr),  2.81 (1H, d, J 12.4, C2HAHB), 2.41-2.32 
(1H, m, C26HMHN),  2.05 (2H, t, J7.3, C 1 2H2), 2.04 (3H, s, OAc), 1.82 (2H, qn, J7.0, 
C19H2), 1.70-1.20 (12H, m, C9H2, C 1 0H2, C1 1 H2,C 1 6112, C 17H2, C 1 8H2); ' 3C NMR ö 
(90.7 MHz, DMSO) 171.8 (1C, C13, Q), 169.5 (1C, OAc, Q), 162.6 (1C, C5, Q), 
157.6 (1C, Ar, Q), 142.3 (1C, C23, Q), 130.4 (1C, Ar, Q), 129.6 (2C, ArH, CH), 
123.4 (1C, C22, CH), 113.5 (2C, ArH, CH), 78.9 (1C, C28, CH), 72.3 (1C, C27, CH), 
64.7 (1C, C29, CH), 60.9 (1C, C7, CH), 5 9. 0 (1C, C3, CH), 58.8 (1C, C26, CH2), 5 5. 0 
(1C, C8, CH), 54.7 (1C, OMe, CH3), 49.0 (1C, C20, CH2), 47.3 (1C, C24, CH2), 39.5 
(1C, C2, CH2), 38.0 (1C, C15, CH2), 34.9 (1C, C12, CH2), 31.9 (1C, C30, CH2), 29.4 
(1C, C19, CH2), 28.6, 27.9, 27.8, 25.5, 25.2, 25.0 (6H, C93  C105  C115 C165  C17, C18 5  
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CH2), 20.4 (1C, OAc, CH3); m/z (FAB, THIOG) 672 ([M+H], 38%), 91 (88); 
HRMS (FAB, THIOG) (Found: [M+H], 672.3540. C33H50N706S requires m/z, 
672.3543). 
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C6-Click 0-linked Boc C(4)-H anisomycin biotin molecular probe 205a 
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To biotinylatéd azide 202 (41.0 mg, 111 tmol) in H20:'BuOH (2 ml, 1:1) was added 
O-propargyl analogue 135 (45.0 mg, 120 tmo1), followed by copper(II) sulfate (3.0 
mg, 10 mol%) and sodium ascorbate solution (25.0 .tl, 1 M solution, 20 mol%). The 
solution was stirred for 18 h at RT. The solution was concentrated in vacuo, and the 
residue was purified by flash chromatography [5% to 15% MeOHIDCM] to give 
205a as a colourless oil (62.0 mg, 84.0 .tmol, 76%); Rf [10% MeOHIDCM] = 0.24; 
'H NMR 8 (360 MHz, CDC13, 323 K) 7.60 (1H, s, C22H), 7.10 (2H, d, J 8.5, An]), 
6.88 (2H, d, J8.5, ArH), 5.16 (2H, s, C24H2), 5.11 (1H, dt, J6.5, 14. 1, C321-f), 4.52-
4.46 (1H, m, C31]), 4.34 (2H, t, J7.0, C20H2), 4.33-4.29 (1H, m, C7H), 4.29-4.21 (1H, 
M, C311]), 3.47-3.27 (2H, m, C34H2), 3.25-3.14 (3H, m, C8H, C 15H2), 3.01-3.92 (1H, 
M, C30HSHT), 2.89 (1H, dd, J 12.6, 4.3, C2HAHB),  2.81 (1H, dd, J 13.8, 8.4 C3OHSHT), 
2.72 (1H, d, J 12.6, C2HAHB),  2.19 (2H, t, J6.9, C 12H2), 2.09-2.00 (1H, m, C33HEHF), 
1.97 (3H, s, OAc), 1.91 (2H, br t, J6.6, C191]), 1.84-1.74 (114, m, C33HEHF), 1.71-
1.56 (4H, m, C9H2, C,,H2), 1.44 (9H, s, tBuO), 1.49-1.27 (8H, m, C 1 0H25  C 16H25  
C 17H2, C 18H2); 13C NMR ö (90.7 MHz, CDC13 , 323 K) 173.1 (1C, C13, Q), 170.7 
(1C, COtBu, Q), 169.7 (1C, OAc, Q), 162.1 (10 5 C5 5  Q), 156.8 (1C, Ar, Q), 144.0 
(10 5  C23, Q), 131.4 (1C, Ar, Q), 130.3 (2C, ArH, CH), 122.5 (1C, C22, CH), 114.7 
(2C, ArH, CH), 79.7 (1C, 'Bu, Q), 73.0 (1C, C32, CH), 62.1 (1C, C24, CH2), 61.8 (1C, 
C7, CH), 60.2 (10 5 C3, CH), 59.1 (1C, C31, CH), 55.4 (10 5 C8, CH), 50.1 (1C, C20, 
CH2), 43.0 (1C, C34, CH2), 40.3 (1C, C2, CH2), 39.1 (1C, C15, CH2), 35.8 (1C, C12, 
CH2), 33.9 (1C, C30, CH2) 5  29.8 (1C, C19, CH2), 29.4, 29.2, 28.5 5 28.3, 28.3, 28.1, 
25.8, 25.4 (b C, C9, C10, C11, C16, C17, C18 5  C33 all CH2 's and 'Bu CH3's), 20.7 (1C, 
OAc, CH3); m/z (FAB, THIOG) 742 ([M+H], 20%), 642 (57), 91(61); HRMS 
(FAB, THIOG) (Found: [M+H], 742.3960. C37H56N707S requires m/z, 742.3962). 
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C6-Click 0-linkedC(4)-H anisomycin biotin molecular probe 205 
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To a solution of carbamate 205a (41.0 mg, 55.0 j.tmol) in DCM (2 ml) was added 
trifluoroacetic acid (41.0 p1, 550 pmol), the solution was stirred for 4 h at RT. The 
reaction was concentrated in vacuo to give 205 (40.0 mg, 52.9 tmo1, 96%) as a 
colourless foam; R [20% MeOH/DCM] = 0.38; 'H NMR 6 (360 MHz, DMSO) 8.23 
(1H, s, C221]), 7.76 (1H, t, J 5.6, N 1411), 7.19 (2H, d, J 8.6, ArH), 7.00 (2H, d, J 8.6, 
An]), 6.44 (1H, br s, N611), 6.38 (1H, br s, N 41]), 5.16 (1H, t, .J3.8, C321]), 5.10 (2H, 
S, C24H2), 4.42 (2H, t, J 7.0, C20H2), 4.31-4.28 (1H, m, C3H), 4.13-4.10 (1H, m, 
C71]), 3.87-3.81 (1H, m, C31 R), 3.34-3.22 (2H, m, C34H2), 3.08 (1H, ddd, 8.5, 6.1, 
4.8, C81]), 2.99 (2H, br q, J 6.0, C 1 5H2), 3.33-3.23 (2H, m, C30H2), 2.80 (1H, dd, J 
12.5, 5. 1, C2H4HB), 2.57 (1H, d, J 12.5, C2HAHB), 2.30-2.18 (1H, m, C33HEHF),  2.12 
(3H, s, OAc), 2.03 (2H, t, J7.3, C 12H2), 2.01-1.97 (1H, m, C33HEHF), 1.80 (2H, qn, J 
7.1, C191]), 1.65-1.19 (12H, m, C9H2, C10H2, C 1 1H2, C 16H2, C 17H2, C 1 8H2); ' 3C NMR 
6 (90.7 MHz, DMSO) 172.0 (1C, C13, Q), 169.8 (1C, OAc, Q), 162.9 (1C, C5, Q), 
157.3 (1C, Ar, Q), 142.9 (1C, C23, Q), 130.3 (2C, ArH, CH), 128.8 (1C, Ar, Q), 
124.8 (1C, C22, CH), 115.1 (2C, ArH, CH), 73.0 (1C, C32, CH), 63.5 (1C, C31, CH), 
61.2 (1C, C7, CH), 61.2 (1C, C24, CH2), 59.4 (1C, C3, CH), 55.7 (1C, C8, CH), 49.5 
(1C, C20, CH2), 42.8 (1C, C34, CH2), 40.0 (1C, C2, CH2), 38.4 (1C, C15, CH2), 35.5 
(1C, C12, CH2), 31.1 (1C, C30, CH2), 30.6 (1C, C33, CH2), 29.9 (1C, C19, CH2), 29. 1, 
28.5, 28.3, 26.0, 25.7, 25.6 (6H, C9, C10, C11, C16, C17, C18, CH2), 21.0 (1C, OAc, 
CH3); m/z (FAB, THIOG) 642 ([M+H], 30%), 91(69); HRMS (FAB, THIOG) 
(Found: [M+H], 642.3437. C32H48N705S requires m/z, 642.3438). 
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To biotinylated iodoacetamide 76 (20.0 mg, 40.0 tmol) in DMF (1.5 ml) was added 
194 (10.0 mg, 40.0 i.tmol), followed by K2CO3 (6.00 mg, 40.0 .imo1). The solution 
was stirred for 48 h at 80 °C. The solution was concentrated in vacuo, and the residue 
was purified by flash chromatography [10% MeOH/DCM] to give 206 as a 
colourless solid (17.0 mg, 34.4 tmol, 86%); Rf [10% MeOH/DCM] = 0.30; 'H 
NMR ö (360 MHz, DMSO) 8.1,2 (1H, t, J5.2, N 171f), 7.87 (1H, t, J5.2, N 1 4H), 7.17 
(2H, d, J 8.7, ArF/), 6.89 (2H, d, J 8.7, An]), 6.42 (1H, bn s, NA, 6.36 (1H, br s, 
N4H), 4.42 (2H, s, C 19H2), 4.30-4.27 (1H, m, CA,  4.15 (2H, t, J7.0, C26H2), 4.12-
4.08 (1H, m, C71]), 3.15 (4H, dt, J9.9, 5.6, C 1 5H2, C 1 6H2), 3.10-3.04 (1H, m, CA, 
2.81 (2H, t, J 7.0, C 5H), 2.80 (1H, dd, J 12.3, 5.2, C2HAHB), 2.56 (1H, d, J 12.3, 
C2HAHB),. 2.04 (2H, t, J 7.3, CiH), 1.97 (3H, s, OAc), 1.64-1.23(6H, m, C9H2, 
C 1 0H2, C1 1 112); '3C NMR ö (90.7 MHz, DMSO) 172.3 (1C, C13, Q), 170.2 (1C, OAc, 
Q), 167.8 (1C, C18, Q), 162.6 (1C, C5, Q), 156.6 (1C, Ar, Q), 130.4 (1C, Ar, Q), 
129.5 (2C, ArH, CH), 114.4 (2C, ArH, CH), 66.7 (1C, C19, CH2), 64.2 (1C, C26, 
CH2), 60.7 (1C, C7, CH), 59.0 (1C, C3, CH), 55.1 (1C, C8, CH), 39.6 (1C, C2, CH2), 
38.3 (1C, C16, CH2), 37.8 (1C, C15, CH2), 34.9 (1C, C12, CH2), 33.2 (1C, C25, CH2), 
28.0 (1C, C10, CH2), 27.8 (1C, C9, CH2), 24.9 (1C, C11, CH2), 20.5 (1C, OAc, CH3); 
m/z (FAB, THIOG) 507 ([M+H]', 29%), 91(75); HRMS (FAB, THIOG) (Found: 
[M+H], 507.2281. C24H35N406S requires m/z, 507.2277). 
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To biotinylated iodoacetamide 76 (25.0 mg, 55.0 p.mol) in DMF (5 ml) was added 
anisomycin 102 (15.0 mg, 55.0 jimol), followed by K2CO3 (7.60 mg, 55.0 jtmol). 
The solution was stirred for 48 h at 80 °C. The solution was concentrated in vacuo, 
and the residue was purified by flash chromatography [5% to 15% MeOHIDCM] to 
give 207 as a colourless solid (11.0 mg, 18.7 tmol, 34%); Rf [14% MeOWDCM] = 
0.33; 'H NMR 8 (360 MHz, DMSO) 7.87 (2H, br s, N 14H, N 17H), 7.08 (2H, d, J 8.6, 
ArH), 6.81 (2H, d, J8.6, ArH), 6.43 (1H, br s, NH), 6.38 (1H, br s, NA, 4.60 (1H, 
dd, J 4.2, 1.5, C23H), 4.31-4.28 (1H, m, C311), 4.13-4.09 (1H, m, C71f), 3.95-3.90 
(1H, m, C2211), 3.70 (3H, s, OMe), 3.49-3.35 (2H, m, C,9HHy, C2IHMHN), 3.17-3.05 
(5H, m, C8H, C 1 5H2, C 16H20, 3.00-2.85 (3H, m, C19HHy, C 21 HMHN), 2.80 (1H, dd, J 
12.5, 5.0, C2HAHB), 2.77-2.71 (1H, m, C25H5H1), 2.66-2.60 (1H, m, C25HSHT), 2.57 
(1H, d, J 12.5, C2HAHB), 2.08 (3H, s, OAc), 2.06 (2H, t, J7.6, C 12H2), 1.76-1.22 (6H, 
M, C9H2,C,0H2, C 11 H2); 13C NMR 6 (151.1 MHz, DMSO) 172.5 (1C, C13, Q), 171.1 
(1C, C18, Q), 169.7 (1C, OAc, Q), 162.8 (1C, C5, Q), 157.7 (1C, Ar, Q), 130.2 (1C, 
Ar, Q), 129.7 (2C, ArH, CH), 113.5 (2C, ArH, CH), 78.5 (1C, C23, CH), 72.5 (1C, 
C22, CH), 69.6 (1C, C24, CH), 60.8 (1C, C7, CH), 60.8 (1C, C21, CH2), 59.0 (1C, C3, 
CH), 58.2 (1C, C19, CH2), 55.2 (1C, C8, CH), 54.7 (1C, OMe, CH3), 39.5 (1C, C2, 
CH2), 38.2 (1C, C16, CH2), 37.8 (1C, C15, CH2), 35.1 (1 C, C12, CH2), 32.4 (1C, C25, 
CH2), 28.2 (1C, C10, CH2), 27.8 (1C, C9, CH2), 25.0 (1C, C11, CH2), 20.7 (1C, OAc, 
CH3); m/z (FAB, THIOG) 592 ([M+H]+, 52%), 91(100); HRMS (FAB, THIOG) 
(Found: [M+H], 592.2804. C28H42N507S requires m/z, 592.2805). 
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To biotinylated iodoacetamide 76 (50.0 mg, 111 jtmol) in DMF (2.5 ml) was added 
134 (37.0 mg, 111 p.mol), followed by K2CO3 (18.0 mg, 130 .tmol). The solution 
was stirred for 48 h at 80 °C. The solution was concentrated in vacuo, and the residue 
was purified by flash chromatography [5% to 15% MeOHIDCM] to give 208a as a 
colourless solid (23.0 mg, 34.0 imo1, 31%); Rf [20% MeOWDCM] = 0.27; 'H 
NMR 6 (600 MHz, CDC13, 323 K) 7.23 (1H, br t, J4.6, N 17H), 7.14 (2H, d, J 8.0, 
Ar!]), 6.85 (2H, d, J 8.0, An]), 6.80 (1H, br s, N141]), 6.35 (1H, br s, N6!]), 5.45 (1H, 
br s, N41]), 5.11 (1H, br q, J6.6, C27!]), 4.52-4.45 (3H, br s, C3H, C 1 9H2), 4.31-4.29 
(1H, m, C71]), 4.24 (1H, br q, J 6.1, C26H), 3.48-3.43 (5H, m, C 15H2, C 16H2, 
C29HMHN), 3.35-3.31 (1H, m, C29HMHN) 3.14-3.12 (1H, m, C81]), 2.95-2.92 (1H, m, 
C25HSHT), 2.89 (1H, dd, J 12.7, 4.4, C2HAHB), 2.82 (1H, dd, 13.5, 5.5, C25H5H1), 
2.71 (1H, d, J 12.7, C2HAHB), 2.21 (2H, br q, J 6.5, C 1 2H2), 2.10-2.05 (1H, m, 
C28HEHF), 2.00 (3H, s, OAc), 1.82-1.65 (5H, m, C9H2, C 11 H2, C28HEHF), 1.46 (9H, s, 
tBuO), 1.30-1.27 (2H, m, C 10H2); ' 3C NMR 6 (151.1 MHz, CDC1 3 , 323 K) 174.3 
(1C, CO'Bu, Q), 174.2 (1C, C13, Q), 170.3 (1C, OAc, Q), 169.9 (1C, C18, Q), 164.1 
(1C, C5, Q), 156.2 (1C, Ar, Q), 132.7 (1C, Ar, Q), 130.9 (2C, ArH, CH), 114.9 (2C, 
ArH, CH), 80.1 (1C, 'Bu, Q), 73.3 (1C, Cv, CH), 67.7 (1C, C19, CH2), 61.9 (1C, C7, 
CH), 60.4 (1C, C3, CH), 59.5 (1C, C26, CH), 55.7 (1C, C8, CH), 43.3 (1C, C29, CH2), 
40.7 (1C, C2, CR2), 39.6 (1C, C16, CH2), 39.6 (1C, C15, CH2), 35.9 (1C, C12, CH2), 
34.4 (1C, C25, CH2), 29.8 (1C, C10, CH2), 29.0 (1C, C28, CH2), 28.4 (3C, 'Bu, CH3), 
28.4 (1C, C9, CH2), 25.5 (1C, C11, CR2), 21.0 (1C, OAc, CH3); m/z (FAB, THIOG) 
662 ([M+H], 3%), 562 (27) 91 (22); HRMS (FAB, THIOG) (Found: [M+H], 
662.3229. C32H48N508S requires m/z, 662.3224). 
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To a solution of carbamate 208a (19.0 mg, 31.0 pmol) in DCM (2 ml) was added 
trifluoroacetic acid (23.0 p.1, 310 p.mol), the solution was stirred for 3 h at RT. The 
reaction was concentrated in vacuo to give 208 (20.0 mg, 29.0 p.mol, 94%) as a 
colourless foam; Rf [20% MeOH/DCM] = 0.36; 'H NMR ö (360 MHz, DMSO) 8.16 
(1H, t, J5.3, N171]), 7.90 (1H, t, J5.3, N 14R), 7.19 (2H, d, J8.6, ArR), 6.93 (2H, d, J 
8.6, ArR), 6.45 (1H, br s, N61]), 6.38 (1H, br s, N 411), 5.15 (1H, t, J3.7, C27kT), 4.43 
(2H, s, C 1 9H2), 4.31-4.28 (1H, m, CA, 4.14-4.10 (1H, m, C 7H), 3.88-3.82 (1H, m, 
C2611), 3.33-3.23 (2H, m, C29H2), 3.20-3.10 (4H, m, C15H2, C 1 6H2), 3.08 (1H, ddd, J 
8.7, 6.2, 4.5, CA, 2.98-2.86 (2H, m, C25H2), 2.80 (1H, dd, J 12.4, 5.0, C2HAHB)5 
2.57 (1H, d, J 12.4, C2HAHB), 2.29-2.18 (1H, m, C28HEHF), 2.12 (3H, s, OAc), 2.05 
(2H, t, J 7.4, C1H), 2.02-1.97 (1H, m, C28HEHF), 1.65-1.25 (6H, m, C9H2, C 1 0H2, 
C 11 H2); ' 3C NMR 8 (90.7 MHz, DMSO) 172.2 (1C, C13, Q), 169.4 (1C, OAc, Q), 
167.7 (1C, C18, Q), 162.5 (1C, C5, Q), 156.4 (1C, Ar, Q), 129.7 (2C, ArH, CH), 128.9 
(1C,Ar, Q), 114.8 (2C,ArH, CH), 72.6 (1C, C27, CH), 66.8 (1C, C19, CH2), 63.1 (1C, 
C26, CH), 60.8 (1C, C7, CH), 59.0 (1C, C3, CH), 55.2 (1C, C8, CH), 42.5 (1C, C29, 
CH2), 39.6 (1C, C2, CH2), 38.3 (1C, C16, CH2), 37.8 (1C, C15, CH2), 35.0 (1C, C12, 
CH2), 30.8 (1C, C25, CH2), 30.2 (1C, C28, CH2), 28.1 (IC, C10, CH2), 27.9 (1C, C9, 
CH2), 25.0 (1C, C11, CH2), 20.6 (1C, OAc, CH3); m./z (FAB, THIOG) 562 ([M+H], 
80%), 91(100); HRMS(FAB, NOBA) (Found: [M+H], 562.2705. C 27H40N506S 
requires m/z, 562.2699). 
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To biotinylated iodoacetamide 210 (20.0 mg, 47.0 imo1) in DMF (5.0 ml) was added 
194 (8.60 mg, 47.0 p.mol), followed by K2CO3 (6.60 mg, 47.0 tmol). The solution 
was stirred for 48 h at 80 °C. The solution was concentrated in vacuo, and the residue 
was purified by flash chromatography [5% to 15% MeOH/DCM] to give 212 as a 
colourless solid (20.0 mg, 33.8 p.mol, 72%); Rf [10% MeOH/DCM] = 0.16; 'H 
NMR ö (600 MHz, DMSO) 8.03 (1H, t, J5.7, N2111), 7.72 (1H, t, J5.7, N 14H), 7.17 
(2H, d, J 8.5, Ark!), 6.88 (2H, d, J 8.5, ArE), 6.41 (1H, br s, N6H), 6.35 (1H, br s, 
NA, 4.42 (2H, s, C23H2), 4.31-4.29 (1H, m, C31]), 4.15 (2H, t, J6.9, C3 0H2), 4.13-
4.11 (1H, m, C7H), 3.10 (2H, br q, J6.8, C20H2), 3.09-3.07 (1H, m, C811), 3.00 (2H, 
brq,J6.7, C 15H2), 2.60 (1H, dd,J 12.5, 5.0, C2HAHB), 2.81(2H, t,J6.7, C29H2), 2.57 
(111, d, J 12.5, C2HAHB), 2.04 (2H, t, J 7.4, C 1 H), 1.97 (3H, s, OAc), 1.64-1.21 
(14H, m, C9H2, C 10H2, C 11 H2, C 1 6H2, C 17H2, C 1 8H2, C 1 9H2); ' 3C NMR 6 (151.5 MHz, 
DMSO) 171.6 (1C, C13, Q), 170.1 (1C, OAc, Q), 167.3 (1C, C22, Q), 162.5 (1C, C5, 
Q), 156.2 (1C, Ar, Q), 130.4 (1C, Ar, Q), 129.7 (2C, ArH, CH), 114.5 (2C, ArH, 
CH), 66.9 (1C, C23, CH2), 64.4 (1C, C30, CH2), 60.9 (1C, C7, CH), 59.0 (1C, C3, CH), 
55.2 (1C, C8, CH), 39.7 (1C, C2, CH2), 38.1 (1C, C15, CH2), 38.0 (1C, C20, CH2), 
35.1 (1C, C12, CH2), 33.3 (1C, C29, CH2), 29.0, 28.9, 28.8, 28.1, 27.9, 25.9, 25.2 (7C, 
C9, C10, C11, C16, C17, C18, C19, CH2), 20.6 (1C, OAc, CH3); m./z (FAB, THIOG) 563 
([M+H], 49%), 91 (70); HRMS (FAB, NOBA) (Found: [M+H], 563.2907. 
C28H43N406S requires m/z, 563.2903). 
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To biotinylated iodoacetamide 210 (20.0 mg, 47.0 j.imol) in DMF (5.0 ml) was added 
102 (12.6 mg, 47.0 .tmol), followed by K2CO3 (6.60 mg, 47.0 .tmol). The solution 
was stirred for 48 h at 80 °C. The solution was concentrated in vacuo, and the residue 
was purified by - flash chromatography [5% to 15% MeOI-i/DCM] to give 213 as a 
colourless solid (11.0 mg, 16.5 tmo1, 35%); Rf [10% MeOH/DCM] = 0.19; 'H 
NMR 6 (360 MHz, DM SO) 7.74 (1H, t, J5.6, N1411), 7.68 (1H, t, J5.6, N21 H'), 7.06 
(211, d, J 8.6, An]), 6.80 (2H, d, J 8.6, An]), 6.43 (1H, br s, NA, 6.36 (1H, br 5, 
NA, 5.29 (1H, d, J 4.8, OH), 4.59 (1H, dd, J 4.9, 2.2, C271]), 4.32-4.28 (1H, m, 
C31]), 4.14-4.10 (1H, m, C71), 3.89-3.85 (1H, m, C261]), 3.70 (3H, s, OMe), 3.42-
3.38 (1H, m, C25HMHN) 3.26 (1H, d, J 15.9, C23HxHy), 3.19-3.13 (1H, m, C28H), 
3.11-2.98 (5H, m, C8H, C 15H2, C20H2,), 2.97 (1H, d, J 15.9, C23 1-IxHy), 2.81 (1H, dd, 
J 12.3, 5.1, C2HAHB), 2.75-2.72 (111, m, C29HSHT), 2.59-2.57 (1H, m, C29HSHT),  2.57 
(1H, d, J 12.3, C2HAHB), 2.31 (1H, dd, J 10.4, 3.5, C25HMHN), 2.06 (3H, s, OAc), 
2.04 (2H, t, J 7.4, C 1 H), 1.49-1.25 (14H, m, C9H2, C10H2, C11H2, C 16H2, C 17H2, 
C 1 8H2, C19H2); ' 3C NMR 6 (90.7 MHz, DMSO) 171.7 (1C, C13, Q), 169.9 (1C, C22, 
Q), 169.6 (1C, OAc, Q), 162.5 (1C, C5, Q), 157.4 (1C, Ar, Q), 130.7 (1C, Ar, Q), 
129.7 (2C,ArH, CH), 113.6 (2C,ArH, CH), 78.9 (1C, C27, CH), 72.9 (1C, C26, CH), 
65.6 (1C, C28, CH), 60.8 (1C, C7, CH), 60.1 (1C, C25, CH2), 59.0 (1C, C3, CH), 57.1 
(1C, C23, Cl2), 55.2 (1C, C8, CH), 54.7 (1C, OMe, Cl3), 39.7 (1C, C2, CH2), 38.2 
(1C, C20, CH2), 37.9 (1C, C15, CH2), 35.0 (1C, C12, CH2), 32.8 (1C, C29, CH2), 29.2, 
28.9, 28.0, 27.8, 25.9, 25.5, 25.2 (7C, C9, Cjo)  C11 5  C16 C17, C18, C, CH2), 20.9 (1C, 
OAc, CH3); m/z (FAB, NOBA) 648 ([M+H], 5%), 307 (50), 77 (70); HRMS (FAB, 
THIOG) (Found: [M+H], 648.3435. C32H50N507S requires m/z, 648.3431). 
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To a solution of Affi-gel-10 214 (25.0 ml, 375 tmo1) in methanol (50 ml) was added 
1-azido-ethylamine 187 (500 mg, 5.81 mmol) and the solution shaken for 48 h. The 
solution was filtered and the matrix washed with methanol (200 ml). The matrix 215 
was stored in isopropylalcohol; bmax (neat)/cm' 34 16, 2919, 2114, 1648. 
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To azide 215 (380 tmol) in H20: 1BuOH (80 ml, 1:1) was added N-propargyl 
anisomycin 140 (109 mg, 360 tmol), followed by copper(II) sulfate (8.0 mg, 10 
mol%) and sodium ascorbate solution (40.0 p.1, 1 M solution, 20 mol%). The solution 
was shaken for 15 h at RT. The reaction was monitored by tic probing for the 
reaction of N-propargyl anisomycin. Upon completion of the reaction by tic, the 
solution was filtered and the matrix washed with isopropylalcohol (200 ml). The 
filtrate was concentrated in vacuo, and the residue analysed by NMR and found to be 
unreacted N-propargyl anisomycin (1 mg). The matrix 216 was stored in a solution 
of isopropylalcohol. 
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Rf [40% EtOAc/hexane] = 0.37; 'H NMR 6 (360 MHz, CDC13) 5.39 (1H, d, J 5.2, 
C61-]), 3.54 (1H, if, J 11.2, 4.1, CA, 2.47 (1H, dd, J 19.3, 8.7, CI6HSHT), 2.33 (1H, 
ddd, J 13.0, 4.9, 2.3, C4HEHF), 2.29-2.23 (1H, m, C4HEHF), 2.14-2.11 (1H, m, 
C7HGHH), 2.09 (1H, dd, J 19.3, 9.5, C16HsHr), 1.96 (1H, ddd, 12.8, 8.7, 6.0, 
CISHQHR), 1.89-1.84 (3H, m, CIHAHB, C2HCHD, C811), 1.71-1.63 (4H, m, C7HGHH, 
CIIHKHL, Cl2HMHN, 01]), 1.57-1.46 (3H, m, C2HCHD,  CI1HKHL, CISHQHR), 1.32-
1,26 (2H, m, C12HMHN, C1411), 1.11 (1H, dt, J 13.8, 4.0, CIHAHB), 1.05 (3H, s, 
C 19H3), 1.02 (1H, ddd, J 12.3, 10.6, 5.3, C9R), 0.90 (3H, s, C 1 8H3); 13C NMR 
(151.2 MHz, CDC13) 221.2 (1C, C17, Q), 140.9 (1C, C5, Q), 120.8 (1C, C6H, CH), 
71.5 (1C, C3H, CH), 51.6 (1C, C 14H, CH), 50.1 (1C, C9H, CH), 47.4 (1C, C13, Q), 
42.1 (1C, C4H2, CH2), 37.0 (1C, C1H2, CH2), 36.5 (1C, C10, Q), 35.7 (1C, C16H2, 
CH2), 31.4 (3C, C2H2, C8H, C12H2, 2CH2, CH), 30.7 (1C, C 7H2, CH2), 21.8 (1C, 
C15H2, CH2), 20.2 (1C, C11H2, CH2), 19.3 (1C, C19H3, CH3), 13.4 (1C, C18H3, CH 3). 
All spectroscopic data was in good agreement with that of the literature. 384,395 
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R1 [20% MeOH/DCM] = 0.35; 'H NMR ö (360 MHz, CD30D) 5.40 (1H, d, J 5.2, 
CA, 4.11 (1H, tt, J 11. 5, 4.8, CA,  2.53 (1H, ddd, J 13.3, 5.0, 2.3, C4HEHF), 2.42 
(1H, dd, J 19.1, 8.6, C16HSHT), 2.37-2.29 (1H, m, C4HEHF), 2.13-2.01 (2H, m, 
C7HGHH,C2HCHD), 2.04 (1H, dd, J 19.1, 9.1, C16HSHT),  1.96 (1H, ddd, 12.2, 9.1, 5.7, 
CI5HQHR), 1.88 (1H, dt, J 13.5, 3.5, C 1 HAHB), 1.76 (1H, ddd, J 12.9, 4.1, 2.8, 
Cl2HMHN), 1.70-1.48 (6H, m, C2HCHD, C7HGHH, C8H, CI5HQHR, C,,H2), 1.31 (IH, 
ddd, J 12.8, 10.6, 5.7, C1411), 1.24 (1H, td, J 12.9, 4.1, Cl2HMHN), 1.09 (1H, td, J 
13.5, 3.8, CIHAHB), 1.03 (3H, s, C 1 9H3), 0.99 (1H, ddd, J 12.4, 4.8, 1.8, C911), 0.86 
(3H, s, C18H3); ' 3C NMR & (90.7 MHz, CD 30D) 223.9 (1C, C17, Q), 141.7 (1C, C5, 
Q), 122.7 (1C, C6H, CH), 79.6 (1C, CI-i, CH), 53.0 (1C, C1 4H, CH), 51.7 (1C, C9H, 
CH), 47.1 (1C, C13, Q), 40.3 (1C, C4H2, CH2), 38.3 (1C, C1H2, CH2), 37.8 (1C, C10, 
Q), 36.7 (1C, C16H2, CH2), 32.7 (1C, C8H, CH), 32.6 (1C, C12H2, CH2), 31.8 (1C, 
C7H2, CH2), 29.9 (1C, C2H2, CH2), 22.8 (1C, C 15H2, CH2), 21.4 (1C, C11H2, CH2), 
19.8 (1C, C19H3, CH3), 13.9 (1C, C 18H3, CH3). 
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To a solution of but-3-ynoic acid 238 (34.0 mg, 400 .tmo1) in DCM (15 ml) at 0 °C 
was added DMAP (35.0 mg, 290 tmol), DIC (64.0 jtl, 400 imol) and DHEA 217 
(100 mg, 360 p.mol) and the solution stirred for 1 h. The reaction was then warmed to 
RT and stirred for a further 48 h, giving a pale yellow solution. The reaction was 
quenched with 1% HC1 (15 ml) and the aqueous extracted (3 x 20 ml). The combined 
organics were washed with brine (20 ml), dried (MgSO4) and concentrated in vacuo. 
The residue was chromatographed on silica gel [35% EtOAc/hexane] to give 239 as a 
colourless solid (95.0 mg, 270 .tmol, 75%); R1 [40% EtOAc/hexane] = 0.67; umax 
(neat)/cm' 1736, 1701, 1524, 1022; laiD +21.9 (c 1.14, CHC13); 'H NMR ö (360 
MHz, CDC13) 5.41 (1H, d, J4.9, C61]), 4.73-4.64 (1H, m, C31]), 2.47 (1H, dd, J 19.2, 
9.0, C16HsH1), 2.41-2.36 (3H, brd, J7.9, C4H2, C24H), 2.16-2.08 (1H, m, C 7HGHH), 
2.07 (1H, dd, J 19.2, 9.0, C16H5Hr), 1.98 (2H, s, C22H2), 1.97-1.81 (4H, m, CIHAHB, 
C2HCHD, C8H, CI5HQHR), 1.71-1.63 (4H, m, C2HCHD, C7HGHH, CIIHKHL, 
C12HMHL), 1.60-1.39 (2H, m, C15HQHR, C11HKHL), 1.32-1.24 (2H, m, Cl2HMHN, 
C,41]), 1.14 (1H, td, J 13.4, 4.0, C1HAHB), 1.04 (3H, s, C 1 9H3), 1.02 (1H, ddd, J 12.4, 
4.8, 1.9, C9R), 0.89 (3H, s, C,8H3); ' 3C NMR ö (90.7 MHz, CDC13) 221.2 (1C, C17, 
Q), 153.3 (1C, C21, Q), 139.7 (1C, C5, Q), 122.4 (1C, C6H, CH), 85.4 (1C, C23, Q), 
75.6 (1C, C3H, CH), 72.9 (1C, C24H, CH), 51.9 (1C, C1 4H, CH), 50.3 (1C, C9H, CH), 
47.7 (1C, C13, Q), 38.0 (1C, C4H2, CH2), 37.0 (1C, C1H2, CH2), 36.9 (1C, C10, Q), 
36.0 (1C, C16H2, CH2), 31.6 (1C, C8H, CH), 31.6 (1C, C12H2, CH2), 30.9 (1C, C7H2, 
CH2), 27.7 (1C, C2H2,CH2), 22.8 (1C, C 15H2,CH2), 21.1 (1C, C 11H2,CH2), 19.5 (1C, 
C19H3, CH3), 13.7 (1C, C18H3, CH3), 4.0 (1C, C22H2, CH2); m/z (FAB, THIOG) 355 
([M+H], 10%), 272 (45); HRMS (FAB, THIOG) (Found: [M+H], 355.2274. 
C23H3103 requires m/z, 355.2273). 
1\ 
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To a solution of DHEA 217 (100 mg, 360 tmol) in DCM (10 ml) was added 
propargyl chloroformate 240 (70.0 jtl, 700 J.Lmol) and pyridine (100 p.1, 1.20 mmol) 
and the solution stirred for 14 h at RI. The reaction was quenched with 1% HC1 (15 
ml) and the aqueous extracted (3 x 30 ml). The combined organics were washed with 
saturated aq. copper sulfate solution (20 ml), water (20 ml), brine (15 ml), dried 
(MgSO4) and concentrated in vacuo. The residue was chromatographed on silica gel 
[30% EtOAc/hexane] to give 241 as a colourless solid (90.0 mg, 260 p.mol, 74%); Rf 
[40% EtOAc/hexane] = 0.61; Umax (neat)/cm' 1737, 1557, 1022; [LID +2.79 (c 1.10, 
CHC13); 'H NMR 8 (360 MHz, CDC13) 5.43 (1H, d, .15.2, C611), 4.72 (2H, d, .12.5, 
C23H2), 4.51 (1H, tt,.111.4,4.8, CA,  2.53 (1H, t, J2.5, C2511), 2.46 (1H, dd,.119.2, 
8. 1, CI6HSHT), 2.46-2.35 (2H, m, C4H2), 2.15-2.10 (1H, m, C7HEJL-IF), 2.08 (1H, dd,.1 
19.2, 9.1, C16HsHr),  2.00-1.91 (2H, m, C2HCI-ID, CI5HQHR), 1.88 (1H, t, J 3.5, 
CIHAHB), 1.85 (1H, ddt, J 12.7, 2.8, 1.3, C811), 1.72-1.60 (4H, m, C2HCHD5  C7HEHF, 
CIIHKHL, Cl2HMHN), 1.58-1.48 (1H, m, CI5HQHR),  1.47 (1H, td, .1 13.5, 4.1, 
C11HKHL), 1.33-1.24 (2H, m, Cl2HMHN, C 14H), 1.14 (1H 5 td, J 13.7, 3.5, CIHAHB), 
1.04 (3H, s, C19H3) 5 1.01 (1H, ddd,.1 10.4, 4.7, 1.9, C91]), 0.88 (3H, s, C 1 8H3); 13C 
NMR 8 (90.7 MHz, CDCI3) 221.3 (1C, C17, Q), 154.0 (1C, C21, Q), 139.6 (1C, C5, 
Q), 122.5 (1C, C6H, CH), 78.5 (1C, C3H, CH), 76.9 (1C, C24, Q), 75.7 (1C, C25, CH), 
55.2 (1C, C23H2, CH2), 51.8 (1C, C1 4H, CH), 50.2 (1C, C9H, CH), 47.7 (1C, C13, Q), 
38.0 (1C, C4H2, CH2), 36.9 (1C, C1H2, CH2), 36.8 (1C, C10, Q), 36.0 (1C, C 16H2 , 
CH2), 31.6 (1C, C8H, CH), 31.5 (1C, C 12H2, CH2), 30.9 (1C, C7H2, CH2), 27.7 (1C, 
C2H2, CH2), 22.0 (1C, C 15H2, CH2), 20.5 (1C, C11H2, CH2), 19.5 (1C, C19H3 , CH3), 
13.7 (1C, C18H3, CH3); m/z (FAB, THIOG) 371 ([M+H], 5%), 271 (80); HRMS 
(FAB, THIOG) (Found: [M+H], 371.2221. C23H31 04 requires m/z, 371.2222). 
194 
Chapter 5 	 Experimental 
O-Propargyl-hydroxylamine hydrochloride 396  243 
HCI 
To a solution of N-(propargyloxy)phthalimide 242 (1.40 g, 6.97 mmol) in DCM (30 
ml) was added methyihydrazine (3 71 tl, 6.97 mmol) and the. solution stirred for 24 h 
at RT. A colourless precipitate was removed by filtration, washed with DCM and the 
solid discarded. Ethereal hydrochloric acid (15 ml) was added to the organic layer, 
leading to the precipitation of a colourless solid. The solid was removed by filtration 
and washed with ether before recrystalysing from methanol. The product 243 was 
obtained as a colourless solid (600 mg, 5.58 mmol, 80%); ,v..,, (thin film)/cm' 3255, 
1523, 1025; 'H NMR 6 (360 MHz, DMSO) 11.50-10.80 (2H, m, NH2), 4.78 (2H, d, 
J2.4, CH2), 3.90 (1H, t, J2.4, Cl]); ' 3C NMR 6 (90.7 MHz, DMSO) 81.3 (1C, Q), 
76.6 (1C, CH), 61.8 (1C, CH2); m/z (FAB, NOBA) 72 ([M+H] 1 , 76%), 46 (100); 
HRMS (El, +) (Found: [M] 4 , 71.0372. C3H5NO requires m/z, 71.0371). 
All spectroscopic data was in good agreement with that of the literature. 396 
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To a solution of DHEA 217 (500 mg, 1.70 mmol) in methanol (40 ml) was added 
hydroxylamine 243 (194 mg, 1.80 mmol). The reaction was stirred for 48 h at RT 
before being concentrated in vacuo. The resultant solid was dissolved in DCM (20 
ml), washed with saturated aq. Na2CO3 solution (20 ml) and the aqueous extracted (3 
x 30 ml). The combined organics were washed with brine (20 ml), dried (MgSO4) 
and concentrated in vacuo. The product 244 was obtained as a colourless foam (563 
mg, 1.65 mmol, 97%); Rf [40% EtOAc/hexane] = 0.45; Vmax (neat)/cm' 3398, 2360, 
1045; [UID -51.7 (c 0.89, CHC13); 'H NMR 8 (360 MHz, CDC13) 5.33 (1H, d, J 5.2, 
CH), 4.60 (2H, d, J2.4, C22H2), 3.50 (1H, tt, J 11.1, 4.4, CA,  2.50 (1H, ddd, J 
19.1, 9.1, 1.9, C16HSHT),  2.45-2.40 (1H, m, Ci6HsH), 2.42 (1H, t, J2.4, C241]), 2.29 
(1H, ddd, J 13.1, 5.2, 1.9, C4HEHF), 2.23 (1H, dd, J 11.1, 1.9, C4HEHF), 2.10-1.93 
(2H, m, C7HGHH,'Cl2HMHN), 1.87-1.73 (3H, m, CIHAHB, C2HCHD, CI5HQHR), 1.69-
1,41 (6H, m, C2HCHD, C7HGHH C8H, C 11H2, Cl2HMHN), 1.34 (1H, U, J 12.7, 9.1, 
C 15HQHR), 1.16 (1H, ddd, J 10.3, 6.0, 4.4, C1411), 1.09 (1H, dd, J 13.2, 3.7, C1HAHB), 
1.01 (3H, s, C19H3), 1.04-0.96 (1H, m, C91]), 0.91 (3H, s, C18H3); '3C NMR ö (90.7 
MHz, CDC13) 172.0 (1C, C17,Q), 141.1 (1C, C5, Q), 121.2 (1C, C6H, CH), 80.3 (1C, 
C23, Q), 74.1 (1C, C24H, CH), 71.6 (1C, C3H, CH), 60.9 (1C, C22H2, CH2), 54.2 (1C, 
C1 4H, CH), 50.3 (1C, C9H, CH), 44.2 (1C, C13, Q), 42.3 (1C, C4H2, CH2), 37.3 (1C, 
C1H2, CH2), 36.7 (1C, Cjo, Q), 34.0 (1C, C12H2, CH2), 31.6 (1C, C2H2, CH 2), 31.4 
(1C, C7H2, CH2), 31.0 (1C, C8H, CH), 26.1 (1C, C 16H2, CH2), 23.4 (1C, C 15H2, CH2), 
20.7 (1C, C11H2, CH2), 19.5 (1C, C19H3, CH3), 17.1 (1C, C18H3, CH3); m/z (FAB, 
THIOG) 342 ([M+H], 33%); HRMS (FAB, THIOG) (Found: [M+H], 342.2436. 
C22H32NO2 requires m/z, 342.2433). 
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tert-Butoxycarbonylaminooxy-acetic acid"' 245 
BocHN ° OH 
To a solution of aminooxy-acetic acid (500 mg, 4.60 mmol) in dioxane/I-120 (20 ml, 
1:1) was added Et3N (805 p.!, 5.80 mmol) and di-tert-butyl dicarbonate (1.11 g, 5.10 
mmol) and the solution stirred for 7 h at RT. The reaction was quenched with 1% 
HC1 (30 ml) and the aqueous extracted with DCM (3x 30 ml). The combined 
organics were washed with brine (30 ml), dried (MgSO4) and concentrated in vacuo. 
The product 245 was obtained as a colourless solid (530 mg, 2.50 mmol, 55%); Rf 
[5% MeOH/DCM] = 0.43; 'H NMR 5 (360 MHz, CDC13) 4.26 (2H, s, CH2), 1.63 
(9H, s, 'BuO); ' 3C NMR ö (90.7 MHz, DMSO) 170.5 (1C, Q), 156.8 (1C, Q), 80.4 
(1C, Q), 72.4 (1C, CH2), 28.3 (3C, CH3); m/z (FAB, THIOG) 192 ([M+H], 51%), 
91(49); HRMS (FAB, THIOG) (Found: [M+H], 192.0869. C 7H 14N05 requires m/z, 
192.0872). 
All spectroscopic data was in good agreement with that of the literature. 383 
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2-(tert-Butoxycarbonylaminooxy)-N-prop-2-ynyl-acetamide 397 246 
BocHN ° N 
To a solution of acid 245 (1.27 g, 6.60 mmol) in DCM (40 ml) at 0 °C was added 
DMAP (891 mg, 7.30 mmol) and DIC (1.14 ml, 7.30 mmol), followed by propargyl 
amine (679 j.xl, 9.90 mmol). The reaction was stirred for 1 h at 0 °C, before warming 
to room temperature and stirring for a further 20 h. The reaction was quenched with 
1% HCl (70 ml) and the aqueous extracted with DCM (3x 50 ml). The combined 
organics were washed with brine (60 ml), dried (MgSO4) and concentrated in vacuo. 
The product 246 was obtained as a pale brown wax (1.25 g, 5.48 mmol, 83%); Rf 
[10% MeOH/DCM] = 0.44; lmax (neat)/cm' 3299, 1725, 1666; 'H NMR 8 (360 
MHz, CDC13) 8.69-8.57 (1H, m, NH), 8.56-8.40 (1H, m, NH), 4.28 (2H, s, 
CH2C=O), 4.02 (2H, dd, J 5.4, 2.5, NHCH2), 2.18 (1H, t, J 2.5, CH), 1.42 (9H, s, 
tBuO); ' 3C NMR 8 (90.7 MHz, CDC13) 169.6 (1C, Q), 158.3 (1C, Q), 83.2 (1C, Q), 
79.5 (1C, Q), 76.1 (1C, CH2), 71.7 (1C, CH), 28.9 (1C, CH2), 28.4 (3C, CH3); m/z 
(FAB, THIOG) 229 ([M+H], 25%), 129 (66); HRMS (FAB, THIOG) (Found: 
[M+H], 229.1186. C 10H 17N204 requires m/z, 229.1188). 
1 H spectroscopic data was in good agreement with that of the literature. 397 
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2-Aminooxy-N-prop-2-ynyl-acetamide hydrochloride 247 
HCI e H2N 
To a solution of carbonate 246 (650 mg, 2.85 mmol) in DCM (40 ml) was added 
TFA (10 ml). The reaction was stirred for 19 h at RT before being concentrated in 
vacuo to give a golden oil. The salt was subjected to ion exchange chromatography 
[Dowex Cl—; prepared by treating Dowex resin with methanol, then 1% HC1, 
followed by flushing with methanol until the eluent returned to pH 7] eluting with 
methanol to give the chloride salt. The residue was chromatographed on silica gel 
[10% MeOHIDCM] to give 247 as a golden oil (350 mg, 2.71 mmol, 95%); Rf [10% 
MeOH/DCM] = 0.16; Vmax (neat)/cm' 3293, 3080, 1668; 'H NMR ö (360 MHz, 
CD30D) 4.37 (2H, s, CH2CO), 4.04 (2H, d, J2.6, NHCH2), 2.60 (11-1, t, J2.6, Cu); 
' 3C NMR 5 (90.7 MHz, CD30D) 171.4 (1C, Q), 80.7 (1C, Q), 74.4 (1C, CH 2), 73.0 
(1C, CH), 29.6 (1C, CH 2); nz/z (FAB, THIOG) 130 ([M+H], 59%), 129 ([M], 
67%); HRMS (FAB, THIOG) (Found: [M], 129.0668. C 5H9N202 requires m/z, 
129.0664). 
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To a solution of DHEA 217 (100 mg, 350 tmol) in methanol (10 ml) was added 
hydroxylamine 247 (96.0 mg, 890 i.tmol). The reaction was stirred for 48 h at RT 
before being concentrated in vacuo. The resultant solid was dissolved in DCM (10 
ml), washed with saturated aq. Na2CO3 solution (10 ml) and the aqueous extracted (3 
x 15 ml). The combined organics were washed with brine (10 ml), dried (MgSO4) 
and concentrated in vacuo. The residue was chromatographed on silica gel [50% to 
70% EtOAc/hexane] to give 248 as a colourless solid (131 mg, 330 .tmol, 94%); R 
[40% EtOAc/hexane] = 0.14; Umax (neat)/cm' 3398, 3304, 1664, 1528, 1061; [U]D - 
46.5 (c 0.99, CHC13); 'H NMR ö (360 MHz, CDC13) 6.45 (1H, br t, N 24H), 5.31 (1H, 
d, J 5.2, C611), 4.45 (2H, s, C22H2), 4.05 (2H, dd, J 5.4, 2.5, C25H2), 3.47 (1H, ii, J 
11.1, 4.6, C3h'), 2.53 (1H, dd, J 19.3, 7.7, CI6HSHT),  2.43 (1H, dt, J 19.3, 8.7, 
CI6HSHT), 2.29-2.16 (2H, m, C4H2), 2.21 (1H, t, J2.5, C2711), 2.02 (1H, ddd, J 12.6, 
5.2, 2.6, C7HGHH), 1.90 (1H, dt, J 12.0, 3.3, C12HMHN), 1.84-1.76 (3H, m, CIHAHB, 
C2HCHD, C15HQHR), 1.65-1.44 (5H, m, C2HCHD, C7HGHH, C8H, C11H2), 1.42-1.32 
(2H, m, C12HMHN, C15HQHR), 1.15 (1H, ddd, J 10. 3, 6.1, 4.4, C 1 4H), 1.11 (1H, dd, J 
13.3, 3.3, C1HAHB), 0.99 (3H, s, C 1 9H3), 1.03-0.93 (1H, m, C91]), 0.90 (3H, s, C 18H3); 
'3C NMR 8 (90.7 MHz, CDC13) 173.1 (1C, C17, Q), 170.2 (1C, C23, Q), 141.2 (1C, 
C5, Q), 120.9 (1C, C6H, CH), 79.4 (1C, C26, Q), 72.5 (1C, C22H2, CH2), 71.7 (1C, 
C3H, CH), 71.5 (1C, C27H, CH), 54.2 (1C, C1 4H, CH), 50.3 (1C, C9H, CH), 44.4 (1C, 
C13, Q), 42.2 (1C, C4H2, CH2), 37.3 (1C, C 1H2, CH2), 36.7 (1C, C10, Q), 34.0 (1C, 
C12H2,CH2), 31.6 (1C, C2H2,CH2), 31.4 (1C, C7H2,CH2), 31.4 (1C, C8H, CH), 28.7 
(1C, C25H2, CH2), 26.2 (1C, C1 6H2, CH2), 23.4 (1C, C1 5H2, CH2), 20.6 (1C, C1 1H2 3  
CH2), 19.5 (1C, C19H3, CH3), 17.1 (1C, C18H3, CH3); nv'z (FAB, THIOG) 399 
([M+H], 33%), 268 (32); HRMS (FAB, NOBA) (Found: [M+H], 399.2650. 
C24H35N203 requires n2/z, 399.2648). 
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To oxime 244 (50.0 mg, 150 .tmol) in pyridine (1 ml) was added sulfur trioxide 
trimethylamine complex (32.0 mg, 230 tmol). The reaction was stirred for 14 h at 
RT before being quenched with 5% NH40Ac solution (2 ml) and the aqueous layer 
extracted with DCM (2 x 10 ml). The aqueous layer was then purified on a reverse 
phase C18 column, initially washing (6 x 7 ml, 2:1, H 20:5% NH40Ac) before eluting 
the product with methanol. The fractions containing the product were then combined 
and concentrated in vacuo. The product 251 was obtained as a colourless solid (56.0 
mg, 128 tmol, 85%); Rf [20% MeOHIDCM] = 0.45; [cuD -24.5 (c 1.02, MeOH); 'H 
NMR 6 (360 MHz, CD30D) 5.41 (111, d, J 5.2, C6H), 4.56 (2H, d, J 2.4, C22H2), 
4.14 (1H, tt, J 11. 5, 4.9, C31]), 2.79 (1H, t, J2.4, C24H), 2.55 (1H, ddd, J 13.1, 4.9, 
2.2, C4HEHF), 2.49 (1H, dd, J9.0, 1.6, C16HSHT),  2.44 (1H, t, J9.0, C16HsHr), 2.39-
2,32 (1H, m, C4HEHF), 2.10-2.05 (211, m, C 7HGHH , C2HCHD),  2.02-1.90 (2H, m, 
CIHAHB, C12HMHN), 1.86-1.78 (1H, m, C15HQHR),  1.72-1.51 (5H, m, C2HCHD, 
C7HGHJ-1', C8H, C 11 H2), 1.48-1.34 (2H, m, Cl2HMHN, CI5HQHR), 1.24-1.02 (311, m, 
CIHAHB, C9H, C 1 4H), 1.07 (3H, s, C19H3), 0.94 (3H, s, C18H3); 13C NMR 6 (90.7 
MHz, CD30D) 173.5 (1C, C17, Q), 141.7 (1C, C5, Q), 122.9 (1C, C6H, CH), 81.1 
(1C, C23, Q), 79.7 (1C, C3H, CH), 75.2 (1C, C24H, CH), 61.6 (1C, C22H2, CH2), 55.6 
(1C, C1 4H, CH), 51.7 (1C, C9H, CH), 45.3 (1C, C13, Q), 40.4 (1C, C4H2, CH2), 38.4 
(1C, C1H2, CH2), 37.8 (1C, CIO, Q), 35.2 (1C, C12H2, CH2), 32.6 (1C, C 8H, CH), 32.4 
(1C, C7H2,CH2), 30.0 (1C, C2H2, CH2), 26.9 (1C, C 16H2,CH2), 24.2 (1C, C 15H2 , 
CH2), 21.7 (1C, C11H2, CH2), 19.8 (1C, C19H3 , CH3), 17.4 (1C, C 18H3, CH3); ,n./z 
(FAB, NOBA) 422 ([M+H], 32%), 330 (16), 324 (16), 255 (40); HRMS (FAB, 
NOBA) (Found: [M+Na], 444.1823. C 22H3 1N05SNa requires m/z 444.1821). 
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3-Su1fony1oxy-androst-5-dn-17-(O-[-N-prOp-2-YflY11 acetamidyl)-oxime 253 
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To oxime 248 (100 mg, 250 j.imol) in pyridine (2 ml) was added sulfur trioxide 
trimethylamine complex (56.0 mg, 400 tmo1). The reaction was stirred for 24 h at 
RT before being quenched with 5% NH40Ac solution (4 ml) . and the aqueous 
extracted with DCM (2 x 10 ml). The aqueous layer was then purified on a reverse 
phase C18 column, initially washing (6 x 7 ml, 2:1, H20:5% NH 40Ac) before eluting 
the product with methanol. The fractions containing the product were then combined 
and concentrated in vacuo. The product 253 was obtained as a colourless solid (123 
mg, 240 p.mol, 96%); Rf [20% MeOHJDCM] = 0.32; [U]D-23.0  (c 1.22, MeOH); 'H 
NMR 8 (360 MHz, CD30D) 5.41 (1H, d, J 5.0, C611), 4.43 (2H, s, C22H2), 4.14 (1H, 
tt, J 11.4, 4.7, C311), 4.02 (2H, d, J 2.5, C25H2), 2.64 (1H, ddd, J 19.3, 7.3, 1.6, 
CI6HSHT), 2.58 (1H, t, J 2.5, C27H), 2.56-2.50 (2H, m, C!6HSHT, C4HEHF), 2.36 (1H, 
br t, J 11.4, C4HEHF), 2.11-2.05 (2H, m, C2HCHD, C7HGHH,), 1.92 (2H, dt, J 12.8, 
3.2, CIHAHB, Cl2HMHN), 1.88-1.81 (lH, m, CI5HQHR), 1.70-1.53 (5H, m, C2HCHD, 
C7HGHH, C8H, C 1 1H2), 1.51-1.36 (2H, m, Cl2HMHN,  C15HQHR), 1.29-1.09 (2H, m, 
CIHAHB, C 14H), 1.06 (3H, s, C 1 9H3), 1.05-1.02 (1H, m, C9H), 0.95 (3H, s, C 1 8H3); 
' 3C NMR 8 (90.7 MHz, CD30D) 174.3 (1C, C17, Q), 172.6 (1C, C23, Q), 141.7 (1C, 
C5, Q), 122.8 (1C, C6H, CH), 80.6 (1C, C26, Q), 79.7 (1C, C3H, CH), 73.2 (1C, 
C22H2, CH2), 72.0 (1C, C27H, CH), 55.5 (1C, C14H, CH), 51.7 (1C, C9H, CH), 45.4 
(1C, C13, Q), 40.4 (1C, C4H2, CH2), 38.4 (1C, C1H2, CH2), 37.8 (1C, C10, Q), 35.1 
(1C, C12H2, CH2), 32.6 (1C, C8H, CH), 32.4 (1C, C 7H2, CH2), 29.9 (1C, C2H2, Cl-I2), 
29.1 (1C, C25H2, CH2), 26.9 (1C, C16H2, CH2), 24.3 (1C, C 15H2, CH2), 21.6 (1C, 
C1 1H2, CH2), 19.7 (1C, C 19H3, CH3), 17.4 (1C, C18H3, Cl-I 3); m/z (FAB, THIOG) 479 
([M+H], 11%); HRMS (FAB, THIOG) (Found: [M], 479.2211. C2 4H35N206S 
requires m/z, 479.2216). 
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To dansyl azide 189 (25.0 mg, 63.0 tmol) in H20: tBuOH (3 ml, 1:1) was added 
oxime 248 (23.0 mg, 70.0 .tmol), followed by copper(II) sulfate (2.0 mg, 10 mol%) 
and sodium ascorbate solution (20.0 tl, 1 M solution, 20 mol%). The solution was 
stirred for 15 h at RT. The solution was concentrated in vacuo, and the residue was 
purified by flash chromatography [5% MeOH/DCM] to give 254 as a pale green wax 
(43.0 mg, 60.0 limo!, 95%); R [5% MeOHIDCM] = 0.16; Xmax (H20)/nm 342; 'H 
NMR 8 (3 60 MHz, CDC13) 8.52 (1H, d, J8.5, C34H), 8.21 (1H, dd, J7.3, 1.3, C361f), 
8.20 (1H, br d, J8.7, C4011), 7.52-7.44 (2H, m, C35H, C39H), 7.45 (1H, s, C271]), 7.15 
(1H, d, J7.6, C3811), 7.01 (1H, t, J5.9, N3111), 6.54 (1H, t, J6.3, N241]), 5.30 (1H, d, 
J 5.2, C611), 4.45 (2H, s, C22H2), 4.43 (2H, d, J 6.3, C25H2), 4.33 (2H, t, .J 5.5, CH), 
3.53-3.44 (1H, m, CA,  3.42 (2H, q, J 6.2, C3 0H2), 2.86 (6H, s, NMe2), 2.48-2.32 
(2H, m, C16H2), 2.30-2.1.6 (2H, m, C4H2), 1.95 (1H, ddd, J 11.9, 5.1, 2.4, C7HGHH), 
1.85-1.77 (3H, m, C1HAHB, C2HCHD , C12HMHN), 1.66-1.40 (6H, m, C2HCHD, 
C7HH11, C8H, C 1 1H2, C15HQHR),  1.33-1.19 (2H, m, C12HMHN, CI5HQHR), 1.09-1.00 
(2H, m, CIHAHB, C1 411), 0.97 (3H, s, C19H3), 0.97-0.91 (1H, m, C9H), 0.82 (3H, s, 
CIA); ' 3C NMR ö (90.7 MHz, CDC13) 174.0 (1C, C17, Q), 171.6 (1C, C23, Q), 15 3. 0 
(1C, Ar, Q), 145.4 (1C, C26, Q), 142.0 (1C, C5, Q), 135.6 (1C, Ar, Q), 131.8 (1C, 
C34H, CH), 130.9 (1C, Ar, Q), 130.5 (1C, C36H, CH), 130.4 (1C, Ar, Q), 129.6 (1C, 
C39H, CH), 124.8 (1C, C27H, CH), 124.1 (1C, C35H, CH), 122.0 (1C, C6H, CH), 
119.7 (1C, C40H, CH), 116.4 (1C, C38H, CH), 73.5 (1C, C 22H2, CR2), 72.6 (1C, 
C3H, CH), 54.9 (1C, C1 4H, CH), 51.4 (1C, C29H2, CR2), 51.1 (1C, C9H, CH), 46.4 
(2C, NMe2, CH3), 45.2 (1C, C13, Q), 43.5 (1C, C30H2, CR2), 43.2 (1C )  C4H2, CH2), 
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38.2(1C, C1H2, CH2), 37.6 (1C, C10, Q), 35.1 (1C, C12H2, CH2), 34.8 (1C, C25H2, 
CH2), 32.6 (1C, C2H2, CH 2), 32.2 (1C, C7H2, CH2), 32.2 (1C, C8H, CH), 27.1 (1C, 
C16H2, CH2), 24.2 (1C, C 15H2, CH2), 21.5 (1C, C11H2, CH2), 20.4 (1C, C 19H3, CH3), 
18.0 (1C, C18H3, CH3); m/z (FAB, THIOG) 718 ([M+H], 27%), 433 (26), 217 (48), 
91(100); HRMS (FAB, THIOG) (Found: [M+H], 718.3746. C38H 52N705 S requires 
m/z, 718.3751). 
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1 -(N-Dansyl-2-aminoeth-1-yl)-4-(3 '3-(methy1oxycarbony1oxy)-androst-5 '-en-
17'-one-1H-I1,2,3] triazole 255 
NMe2 
35 	34 
W3831 N" OZZ 
'N' 
0 H 
To dansyl azide 189 (19.0 mg, 54.0 tmol) in H20: tBuOH (4 ml, 1:1) was added 
oxime 241 (20.0 mg, 60.0 i.mo1), followed by copper(II) sulfate (2.0 mg, 10 mol%) 
and sodium ascorbate solution (20.0 pJ, 1 M solution, 20 mol%). The solution was 
stirred for 17 h at RT. The solution was concentrated in vacuo, and the residue was 
purified by flash chromatography [5% MeOHIDCM] to give 255 as a pale green wax 
(30.0 mg, 44.0 tmol, 81%); Rf [5% MeOH/DCM] = 0.45; ?.max (H20)/nm 341; 'H 
NMR 8 (3 60 MHz, CDC13) 8.56 (1H, d, J8.5, C321]), 8.24 (1H, dd, J7.3, 1.0, C3411), 
8.18 (1 H, d, J 8.5, C3811), 7.56-7.5 1 (2H, m, C33H, C3711), 7.54 (1H, s, C2511), 7.19 
(1H, br d, J7.5, C36H), 5.66 (1H, t, J6.2, N291]), 5.43 (1H, d, J5.0, C6JI), 5.17 (2H, 
S, C23H2), 4.49 (111, tt, J 11.3, 5.0, C311), 4.40 (2H, t, J5.6, C27H2), 3.44 (2H, q, J6.1, 
C28H2), 2.89 (6H, s, NMe 2), 2.46 (111, dd, J 19.2, 9.1, CI6HSHT),  2.44-2.31 (2H, m, 
C4H2), 2.14-2.07 (1H, m, C7HEHF), 2.08 (1H, dd, J 19.2, 9.1, CI6HSHT), 1.99-1.90 
(2H, m, C2HCHD, C 15HQHR), 1.88-1.86 (1H, m, CIHAHB), 1.83 (1H, br t, J3.3, C811), 
1.72-1.60 (4H, m, C2HCHD, C7HEHF, CIIHKHL, Cl2HMHN), 1.58-1.50 (1H, m, 
CJSHQHR), 1.48-1.43 (1H, m, C11HKHL), 1.33-1.26 (2H, m, Cl2HMHN, C 14]]), 1.14 
(1H, td, J 13.5, 3.4, CIHAHB), 1.03 (3H, s, C19H3), 1.06-0.98 (1H, m, C9]]), 0.89 (3H, 
S, C,8H3); '3C NMR 8 (90.7 MHz, CDC13) 221.3 (1C, C17, Q), 154.4 (1C, C21, Q), 
152.3 (1C, Ar, Q), 142.3 (1C, C24 , Q), 139.7 (1C, C5, Q), 134.4 (1C, Ar, Q), 131.1 
(1C, C32H, CH), 130.1 (1C, Ar Q), 129.7 (1C, C34H, CH), 129.6 (1C, Ar, Q), 128.9 
(1C, C3 7H, CH), 125.2 (1C, C25H, CH), 123.3 (1C, C33H, CH), 122.4 (1C, C6H, CH), 
118.6 (1C, C38H, CH), 115.6 (1C, C36H, CH), 78.2 (1C, C3H, CH), 60.6 (1C, C23H2, 
CH2), 51.9 (1C, CDII, CH), 50.4 (1C, C27H2, CH2), 50.3 (1C, C9H, CH), 47.7 (1C, 
C13, Q), 45.6 (2C, NMe2, CH3), 42.8 (1C, C28H2, CH2), 38.1 (1C, C4H2, CH2), 36.9 
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(1C, C1H2, CR2), 36.8 (1C, C10, Q),.36.0 (1C, C16H2, CH 2), 31.6 (1C, C8H, CH), 31.5 
(1C, C12H2,CH2), 30.9 (1 C, C 7H2, CH 2),  27.8 (1C, C2H2, CH2), 22.0 (1C, C15H2, 
CH2), 20.5 (1C, C11H2, CH2), 19.5 (1C, C1 9H3 , CH3), 13.7 (1C, C 181-13 , CH3); m/z 
(FAB, THIOG) 690 ([M+H], 14%), 226 (82), 91 (84); HRMS (FAB, THIOG) 
(Found: [M+H], 690.3325. C37H48N506S requires m/z, 690.3325). 
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5.3 General Biological Experimental 
'Complete' Protease Inhibitor tablet was obtained from Roche (Lewes, Sussex, UK), 
cell culture media from Gibco (Paisley, UK), precast Bis-Tris gradient SDS-
polyacylamide gels, running buffer and transfer buffer from Invitrogen (Paisley, UK) 
and enhanced chemiluminescence (ECL) reagents from Amersham (Bucks, UK). 
Phospho-specific antibodies that recognize JNK1/2 phosphorylated at Thri 83, or 
unphosphorylated JNK1/2 were purchased from Biosource (Nivelles, Belgium), 
while horseradish peroxidase-conjugated secondary antibodies were from Pierce 
(Cheshire, UK). 
WesternBlotting 
Cell culture and stimulation 
Human embryonic kidney (HEK) 293 cells were cultured at 37 °C, 95% air / 5% 
CO2, in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% 
foetal bovine serum, 100 U/mi penicillin, 100 .tg/ml streptomycin and 2 mM L-
glutamine. Anisomycin was dissolved at 10 mg/ml (38 mmol U') in DMSO, while the 
other compounds were dissolved in DMSO at 38 mmol U'. Cells (9 ml of cell 
culture) were incubated with the library members by addition of 9 il of anisomycin 
solution, anisomycin analogue in DMSO, or DMSO as a control. 
Cell Lysis 
After stimulation for 30 min the media was aspirated and the cells lysed in 50 mM 
Tris/HC1, pH 7.5, containing 1 mM EDTA, 1 mM EGTA, 1 mM sodium 
orthovanadate, 10 mM sodium 3-glycerophosphate, 5 mM sodium pyrophosphate, 50 
mM sodium fluoride, 0.27 M sucrose, 1% (v/v) Triton X-iOO, 0.1 % (v/v) 2-
mercaptoethanol and 'Complete' protease inhibitor cocktail (one tablet per 50 ml). 
Lysates were centrifuged at 13000 g for 10 min at 4 °C and the supernatants (termed 
'cell extract') were removed. Protein concentrations were determined according to 
the method of Bradford. 255 
207 
Chapter 5 	 Experimental 
Immunoblotting246 ' 258 
Samples were denatured in SDS, run on polyacylamide gels and transferred to 
nitrocellulose membranes. The membranes were incubated for 1 h at room 
temperature in 50 mM Tris-HC1 pH 7.5, 150 mM NaCl, 0.2% (v/v) Tween and 5% 
(w/v) skimmed milk powder. Primary antibodies were added to 10 ml of the previous 
buffer and incubated at 4 °C overnight. The membranes were then washed four times 
with buffer (5 min per wash) to remove the excess primary antibody. The membranes 
were then incubated with the secondary antibody at room temperature for 1 h. After 
washing six times with buffer to remove the excess secondary antibody (5 min per 
wash), immunoreactive proteins were visualized via enhanced chemiluminescence 
reagent according to the manufacturer's instructions. 
FACS analysis 
Cells (cultured as above, 350 tl of cell culture) were incubated with molecular probe 
191 (22-162 jiM). After stimulation for 30 min the media was aspirated and the cells 
washed with PBS buffer (350 p1). The PBS buffer was aspirated, replaced with 
tripsin (200 tl) and the cells incubated for 5 mm. Media (200 p.1) was added to the 
cells and the combined solution was centrifuged at 1000 g for 4 mm. The media was 
aspirated and the cells re-suspended in PBS - 2% serum (200 p.1). The cells were 
analyzed on a DakoCytomation MoFlo MLS high speed sorter using a multi-line UV 
laser (350-360 nn). 
Confocal microscopy 
Cells (cultured as above, 1.5 ml of cell culture) were incubated with molecular probe 
191 (109 p.M) or dansyl azide 189 (109 p.M) as a control. After stimulation for 30 
min the media was aspirated and the cells washed with PBS buffer (1.5 ml). The cells 
were fixed using 4% paraformaldehyde in PBS (1.2 ml). Confocal microscopy 
experiments were carried out using a Leica DM IRE2 microscope with a UV laser; 
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ABPP Affinity Based Protein Profiling 
AD Alzheimer's Disease 
ADP Adenosiné DiPhosphate 
AMP Adenosine MonoPhosphate 
AP Activator Protein 
aq. aqueous 
Ar Aryl 
ASK Apoptosis Signal-regulating Kinase 
Asc Ascorbate 
ATF Activating Transcription Factor 
ATP Adenosine TriPhosphate 
atm atmosphere 
Aux chiral Auxiliary 
BCP Biotin Carrier Protein 
BMK Big Mitogen activated protein Kinase 
Bn Benzyl 
Boc t-Butyloxycarbonyl 
BPL Biotin Protein Ligase 
CAN Ceric Ammonium Nitrate 
CDI CarbonylDilmidazole 
CNS Central Nervous System 
COSY COrrelation SpectroscopY 
CoA Coenzyme A 
CREB Cyclic AMP Response Element Binding 
Da Dalton 
DBU Diaza- 1 ,3-Bicyclo[5 .4.O]Undecane 
DCC DiCyclohexylCarbodiimide 
DCM DiChloroMethane 
DEPT Distortionless Enhancement Polarisation Transfer 








DMEM Dulbecco's Modified Eagle's Medium 
DMF DiMethylFormamide 
DM50 DiMethylSuiphOxide 
DNA DeoxyriboNucleic Acid 
DPC4 Deleted in Pancreatic Cancer 
ECL Enhanced ChemiLuminescence 
EDC or ED! 1 -Ethyl-3 -(-3 -Dimethylaminopropyl)-Carbodimide 
ee enantiomeric excess 
ELISA Enzyme-Linked ImmunoSorbent Assay 
eNOS endothelial Nitric Oxide Synthases 
ERK Extra cellular signal-Regulated protein Kinase 
ES! ElectroSpray Ionisation 
Et Ethyl 
FAB Fast Atom Bombardment 
GABA y-AminoButyric Acid 
GCK Germinal Centre Kinase 
GFP Green Fluorescent Protein 
GTP Guanidine TriPhosphate 
h hours 
HEK Human Embryonic Kidney 
HMBC Heteronuclear Multiple Bond Correlation 
HOBt HydrOxyBenzotriazole 
HPLC High Performance Liquid Chromatography 
HRP HorseRadish Peroxidase 
HSDH HydroxySteroid DeHydrogenase 




JR Infra Red 
iNK c-Jun N-terminal Kinase 
LG Leaving Group 
LiHMDS Lithium HexaMethylDiSilazide 
Ln Ligand 
MAP Mitogen Activated Protein 
MAPK Mitogen Activated Protein Kinase 
MAP2K Mitogen Activated Protein Kinase Kinase (or MAPKK or MKK) 
MAP3K Mitogen Activated Protein Kinase Kinase Kinase 
(or MAPKKK or MKKK) 
MAPKAP-K2 Mitogen Activated Protein Kinase-Activated Protein Kinase 2 (or 
MK2) 
MBP Maltose Binding Protein 
mp melting point 
Me Methyl 
MEF Myocyte Enhancer Factor. 
min minutes 
MLK Mixed Linkage Kinase 
ml millilitre 
MRC PPU Medical Research Council Protein Phosphorylation Unit 
MS Mass Spectrometry 
NADP Nicotinamide Adenine Dinucleotide Phosphate 
NHS N-Hydroxy Succinamide 
NIH National Institute of Health 
nm nanometer 
NMDA N-Methyl-D-Aspartate 
NMR Nuclear Magnetic Resonance 
NOBA 3-NitrO Benzyl Alcohol 
nOe nuclear Overhauser effect 
Nu Nucleophile 
OMP Outer Membrane Protein 
P450 cytochrome P450 
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Abbreviations 
PBS 	Phospho-Buffered Saline 
PDK 	Phosphoinositide-Dependent protein Kinase 
PEG 	PolyEthylene Glycol 
Ph 	Phenyl 
P13K 	Phospholnositide 3-Kinases 
pJNK 	phosphorylated c-Jun N-terminal Kinase 
PKC 	Protein Kinase C 
P 1 	monophosphate 
PP1 	diphosphate 
Poc 	Propargyloxycarbonyl 
ppm 	parts per million 
Py 	Pyridine 
Quant 	Quantitative 
R&D 	Research and Development 
RNA 	RiboNucleic Acid 
RT 	Room Temperature 
SAPK 	Stress Activated Protein Kinase 
SAR 	Structure Activity Relationship 
scc 	side chain cleavage 
SDS PAGE Sodium Dodecyl Sulfate PolyAcylamide Gel Electrophoresis 
SULT 	SULfoTransferases 
Suc 	Succinimide 
TAK 	Transforming growth factor-13-Activated Kinase 
TB SOTf 	t-ButyldimethylSilyl Trifluoromethane sulfonate 
TBS 	t-ButyldimethylSilyl 
TBTU 	O-BenzoTriazol- 1-yl-N, N,N', N'-TetramethylUronium tetrafluoroborate 
TCEP 	Tris(CarboxyEthyl)-Phosphine 
Tf 	TriFluoromethanesulfonate, TriFlate 
TFA 	TriFluoroacetic Acid 
THF 	TetraHydroFuran 
THIOG 	THlOGlycerol 
TIBSC1 	TrilsopropylBenzeneSulfonyl Chloride 
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Abbreviations 
TIB S TrilsopropylBenzeneSulfonyl 
tic thin layer chromatography 
TNF Tumour Necrosis Faôtor 
TOCSY TOtal Correlated SpectroscopY 
Ts p-Toluene Sulfonyl, ToSyl 
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(a)- 	196 197 207 (b) 
	
196 197 207 
- 	 m 
Lane 1 2 3 4 5 6 7 8 
	
1 2 3 4 5 6 7 8 Lane 
Western Blotting: HEK293 cells were exposed to DMSO (Lane 1/2), 196 (Lane 2/3), 
197 (Lane 4/5), or 207 (Lane 6/7), each dissolved in DMSO. The cells were lysed 
and an aliquot (20 .xg of lysate protein) was separated by SDS (a) or native gel (b) 
electrophoresis. The proteins were transferred to a nitrocellulose membrane and 
immunoblotted with an antibody that recognized biotin (avidin-HRP), before 
identifying the inimunoreactive proteins using ECL. 
(c) - 	196 	197 (d) 	- 	196 	197 
_ - 
to" saw" form 
— 
Lane 1 2 	3 4 	5 6 	1 2 	3 4 	5 6 Lane 
Far Western Blotting: HEK293 cells were lysed and an aliquot (20 tg of lysate 
protein) was separated by SDS (c) or native gel (d) electrophoresis. The proteins 
were transferred to a nitrocellulose membrane and incubated with DMSO (Lane 1/2), 
196 (Lane 2/3), 197 (Lane 4/5), each dissolved in DMSO. The membranes were then 
immunoblotted with an antibody that recognized biotin (avidin-HRP), before 
identifying the immunoreactive proteins using ECL. 
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Appendix 6 
Part A: CRYSTAL DATA 
Empirical formula C23 1-1 3004 
Formula weight 370.47 
Wavelength 0.71073 A 
Temperature 150(2) K 
Crystal system Monoclinic 
Space group P21 
Unit cell dimension a = 5.9268(2) A 	alpha = 90 deg. 
b = 10.1731(4) A 	beta= 93.990(2) deg. 
c = 16.5161(6) A gamma = 90 deg. 
Volume 993.41(6) A3 
Number of reflections for cell 4185 (2 <theta <28 deg.) 
Z 2 
Density (calculated) 1.239 Mg/M3 
Absorption coefficient 0.083 mm -1 
F(000) 400 
Part B: DATA COLLECTION 
Crystal description colourless block 
Crystal size 0.49 x 0.45 x 0.24 mm 
Instrument Bruker Smart Apex CCD 
Theta range for data collection 2.35 to 30.39 deg. 
Index ranges -8<=h<=8, -11<=k<=13, -21<=k=23 
Reflections collected 11941 
Independent reflections 4892 [R(int) = 0.0582] 
Scan type omega and phi 
Absorption correction Multiscan (Tmin= 0.2695,Tax=0.8614) 
Table 1: Crystal data and structure refinement for 241. 
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Part C: SOLUTION AND 
REFINEMENT 
Solution direct (S1R92) 
Refinement type Full-matrix least-squares on F 2 
Program used for refinement SHELXL-97 
Hydrogen atom placement Geom 
Hydrogen atom treatment riding 
Data/Restraints/Parameters 4892/1/244 
Goodness-of-fit on F 2 1.050 
Conventional R [F>4sigma(F)] RI = 0.0574 [3472 data] 
Weighted R (F 2 and all data) wR2 = 0.1585 
Absolute structure parameter -0.2(14) 
Final maximum delta/sigma 0.001 
Weighting scheme calc 
W= 1 /[\sA2(FoA2A)+(0.0836P)A2A+O.O000 
P] where P=(Fo"2"+2Fc'2")/3 
Largest duff, peak and hole 0.321 and -0.384 e. AC3 
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x y Z U(eq) 
 4761(4) 1010(3) 5786(2) 27(1) 
 51 80(4) 527(3) 4938(2) 29(1) 
 6431(4) 1574(3) 4505(2) 26(1) 
 8701(4) 1861(3) 4951(2) 28(1) 
 8381(4) 2282(3) 5820(2) 23(1) 
 9327(4) 3372(2) 6112(2) 27(1) 
 9143(5) 3890(3) 6954(2) 30(1) 
 8216(4) 2871(2) 7524(2) 23(1) 
 6226(4) 2103(2) 7089(2) 24(1) 
 6937(4) 1371(2) 6314(2) 22(1) 
 5055(4) 1183(3) 7669(2) 30(1) 
 4351(4) 1877(3) 8439(2) 33(1) 
 6383(4) 2562(3) .8868(2) 25(1) 
 7383(4) 3520(2) 8275(2) 25(1) 
 8973(5) 4393(3) 8818(2) 31(1) 
 7588(5) 461 9(3) 9560(2) 33(1) 
 5917(4) 3482(3) 9558(2) 29(1) 
0(17) 4486(3) 3342(2) 10043(1) 41(1) 
 8116(4) 1567(3) 9245(2) 30(1) 
 8316(4) 120 3) 6530(2) 29(1) 
 6806(4) 2007(3) 3118(2) 28(1) 
 6747(5) 2270(3) 1707(2) 41(1) 
 8982(5) 2745(3) 1516(2) 32(1) 
 10689(5) 3122(3) 1291(2) 37(1) 
0(24) 6753(3) 1089(2) 3686(1) 29(1) 
0(25) 6812(4) 3169(2) 3213(1) 44(1) 
0(26) 6862(3) 1391(2) 2403(1) 34(1) 
Table 2: Atomic coordinates (x 104  ) and equivalent isotropic displacement parameters (A 2 x 
10) for XXX. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
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C(9)-C(1 1) 1.540(3) 














C(21 )-O(26) 1.455(3) 
C(21)-C(22) 1.465(4) 
- C(22)-C(23) 1.167(4) 


















C(1 1)-C(9)-C(8) 112.3(2) 
C(1 I )-C(9)-C(1 0) 112.3(2) 
C(8)-C(9)-C(1 0) 112.4(17) 
C(5)-C(1 0)-C(1 9) 108.4(18) 
C(5)-C(1 0)-C(1) 108.5(19) 
C(1 9)-C(1 0)-C(1) 110.0(2) 
C(5)-C(1 0)-C(9) 109.9(2) 
C(1 9)-C(1 0)-C(9) 111.9(2) 
C(1)-C(10)-C(9) 108.2(17) 
Table 4: Bond angles for 241. 
BOND ANGLES 
C(1 2)-C(1 1)-C(9) 113.3(2) 





C(1 2)-C(1 3)-C(1 8) 111.8(2) 
C(14)-C(13)-C(18) 113.5(18) 

















Ull U22 U33 U23 U13 U12 
 24(1) 31(1) 26(1) -3(1) 5(1) -5(1) 
 26(1) 33(2) 27(1) -2(1) 4(1) -4(1) 
 31(1) 22(1) 27(1) -5(1) 9(1) 3(1) 
 27(1) 27(1) 31(1) -1(1) 10(1) -2(1) 
 19(1) 21(1) 30(1) 4(1) 7(1) 3(1) 
 30(1) 24(1) 29(1) 6(1) 9 1) -4(1) 
 41(1) 23(1) 28(2) -2(1) 8(1) -7(1) 
 22(1) 20(1) 27(1) -1(1) 5(1) -3(1) 
 19(1) 26(1) 27(1) 0(1) 5(1) 1(1) 
 20(1) 21(1) 26(1) 1(1) 7(1) 0(1) 
 27(1) 34(2) 30(1) -3(1) 8(1) -11(1) 
 25(1) 47(2) 29(1) -3(1) 9(1) -7(1) 
 25(1) 26(1) 27(1) 1(1) 9(1) 1(1) 
 26(1) 21(1) 28(1) 2(1) 7(1) 2(1) 
 41(1) 22(1) 33(2) -3(1) 8(1) -4(1) 
 43(1) 23(1) 32(2) -2(1) 6(1) 5(1) 
 28(1) 37(2) 22(1) -2(1) 1(1) 8(1) 
0(17) 37(1) 58(2) 31(1) -5(1) 13(1) 4(1) 
 36(1) 26(1) 28(1) 3(1) 6(1) 1(1) 
 30(1) 21(1) 35(2) 1(1) 9(1) 2(1) 
 27(1) 29(2) 30(1) 0(1) 9(1) 2(1) 
 34(1) 51(2) 36(2) 10(1) 5(1) -2(1) 
 38(1) 27(1) 32(2) -1(1) 4(1) 3(1) 
 36(1) 31(2) 45(2) 1(1) 8(1) 4(1) 
0(24) 42(1) 22(1) 25(1) -1(1) 9(1) 1(1) 
0(25) 67(1) 25(1) 41(1) 4(1) 18(1) 9(1) 
0(26) 44(1) 33(1) 27(1) 0(1) 9(1)  
Table 5: Anisotropic displacement parameters (A2 x 10) for 241. The anisotropic 
displacement factor exponent takes the form: -2 pi 2 [h2 a*2  U11+ ...+ 2 h k a* b* U12]. 
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A nnendzx 
x y z U(eq) 
H(1A) 3942 318 6069 32 
H(1 B) 3770 1794 5738 32 
H(2A) 6085 -292 4973 34 
H(2B) 3720 334 4633 34 
H(3) 5504 2396 4468 32 
H(4A) 9478 2568 4667 33 
H(4B) 9661 1065 4954 33 
H(6) 10195 3870 5759 33 
H(7A) 8139 4669 6931 36 
H(76) 10658 14176 7177 36 
 9449 2237 7694 28 
 5077 2773 6898 28 
H(1 1A) 3694 801 7378 36 
H(1IB) 6093 451 7829 36 
H(12A) 3156 2531 8291 40 
H(126) 3729 1225 8808 40 
H(14) 6104 4103 8076 30 
H(15A) 9298 5232 8546 38 
H(15B) 10415 3938 8973 38 
H(1 6A) 8585 4621 10066 39 
H(16B) 6778 5470 9513 39 
H(18A) 8504 932 8831 445 
H(1 813) 7462 1102 9693 45 
H(18C) 9484 2034 9451 45 
H(19A) 7417 -474 6846 43 
H(19B) 9709 358 6851 43 
H(1 9C) 8698 -322 6030 43 
H(21A) 5778 3032 1820 49 
H(21 B) 6037 1802 1229 49 
H(23) —__12078 3429 1107 45 
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A truncated approach to the design of molecular probes from small molecule libraries is outlined, based 
upon the incorporation of a hioorthogonal marker. The applicability of this strategy to small molecule 
chemical genetics screens has been demonstrated using analogues of the known stress activated protein 
kinase (SAPK) pathway activator, anisomycin. Compounds marked with a propargyl group have shown 
activation of the SAPK pathways comparable to that induced by their parent structures, as 
demonstrated by immunoblot assays against the downstream target JNKI /2. The considerable 
advantages of this new approach to molecular probe design have been illustrated through the rapid 
development of a functionally active fluorescent molecular probe, through coupling of the marked 
analogues to fluorescent azides using the copper(i)-catalyzed l-!uisgen 1,3-dipolar cycloaddition 
reaction. Active molecular probes generated in this study were used to investigate cellular uptake 
through FACS analysis and confocal microscopy. 
Introduction 
Chemical tools to alter the functions of gene-products with 
temporal and spatial control in tissue culture cells, or animals, 
provide a highly attractive alternative to traditional genetic 
approaches when studying basic cell biology.' Chemical genetics 
screens frequently make use of large compound libraries which are 
screened for activity and, following 'hit' identification, strategies 
for gene-product target identification may be pursued.` Frequently 
the target identification process may require a tedious resynthesis 
and/or redesign of the synthetic strategy for the library member.' 
Hence, there are as yet only a handful of examples of target 
identification, even though a number of groups world-wide have 
carried out such chemical genetics screens.' Indeed, it is in carrying 
out the target identification stage of such a screen in our study 
of the activation of the stress activated protein kinase (SAPK) 
pathways by both the Strepiorni'ces sp. metabolite, anisomycin 1* 
(Scheme l). and a small library of anisomycin analogues,' that 
we have encountered these challenges at first hand. 
Anisomycin was first isolated from the fermentation broths of 
Streptomvces griseo/us and S. roseoe/1ronwgene.c in 1954,' while 
more recently it has been isolated from Sircptotnvces sp. SA3079 
and No. 638.8  Its structure was elucidated in 1965. whilst its 
relative stereochemistry was established three years later by NMR 
studies and X-ray crystallography.' 0 Anisomycin was found to ex-
hibit selective and potent activity against pathogenic protozoa and 
certain strains of fungi as well as inhibiting Ent amoeba hicto/viica, 
Tricho,nona.s' vagina/is, Tritriehomonas foetus and candida 
a/hica,tc." This led to clinical trials for the treatment of amoebic 
dysentery and vaginitis. However, anisomycin was found to be 
School of Chen,j.cirv. The university of Edinburgh. West Main..; Road, 
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t Electronic supplementary information (ESI) available: Preparation of 
compounds 2b from 3. NMR spectra of key compounds. See DOl: 
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Scheme I Reagents and conditions: (a) BnBr. K,CO,. DMF (89%): 
(b) HCCCHBr. K2CO,. DMF (95%). 
inactive towards bacteria at medicinally useful concentrations, 
with Staphylococcus aureus, Streptom ices /àecalis and gram 
positive organisms all requiring greater than 100 jig per ml of 
cell culture for inhibition. More recently it was reported that 
anisomycin had been identified as an antitumour substance 
showing in vitro cytotoxicity against human tumour lines, such 
as mammalian cell lines HBL 100, RAS A and MCF 7 in the nM 
region .1.12  Recent studies have implied that anisomycin may be 
used in a synergistic fashion with a cyclin-dependent protein 
kinase inhibitor to kill carcinoma cells." 
Anisomycin has found widespread use by the biochemical and 
medical communities in studies of protein synthesis both in vivo 
and in vitro, as it is a known peptidyl transferase inhibitor, binding 
to the 60S ribosomal subunit in eukaryotes) 4 More recently it 
has been utilized at 'sub-inhibitory' concentrations, as a chemical 
stimulant for the activation of the SAPK pathways (Fig. I )l5  The 
stress kinase pathways are a sub-section of the mitogen activated 
protein kinase (MAPK) pathways, and play a vital role in the 
intracellular signaling which results from a range of stressors 
including: oxidative stress; inflammatory cytokines; UV radiation; 
heat; and chemical stimulants.' 6 However, the cellular target of 
anisomycin and therefore its precise mode of activation of this 
signaling pathway have yet to be elucidated. 
Despite rapid advances in the generation and testing of small 
molecule libraries in recent years. current strategies for the 
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Fig. I Stress activated protein kinase (SAPK) pathways 
identification of the biological targets of library members in 
forward chemical genetics screens still require the synthesis of 
an appropriate molecular probe. The structure of this molecular 
probe is typically based on an active library member which has 
been modified by introduction of a tag, such as a biotin moiety. 
or a photoactivatable-, radio-, or fluorescent-label [Fig. 2(a)].' 7 
In a number of instances, this molecular probe-based approach 
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Fig. 2 Strategies for small molecule library design: (a) traditional 
approach involves library synthesis, biological screening. redesign of 
synthesis to form molecular probes, re-screening and target identification: 
(b} marked library strategy involves library synthesis incorporating a bio-
compatible marker, biological screening, rapid molecular probe formation. 
re-screening followed by target identification. 
interaction.' However, the synthesis of molecular probes can 
often be a cumbersome process: more often that not, the synthetic 
route to the active library member may have to be redesigned to 
allow tagging of the small molecule at various sites around its 
molecular scaffold [Fig. 2(a), part 4]. Moreover, a number of the 
molecular probes synthesized in this manner will have lost their 
activity due to structural perturbations upon addition of the tag 
[Fig. 2(a), part 51. These factors combined can make the synthesis 
of molecular probes a time consuming and challenging process. 
We have therefore designed a more direct approach which is 
based on the concept of a marked library, where each individual 
library member carries a small hiocompatible marker which plays 
no role in the screening process itself, but may be used in the 
target identification process once screening is complete [Fig. 2(b)]. 
Although this is a new approach to small molecule library design, 
this concept has precedent in chemical biology, where, for example. 
modified amino acids, sugars, etc., with chemical markers such as 
azides, alkynes and phosphines, etc., have been incorporated into 
a range of hiomolecules.' These markers may then be coupled 
to orthogonally reactive tags such as biotin, fluorophores, etc.. 
utilizing biologically compatible reactions such as the Staudinger -
Bertozzi ligation, and the Huisgen 1,3-dipolar cycloaddition. thus 
allowing the visualization,25 purification" and identification of 
the biomolecule of interest. This strategy has also been used 
by Cravatt and co-workers using activity-based protein profiling 
(ABPP) to interrogate the proteome, where the design of the 
functional probe relies upon a known protein activity. a a 
closely related example to our proposed marked small molecule 
library strategy, Chang and Khersonsky have designed a triazine 
library with a built-in linker containing an amino functionality 
to facilitate target identification. 23 More recently, Cravatt's group 
has generated a natural product analogue library based on a 
protein-reactive moiety with a pendant alkynyl functionality: 
allowing subsequent target identification after functionalization 
with a fluorescent, and/or biotinylated azide. In this paper, 
we demonstrate an analogous strategy which incorporates a 
functionally inert marker directly onto the small molecule library 
members: we also demonstrate the efficacy of this approach to 
the synthesis of molecular probes through the rapid generation of 
a biologically active fluorescent probe. We believe that adoption 
of this 'marked library' approach may address the problem of 
molecular probe synthesis in harmony with current molecular 
screening strategies: and thus offers the potential for acceleration 
of the hit-to-target identification process. 
Results and discussion 
Over the past few years 1.3-dipolar cycloaddition reactions. 
notably the Huisgen cycloaddition, have enjoyed a renaissance. 
due to the introduction of the copper(i)-catalyzed variant (click 
reaction) developed by Sharpless and co-workers, 25 Following 
the recent explosion of interest in this reaction as applied to 
complex biological systems,"' and the validation of both the 
propargyl and azide components of this reaction in a number of 
settings,  19  we chose to base our marker around a propargyl group. 
This marker was particularly attractive due to the commercial 
availability of a wide range of reactive precursors, including 
propargyl bromide, propargylamine. propargyl chloroformate, 
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allows the ready functionalization of a range of groups in the 
small molecule and the tailoring of the resultant functionalities to 
known structure activity relationship (SAR) constraints. In order 
to demonstrate the compatibility of the propargyl marker with 
a small molecule library in a forwards chemical genetics screen, 
we set out to synthesize a series of marked anisomycin analogues. 
Using the known phenotypic response to activation of the SAPK 
pathways, phosphorylation of the downstream protein kinase c-
Jun N-terminal kinase (iNK), we would then be able to validate 
the addition of a propargyl marker to the small molecule scaffold 
in these screens. 
Previous studies into the SAR profile of anisomycin Is indicated 
that the phenolic oxygen had potential as the site of attachment 
of the key propargyl marker,°' 2 since minor structural variation at 
this position was possible whilst still retaining activity. However, 
in order to validate the marked library strategy more thoroughly, 
we wished to investigate alternative sites of attachment of the 
propargyl marker to the small molecule core. The di-benzyl 
analogue lb, an intermediate in previous synthetic studies, has 
been shown to be inactive in assays for SAPK pathway activation.' 
Nonetheless, the pyrrolidine nitrogen presents an attractive target 
for functionalization either as an amine, or amide derivative. Thus, 
in order to investigate more closely the reasons for the loss of 
activity by the di-benzyl analogue Ib, we synthesized the mono-
benzyl analogue Ic (Scheme I). This new analogue gave strong 
activation of the SAPK pathways, suggesting that the loss of 
activity in lb was due to functionalization of the C(4)-OH position, 
rather than of the pyrrolidine nitrogen. We these results in hand. 
we focused our attention on two potential marking sites within 
the molecule: the phenolic oxygen and the pyrrolidine nitrogen. 
Access to the O-propargyl C(4)-H analogue 2b was envisaged 
through modification of our previous synthetic route to the C(4)-
H series.' Thus, protected amino acid 4 was readily accessed 
from D-tyrosine 3 in four steps (Scheme 2). Chain extension via a 
Claisen condensation, followed by stereoselective reduction gave 
-hydroxy ester 5. Reduction of the ester with L1AIH 4 , followed 
by selective activation of the primary alcohol with the hindered 
reagent triisopropylbenzene sulfonyl chloride (TI BSCI), resulted 
in cyclization to give pyrrolidinium salt 6. Careful manipulation 
of the protecting groups to give key intermediate 7, allowed 
for a highly efficient end-sequence of selective formation of the 
propargyl ether, before a final Boc-deprotection of the pyrrolidine 
nitrogen to give 2b. The required N-propargyl analogue Id 
was very readily synthesized from anisomcin Ia using a single 
equivalent of propargyl bromide in the presence of potassium 
carbonate in almost quantitative yield (Scheme I). 
Although the precise target of anisomycin is unknown, the 
downstream effects on the SAPK pathways have been well 
documented) 6  Treatment of mammalian, yeast and insect cells 
with anisomycin la is known to strongly activate both the 
JNK/SAPKI and the p38/SAPK2 pathways, resulting in phos-
phorylation of their respective substrates, including iNK and 
MAPKAP-K2. In order to assess the relative levels of activation 
by marked compounds, they were screened using an immunoblot 
assay for phosphorylation of iNK 1/2 in HEK-293 cells. The 
activation levels induced by these compounds were scaled against 
anisomycin, deacetylanisomycin. and DMSO (strong and moder-
ate activators, and control respectively). Selected results of these 
assays are shown in Fig. 3; which demonstrates that the level 
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Scheme 2 Reagents and conditions: (a) AcCI. MeOH. retlus (I 00%); 
(b) HnBr. KCO,. MeCN (91%): (c) L1OH. TI-IF-H.O (4 : I). retlux 
(87/n); (d)i) TBSOTf. 2,6-lutidine, CI-lCl ii) AcOH-THF--HO (3: 1: 
1) (9(Y); (c) I) CDI. THF: ii) CH=C(OLi)OEt (71 0/4); (f) NaCNBH. 
MeOH. AcOH. Et 20 (80%): (g) LiAlH. THF (91%): (h) i) TIBSCI. 
DMAP. CHCl.: ii) Dowex (Cl) ion-exchange resin (92%); (i) ft. 5% 
Pd/C. K.CO,. MeOH (801/.,); (j) Ac,O, EtnN. DMAP. CH .C1- (94%); 
(k) ft.  EtOH. Pd(OH)-,  (95%): (I) Boc.O, Et,N, CI-1.Cl (891/.); (m) 
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of iNK 1/2 isoforms in HEK-293 cells. The cells were exposed to DMSO 
(lanes I and 2). anisomycin la (lanes 3 and 4). deacetylanisomnycin (lanes 5 
and 6). or the anisomycin analogues 2b (lanes 7 and 8) and Id (lanes 9 and 
10). each dissolved in DMSO. The cells were lysed and an aliquot (20 j.tg 
of lysate protein) was denatured in SDS. subjected to electrophoresis on 
101/4 polyacrylamide gel. transferred to a nitrocellulose membrane and 
immunoblotted with an antibody that recognized JNK 1/2 phosphorylated 
at Thr183. or with an antibody that recognizes phosphorylated and 
unphosphorylated iN K 1/2 equally well4 
of JNKI/2 activation by the marked analogues Id and 2b is 
comparable with that induced by deacetylanisoniycin. Thus we 
have successfully exchanged the benzyl group of ic for a propargyl 
group in Id, and the methyl group in 2a for a propargyl group 
in 2b, whilst retaining comparable activity; hence validating the 
hypothesis that a chemical marker can be incorporated into a 
small molecule library. 
The next step in our abbreviated small molecule to molecular 
probe synthetic process [Fig. 2(b)] is the direct conversion of an 
active marked library member to a fully functional probe. We 
The immunoblots show two distinct bands per lane due to phosphoryla-
tion of the 46 kDa and the 54 kDa spliced variants of iNK 1/2. 
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Fig. 4 (a) Reagents dconditions: CuS05H0 (10 mol%). NaAsc (IM aq, 20 mol%(. 'BuOH-H.O (I: I), it. 4-5 h (Id 	9,71%:2b —+ 10. 77%): 
(b) effect of molecular probes 9 and 10 on the phosphorylation of iNK 1/2 isoforms in HE K-293 cells. The cells were exposed to DMSO (lanes I and 2). 
anisomycin I  (lanes 3 and 4). and the molecular probe 9 or 10 (lanes 5 and 6). each dissolved in DMSO. Immunoblot assays were conducted as described 
in Fig. 3. 
chose the dansyl fluorophore due to the ease with which it could 
be synthetically modified to give a reactive azide partner. and 
its widespread use in small molecule target i nvestigation.v To 
this end, library members Id and 2b were both readily converted 
to the corresponding fluorescent molecular probes through a 
copper(i)-catalyzed Huisgen 1.3-dipolar cycloaddition reaction 
with 2-azido- I -N-dansylethylamine 8 [Fig. 4(a)].' Rigorous char-
acterization was then carried out on the fluorescent molecular 
probes 9 and lO, utilizing a series of 2D NMR experiments 
including COSY, HSQC and HMBC to fully assign the structure 
of these molecules. The COSY spectrum showed that, as expected, 
a single regioisomer had been obtained from the copper(I)
catalyzed Huisigen cycloaddition: whereas the HSQC and HMBC 
experiments allowed full assignment of the carbon backbone. The 
HSQC (Fig. 5) also illustrated the formation of the triazole, with a 
distinctive CH signal [at 7.57 (' H), 126.4 ( `C) ppmj corresponding 
to the 5-position of the triazole. The fluorescence properties of the 
probes were then compared with that of the parent dansyl azide 
8, and were found to be equivalent (8: A, = 345, ), = 550 nm). 
Thus, in one simple step, we have successfully converted our active 
marked library members to functional molecular probes. 
These fluorescent probes (9 and 10) were then screened for 
activation of the SAPK I pathway in HEK-293 cells, using an 
immunoblot assay for phosphorylation ofJNK as for the original 
small molecule library. The resultant immunoblot assays [Fig. 4(b)] 
demonstrate that extension of the propargyl ether marker in the 
C(4)-H analogue 2b as the fluorescent probe 10 led to the loss 
of the phenotypic SAPK response. In contrast, formation of 
fluorescent molecular probe 9, using the propargyl amine marker 
of anisomycin derivative Id. led to a strong phenotypic response 
in the SAPK pathway assay, with activation levels comparable to 
that of the natural product itself. 
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Fig. 5 HSQC spectrum of molecular probe 9 in CD,CN at 360 MHz. 
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lie use of fluorescent probe 9 as a means to determine 
anisomycin's site of interaction within HEK-293 cells was assessed 
by two means. In the first instance. HEK-293 cells were incubated 
with increasing concentrations (22-162 I.LM) of probe 9 for 30 mm. 
Fluorescence-activated cell sorting (FACS) was used to assess 
probe uptake, and a direct correlation was observed between 
the level of dansyl fluorescence observed in the cell populations 
and the initial dosing concentrations (Fig. 6). Using the results 
of FACS sorting, an optimum concentration for cell stimulation 
was selected (109 j.tmol) which allowed visualization of the probe 
uptake, initially at 20-fold magnification and subsequently at 63-
fold magnification (Fig. 7). In a preliminary experiment. HEK-
293 cells were incubated with dansyl azide 8 for 30 min and 
then washed with phosphate buffered saline (PBS) buffer. A series 
of confocal optical sections at 63-fold magnification showed the 
fluorescent azide to be distributed evenly throughout the cell. 
indicating that the dansyl azide itself was cell-permeable and that 
it was not expected to confer any inherent cellular distribution on 
the fully-formed probe 9. In contrast, con focal optical sections at 
63-fold magnification through a group of H EK-293 cells incubated 
with fluorescent probe 9 showed diffuse intracellular staining 
throughout the cytosol. Whilst these preliminary studies must 
be viewed with caution, since the incorporation of fluorescent 
labels can themselves lead to a distortion of the intracellular 
distribution of any particular small molecule,"' they suggest a 
cytosolic distribution of the biological target of this molecular 
probe. This hypothesis is in good agreement with the results of 
recent studies which suggest that anisomycin-induced activation 
of the SAPK pathways might be through the cytosolic MAP3K 
protein MLK7, 29 suggesting a target at the MAP3K level or 
above. The application of a range of functional molecular probes 
generated using this strategy should allow us to interrogate the 
biological function of this interesting small molecule. 
Fig. 6 FACS analysis of cellular uptake of molecular probe 9 in H EK-293 
cells. Cells were incubated with 22-162 aM of molecular probe for 30 mm 
and were analyzed using a Moflo FACS instrument with a UV laser. 
(a) Histograms of unlabeled cells as a control (red) and cells incubated 
with 9 at 162 aM (green); (b) histograms illustrating increasing fluorescence 
intensity with increasing concentrations of 9 (0. 22. 42. 66. 86. lOS. 131. 
162 saM). 
Conclusions 
Small molecule chemical genetics screens can generate large 
numbers of active compounds: however, current strategies for the 
Fig. 7 ( e1JUIM i 0C L 1l1ZJLWJ1 J11d uptake ol parent d.insI azidc$ia -C) and 
molecular probe 9 (d--fl. Cells were incubated for 30 min with 109 1aM of 8 
or 9, washed with PBS and fixed. Analysis of cells was carried out using a 
Leica DM IRE2 confocal microscope. (a and d) Brightfield image of cells 
at 63-fold magnification: (b and e) fluorescent image of cells at 63-fold 
magnification: (c and I) overlay of brightfield and fluorescent images. 
development of these 'hits' into active molecular probes for further 
biological investigation are often cumbersome. In this study we 
have demonstrated that the incorporation of a biocompatible 
propargyl marker into the molecular scaffold of library members 
can lead to the rapid generation of active molecular probes. Given 
the range of robust, biocompatible reactions which have been 
developed in the past five years, there are a number of options for 
the choice of bioorthogonal markers (alkynes, azides. phosphines, 
etc.) which allow tailoring of this strategy to the small molecule 
library under investigation. As a result, this approach should allow 
the rapid coupling of a diverse range of functional tags, such 
as fluorophores, NMR spin labels and biotin to any individual 
marked library member. Therefore, future library design using 
this marked library approach should provide a useful truncation 
of the small molecule to the molecular probe synthetic process. 
Experimental 
General methods 
All reactions involving air- or water-sensitive reagents were carried 
out under an atmosphere of argon using flame- or oven-dried 
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glassware. Unless otherwise noted, starting materials and reagents 
were obtained from commercial suppliers and were used without 
further purification. THF was distilled from Na-benzophenone 
ketyl immediately prior to use. CHCl 1 . 2.6-lutidine, ethyl acetate, 
acetyl chloride, acetic anhydride and EtN were distilled from 
calcium hydride. Anhydrous methanol. DMF, and acetonitrile 
were used as supplied. Unless otherwise indicated, organic extracts 
were dried over anhydrous sodium sulfate and concentrated under 
reduced pressure using a rotary evaporator. Purification by flash 
column chromatography was carried out using Merck Kieselgel 
60 silica gel as the stationary phase. Chiral high performance 
liquid chromatography (HPLC) was carried out on a Waters 786 
instrument equipped with a Chiracel OD-H column (internal 
diameter 4.6 mm) and a UV detector. A standard flow rate of 
0.5 cm' min was used. All solvents used for HPLC analysis 
were vacuum filtered and degassed prior to use. IR spectra were 
measured on a Perkin-Elmer Paragon 1000 FT-IR spectrometer as 
thin films unless otherwise stated. H and ' 3 C NMR spectra were 
measured on Varian Gemini 200, Bruker AC250. Bruker DPX360 
instruments; J values are in Hz. Melting points were determined 
on a Gallenkamp Electrothermal Melting Point apparatus and 
are uncorrected. Optical rotations were measured on an AA-1000 
polarimeter with a path length of 1.0 dm, at the sodium D-line at 
room temperature. Fast atom bombardment (FAB) mass spectra 
were obtained using a Kratos MS50TC mass spectrometer at The 
University of Edinburgh. Luminescence measurements were car-
ried out in Hellma 109.000E-QS 10 mm precision cell using a flu-
orimeter with phosphorimeter Jobin-Yvon-Horiba Fluoroniax-P. 
'Conaplete' Protease Inhibitor tablets were obtained from Roche 
(Lewes, Sussex, UK), cell culture media from Gibco (Paisley, 
UK), precast Bis-Tris gradient SDS-polyacrylamide gels, running 
buffer and transfer buffer from Invitrogen (Paisley, UK) and 
enhanced chemiluminescence (ECL) reagents from Amershana 
(Bucks, UK). Phospho-specific antibodies that recognize iNK 1/2 
phosphorylated at Thri 83. or unphosphorylated iNK 1/2 were 
purchased from Biosource (Nivelles, Belgium). while horseradish 




pyrrolidine Ic. To a solution of anisonlycin la (20.0 mg, 
80.() j.imol) in DMF (I ml) was added potassium carbonate 
(11.0111g. 80.0 j.tmol) and benzyl bromide (10.0 1.d, 80.0 xmoI), the 
solution was stirred at room temperature for 4 h. The solution was 
then concentrated in vacuo, and the residual colorless solid was 
purified by flash chromatography (4% MeOH/CH,Cl 2 ] to give Ic 
as an oil (25.0 mg. 70.0 tmol, 89%); R, (5% MeOH/CH : Cl : ) = 
0.33; [a],, -98.0 (c 1.00, CHCI,): V,,n. ( neat)/cm -1 3399, 3053. 
1730. 1612. 1512: 'H NMR (360 MHz, CD,OD) 7.42-7.35(5H, 
na, ArH), 7.14 (2H, d, 1 8.4, ArH). 6.87 (2H, d, 1 8.4, ArH), 
4.81 (IH. br d. 1 3.0. C,!!). 4.15 (1 H, d, J 12.6, NCH X H.Ph). 
4.11 4.09 0 H, m, C4 H). 3.79 (3H. s, OMe), 3.67 (1 H. d, 1 12.61 
NCHHPh), (I H. m, CH), 3.36-3.34 (11-1, m, C5H M H N ), 2.91 
(I H, dd, 1 13.5, 5.3, CH,H 1 Ar). 2.83 (1 H. dd. J 13.5, 9.8, 
CHH,Ar). 2.58-2.56 (lH. m C,H M HN ), 2.14 (3H, s. OAc); "C 
NMR6(90.7 MHz, CD,OD)17l.8 (IC Q), 160.9(lC,Q). 131.2 
(IC, Q). 130.9 (2C. CH). 130.8 (IC, Q). 130.7 (2C, CH). 129.6  
(2C. CH), 129.0 (IC, CH), 115.0 (2C, CH). 80.8 (IC. CH ), 74.5 
(IC. CH ), 68.7 (IC. CH ). 60.8 (IC, CH). 60.5 (IC, CH.). 55.6 
(IC, CH,), 33.7 (IC. CH .). 20.9 (IC. CH ,); ?n/: (FAB. THIOG) 
356 ([M + H]. 90%), 296 (63). 91(95): HRMS (FAB. NOBA) 
(Found: [M + H]'. 356.1861. C,,H, 6 NO, requires m/:. 356.1862). 
(2R,3S.4S)-3-Acetoxy-4-hydroxy-2-(4'-methoxybenzyl)- I-pro-
pargylpyrrolidine Id. To a solution of anisomycin la (20.0 mg. 
80.0 J2naoI) in DMF (2 m)) was added potassium carbonate 
(11.0 mg, 80.0 iniol) and propargyl bromide (12.0 viI. 80.0 moI). 
the solution was stirred at room temperature for 9 h. The solution 
was then concentrated in VOCUO, and the residue was purified by 
flash chromatography (5% MeOH/CHCl 2 ) to give Id as an oil 
(22.0 mg, 70.0 jmoI. 95%); R (5% MeOH/CH2Cl 2 ) = 0.22: [a],, 
-116 (C 0.90, CHCI,); (neat)/cm' 3305. 3019, 1726, 1613, 
1513; 'H NMR O (360 MHz, CDCI) 7.10 (2H, d, 1 8.6, ArH), 
6.81 (2H, d, 1 8.6, ArH), 4.47 (1 H, dd. 1 5.6, 1.5, C, H), 4.13 
(I H, td. 1 6.8. 1.5, C4!!). 3.79 (3H, s. OMe), 3.58 (2H. t, J 2.3, 
HCCCH,). 3.36(IH, dd. J 9.9, 7.1, CcH M HN), 3.22 (1 H, qn, 
1 5.2 C.!!), 2.86 (lH, dd, J 13.3, 4.7. CH5HAr). 2.71 (1 H. dd. 
1 13.3, 10.3, CH S HT Ar), 2.62 (IH, dd, 1 9.9, 6.7, CSHMHN), 
2.32 (1 H, t, 1 2.3, HCCCH.), 2.14 (3H. s, OAr); "C NMR ô 
(90.7 MHz, CDC],) 172.0 (IC. 0). 158.2 (IC, Q), 130.2 (IC. Q). 
130.0 (2C. CH). 114.0 (2C, CH), 82.5 (IC, CH), 76.7 (IC, Q). 75.7 
(IC, CH), 74.5 (IC, Cl-!), 63.6 (IC, CH). 58.0 (IC, CH.). 55.4 (IC, 
CH), 40.0 (IC, CH.). 32.1 (IC. CH ,), 21.3 (IC,CH,); nil: (FAB. 
THIOG) 304 (EM + H, 67%), 244(42), 121 (100), 91(88); HRMS 
(FAB. THIOG) (Found: [M + H], 304.1540. C I ,H, NO4 requires 
ml:, 304.1549). 
(2R,3R)-3-Acetoxy-2-(4-propargyloxybenzyl)-pyrrolidine 2b. 
See ESIt for the preparation of 2b; R, (5% MeOH/CH,CI,) = 
0.11; [a],, -24.2 (e 0.95, CHCI,); v,, (neat)/cm' 3282, 2925, 
1730, 1610, 1510; 'H NMR 6 (360 MHz, CDCI,, 323 K) 7.09 
(2H. d. J 8.7, ArH), 6.90 (21-!, d, 1 8.7, Ar!!), 5.29-5.27 (I H, m, 
C, H), 4.63 (2H, d. 1 2.4, HCCCH.), 3.85-3.80(IH, ni, C.H). 
3.45-3.32 (2H, m, CH), 3.05-2.99 (2H. m. CH.Ar), 2.50(1 H, t, 
J 2.4, HCCCH,), 2.29-2.17 (2H, m. C4 H.). 2.18 (3H, s, OAr): 
"C NMR 6(90.7 MHz, CDCI,. 323 K) 169.9 (IC, Q), 157.3 (IC. 
Q), 130.0 (2C, CH), 128.2 (IC, Q), 115.9 (2C, CH). 78.7 (IC, Q), 
75.8 (IC. CH ). 72.6(1 C, CH), 64.5 (IC, CH), 56.2 (IC. CH ,), 43.2 
(IC. CH .). 31.8 (IC, CH.). 33.3 (IC, CH.), 20.7 (IC, CH,); nil: 
(FAB. THIOG) 274 [M + H]', (87%), 214 (57); HRMS (FAB. 
THIOG) (Found: [M + H] - . 274.1441. requires in!:. 
274.1443). 
2-Azido- I -ethylamine. To a solution of 2-chloro- 1 -ethylamine 
(500 mg. 4.31 mmol) in water (5 ml) was added sodium azide 
(844) mg. 12.9 mmol) and the reaction mixture was heated at 80 'C 
for IS h. The solution was basifled with KOH (solid) and extracted 
with diethyl ether. The organics were dried and concentrated to 
give a volatile colourless oil (371 mg, 4.31 mmol. 100%); i',,,, 
(neat)/cm' 3375. 2104: IH NMR 6 (364) MHz, CDCI,) 3.30 (2H, 
t, 1 5.7, C!!..), 2.79-2.74 (2H. m, Cl!.). 1.43 (2H, s. NH.); "C 
NMR a (90.7 MHz. CDC1,) 54.2 (IC. CH ,), 40.9 (IC, CH.): ml: 
(ESI+) 194 ([2M + H]'). Spectroscopic data in good agreement 
with the literature. 10 
2-Azido-I-N-dansylethylamine 8. To a solution of 2-azido-l-
ethylamine (371 mg, 4.31 mmol) in CHC1, (7 ml) was added dansyl 
chloride (225 nag. 840 iimol) and the reaction mixture was stirred 
T' 	 Ryi ocety • CIrrstry 2007 	 Org. Biomol. Chem., 2007, 5, 636-643 1 641 
for 2 h. The solution was concentrated in VaCUO, and the residue 
was purified by flash chromatography (25 1Y. EtOAc/hexane) to 
give 8 as a pale yellow oil (260 mg, 820 liniol, 98%); R, (30'V0 
EtOAc/hexane) = 0.27; ),,,. (HO)/nm 345 nm: v (neat)/cnr 
3301. 2942,2103,1318;'H NMR ö (360 MHz, CDCI,) 8.57(1 H, 
br d, J 8.5, ArH), 8.29(1 H, br d. J 8.6, ArH), 8.26(1 H, dd, J 7.3, 
1.3, ArH), 7.59 (1 H. dd. J 8.6, 7.6, ArH). 7.53 (1 H. dd. J 8.5, 7.3 
ArH), 7.20(1 H, hr d, J 7.6, ArH), 5.28 (1 H, t, J 5.9. NH), 3.30 
(2H. t. J 5.7. CH,), 3.06(2H. q. J 6. 1, CH), 2.90 (ÔH. s, NMe2); 
13 C NMRO(90.7 M Hz, CDCI 3 ) 152.1 (IC. Q). 134.6(IC, Q), 130.9 
(IC,CH), 130.0(IC.Q). 129.7(IC,CH), 129.6(IC.Q), 128.8(IC, 
CH), 123.3 (IC, CH). 118.7 (IC. CU ), 115.5 (IC, Cl-I). 51.0 (IC. 
CH ), 45.5 (2C. CH 3 ), 42.5 (IC. CH ); ,n/: (FAB. NOBA) 319 
(LM]. 90%), 170 (100); HRMS (FAB, THIOG) (Found: [M + 
H]'. 320.1184. C, 4 HNOS requires ml:. 320.II8I). 
N-Linked dansyl molecular probe 9. To propargyl amine Id 
(27.0 mg, 90.0 j.imol) in BuOH- HO (2 ml. I : I) was added dansyl 
azide 8(26.0mg. 80.0 imol). followed by copper(ii) sulfate (2.0 mg, 
10 mol%) and sodium ascorbate solution (20.0 sI, I M solution, 
20 mol¼). After S h the reaction was complete by TLC. The 
solution was concentrated in vacuo, and the residue was purified 
by flash chromatography (5 to 10% MeOH/CH 2 Cl 2 ) to give 9 as a 
foam (40.0 mg. 60.0 imoI. 71'Y.,); R1 (1(Y% MeOH/CftCl 2 ) = 0.34, 
).,., (H2O)/nrn 345 nm; 'H NMR6(360 MHz, CD 3 CN)8.54(l H. 
d, J 8.5, ArH). 8.19 (1 H, d. J 8.7, ArH), 8.16(1 H, dd. J 7.3, 1.3 
ArH), 7.59--7.54(3H, m. 2ArH + CH), 7.25 (1 H, d. J 7.6. ArH), 
7.21 (2H, d. J 8.5, ArH), 6.87 (2H, d. J 8.5, ArH), 4.66(1 H, br s. 
CH), 4.35 (2H. q, J 5.0, CH.), 4.03(1 H, br s. CH). 3.97(1 H, br d, 
J 13.6, CHA H H ), 3.86-3.84 (1 H, m, CH. H 8 ), 3.76 (3H. s, OMe). 
3.56-3.540H, m, CH), 3.47 3.43 (1 H, m. CH, H,,), 3.30 (2H, br 
t, J 6.1. CH,), 3.05 (1 H, dd. f 13.4. 5.7, CH, H.,), 2.86 (ÔH, s. 
NMe), 2.85(1 H, m, CH, H,,), 2.84 (I H, dd, J 7.2, 5.7, CH, H,,), 
2.07 (3H. s, OAc); ' 1 C NMR tJ (90.7 MHz, CD,CN) 170.9 (IC, 
Q). 159.4 (IC. Q). 152.6 (IC, Q), 141.6 (IC, Q). 136.1 (IC. Q). 
131.2 (2C. CH). I30.60C. Q), 130.3(IC.Q), 130.2(IC,Q). 130.1 
(IC, Q). 130.0 (IC. CU ), 129.2 (IC, CH). 126.4 (IC, CH). 124.4 
(IC, CH). I 19.9(IC, CH). 116.2 (IC, CH), 114.9 (2C. CH). 79.7 
(IC. CH ). 73.9 (IC, CH), 67.7 (IC, CH), 59.6 (IC. CH ), 55.8 
(IC, CH,), 50.9 (IC. CH,). 49.0 (IC, CH), 45.7 (2C, CH J ), 43.6 
(IC,CH,),32.2(IC,CH 2 ).2I.I (IC.CHd;,nl:(FAB.NOBA)623 
([M + H]'. 60%), 501 (46) 1 91 (68); HRMS(FAB, NOBA)(Found: 
EM + H], 623.2655. C 31 H 39 NOS requires ml:. 623.2652). 
0-Linked dansyl molecular probe 10. To propargyl ether 2b 
(32.6 mg. 120 tniol) in 'BuOH ftO (3 ml. I : I) was added dansyl 
azide 6(40.0 mg. 130 LimoI), followed by copper(ii) sulfate (3.0 mg. 
10 niol%) and sodium ascorhate solution (25.0 iiI, I M solution, 
20 mol"/). After 4 h the reaction was complete by TLC. The 
solution was concentrated in vacua, and the residue was purified 
by flash chromatography (5 to 10% MeOH/CHCl 2 ) to give 10 
as a foam (54.5 mg, 90.0 jmoI. 77%); R1 (5% MeOHICH 2 Cl 2 ) = 
0.24; 'H NMR 6 (360 MHz. DMSO) 8.47 (I H, br d. J 8.5, An), 
8.27 (1 H. t. J 5.8. NH). 8.22 (I H. br d. J 8.7, An), 8.26 (I H. 
d. J 7.9, ArH). 8.06 (1 H, s. CH), 7.65-7.56 (2H, m. ArH), 7.27 
(I H, d, J 7.4, An), 7.20 (2H. d, J 8.6, ArH), 7.00 (2H. d. J 8.61 
ArH).5.I6(IH,t,J3.8.CH),5.03(2H,S,CH).4.4I (2H.t,J5.9, 
CH). 3.89-3.8 I (1 H, m, CH), 3.34-3.24 (2H, m. CH), 3.26 (2H. 
br q. J 5.8, CH). 2.98-2.88 (2H, m, CH,). 2.84 (6H, s, NMe.). 
2.30-2.190H. m, CH,, HO, 2.12 (3H. S. OAc), 2.05-1.98(1 H. in, 
C. S HA H H ); ' 1 C NMRo(62.9 MHz. DMSO) I69.7(IC, Q). 157.2 
(I C, Q), 151.2 (IC. Q), 142.5 (IC. Q), 135.5 (IC, Q), 130.1 (2C. 
CH). 129.7 (IC, CH), 129.1 (IC. Q), 129.0(IC.Q), 128.8 (IC. Q), 
128.5 (IC, CH). I28.I (IC, CH), 125.0(IC. CH ). 123.8 (IC, CH). 
119.3 (IC, CH). I 15.4(IC. CH ). 114.9 (2C, CH). 72.9 (IC, CH). 
63.5 (IC, CH). 61.1 (IC, CH). 49.40C, CH), 45.2 (2C, CH,), 
42.8(IC, CH,). 42.5 (IC. CH ,). 31.1 (IC. CH .). 30.6 (IC, CH). 
20.9 (IC, CH,); m/:(FAB. NOBA) 593 ([M + H]', 43%), 91(52): 
HRMS (FAB. NOBA)(Found: [M + H]', 593.2548. CH 3,N 6 0,S 
requires in!:. 593.2546). 
I mmunoblot assays"` 
Cell culture and stimulation. Human embryonic kidney (HEK) 
293 cells were cultured at 37 ° C. 95% air/S>' CO, in Dulbecco's 
modified Eagle's medium (DMEM)supplemented with 10% foetal 
bovine serum. 100 U ml ' penicillin. 100 jig ml ' streptomycin 
and 2 m L-glutamine. Anisomycin was dissolved at 10 mg m1 
(38 mM) in DMSO. while the other compounds were dissolved in 
DMSO at 38 mM. Cells (9 ml of cell culture) were incubated with 
the library members by addition of 9 jil of anisomycin solution, 
anisomycin analogue in DMSO. or DMSO as a control. 
Cell lysis. After stimulation for 30 min the media was aspirated 
and the cells lysed in 50 mM Tris/HCI, pH 7.5, containing 
I mM EDTA, 1 mM EGTA, I mM sodium orthovanadate. 
10 in M sodium 3-glycerophosphate. 5mM sodium pyrophosphate, 
50 mM sodium fluoride. 0.27 M sucrose, 1% (v/v) Triton X-I00. 
0.1% (v/v) 2-mercaptoethanol and 'Complete' protease inhibitor 
cocktail (one tablet per 50 ml). Lysates were centrifuged at 13 000 g 
for 10 min at 4 °C and the supernatants (termed 'cell extract') were 
removed. Protein concentrations were determined according to the 
method of Bradford. 2 
Immunoblotting. Samples were denatured in SOS, run on 
polyacylamide gels and transferred to nitrocellulose membranes. 
The membranes were incubated for I h at room temperature in 
50 mM Tris-HCI pH 7.5, 150 mM NaCl. 0.2% (v/v) Tween and 
5% (w/v) skimmed milk powder. Primary antibodies were added 
to 10 ml of the previous buffer and incubated at 4 °C overnight. 
The membranes were then washed four times with buffer (5 mm 
per wash) to remove the excess primary antibody. The membranes 
were then incubated with the secondary antibody at room 
temperature for I h. After washing six times with buffer to remove 
the excess secondary antibody (5 min per wash), immunoreactive 
proteins were visualized via enhanced chemiluminescence reagent 
according to the manufacturer's instructions. 
FACS analysis. Cells (cultured as above, 350 jil of cell culture) 
were incubated with molecular probe 9 (22-162 jiM). After 
stimulation for 30 min the media was aspirated and the cells 
washed with PBS buffer (350 jil). The PBS buffer was aspirated. 
replaced with tripsin (200 jtI) and the cells incubated for 5 mm. 
Media (200 l.il) was added to the cells and the combined solution 
was centrifuged at 1000 g for 4 mm. The media was aspirated and 
the cells re-suspended in PBS - 2% serum (200 j.il). The cells were 
analyzed on a DakoCytomation MoFlo MLS high speed sorter 
using a multi-line UV laser (350-360 nm). 
Confocal microscopy. Cells (cultured as above, 1.5 ml of cell 
culture) were incubated with molecular probe 9 (109 jiM). After 
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stimulation for 30 min the media was aspirated and the cells 
washed with PBS butler (1.5 ml). The cells were fixed using 
4% paraformaldehyde in PBS (1.2 ml). Confocal microscopy 
experiments were carried out using a Leica DM IRE2 microscope 
with a UV laser; cells were analyzed at 20-fold and 63-fold 
magnification. 
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